hydroxychloroquine has been researched along with 2019 Novel Coronavirus Disease in 1379 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "severe distinctive cutaneous drug reaction, generalized pustular figurate erythema, closely linked with hydroxychloroquine (HCQ), has been documented." | 9.22 | Generalized Pustular Figurate Erythema in Patients with COVID-19 Treated with Hydroxychloroquine: A Systematic Review. ( Al Muqarrab, F; Almohssen, AA; Schwartz, RA, 2022) |
| " In the absence of evidence-based proven prophylactic or therapeutic options, chloroquine/hydroxychloroquine (CQ/HCQ) patented as first line choice in COVID- 19 treatment, which raised concerns about drug poisoning, especially ocular toxicity." | 9.05 | Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? ( Ahur, MH; Bagheri, M; Eidizadeh, M; Rashe, Z, 2020) |
| "On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning." | 9.05 | Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. ( Alhatali, B; Berling, I; Ghannoum, M; Gosselin, S; Hoffman, RS; King, JD; Lavergne, V; Nolin, TD; Roberts, DM; Shepherd, G; Wilson, G, 2020) |
| "Hydroxychloroquine (HCQ) is used in the treatment of inflammatory rheumatic diseases and is considered a safe drug." | 8.31 | Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study. ( Costa, L; Macedo, F; Madureira, P; Martins Carvalho, M; Pinheiro, FO; Seabra Rato, M, 2023) |
| "This study confirms the efficacy of patch tests in patients with delayed hypersensitivity reactions to hydroxychloroquine." | 8.31 | [Multiform exudative erythema caused by hydroxychloroquine, diagnosed by epicutaneous tests: A case report]. ( Castro-Jiménez, A; Florido López, F; Gratacós-Gómez, AR, 2023) |
| " We describe using the electronic PharmaCheck system to screen high-risk situations of adverse drug events (ADEs), particularly targeting prescriptions of lopinavir/ritonavir (LPVr) and hydroxychloroquine (HCQ) in the presence of contraindications or prescriptions outside institutional guidelines." | 8.31 | Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. ( Bonnabry, P; Eggimann, F; Grauser, D; Grosgurin, O; Guignard, B; Reny, JL; Samer, C; Skalafouris, C; Stirnemann, J, 2023) |
| "Hydroxychloroquine is generally considered safe in pregnancy for the treatment of rheumatic conditions, but studies have been too small to evaluate teratogenicity." | 8.02 | Hydroxychloroquine early in pregnancy and risk of birth defects. ( Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Straub, L; Zhu, Y, 2021) |
| "To compare the incidence of COVID-19 in Spanish patients with autoimmune rheumatic diseases treated with and without hydroxychloroquine." | 8.02 | Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. ( Corma, A; González-Moreno, P; González-Serna, A; Macho, M; Macías, J; Martínez, M; Morillo-Verdugo, R; Pérez-Venegas, JJ; Pineda, JA; Pinilla, A; Real, LM; Sánchez-García, E, 2021) |
| "The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy." | 7.96 | Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. ( Houston, T; Pati, S, 2020) |
| " During the hospitalization, she experienced unexpected sinus bradycardia with prolonged QTc, which was thought to be closely related to the short-term use of hydroxychloroquine (HCQ), an old drug used to treat malaria and autoimmune diseases, but now used against COVID-19." | 7.96 | Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19. ( Chen, H; Kang, Y; Ran, Q; Wang, B; Wang, H; Wei, J; Yang, Y; Zhao, X, 2020) |
| " Four weeks prior, she had been initiated on hydroxychloroquine for a presumed diagnosis of cutaneous sarcoidosis." | 7.96 | Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report. ( Ackerman, L; Brahmbhatt, S; Coleman, I; Ruiz, G, 2020) |
| " We report a case of coronavirus disease 2019 (COVID-19) pneumonia in a patient under hydroxychloroquine (HCQ) treatment for rheumatoid arthritis." | 7.96 | COVID-19 Pneumonia during Hydroxychloroquine Treatment of Rheumatoid Arthritis. ( Demirbilek, SG; Dogan, E; Gürsoy, C; Tapan, ÖO; Togan, T, 2020) |
| "Data regarding knowledge and attitude about COVID-19, the prevalence of acceptance of hydroxychloroquine prophylaxis and anxiety amidst COVID-19 pandemic among health care students/professionals in India is scarce." | 7.96 | Knowledge, anxiety and the use of hydroxychloroquine prophylaxis among health care students and professionals regarding COVID-19 pandemic. ( Bansal, AS; Garg, A; Jindal, V; Kaur, G; Kaur, P; Kaur, T; Mittal, S; Sati, HC, 2020) |
| "HCQ is a potential cause of sudden cardiac death in COVID-19 patients." | 6.72 | COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. ( Agarwal, V; Gupta, L; Raza, HA; Tariq, J, 2021) |
| " The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart." | 5.91 | Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress. ( Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023) |
| "Hydroxychloroquine has been applied as one of the COVID-19 treatment strategies." | 5.72 | Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells. ( Chen, SL; Jhanji, V; Liang, JJ; Ma, D; Ng, TK; Xu, Y; Yao, Y; Yuan, XL, 2022) |
| "Hydroxychloroquine (HCQ) has been used during the coronavirus disease 2019 (COVID-19) pandemic because of its reported anti-viral activity." | 5.72 | Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. ( Al Maimouni, HM; Al-Najjar, AH; Alajra, RK; Alali, AS; Alanazi, DS; Albadi, MA; Albarqi, HA; Alghanim, NS; Alkahtani, SA; Alqahtani, F; Alqhtani, H; Alsaweed, OS; Alshabi, AM; Hazzazi, MA; Sabei, AA; Walbi, IA, 2022) |
| "The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumonia." | 5.72 | EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA. ( Berber, N; Cagasar, O; Delen, LA; Derya, S; Gok, A; Gok, Z; Kasapoglu, US; Tetik, B, 2022) |
| "There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak." | 5.62 | Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. ( Abreu, MM; Albuquerque, CP; Araújo, NC; Bacchiega, AB; Bianchi, DV; Bica, B; Bonfa, ED; Borba, EF; Brito, DCSE; de Souza, VA; Duarte, ÂLBP; Fernandes, PR; Ferreira, GA; Gomes, KWP; Guimarães, MP; Junior, LFR; Kakehasi, AM; Klumb, EM; Lacerda, MVG; Lanna, CCD; Marques, CDL; Monticielo, OA; Mota, LMH; Munhoz, GA; Paiva, ES; Pereira, HLA; Pileggi, GS; Pinheiro, MM; Provenza, JR; Reis, APMG; Reis-Neto, ET; Ribeiro, SLE; Sampaio, CSJC; Sampaio, VS; Santo, RCE; Sato, EI; Skare, T; Valim, V; Xavier, RM, 2021) |
| "Hydroxychloroquine has attracted attention in the treatment of COVID-19." | 5.62 | Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. ( Abusoglu, G; Abusoglu, S; Eryavuz Onmaz, D; Onmaz, M; Tezcan, D; Unlu, A; Yerlikaya, FH; Yilmaz, S, 2021) |
| "The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly." | 5.62 | Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. ( Akat, H; Laloglu, F; Orbak, Z, 2021) |
| "Also, no malignant ventricular arrhythmia or death secondary to ventricular arrhythmia occurred during the treatment in both groups." | 5.62 | Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. ( Bilge, AR; Çetin, N; Gündüz, R; Özdemir, İH; Özen, MB; Özlek, B, 2021) |
| "Chloroquine has been sporadically used in treating SARS-CoV-2 infection." | 5.56 | In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ( Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020) |
| "Hydroxychloroquine is an immunomodulatory drug that has been used to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis." | 5.56 | Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine ( Tomcsányi, J; Tomcsányi, K, 2020) |
| "Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties." | 5.56 | Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. ( Airó, P; Andreoli, L; Bertasi, V; Bianchi, M; Bottone, D; Brucato, A; Civelli, P; Colombo, E; Cotelli, MS; Damiolini, E; Franceschini, F; Furloni, R; Galbassini, G; Gatta, D; Ghirardelli, ML; Magri, R; Malamani, P; Mendeni, M; Miclini, M; Molinari, S; Morotti, A; Piantoni, S; Richini, D; Salada, L; Scarsi, M; Tincani, A; Turla, M; Vender, A, 2020) |
| " Some studies have shown that COVID-19 combined with diabetes is an independent risk factor for death or other adverse outcomes." | 5.56 | Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. ( Fu, X; Liu, Y; Xie, C, 2020) |
| "The pregnancy is still ongoing without any visible sequelae on the foetus so far." | 5.56 | COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report. ( Calès, P; Delaroche, L; Descamps, P; Dieli-Crimi, R; Guerin, A; Lamazou, F; Letouzey, V; Octernaud, S; Oger, P; Place, V, 2020) |
| "severe distinctive cutaneous drug reaction, generalized pustular figurate erythema, closely linked with hydroxychloroquine (HCQ), has been documented." | 5.22 | Generalized Pustular Figurate Erythema in Patients with COVID-19 Treated with Hydroxychloroquine: A Systematic Review. ( Al Muqarrab, F; Almohssen, AA; Schwartz, RA, 2022) |
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| " In the absence of evidence-based proven prophylactic or therapeutic options, chloroquine/hydroxychloroquine (CQ/HCQ) patented as first line choice in COVID- 19 treatment, which raised concerns about drug poisoning, especially ocular toxicity." | 5.05 | Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? ( Ahur, MH; Bagheri, M; Eidizadeh, M; Rashe, Z, 2020) |
| "On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning." | 5.05 | Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. ( Alhatali, B; Berling, I; Ghannoum, M; Gosselin, S; Hoffman, RS; King, JD; Lavergne, V; Nolin, TD; Roberts, DM; Shepherd, G; Wilson, G, 2020) |
| "Hydroxychloroquine (HCQ) is used in the treatment of inflammatory rheumatic diseases and is considered a safe drug." | 4.31 | Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study. ( Costa, L; Macedo, F; Madureira, P; Martins Carvalho, M; Pinheiro, FO; Seabra Rato, M, 2023) |
| "This study confirms the efficacy of patch tests in patients with delayed hypersensitivity reactions to hydroxychloroquine." | 4.31 | [Multiform exudative erythema caused by hydroxychloroquine, diagnosed by epicutaneous tests: A case report]. ( Castro-Jiménez, A; Florido López, F; Gratacós-Gómez, AR, 2023) |
| " We describe using the electronic PharmaCheck system to screen high-risk situations of adverse drug events (ADEs), particularly targeting prescriptions of lopinavir/ritonavir (LPVr) and hydroxychloroquine (HCQ) in the presence of contraindications or prescriptions outside institutional guidelines." | 4.31 | Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. ( Bonnabry, P; Eggimann, F; Grauser, D; Grosgurin, O; Guignard, B; Reny, JL; Samer, C; Skalafouris, C; Stirnemann, J, 2023) |
| " Late gadolinium enhancement (LGE) imaging was evaluated for myocarditis." | 4.12 | COVID-19 myocarditis cardiac magnetic resonance findings in symptomatic patients. ( Altay, S, 2022) |
| "Hydroxychloroquine is generally considered safe in pregnancy for the treatment of rheumatic conditions, but studies have been too small to evaluate teratogenicity." | 4.02 | Hydroxychloroquine early in pregnancy and risk of birth defects. ( Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Straub, L; Zhu, Y, 2021) |
| "To compare the incidence of COVID-19 in Spanish patients with autoimmune rheumatic diseases treated with and without hydroxychloroquine." | 4.02 | Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. ( Corma, A; González-Moreno, P; González-Serna, A; Macho, M; Macías, J; Martínez, M; Morillo-Verdugo, R; Pérez-Venegas, JJ; Pineda, JA; Pinilla, A; Real, LM; Sánchez-García, E, 2021) |
| "To ascertain if the use of hydroxychloroquine(HCQ)/cloroquine(CLQ) and other conventional DMARDs (cDMARDs) and rheumatic diseases per se may be associated with COVID-19-related risk of hospitalization and mortality." | 4.02 | Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. ( Atzeni, F; Baracco, S; Belleudi, V; Crisafulli, S; Ferroni, E; Gini, R; Giorgi Rossi, P; Kirchmayer, U; Kurotschka, PK; Leoni, O; Ludergnani, M; Mancuso, P; Massari, M; Salvarani, C; Spila Alegiani, S; Trifirò, G, 2021) |
| " This document attempts to provide reasonable guidance for the use of antimicrobials which have uncertain benefit but may increase risk of QT interval prolongation and ventricular proarrhythmia, notably, chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir." | 3.96 | Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. ( Alqarawi, W; Healey, JS; Krahn, AD; Laksman, Z; MacIntyre, CJ; Roberts, JD; Sapp, JL; Steinberg, C; Tadros, R, 2020) |
| "Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2." | 3.96 | Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. ( Al-Kofahi, M; Boulware, DR; Jaber, MM; Jacobson, P; Kandaswamy, R; Matas, A; Nicol, MR; Rajasingham, R; Young, JH, 2020) |
| "A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%." | 3.96 | Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin. ( Bartoletti, M; Viale, P, 2020) |
| "The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy." | 3.96 | Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. ( Houston, T; Pati, S, 2020) |
| "There is limited data regarding the electrophysiological abnormalities and arrhythmias in children with COVID-19, including those associated with treatment using potentially proarrhythmic hydroxychloroquine (HCQ) and azithromycin (AZN)." | 3.96 | Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval. ( Blaufox, AD; Friedman, RA; Ganigara, M; Mitchell, E; Samuel, S; Schleien, C; Sharma, C, 2020) |
| "Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment." | 3.96 | Concentration-dependent mortality of chloroquine in overdose. ( Baud, FJ; Clemessy, JL; Hoglund, RM; Megarbane, B; Tarning, J; Watson, JA; White, NJ, 2020) |
| " During the hospitalization, she experienced unexpected sinus bradycardia with prolonged QTc, which was thought to be closely related to the short-term use of hydroxychloroquine (HCQ), an old drug used to treat malaria and autoimmune diseases, but now used against COVID-19." | 3.96 | Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19. ( Chen, H; Kang, Y; Ran, Q; Wang, B; Wang, H; Wei, J; Yang, Y; Zhao, X, 2020) |
| "The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin therapy." | 3.96 | Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era. ( Chang, D; Epstein, LM; Fishbein, J; Gabriels, J; Mountantonakis, SE; Qiu, M; Saleh, M, 2020) |
| " Four weeks prior, she had been initiated on hydroxychloroquine for a presumed diagnosis of cutaneous sarcoidosis." | 3.96 | Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report. ( Ackerman, L; Brahmbhatt, S; Coleman, I; Ruiz, G, 2020) |
| " We report a case of coronavirus disease 2019 (COVID-19) pneumonia in a patient under hydroxychloroquine (HCQ) treatment for rheumatoid arthritis." | 3.96 | COVID-19 Pneumonia during Hydroxychloroquine Treatment of Rheumatoid Arthritis. ( Demirbilek, SG; Dogan, E; Gürsoy, C; Tapan, ÖO; Togan, T, 2020) |
| "Hydroxychloroquine is being used for COVID-19 symptoms and in clinical trials, but can cause a toxic myopathy that leads to muscle weakness." | 3.96 | Challenges in diagnosing hydroxychloroquine myopathy during the COVID-19 pandemic. ( Chan, RC; Pamphlett, R; Wang, MX, 2020) |
| "Data regarding knowledge and attitude about COVID-19, the prevalence of acceptance of hydroxychloroquine prophylaxis and anxiety amidst COVID-19 pandemic among health care students/professionals in India is scarce." | 3.96 | Knowledge, anxiety and the use of hydroxychloroquine prophylaxis among health care students and professionals regarding COVID-19 pandemic. ( Bansal, AS; Garg, A; Jindal, V; Kaur, G; Kaur, P; Kaur, T; Mittal, S; Sati, HC, 2020) |
| " The HCQ dosing included a loading dose of HCQ 600 mg twice on day 1, followed by 400 mg daily for 29 days." | 3.30 | Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ). ( Anderson, DJ; Anstrom, KJ; Cahuayme-Zuniga, L; Castro, M; Cohen, LW; Collins, SP; Currier, J; Fraulo, E; Friedland, A; Garg, J; George, A; Hernandez, AF; Lakshmi, S; Milstone, A; Mulder, H; Naggie, S; O'Brien, EC; Olson, RE; Rothman, RL; Shenkman, E; Shostak, J; Turner, KB; Woods, CW, 2023) |
| " A phase II selection design will be used to determine hdroxychloroquine's efficacy, using prednisolone dosage and Birmingham Vasculitis Activity Score as a measure of disease activity." | 3.30 | The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. ( Arnold, L; Beckley-Hoelscher, N; Cape, A; Casian, A; D'Cruz, D; Douiri, A; Galloway, J; Jayne, D; John, S; Kim, S; Learoyd, AE; Luqmani, R; Morton, N; Nel, L; Reid, F; Sangle, S; Shivapatham, D, 2023) |
| "Hydroxychloroquine/Chloroquine was identified as an early potential therapeutic candidate drawing on evidence from reports of both in vitro and in vivo testing." | 3.30 | Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger. ( Grais, RF; Guindo, O; Kabore, Y; Moussa, SH; Schilling, WHK; Vatrinet, R, 2023) |
| "The safety assessment revealed no adverse effect of the drugs in COVID-19 patients after treatment." | 3.30 | Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria. ( Abiola, A; Adeyemo, WL; Agabi, OP; Aina, OO; Ajibaye, O; Akase, IE; Akinbode, GO; Akintan, PE; Amoo, OS; Audu, RA; Bamidele, TA; Bode, C; Busari, AA; David, AN; Esezobor, C; Ezechi, OC; Fadipe, B; Ima-Edomwonyi, E; James, AB; Musa, AZ; Nmadu, N; Okoyenta, CO; Okwuraiwe, AP; Oladele, DA; Olakiigbe, AK; Olopade, OB; Osuolale, KA; Otrofanowei, E; Raheem, TY; Salako, AO; Salako, BL; Tade, T, 2023) |
| "7%) participants experienced adverse event (AE) level II or lower (total AEs n = 589), similar rates in all randomized groups (P = ." | 3.11 | Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study. ( Kilgore, P; Maksimowicz-McKinnon, K; Marshall-Nightengale, L; McKinnon, JE; O'Neill, WW; Pabla, P; Saval, M; Szandzik, E; Wang, DD; Zervos, M, 2022) |
| " Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice." | 3.01 | How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. ( Brosnan, M; Fairley, JL; Mack, HG; Nikpour, M; Pellegrini, M; Saracino, AM; Wicks, IP, 2023) |
| "Hydroxychloroquine (HCQ) is a widely used antimalarial and anti-inflammatory drug and its hyperglycemia-controlling effect in diabetic patients is also under investigation." | 3.01 | Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19? ( Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L, 2023) |
| "Hydroxychloroquine (HCQ) was initially promoted as an oral therapy for early treatment of coronavirus disease 2019 (COVID-19)." | 3.01 | Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials. ( Alexander, J; Baeten, JM; Boulware, DR; Carter, D; Chew, KW; Corbacho, M; Curran, M; Daar, E; Dunne, M; Hess, R; Hill, MD; Hughes, M; Hullsiek, KH; Johnston, C; Kremsner, P; Lee, TC; McDonald, EG; Metz, L; Mitjà, O; Reis, G; Richer, L; Sarwar, A; Schwartz, I; Smith, D; Spivak, AM; Webb, B; Wohl, D, 2023) |
| "The high prevalence and incidence of coronavirus disease 2019 (COVID-19) underline the importance of searching for a safe and effective treatment for the disease, and drug repositioning is the most rational strategy to achieve this goal in a short period of time." | 3.01 | Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. ( Giarolla, J; Parise-Filho, R; Polli, MC; Vassiliades, SV; Vaz, ES, 2023) |
| " From 25 March 2020 to 29 May 2020, the Inserm Safety Department had to manage 585 Serious Adverse Events (SAEs) initial notification and 396 follow-up reports." | 3.01 | Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial. ( Ader, F; Andrejak, C; Belhadi, D; Burdet, C; Costagliola, D; DeChanet, A; Delmas, C; Diallo, A; Dumousseaux, M; Espérou, H; Ferrane, A; Fougerou-Leurent, C; Greil, R; Hites, M; Le Mestre, S; Mentre, F; Mercier, N; Paiva, JA; Peiffer-Smadja, N; Poissy, J; Saillard, J; Staub, T; Tacconelli, E; Yazdanpanah, Y, 2023) |
| "The primary efficacy outcome was PCR-confirmed SARS-CoV-2 infection and the primary safety outcome was incidence of adverse events." | 3.01 | Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. ( Abella, BS; Amaravadi, R; Anstrom, KJ; Boulware, DR; Friedland, A; Halabi, S; Hernandez, AF; Hong, H; Hu, M; McKinnon, JE; Naggie, S; Portillo-Vázquez, AM; Rajasingham, R; Rojas-Serrano, J; Woods, CW, 2023) |
| " Secondary outcomes included adverse effects, treatment discontinuation, presence of SARS-CoV-2 antibodies, frequency of QTc prolongation, and clinical outcomes for SARS-CoV-2-positive participants." | 3.01 | Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. ( Abella, BS; Amaravadi, RK; Babushok, DV; Biney, BT; Frank, I; Gill, S; Gimotty, PA; Hensley, SE; Huang, AC; Hyman, MC; Jolkovsky, EL; Maillard, I; Milone, MC; Nasta, SD; Uspal, JE; Vogl, DT; Walsh, JC; Wiletyo, EP, 2021) |
| "To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia." | 3.01 | Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. ( Al Bahrani, M; Al Balushi, Z; Al Barwani, U; Al Lawati, A; Al Naabi, H; Al Salmi, I; Al Sharji, M; Al-Zakwani, I; Ambusaidi, Z; Khamis, F; Pandak, N, 2021) |
| "Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies." | 3.01 | Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. ( Baeten, JM; Barnabas, RV; Bershteyn, A; Brown, ER; Celum, C; Chu, HY; Deming, M; Greninger, AL; Haugen, HS; Hoffman, R; Huang, ML; Jerome, KR; Johnston, C; Kidoguchi, L; Kissinger, PJ; Kottkamp, A; Krows, ML; Landovitz, RJ; Laufer, MK; Luk, A; Morrison, S; Neuzil, KM; Paasche-Orlow, MK; Paolino, K; Schaafsma, TT; Stankiewicz Karita, HC; Thomas, KK; Thorpe, LE; Wald, A; Wener, M, 2021) |
| "Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking." | 3.01 | A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. ( Admella, P; Alemany, A; Ara, J; Argimon, JM; Ballana, E; Bertran, L; Cañadas, P; Casabona, J; Clotet, B; Clua, M; Corbacho-Monné, M; Cuatrecasas, G; Elizalde-Torrent, A; Fabregat, R; Farré, M; Flores-Mateo, G; Forcada, A; Gavilán, S; González-Beiras, C; Laporte, P; López, C; Mitjà, J; Mitjà, O; Muntada, E; Nadal, N; Narejos, S; Nieto, A; Peñafiel, J; Pérez, CA; Prat, N; Puig, J; Quiñones, C; Ramírez-Viaplana, F; Reyes-Urueña, J; Riera-Martí, N; Riveira-Muñoz, E; Ruiz, L; Sanz, S; Sarquella, M; Sentís, A; Sierra, A; Suñer, C; Tebé, C; Tobias, A; Ubals, M; Vall-Mayans, M; Velasco, C; Vivanco-Hidalgo, RM; Zamora, J, 2021) |
| " The secondary outcome is the incidence of serious adverse drug reactions within seven days of randomization." | 3.01 | The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. ( Dadvand, H; Davoodian, P; Fathalipour, M; Ghazizadeh, S; Hassaniazad, M; Hassanipour, S; Hosseini, FS; Kahoori, S; Malektojari, A; Nikoofal-Sahlabadi, S; Nikpoor, AR; Sepandi, M, 2021) |
| "Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients." | 3.01 | Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. ( Dabbous, HM; Ebeid, FFS; El Assal, G; El-Sayed, MH; Elgaafary, M; Elghazaly, H; Fawzy, E; Hassany, SM; Riad, AR; Sherief, AF; TagelDin, MA, 2021) |
| " In this study; it was aimed to investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation." | 3.01 | Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. ( Avcı, İY; Çetinkaya, RA; Demirtürk, N; Eser, F; Güner, R; Karalezli, A; Kayaaslan, B; Konya, P; Okumuş, N; Orhan, S; Savaşçı, Ü; Şaylan, B; Taşkın, G; Yamanel, L; Yılmaz, G, 2021) |
| " Additionally, the data collected remotely in this trial will provide critical information regarding the accuracy of teleresearch in lupus, the impact of adherence to hydroxychloroquine on disease activity and a pharmacokinetic analysis to inform paediatric-specific dosing of hydroxychloroquine." | 3.01 | Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial. ( Balevic, SJ; Cohen-Wolkowiez, M; Cunningham, A; Hornik, CP; Randell, RL; Schanberg, LE; Singler, L, 2021) |
| "Hydroxychloroquine was the most common drug type, combined with azithromycin (n = 27, 20%) or alone (n = 22, 16%), followed by IL-6 inhibitors (n = 36, 27%) and corticosteroids (n = 26, 20%)." | 3.01 | Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. ( Ben Ami, R; Goldvaser, H; Shepshelovich, D; Tau, N; Yahav, D, 2021) |
| "Hydroxychloroquine has shown potential to block viral replication of SARS-CoV-2 in some in vitro studies." | 3.01 | Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. ( Freitas-Santos, RS; Levi, JE; Lopes, ATA; Pierrotti, LC; Rodrigues, C; Santos, SR; Senerchia, AA; Siciliano, RF, 2021) |
| " The dosage is two tablets daily, once a week for one to three months (based on the duration of the Coronavirus epidemic in Tehran)." | 2.94 | Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial. ( Dehpour, AR; Mohammad Jafari, R; Moini, A; Pirjani, R; Sepidarkish, M; Shizarpour, A; Soori, T, 2020) |
| "Nitazoxanide has powerful antiviral effects and proven efficacy against a range of viruses including SARS and MERS." | 2.94 | Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial. ( Calderón, JM; Padmanabhan, S; Zerón, HM, 2020) |
| "1) To determine whether chemoprophylaxis with daily versus weekly dosing of hydroxychloroquine increases time to contracting COVID-19 disease in frontline healthcare workers." | 2.94 | ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial. ( Cheriyan, J; Fisk, M; Hubsch, A; Kaloyirou, F; McEniery, CM; Miles, K; Smith, J; Wilkinson, IB, 2020) |
| " Secondary outcomes were duration of hospital stay, length of intensive care unit stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects, and complications during the hospitalization." | 2.94 | A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. ( Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS, 2020) |
| "Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2." | 2.94 | PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial. ( Altini, M; Bertoni, L; Biggeri, A; Colamartini, A; Donati, C; Falcini, F; Gaggeri, R; Galardi, F; Grossi, V; Lilli, C; Martinelli, G; Masini, C; Massa, I; Monti, M; Nanni, O; Scarpi, E; Serra, P; Vertogen, B; Vespignani, R; Viale, P; Zingaretti, C, 2020) |
| "To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical trials." | 2.94 | Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. ( Ader, F, 2020) |
| " Secondary Endpoints: All causes mortality, Frequency of respiratory progression (defined as SPO2≤ 94% on room air or PaO2/FiO2 <300mmHg and requirement for supplemental oxygen or more advanced ventilator support), time to defervescence (in those with fever at enrolment), frequency of requirement for supplemental oxygen or non-invasive ventilation, frequency of requirement for mechanical ventilation, frequency of serious adverse events as per DAIDS table grade of severity." | 2.94 | Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. ( Bahurupi, YA; Bandyopadhyay, A; Chikara, G; Moirangthem, B; Panda, PK; Saha, S; Singh, BC, 2020) |
| "Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days." | 2.94 | A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. ( Berdal, JE; Dalgard, O; Eskesen, A; Jonassen, CM; Kvale, D; Lyngbakken, MN; Olsen, IC; Omland, T; Rangberg, A; Rueegg, CS; Røsjø, H, 2020) |
| " This primary evidence may concern preventing potential or unintentional effects resulting from Drug-drug interaction, Improving patient quality of life." | 2.82 | Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases. ( B, S; Kalala, KP; P A, A; Pm, A; S K, SR; Sabarathinam, S, 2022) |
| "Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic." | 2.82 | COVID-19 in patients with systemic lupus erythematosus: A systematic review. ( Chen, HL; Du, L; Fu, XL; Jin, XH; Qian, Y; Shi, YQ; Wu, H; Yu, HR, 2022) |
| "Hydroxychloroquine was not significantly associated with mortality: pooled relative risk (RR) 0." | 2.72 | Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. ( Fiolet, T; Guihur, A; Mahamat-Saleh, Y; Mulot, M; Peiffer-Smadja, N; Rebeaud, ME, 2021) |
| "Hydroxychloroquine (HCQ) has been implicated in antiviral activity in vitro against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)." | 2.72 | Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. ( Han, X; He, M; Li, Y; Shi, J; Zang, Y, 2021) |
| "Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern." | 2.72 | Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. ( Bassetti, M; Ferro Desideri, L; Nicolò, M; Traverso, CE, 2021) |
| "Hydroxychloroquine (HCQ) was not associated with the incidence of death (risk ratio (RR)=1." | 2.72 | Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. ( Deng, M; Hu, Y; Jiang, L; Luo, X; Pan, L; Wang, M; Wu, T; Xia, Z; Yang, X; You, Y; Zuo, Z, 2021) |
| " The choice of (typically subtherapeutic) dosing regimens, influenced partly by "QT-phobia," varied widely and seems anecdotal without any pharmacologically reliable supporting clinical evidence." | 2.72 | Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. ( Shah, RR, 2021) |
| "The incidence and nature of arrhythmias in the setting of COVID-19 were poorly documented across studies." | 2.72 | Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. ( Amarasekera, AT; Kayes, T; Kodsi, M; MacIntyre, CR; Malaty, M; Tan, TC, 2021) |
| " Twenty-four (47%) RCTs did not describe plans to assess safety outcomes; when assessed, safety outcomes were determined in generic terms of total, severe or serious adverse events." | 2.72 | Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic. ( Junqueira, DR; Rowe, BH, 2021) |
| "Hydroxychloroquine has been used for rheumatological diseases for many decades and is considered a safe medication." | 2.72 | Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. ( Basir, MB; Fram, G; Kang, G; Khan, A; Malette, K; McKinnon, JE; O'Neill, WW; So, K; Villablanca, P; Wang, DD; Zervos, M, 2021) |
| "Treatment with hydroxychloroquine (HCQ) and lopinavir/ritonavir did not show any mortality benefit in either the RECOVERY or World Health Organization (WHO) Solidarity trials." | 2.72 | Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. ( Emani, SR; Emani, VR; Goswami, S; Nandanoor, D; Reddy, NK; Reddy, R, 2021) |
| " The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4." | 2.72 | Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials. ( Grossi, A; Maraolo, AE, 2021) |
| " Recommendations were made based on available data, consideration of pharmacokinetic properties (including variability), the dosing and anticipated treatment duration of each regimen in COVID-19 and known toxicities." | 2.72 | Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. ( Back, D; Boyle, A; Burger, D; Davidson, K; El-Sherif, O; Gibbons, S; Khoo, S; Marra, F; Marzolini, C; Siccardi, M; Smolders, EJ; Sommerville, AJ, 2021) |
| "HCQ is a potential cause of sudden cardiac death in COVID-19 patients." | 2.72 | COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. ( Agarwal, V; Gupta, L; Raza, HA; Tariq, J, 2021) |
| " Therefore, it is important to know the utility and safety of the medications to avoid untoward adverse effects on pregnant women and fetuses." | 2.72 | Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. ( Bhagat, R; Manchanda, K; Singh, H; Singh, J; Tiwana, IK, 2021) |
| "Hydroxychloroquine has in vitro antiviral properties against SARS CoV-2." | 2.72 | The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. ( Alhazzani, W; Alshamsi, F; Carayannopoulos, L; Chagla, Z; Chaudhuri, D; Dearness, K; Lewis, K, 2021) |
| "The whole world is battling through coronavirus disease 2019 (COVID-19) which is a fatal pandemic." | 2.72 | Antiviral treatment in COVID-19: which is the most promising?-a narrative review. ( Wen, S; Xu, X; Yadav, AK; Yu, L, 2021) |
| "Favipiravir has resulted in a higher viral clearance than remdesivir." | 2.72 | A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. ( Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M, 2021) |
| "Since the emergence of coronavirus disease 2019 (COVID-19), neurological symptoms, syndromes, and complications associated with this multi-organ viral infection have been reported and the various aspects of neurological involvement are increasingly uncovered." | 2.72 | Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. ( Aghavali, S; Babadi, M; Daraie, P; Emamikhah, M; Jalili, M; Mehrabani, M; Mohaghegh, F; Pouranian, M; Rohani, M; Zaribafian, M, 2021) |
| "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posed a serious public health concern and started a race against time for researchers to discover an effective and safe therapy for coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2." | 2.72 | The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. ( Abou-Sleymane, G; Al Faraj, A; Badro, DA; Daou, F; Khanafer, N; Tobaiqy, M, 2021) |
| " However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence." | 2.72 | COVID-19 and Its Implications for Thrombosis and Anticoagulation. ( Berkman, SA; Tapson, VF, 2021) |
| "Hydroxychloroquine was not beneficial at any disease stage, one RCT with anakinra was negative, one RCT with baricitinib+remdesivir was positive, and individual trials on some other compounds provided interesting, although preliminary, results." | 2.72 | Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. ( Alunno, A; De Marco, G; Emmel, J; Machado, PM; Mariette, X; Mason, L; McGonagle, DG; Najm, A, 2021) |
| " Nine trials compared HCQ with standard care (7779 participants), and one compared HCQ with placebo (491 participants); dosing schedules varied." | 2.72 | Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. ( Chaplin, M; Fletcher, T; Kredo, T; Ryan, H; Singh, B, 2021) |
| " HCQ group has a significantly higher rate of any adverse event (RR 2." | 2.72 | Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. ( Jain, S; Kumar, J; Meena, J; Yadav, A, 2021) |
| " The scientific community is studying and testing numerous compounds that can be effective and safe for treating people with covid-19." | 2.72 | [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.] ( Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021) |
| "Hydroxychloroquine was the most frequently used drug for COVID-19." | 2.72 | Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review. ( Kumar Gupta, A; Meena, JP; Mohan Pandey, R; Ram Jat, K; Seth, R; Tanwar, P, 2021) |
| " Authors discretion is to conduct more studies considering the optimal dosing regimen and pharmacokinetics assessment." | 2.72 | Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. ( Joshi, G; Poduri, R; Thakur, S, 2021) |
| "Hydroxychloroquine (HCQ) has been one of the most widely tested drugs for SARS CoV2 on account of its antiviral properties." | 2.72 | The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis. ( Ahuja, B; Biswas, PS; Choudhuri, AH; Duggal, S, 2021) |
| " The studies of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement, and rate of serious adverse events." | 2.72 | The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. ( Gao, Z; Gong, H; Li, J; Li, W; Qiu, R; Wang, C; Weng, Y; Xiao, Y; Zhang, Q, 2021) |
| "Retractions of coronavirus disease 2019 (COVID-19) papers in high impact journals, such as The Lancet and the New England Journal of Medicine, have been panned as major scientific fraud in public media." | 2.72 | Reimagining the peer-review system for translational health science journals. ( Smith, EM, 2021) |
| " However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19." | 2.72 | Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. ( Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D, 2021) |
| "Lopinavir/ritonavir has no more treatment effects than other therapeutic agents used herein in COVID-19 patients." | 2.72 | Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis. ( Amani, B; Hashemi, P; Khanijahani, A, 2021) |
| "The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world." | 2.66 | The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. ( Li, T; Liu, Z; Qin, Y; Wang, J; Wang, Q; Yan, X; Zeng, X; Zhang, F; Zhang, S; Zhang, W; Zhang, X; Zhao, Y, 2020) |
| "The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world." | 2.66 | Potential therapeutic agents against COVID-19: What we know so far. ( Chang, YL; Chen, MY; Lee, WS; Lu, CC, 2020) |
| "Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended." | 2.66 | Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. ( Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM, 2020) |
| "Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician." | 2.66 | Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. ( Bergan, S; Elens, L; Hesselink, DA; Langman, LJ; Lemaitre, F; Moes, DJAR; Molinaro, M; Venkataramanan, R, 2020) |
| "As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy." | 2.66 | Current status of potential therapeutic candidates for the COVID-19 crisis. ( Hashimoto, K; Xie, B; Zhang, J, 2020) |
| "COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time." | 2.66 | COVID-19 in Children: Clinical Approach and Management. ( Dhochak, N; Kabra, SK; Lodha, R; Sankar, J, 2020) |
| "The full impact of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on the field of hematopoietic cell transplantation (HCT) is unknown." | 2.66 | Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. ( Ardura, M; Auletta, JJ; Dandoy, C; Hartley, D; Jaglowski, S; Lehmann, L, 2020) |
| "The disease caused by SARS-CoV-2, coronavirus disease 2019 (COVID-19), presents flu-like symptoms which can become serious in high-risk individuals." | 2.66 | COVID-19 diagnosis and management: a comprehensive review. ( Agrò, FE; Bruno, F; Costa, F; Del Buono, R; Pascarella, G; Piliego, C; Scarlata, S; Strumia, A, 2020) |
| " However, some of these medications have potential cardiac adverse effects." | 2.66 | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020) |
| "Hydroxychloroquine has been demonstrated to limit the replication of SARS-CoV-2 virus in vitro." | 2.66 | Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. ( Akram, J; Klonoff, DC; Meo, SA, 2020) |
| "Hydroxychloroquine (HCQ) is an old medication for malaria." | 2.66 | Smooth or Risky Revisit of an Old Malaria Drug for COVID-19? ( Pahan, K; Pahan, P, 2020) |
| " The review elaborates the mechanism of action, safety (side effects, adverse effects, toxicity) and details of clinical trials for chloroquine and hydroxychloroquine to benefit the clinicians, medicinal chemist, pharmacologist actively involved in controlling the pandemic and to provide therapeutics for the treatment of COVID-19 infection." | 2.66 | A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. ( Masand, N; Patil, VM; Singhal, S, 2020) |
| " Although in some recent studies a clinical improvement in COVID-19 patients has been observed, the clinical efficacy of CQ and HCQ in COVID-19 has yet to be proven with randomized controlled studies, many of which are currently ongoing, also considering pharmacokinetics, optimal dosing regimen, therapeutic level and duration of treatment and taking into account patients with different severity degrees of disease." | 2.66 | The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? ( Biasiotto, G; Magro, P; Quiros Roldan, E; Zanella, I, 2020) |
| "The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020." | 2.66 | Cardiovascular manifestation and treatment in COVID-19. ( Chien, CS; Chou, SJ; Kuo, MJ; Leu, HB; Lin, TY; Su, YB; Yang, YP, 2020) |
| "Due to the coronavirus disease 2019 (COVID-19) pandemic, a wide number of compounds are under scrutiny regarding their antiviral activity, one of them being hydroxychloroquine." | 2.66 | [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic]. ( Baranchuk, A; Barbosa, M; Márquez, MF; Mendoza, I; Nuñez, E; Sosa Liprandi, Á; Wyss Quintana, FS; Zaidel, EJ, 2020) |
| "Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge." | 2.66 | Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. ( Ader, F; Guedj, J; Lê, MP; Mentré, F; Néant, N; Peiffer-Smadja, N; Peytavin, G; Yazdanpanah, Y, 2020) |
| "Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system." | 2.66 | A current review of COVID-19 for the cardiovascular specialist. ( Bohula, EA; Lang, JP; Morrow, DA; Moura, FA; Siddiqi, HK; Wang, X, 2020) |
| "The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic." | 2.66 | Approach to Acute Cardiovascular Complications in COVID-19 Infection. ( Abdalla, M; Anstey, DE; Fried, JA; Givens, RC; Karmpaliotis, D; Kirtane, AJ; Kodali, SK; Kumaraiah, D; Leon, MB; Masoumi, A; Rabbani, LE; Ranard, LS; Sayer, G; Schwartz, A; Takeda, K; Uriel, N, 2020) |
| "Hydroxychloroquine has been promoted for its use in treatment of COVID-19 patients based on in-vitro evidences." | 2.66 | Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review. ( Barvaliya, M; Bhalla, HL; Kevadiya, BD; Patel, PB; Patel, TK, 2020) |
| "This paper reviews the mechanism, clinical efficacy and safety, pharmacokinetic characteristics, exposureresponse relationship and precautions and drug interactions of HCQ, and summarizes dosage recommendations for HCQ sulfate." | 2.66 | Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19. ( Cui, C; En, VSJ; Li, H; Li, X; Liu, D; Tu, S; Yao, X, 2020) |
| "The emergence of coronavirus disease 2019 (COVID-19) is caused by the 2019 novel coronavirus (2019-nCoV)." | 2.66 | Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. ( Al-Bari, AA, 2020) |
| "A 61-year old patient with ankylosing spondylitis who was on secukinumab therapy for 5 months admitted with newly onset fever and gastrointestinal complaints." | 2.66 | Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. ( Coskun Benlidayi, I; Guzel, R; Kurtaran, B; Tirasci, E, 2020) |
| "Since coronavirus disease 2019 (COVID-19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 randomised controlled trials." | 2.66 | Clinical trials for the prevention and treatment of COVID-19: current state of play. ( Davis, JS; Denholm, JT; Ferreira, D; Tong, SY, 2020) |
| " Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions." | 2.66 | Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. ( Barin-Le Guellec, C; Elens, L; Grégoire, M; Lagarce, L; Lemaitre, F; Polard, E; Saint-Salvi, B; Solas, C; Sommet, A; Tod, M, 2020) |
| "The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic." | 2.66 | Clinical management of COVID-19. ( Abraham, OC; John, R; Karthik, R; Manesh, A; Varghese, GM, 2020) |
| "The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019." | 2.66 | Is hydroxychloroquine beneficial for COVID-19 patients? ( Agostinis, P; Carafoli, E; Li, X; Melino, G; Rabson, A; Shi, Y; Sun, E; Wang, Y, 2020) |
| "With the emergence of coronavirus disease 2019 (COVID-19) in late December 2019, many clinical studies on a group of the pre-existing medications have been conducted to treat this disease." | 2.66 | Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. ( Dizaye, K; Marouf, BH, 2020) |
| " Long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders." | 2.66 | Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. ( Khuroo, MS, 2020) |
| "After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy." | 2.66 | Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. ( Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N, 2020) |
| "This can be independent from coronavirus disease 2019 gravity." | 2.66 | Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case report. ( Calmy, A; Coen, M; Lolachi, S; Morin, S; Samii, K; Serratrice, J, 2020) |
| "This is also true with regards to cancer treatments and screening." | 2.66 | Cancer therapy and treatments during COVID-19 era. ( Abrams, SL; Akula, SM; Basecke, J; Blalock, WL; Candido, S; Cervello, M; Cocco, L; Follo, MY; Lerpiriyapong, K; Libra, M; Martelli, AM; McCubrey, JA; Montalto, G; Notarbartolo, M; Piazzi, M; Ramazzotti, G; Ratti, S; Steelman, LS, 2020) |
| "Gitelman's syndrome (GS) and Bartter's syndrome (BS) are rare inherited salt-losing tubulopathies whose variations in genotype do not correlate well with either clinical course or electrolyte requirements." | 2.66 | Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype? ( Calò, LA; Davis, PA, 2020) |
| "The development of our RMA approach was motivated by a currently relevant clinical question: is ocular toxicity and vision compromise a side effect of hydroxychloroquine therapy? At the time of designing this study, hydroxychloroquine was a leading candidate in the treatment of coronavirus disease (COVID-19)." | 2.66 | Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine. ( Chow, T; Martin, NA; Michelson, M; Minton, S; Ross, M; Tee Qiao Ying, A, 2020) |
| " Surges in volume of patients requiring mechanical ventilation coupled with prolonged ventilator days and the high sedative dosing requirements observed quickly led to the depletion of "just-in-time" inventories typically maintained by institutions." | 2.66 | It Takes a Village…: Contending With Drug Shortages During Disasters. ( Barletta, JF; Burry, LD; Christian, MD; Dichter, J; Erstad, BL; Geiling, J; Kanji, S; Maves, RC; Williamson, D, 2020) |
| " There is a high incidence of myocardial injury and arrhythmia reported with COVID-19 infection, and as such this population may be more susceptible to this side-effect profile." | 2.66 | Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified? ( Ahmad, M; Conway, S; Kirresh, A; Little, C; Stevenson, A; White, L, 2020) |
| "We treated two patients with severe respiratory failure due to coronavirus disease 2019 (COVID-19)." | 2.66 | High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19. ( Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T, 2020) |
| "Hydroxychloroquine can cause retinopathy and rarely cardiac and auditory toxicity, retinopathy being dose and time dependent." | 2.66 | Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. ( Gasparyan, AY; Misra, DP; Zimba, O, 2020) |
| "Hydroxychloroquine (HCQ) has shown some promise in the management of COVID 19." | 2.66 | Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. ( Garg, VK; Gautam, CS; Gautam, SS; Singh, H, 2020) |
| "During the current coronavirus disease 2019 (COVID-19) pandemic, in vivo and in vitro investigations of these drugs have demonstrated potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)." | 2.66 | Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals. ( Ahmad, A; Alotaibi, NH; Butt, MH; Khan, YH; Mallhi, TH; Misbah, S, 2020) |
| "The rapid spread of the new Coronavirus Disease 2019 (COVID-19) has actually become the newest challenge for the healthcare system since, to date, there is not an effective treatment." | 2.66 | Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. ( De Tommasi, N; Faraone, I; Labanca, F; Milella, L; Ponticelli, M, 2020) |
| " This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD." | 2.66 | Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. ( Govil, A; Luckett, K; Miller-Handley, H, 2020) |
| "Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed." | 2.66 | The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. ( Lee, H; Won, JH, 2020) |
| " The outcomes of interest were mortality, progression to severe disease (severe pneumonia, admission to intensive care unit (ICU), and/or mechanical ventilation), viral clearance rate, QT prolongation, fatal cardiac complications, and noncardiac serious adverse events." | 2.66 | Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. ( An, MH; Hwang, TH; Kim, MS; Kim, WJ, 2020) |
| "Soon after the outset of the Coronavirus Disease 2019 (COVID-19) pandemic (March-April 2020), formulations of the old antimalarial racemic drug hydroxychloroquine (HCQ) sulfate were authorized by the U." | 2.44 | Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2. ( Agranat, I; Aiello, F; Balzano, F; D'Acquarica, I; Mazzoccanti, G; Uccello Barretta, G, 2024) |
| " A disproportionality analysis was performed to determine adverse effects reported in non-Covid and Covid patients." | 1.91 | Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions. ( Fernandez-Araque, AM; Martín Arias, LH; Merino Kolly, N; Sainz-Gil, M; Sanz Fadrique, R; Velasco-González, V; Verde Rello, Z, 2023) |
| "6% probability of improving 6-month survival across varying hydrocortisone dosing strategies." | 1.91 | Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. ( Al-Beidh, F; Angus, DC; Annane, D; Arabi, YM; Beane, A; Berry, LR; Berry, S; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Burrell, A; Buxton, M; Buzgau, A; Charles, WN; Cove, M; Derde, LPG; Detry, MA; Estcourt, LJ; Fagbodun, EO; Fitzgerald, M; Girard, TD; Goligher, EC; Goossens, H; Gordon, AC; Green, C; Haniffa, R; Higgins, AM; Hills, T; Horvat, CM; Huang, DT; Ichihara, N; Lamontagne, F; Lawler, PR; Lewis, RJ; Lorenzi, E; Marshall, JC; McArthur, CJ; McAuley, DF; McGlothlin, A; McGuinness, SP; McQuilten, Z; McVerry, BJ; Mouncey, PR; Murthy, S; Neal, MD; Nichol, AD; Parke, RL; Parker, JC; Parry-Billings, K; Peters, SEC; Reyes, LF; Rowan, KM; Saito, H; Santos, MS; Saunders, CT; Serpa-Neto, A; Seymour, CW; Shankar-Hari, M; Stronach, LM; Turgeon, AF; Turner, AM; van Bentum-Puijk, W; van de Veerdonk, FL; Webb, SA; Zarychanski, R, 2023) |
| " Based on its structure and riboswitch dose-response activity we identified that the antagonist activity of hydroxychloroquine is consistent with it being a conformationally restricted analog of the polyamine spermidine." | 1.91 | 4-Aminoquinolines modulate RNA structure and function: Pharmacophore implications of a conformationally restricted polyamine. ( Aldhumani, AH; Boesger, H; Herath, D; Hines, JV; Hossain, MI; Myers, M, 2023) |
| "Recently, due to the coronavirus disease 2019 (COVID-19) pandemic, much concern has been raised about patients with chronic diseases who may become more susceptible to the disease." | 1.91 | The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report. ( Abdolahi, N; Aghaie, M; Damirchi, M; Hassani, M; Roshandel, G; Sedighi, S; Tavassoli, S, 2023) |
| " There is a large degree of uncertainty in HCQ pharmacokinetic (PK) parameters which complicates dose selection when investigating its use in new disease states." | 1.91 | A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations. ( Agrawal, V; Arnold, SLM; Barnabas, RV; Bershteyn, A; Chhonker, YS; Heller, KB; Johnston, C; Krows, ML; Landovitz, R; Laufer, M; Leingang, H; Murry, DJ; Paasche-Orlow, M; Stankiewicz Karita, HC; Steinbronn, C; Stewart, J; Wener, M, 2023) |
| "Hydroxychloroquine is an FDA-approved drug for the treatment of COVID-19." | 1.91 | Validated spectrofluorimetric assay of two co-administered drug mixtures containing hydroxychloroquine with either moxifloxacin or ofloxacin as a drug regimen for hospital-acquired pneumonia in patients with COVID-19. ( Eid, M; El-Sayed, A; Elmansi, HM; Shalan, S, 2023) |
| " The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart." | 1.91 | Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress. ( Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023) |
| "Although the evidence of treatment for coronavirus disease 2019 (COVID-19) changed rapidly, little is known about the patterns of potential pharmacological treatment during the early period of the COVID-19 pandemic in Korea and the risk factors for ineffective prescription." | 1.91 | Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea. ( Bang, J; Choe, PG; Jeong, J; Kim, NJ; Kim, S; Lee, E; Lee, SY; Oh, J; Oh, MD; Shin, SD, 2023) |
| "Physiologically based pharmacokinetic (PBPK) models were used to study the change in the pharmacokinetics (PK) of drugs repurposed for COVID-19 in geriatric patients, different race groups, organ impairment and drug-drug interactions (DDIs) risks." | 1.91 | Pharmacokinetics under the COVID-19 storm. ( El-Khateeb, E; Giovino, N; Jamei, M; Jo, H; Lythgoe, E; Pilla Reddy, V; Rastomi-Hodjegan, A; Sharma, S; Tang, W, 2023) |
| "Favipiravir was the most prescribed drug (74." | 1.72 | The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. ( Atli, Z; Aydin, T; Balkan, II; Fresko, I; Hamuryudan, V; Hatemi, G; Melikoglu, M; Ozcifci, G; Ozguler, Y; Oztas, M; Seyahi, E; Tabak, F; Ugurlu, S, 2022) |
| "Hydroxychloroquine has been applied as one of the COVID-19 treatment strategies." | 1.72 | Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells. ( Chen, SL; Jhanji, V; Liang, JJ; Ma, D; Ng, TK; Xu, Y; Yao, Y; Yuan, XL, 2022) |
| " A physiologically based pharmacokinetic model with detailed respiratory physiology was used to predict regional airway exposure and optimize dosing regimens." | 1.72 | Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections. ( Calvino-Martin, F; Hoeng, J; Kolli, AR, 2022) |
| "Hydroxychloroquine (HCQ) was proposed as possible therapy for shortening the duration of COVID-19, but soon after this, it was discarded." | 1.72 | Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2. ( Mishra, A; Rathore, AS, 2022) |
| "Hydroxychloroquine (HCQ) has been used during the coronavirus disease 2019 (COVID-19) pandemic because of its reported anti-viral activity." | 1.72 | Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. ( Al Maimouni, HM; Al-Najjar, AH; Alajra, RK; Alali, AS; Alanazi, DS; Albadi, MA; Albarqi, HA; Alghanim, NS; Alkahtani, SA; Alqahtani, F; Alqhtani, H; Alsaweed, OS; Alshabi, AM; Hazzazi, MA; Sabei, AA; Walbi, IA, 2022) |
| "Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous reactions characterized by necrosis and detachment of the epidermis." | 1.72 | The role of treatment with plasma exchange therapy in two pediatric toxic epidermal necrolysis cases related to COVID-19. ( Akin, T; Can, YY; Durak, C; Gursoy, F; Kilic, A; Sahin, C; Sahin, E; Varol, F, 2022) |
| " Hydroxychloroquine (HCQ)-associated cardiovascular adverse events (CVAEs) have been increasingly reported." | 1.72 | An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19. ( Li, Y; Luo, M; Wu, B; Wu, F, 2022) |
| "In this study we investigated COVID-19 vaccination-related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs)." | 1.72 | COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies. ( Agarwal, V; Aggarwal, R; Cavagna, L; Chatterjee, T; Chinoy, H; Day, J; Distler, O; Gaur, PS; Gheita, T; Gil-Vila, A; Gonzalez, RA; Gracia-Ramos, AE; Gupta, L; Joshi, M; Kardes, S; Kim, M; Knitza, J; Kuwana, M; Lilleker, JB; Makol, A; Milchert, M; Nikiphorou, E; Nune, A; Parodis, I; Ravichandran, N; Saavedra, MA; Salim, B; Selva-O'Callaghan, A; Sen, P; Shinjo, SK; Tan, AL; Velikova, T; Ziade, N, 2022) |
| "COVID-19 and preeclampsia (preE) share the ANG-II mediated endothelial dysfunction, resulting from a significant dysregulation of RAS and an imbalanced proportion of anti-angiogenic and pro-angiogenic soluble plasmatic factors." | 1.72 | Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection. ( Acampora, E; Arienti, F; Carrer, A; Casati, M; Gambacorti-Passerini, C; Giardini, V; Ornaghi, S; Vasarri, MV; Vergani, P, 2022) |
| "Hydroxychloroquine was also the most interacting drug in the C risk category (n=101, 29." | 1.72 | Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients. ( Erarslan, S; Kilit, TP; Onbaşı, K; Özyiğit, F, 2022) |
| "The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumonia." | 1.72 | EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA. ( Berber, N; Cagasar, O; Delen, LA; Derya, S; Gok, A; Gok, Z; Kasapoglu, US; Tetik, B, 2022) |
| "There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak." | 1.62 | Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. ( Abreu, MM; Albuquerque, CP; Araújo, NC; Bacchiega, AB; Bianchi, DV; Bica, B; Bonfa, ED; Borba, EF; Brito, DCSE; de Souza, VA; Duarte, ÂLBP; Fernandes, PR; Ferreira, GA; Gomes, KWP; Guimarães, MP; Junior, LFR; Kakehasi, AM; Klumb, EM; Lacerda, MVG; Lanna, CCD; Marques, CDL; Monticielo, OA; Mota, LMH; Munhoz, GA; Paiva, ES; Pereira, HLA; Pileggi, GS; Pinheiro, MM; Provenza, JR; Reis, APMG; Reis-Neto, ET; Ribeiro, SLE; Sampaio, CSJC; Sampaio, VS; Santo, RCE; Sato, EI; Skare, T; Valim, V; Xavier, RM, 2021) |
| "Hydroxychloroquine has attracted attention in the treatment of COVID-19." | 1.62 | Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. ( Abusoglu, G; Abusoglu, S; Eryavuz Onmaz, D; Onmaz, M; Tezcan, D; Unlu, A; Yerlikaya, FH; Yilmaz, S, 2021) |
| " However, the hypothesis that Hydroxychloroquine might have a beneficial role in subgroups of patients at low risk and/or when used at low dosage (≤ 400 mg/day) deserves to be tested in large, well designed randomised clinical trials." | 1.62 | Hydroxichloroquine for COVID-19 infection: Do we have a final word after one year? ( Costanzo, S; de Gaetano, G; Di Castelnuovo, A; Gialluisi, A; Iacoviello, L, 2021) |
| " Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used." | 1.62 | Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. ( Brown, JD; Cicali, B; Henriksen, CH; Sarayani, A, 2021) |
| "Treatment with lopinavir-ritonavir (adjusted hazard ratio [aHR], 2." | 1.62 | Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. ( Choe, JY; Hong, HL; Jung, CY; Kim, EJ; Kim, JW; Kim, KC; Kwon, HH, 2021) |
| "Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action." | 1.62 | Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. ( Catrinoiu, D; Ceriello, A; Rizzo, M; Stoian, AP, 2021) |
| "To assess clinical outcomes and adverse drug events in patients hospitalised with COVID-19 treated with off-label hydroxychloroquine (HCQ) and azithromycin (Az)." | 1.62 | Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. ( Bannan, C; Bergin, C; Carr, B; Clarke, S; Coghlan, M; Doyle, C; Kelly, M; Melanophy, G; Merry, C; Moriarty, M; O'Connor, R; O'Riordan, R; Relihan, E; Townsend, L, 2021) |
| "Over the last few months, coronavirus disease 2019 (COVID-19) pandemic caused by the novel coronavirus SARS-CoV-2 has posed a serious threat to public health on a global scale." | 1.62 | Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. ( Alejandro, R; Caprio, M; Fabbri, A; Infante, M; Ricordi, C, 2021) |
| "To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study." | 1.62 | Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. ( Bajocchi, G; Boiardi, L; Carrozzi, G; Cassone, G; Costantini, M; Croci, S; Galli, E; Giorgi Rossi, P; Gradellini, F; Mancuso, P; Marata, AM; Muratore, F; Pandolfi, P; Pipitone, N; Reta, M; Salvarani, C; Sandri, G; Viani, N, 2021) |
| "Dyspnea is associated with a more severe infection." | 1.62 | Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain. ( Algaba, A; Bermejo, F; Bonillo, D; Garza, D; Guerra, I; Jiménez, L; Mar Aller, M; Molina Esteban, LM, 2021) |
| " The use of such drugs may be considered as safe relating to arrhythmic risk in the treatment of COVID-19 patients as no arrhythmic fatalities occurred." | 1.62 | Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen. ( Bernardini, A; Castelvecchio, S; Ciconte, G; de Innocentiis, C; Giannelli, L; Locati, ET; Marrocco-Trischitta, MM; Mecarocci, V; Menicanti, L; Negro, G; Pappone, C; Rondine, R; Santini, F; Vicedomini, G; Viva, T; Witkowska, E, 2021) |
| " Food and Drug Administration Adverse Events Reporting System (FAERS) database to assess HCQ/CQ-associated cardiovascular adverse events (CVAEs) in pre-COVID-19 reports." | 1.62 | Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. ( Bomze, D; Boursi, B; Dankner, R; Goldman, A; Hod, H; Maor, E; Meirson, T, 2021) |
| "Hydroxychloroquine (HQ) has been used for the treatment of novel coronavirus disease (COVID-19) even though there is no clear evidence for its effectiveness yet." | 1.62 | Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases. ( Dincer, MT; Karaca, C; Murt, A, 2021) |
| "To compare survival of individuals with coronavirus disease 2019 (COVID-19) treated in hospitals that either did or did not routinely treat patients with hydroxychloroquine or chloroquine." | 1.62 | Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. ( Beudel, M; Bomers, MK; Buijs, J; Collard, D; De Haan, LR; De Ruijter, W; Douma, RA; Elbers, PW; Goorhuis, A; Gritters van den Oever, NC; Knarren, LG; Moeniralam, HS; Mostard, RL; Peters, EJ; Quanjel, MJ; Reidinga, AC; Renckens, R; Sikkens, JJ; Van Assen, S; Van Den Bergh, JP; Vlasveld, IN, 2021) |
| "The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly." | 1.62 | Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. ( Akat, H; Laloglu, F; Orbak, Z, 2021) |
| "Treatment with hydroxychloroquine and azithromycin was associated with lower mortality in these patients." | 1.62 | COVID-19 mortality risk factors in older people in a long-term care center. ( Anglada, M; Boix, M; Castillo, J; Curbelo, Y; Garibaldi, P; Gonzalez, E; Heras, E; Llovera, R; Llull, P; Mendoza, O; Miralles, JC; Piqué, JM; Valero, O, 2021) |
| "Also, no malignant ventricular arrhythmia or death secondary to ventricular arrhythmia occurred during the treatment in both groups." | 1.62 | Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. ( Bilge, AR; Çetin, N; Gündüz, R; Özdemir, İH; Özen, MB; Özlek, B, 2021) |
| "Hiccups are involuntary diaphragmatic muscle contractions with early glottis closure terminating inspiration." | 1.62 | Persistent hiccup: A rare presentation of COVID-19. ( Bakheet, N; El-Shazly, M; Fouad, R; Hussin, W; Kassem, AM, 2021) |
| " Lower white blood cell count and lactate dehydrogenase at the time of drug administration as well as shorter time from supplemental oxygen initiation to dosing were significantly associated with clinical improvement in the univariate analysis." | 1.62 | Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study. ( Daniel, NM; Hilden, P; Raja, K; Smoke, SM, 2021) |
| " The objective of this study was to analyse the potential drug-drug interactions (pDDIs) derived from the medication used in COVID-19 patients in the first pandemic wave and to evaluate the real consequences of such interactions in clinical practice." | 1.62 | Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments. ( Álvarez-Payero, M; Casanova-Martínez, C; Castro-Núñez, I; García-Beloso, N; González-Costas, S; Inaraja-Bobo, MT; Leboreiro-Enríquez, B; López-López, A; Lorenzo-Lorenzo, K; Martínez-López-de-Castro, N; Martínez-Reglero, C; Otero-Millán, L; Paradela-Carreiro, A; Pérez-Landeiro, A; Piñeiro-Corrales, G; Regueira-Arcay, AM; Robles-Torres, D; Samartín-Ucha, M; Vázquez-López, C; Yaiza Romero-Ventosa, E, 2021) |
| "KEY POINTS: • COVID19 studies show higher mortality in men, due to severe pneumonia and ARDS, indicating possible X-linked mediated differences • G6PD, the most common X-linked enzymopathy, highly prevalent in African Americans and Italians, maintains redox homeostasis." | 1.62 | G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg? ( Ensor, J; Iyer, SP; Padmanabhan, S; Pingali, SR; Sahay, S; Youssef, G; Youssef, JG; Zahiruddin, F; Zu, Y, 2021) |
| "Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial." | 1.62 | Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. ( Ahn, J; Bednarz, U; Calise, AG; Cunningham, FJ; Eagan, MP; Goldberg, SL; Goy, AH; Hansen, E; Ip, A; La Capra, S; Marafelias, M; Mastrokyriakos, P; Mojares, GE; Pecora, AL; Ponce, MG; Prasad, R; Pulver, BL; Ruocco, D; Sawczuk, IS; Sinclaire, BA; Sweeney, RL; Underwood, JP; Walker, DM; Zhou, Y; Ziontz, KL, 2021) |
| "Hydroxychloroquine is an antimalarial drug that has been prescribed for the treatment of patients with COVID-19 infection." | 1.62 | Estimation of the uncertainty of values assigned to calibration materials prepared in-house: An example for hydroxychloroquine calibrators in blood-hemolysate-based matrix. ( Canalias, F; Rigo-Bonnin, R, 2021) |
| "There are limited data on Coronavirus disease 2019 (COVID-19) in solid organ transplant patients, especially in heart transplant recipients, with only a few case reports and case series described so far." | 1.62 | Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients. ( Amabili, P; Ancion, A; Defraigne, JO; Delbouille, MH; Delvenne, P; Detry, O; Hayette, MP; Hougrand, O; Lancellotti, P; Lavigne, JP; Maquoi, I; Minga Lowampa, E; Morimont, P; Ponte, C; Sakalihasan, N; Senard, M; Szecel, D; Tchana-Sato, V; Tridetti, J; Van Den Bulck, M, 2021) |
| "Moreover, PTSD in patients with COVID-19 is not associated with the increased risk of CFS." | 1.62 | Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. ( Aalipour, MA; Darazam, IA; Ghorbani, F; Pakdaman, H; Ramezani, M; Sagharichi, M; Simani, L, 2021) |
| "The Surviving Sepsis Campaign Coronavirus Disease 2019 panel has expanded to include 43 experts from 14 countries; all panel members completed an electronic conflict-of-interest disclosure form." | 1.62 | Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. ( Al Duhailib, Z; Alhazzani, W; Alshahrani, M; Alshamsi, F; Antonelli, M; Arabi, YM; Arrington, A; Bala, M; Belley-Cote, E; Bridges, E; Burry, L; Cecconi, M; Chertow, DS; Citerio, G; Coopersmith, CM; Crowther, M; Derde, L; Du, B; Dzierba, A; Evans, L; Fan, E; Greco, M; Hammond, N; Hayden, FG; Kaplan, LJ; Kesecioglu, J; Kleinpell, R; Koh, Y; Levy, MM; Lewis, K; Loeb, M; Machado, F; Mammen, MJ; Martin, GS; McGeer, A; Memish, ZA; Mermel, L; Møller, MH; Nainan Myatra, S; Ng Gong, M; Oczkowski, S; Ostermann, M; Prescott, HC; Rhodes, A; Szczeklik, W; Wunsch, H; Zarychanski, R, 2021) |
| "Hydroxychloroquine use was significantly associated with increased risks of ICU admission and intubation in patients with mild, moderate, and severe symptoms of COVID-19." | 1.62 | Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection. ( Awad, N; Chak, A; Fulman, M; Schiller, DS, 2021) |
| "Pregnancy seems to increase the risk of thrombotic thrombocytopenic purpura (TTP) relapses and make the TTP more severe in any of the pregnancy trimesters, or even during the postpartum period." | 1.62 | A COVID-19 pregnant patient with thrombotic thrombocytopenic purpura: a case report. ( Afrooz, N; Aminimoghaddam, S; Mahmoudzadeh, F; Motaghi Nejad, O; Nasiri, S, 2021) |
| "To describe the characteristics of adverse event reporting in the United States (US) Food and Drug Administration Adverse Event Reporting System (FAERS) before and after the outbreak of the COVID-19 pandemic." | 1.62 | Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system. ( Dörks, M; Douros, A; Hoffmann, F; Jobski, K, 2021) |
| "The effects of treatment of coronavirus disease 2019 (COVID-19) with a triple combination composed of hydroxychloroquine, an an-tiviral, and an antibiotic on electrocardiography (ECG) parameters in patients with mild-to-moderate symptoms are not wholly understood." | 1.62 | Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019. ( Akbulut Koyuncu, İM; Kızıltunç, E; Uğurlu Ilgın, B, 2021) |
| " The goal of this study was to predict the potential of 25 small molecule drugs in clinical trials for COVID-19 to cause clinically relevant drug-drug interactions (DDIs), which could lead to potential adverse drug reactions (ADRs) with the use of concomitant medications." | 1.62 | Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. ( Enogieru, OJ; Giacomini, KM; Jakobsen, S; Koleske, ML; Kosti, I; Oskotsky, T; Rödin, M; Sirota, M; Vora, B; Yee, SW; Zou, L, 2021) |
| "Hydroxychloroquine has recently received attention as a treatment for COVID-19." | 1.62 | Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice. ( Choi, BJ; Chung, WY; Jung, YJ; Kim, TY; Koo, Y; Lim, HS; Park, B; Park, JE; Yoon, D, 2021) |
| "The novel coronavirus disease 2019 (COVID-19) is a respiratory infection that has received much attention due to its rapid expansion." | 1.62 | COVID-19 progression in kidney transplant recipients: a single-center case series. ( Keykhaei, M; Mansouri, ES; Rahimzadeh, H; Razeghi, E; Zivari, E, 2021) |
| "Hydroxychloroquine (HCQ) was one of the earliest drugs to be recommended for tackling the COVID-19 threat leading to its widespread usage." | 1.62 | System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. ( Bhalla, A; Gupta, A; Gupta, PC; Kakkar, AK; Kumar-M, P; Kumari, D; Malhotra, S; Mohindra, R; Pandey, AK; Patil, A; Shafiq, N; Suri, V, 2021) |
| "Mucormycosis is an invasive fungal infection (IFI) due to several species of saprophytic fungi, occurring in patients with underlying co-morbidities (including organ transplantation)." | 1.62 | Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature. ( Berlinrut, I; Chang, KM; Khatri, A; Wallach, F, 2021) |
| "Disease progression was observed in 18 patients (16." | 1.62 | Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital. ( Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W, 2021) |
| "The kinetics of IgG antibodies after coronavirus disease 2019 (COVID-19) remain poorly understood." | 1.62 | Determinants of IgG antibodies kinetics after severe and critical COVID-19. ( Aboubakar, F; Belkhir, L; De Greef, J; Gerard, L; Pilette, C; Pothen, L; Scohy, A; Yildiz, H; Yombi, JC; Zech, F, 2021) |
| "Hydroxychloroquine and CP were each associated with higher risk for death, although CP was without titers and was administered at a median of five days from admission." | 1.62 | Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis. ( Cardasis, J; Cook, B; Jafri, F; Kim, H; La, L; Raff, J; Sammartino, D, 2021) |
| "Hypertension and chronic obstructive pulmonary disease were also related to admission." | 1.62 | Biological markers and follow-up after discharge home of patients with COVID-19 pneumonia. ( Andrés, EM; Domínguez García, MJ; Gutiérrez Gabriel, S; Moreno García, N; Pérez Mañas, G; Silvan Domínguez, M, 2021) |
| "The famotidine nonuser group was derived from the same source population with no history of exposure to any drug with famotidine as an active ingredient before or on the day of admission." | 1.62 | Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients. ( Berlin, JA; Fortin, SP; Ryan, P; Shoaibi, A; Weinstein, R, 2021) |
| "Three patients had concurrent positive coronavirus disease 2019 (COVID-19) infection, and the other 2 patients had contact with suspected COVID-19 positive patients." | 1.62 | Multi-system inflammatory syndrome in children during the coronavirus disease 2019 in Saudi Arabia: Clinical perspective from a case series. ( Al-Qahtani, SM; AlHelali, I; Ali, AS; Asseri, AA; Awadalla, NJ; Elbastawisi, E; Shati, AA, 2021) |
| "Primary aim was to assess prevalence and severity of potential and real drug-drug interactions (DDIs) among therapies for COVID-19 and concomitant medications in hospitalized patients with confirmed SARS-CoV-2 infection." | 1.62 | Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. ( Cantudo-Cuenca, MD; Contreras-Macías, E; Fernández-Fuertes, M; Gutiérrez-Pizarraya, A; Lao-Domínguez, FA; Macías, J; Morillo-Verdugo, R; Pineda, JA; Pinilla-Fernández, A; Rincón, P, 2021) |
| "Hydroxychloroquine (HCQ) was proposed as an early therapy for coronavirus disease 2019 (COVID-19) after in vitro studies indicated possible benefit." | 1.62 | Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. ( Begoli, E; Cho, K; Costa, L; Danciu, I; Freiberg, MS; Gagnon, DR; Gaziano, JM; Gerlovin, H; Goethert, ID; Ho, YL; Jacobson, DA; Justice, AC; King, JT; Kurgansky, KE; Linares, FA; Muralidhar, S; Posner, DC; Ramoni, RB; Rentsch, CT; Tate, JP; Tourassi, G, 2021) |
| "We assessed the impact of the coronavirus disease 2019 (COVID-19) epidemic in India on the consumption of antibiotics and hydroxychloroquine (HCQ) in the private sector in 2020 compared to the expected level of use had the epidemic not occurred." | 1.62 | Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. ( Batomen, B; Gandra, S; Kotwani, A; Pai, M; Sulis, G, 2021) |
| "Chloroquine has been sporadically used in treating SARS-CoV-2 infection." | 1.56 | In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ( Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020) |
| "The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release." | 1.56 | COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. ( Dai, SM; Tong, Q; Zhou, D, 2020) |
| "Hydroxychloroquine (HCQ) was used by 78." | 1.56 | Early impact of COVID-19 on transplant center practices and policies in the United States. ( Avery, RK; Boyarsky, BJ; Durand, CM; Garonzik-Wang, JM; Getsin, SN; Jackson, KR; Kernodle, AB; Massie, AB; Po-Yu Chiang, T; Segev, DL; Van Pilsum Rasmussen, SE; Werbel, WA, 2020) |
| "Novel coronavirus disease 2019 is rapidly spreading throughout the New York metropolitan area since its first reported case on March 1, 2020." | 1.56 | Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. ( Andrikopoulou, M; Aubey, J; Baptiste, C; Bernstein, K; Breslin, N; D'Alton, ME; Friedman, AM; Fuchs, K; Goffman, D; Gyamfi-Bannerman, C; Landau, R; Martinez, R; Miller, R; Moroz, L; Mourad, M; Purisch, S; Ring, L; Rupley, D; Sheen, JJ; Simpson, LL; Sutton, D; Wapner, R; Zork, N, 2020) |
| "In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world." | 1.56 | Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs. ( Choi, SW; Kang, S; Lee, S; Lim, DH; Seo, KW; So, MW; Song, J, 2020) |
| "Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases." | 1.56 | Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19. ( Antunes de Brito, CA; Falcão, MB; Filgueiras Filho, NM; Pamplona de Góes Cavalcanti, L, 2020) |
| "Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria." | 1.56 | Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. ( Abena, PM; Adejumo, P; Bottieau, E; Decloedt, EH; Eholie, SP; Kallay, O; Mills, EJ; Muyembe TamFum, JJ; Nachega, JB; Sam-Agudu, NA; Seydi, M; Suleman, F; Zumla, A, 2020) |
| "Hydroxychloroquine is an immunomodulatory drug that has been used to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis." | 1.56 | Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine ( Tomcsányi, J; Tomcsányi, K, 2020) |
| "The fatality of novel coronavirus disease 2019 (COVID-19) is precipitously increased in patients with underlying comorbidities or elderly people." | 1.56 | Two distinct cases with COVID-19 in kidney transplant recipients. ( Han, S; Hyun, M; Jin, K; Kim, HA; Kim, Y; Kwon, O; Lee, JY; Paek, JH; Park, WY, 2020) |
| "The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies." | 1.56 | Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. ( Ni, Y; Sun, X; Zhang, M, 2020) |
| "Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China." | 1.56 | Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report. ( Bhatt, PJ; Narayanan, N; Radbel, J, 2020) |
| "In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxychloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported." | 1.56 | Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. ( Beldner, S; Chang, D; Chinitz, J; Epstein, LM; Gabriels, J; Goldner, B; Ismail, H; John, R; Mahmood, E; Makker, P; Mansoor, A; Mitra, R; Mountantonakis, S; Saleh, M; Skipitaris, N; Soo Kim, B; Willner, J, 2020) |
| "The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease." | 1.56 | Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. ( Avdic, E; Avery, R; Cameron, AM; Chen, PH; Fine, DM; Garibaldi, B; Garneau, WM; Gurakar, A; Hammami, MB; Jain, T; Kim, AK; Liu, G; Monroy Trujillo, JM; Niranjan-Azadi, A; Petty, B; Shah, P; Strout, S, 2020) |
| "Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs." | 1.56 | Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. ( Baldwin, M; Barr, RG; Geleris, J; Hripcsak, G; Kubin, C; Labella, A; Manson, DK; Platt, J; Schluger, NW; Sobieszczyk, ME; Sun, Y; Zucker, J, 2020) |
| "Hydroxychloroquine was used in 79 patients (80." | 1.56 | Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study. ( Ahn, JH; Choi, EY; Chung, JH; Hong, KS; Jang, JG; Jin, HJ; Lee, KH; Lee, W; Shin, KC, 2020) |
| "Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation)." | 1.56 | Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. ( Blog, DS; DeHovitz, J; Dufort, EM; Holtgrave, DR; Hutton, B; Kirkwood, J; Kumar, J; Muse, A; Rosenberg, ES; Tesoriero, J; Udo, T; Weinberg, P; Wilberschied, LA; Zucker, HA, 2020) |
| " Concretely, this relates to (a) the inconsistent individual bioavailability of these drugs at the alveolar target cells, depending on intestinal resorption, hepatic first-pass metabolism and accumulation in liver, spleen and lung, and (b) the need for a relatively high concentration of 1-5 µM at the alveolar surface." | 1.56 | Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. ( Hefner, G; Klimke, A; Voss, U; Will, B, 2020) |
| "Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies." | 1.56 | Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. ( Audureau, E; Carlier, N; Chabrol, A; Costedoat-Chalumeau, N; Crickx, E; Dang, J; de Lastours, V; Fois, E; Gallien, S; Godeau, B; Guillaud, C; Kerneis, S; Khellaf, M; Legendre, P; Lepeule, R; Lescure, FX; Mahévas, M; Matignon, M; Ménager, P; Michel, M; Morbieu, C; Mouthon, L; Ourghanlian, C; Paule, R; Pawlotsky, JM; Perrodeau, E; Ravaud, P; Roche, N; Roumier, M; Schlemmer, F; Schoindre, Y; Szwebel, TA; Terrier, B; Tran, VT, 2020) |
| "One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure." | 1.56 | Early experience with remdesivir in SARS-CoV-2 pneumonia. ( Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R, 2020) |
| "It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments." | 1.56 | COVID-19 and lung cancer: risks, mechanisms and treatment interactions. ( Addeo, A; Friedlaender, A; Obeid, M, 2020) |
| "There is little information about Coronavirus Disease 2019 (COVID-19) in children with underlying chronic renal pathologies." | 1.56 | SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. ( Alvárez, O; Lumbreras, J; Madrid, A; Melgosa, M; Nieto, F; Parada, E; Perez-Beltrán, V, 2020) |
| "Eight percent died and 5% developed acute respiratory distress syndrome (ARDS)." | 1.56 | A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. ( Affatato, S; Alberici, F; Boni, F; Bossini, N; Bove, S; Bracchi, M; Calcaterra, E; Camerini, C; Cortinovis, R; Costantino, EM; Delbarba, E; Econimo, L; Gaggia, P; Gaggiotti, M; Gallico, A; Guerini, A; Lucca, B; Maffei, C; Manenti, C; Movilli, E; Mucchetti, A; Pezzini, E; Piarulli, P; Pola, A; Possenti, S; Saccà, C; Scolari, F; Terlizzi, V; Valerio, F; Zappa, M; Zubani, R, 2020) |
| " However, polypharmacy predisposes patients to increased risk of drug-drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials." | 1.56 | COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. ( Battu, K; Bonnici, A; Downar, J; Elsayed, S; Huang, A; Lee, TC; McDonald, EG; Papillon-Ferland, L; Pilote, L; Porter, S; Rashidi, B; Ross, SB; Tamblyn, R; Wilson, MG; Wu, PE, 2020) |
| "We reviewed 1069 medical records of all cancer patients admitted at Oncology department between Feb 1 and April 7, 2020." | 1.56 | Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. ( Gullón, P; Lara, MÁ; López-Alfonso, A; Martín Marino, A; Obispo, B; Pangua, C; Pérez-Pérez, M; Rogado, J; Serrano-Montero, G, 2020) |
| "Data on patients with COVID-19 who have cancer are lacking." | 1.56 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. ( Bakouny, Z; Batist, G; Bekaii-Saab, T; Bilen, MA; Bouganim, N; Castellano, D; Choueiri, TK; de Lima Lopes, G; Del Prete, SA; Desai, A; Doroshow, DB; Egan, PC; Elkrief, A; Farmakiotis, D; Flora, D; Galsky, MD; Glover, MJ; Griffiths, EA; Grivas, P; Gulati, AP; Gupta, S; Hafez, N; Halfdanarson, TR; Hawley, JE; Hsu, CY; Hsu, E; Kasi, A; Khaki, AR; Kuderer, NM; Larroya, MB; Lemmon, CA; Lewis, C; Logan, B; Lyman, GH; Masters, T; McKay, RR; Mesa, RA; Mishra, S; Morgans, AK; Mulcahy, MF; Painter, CA; Panagiotou, OA; Peddi, P; Pennell, NA; Peters, S; Reynolds, K; Rini, BI; Rivera, DR; Rosen, LR; Rosovsky, R; Rubinstein, SM; Salazar, M; Schmidt, A; Shah, DP; Shah, SA; Shaya, JA; Shete, S; Shyr, Y; Steinharter, J; Stockerl-Goldstein, KE; Subbiah, S; Thompson, MA; Vinh, DC; Warner, JL; Wehbe, FH; Weissmann, LB; Wu, JT; Wulff-Burchfield, E; Xie, Z; Yeh, A; Yu, PP; Zhou, AY; Zubiri, L, 2020) |
| "Hydroxychloroquine prophylaxis was initiated without electrocardiography by 80." | 1.56 | HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. ( Dey, T; Dhar, D; Khan, MA; Manjula, J; Mondal, MS; Nagaraja, BS; Pratik, K; Ramesh, KN; Rutul, SD; Saha, S; Sangeeth, TA; Singh, V, 2020) |
| "Hydroxychloroquine was recently promoted in patients infected with COVID-19 infection." | 1.56 | A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study. ( Montastruc, JL; Toutain, PL, 2020) |
| "Hydroxychloroquine (HCQ) has its own side effects, some of which are very serious like acute haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients." | 1.56 | A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. ( Clevenbergh, P; De Bels, D; Leemans, S; Mahadeb, B; Maillart, E; Salaouatchi, MT; Van Noten, H; Vandergraesen, T, 2020) |
| " Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine." | 1.56 | Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ( Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020) |
| "The worldwide incidence of coronavirus disease 2019 (COVID-19) infection is rapidly increasing, but there exists limited information on coronavirus disease 2019 in pregnancy." | 1.56 | Coronavirus disease 2019 in pregnancy: early lessons. ( Baptiste, C; Breslin, N; D'Alton, M; Fuchs, K; Goffman, D; Gyamfi-Bannerman, C; Miller, R, 2020) |
| " Although a number of different dosage regimens were assessed, the purpose of our study was not to provide recommendations for a dosing strategy, but to demonstrate the utility of a physiologically-based pharmacokinetic modeling approach to estimate lung concentrations." | 1.56 | Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling. ( Almond, LM; Ban Ke, A; Jones, HM; Pan, X; Rowland Yeo, K; Wesche, D; Zhang, M, 2020) |
| "Severe and potentially fatal deep cerebral thrombosis may complicate the initial clinical presentation of COVID-19." | 1.56 | Cerebral Venous Thrombosis Associated with COVID-19. ( Cavalcanti, DD; Dehkharghani, S; Jain, R; Lillemoe, K; Nelson, PK; Nossek, E; Radmanesh, A; Raz, E; Riina, HA; Shapiro, M; Torres, J; Yaghi, S, 2020) |
| "Hydroxychloroquine was administered in 11 patients, associated with lopinavir/ritonavir and interferon β in 2 cases each." | 1.56 | Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain. ( Aguado, JM; Calvo, J; Cambra, F; Caso, O; Fernández-Ruiz, M; Folgueira, MD; García-Sesma, A; Justo, I; Loinaz, C; Lumbreras, C; Manrique, A; Marcacuzco, A; Pérez-Jacoiste Asín, MA; San Juan, R, 2020) |
| "A treatment with lopinavir/ritonavir and hydroxychloroquine twice daily was started." | 1.56 | Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection. ( Bernasconi, E; Bertoli, R; Cerny, A; Ceschi, A; De Gottardi, A; Fratila, C; Gianella, P; Magenta, L; Majno-Hurst, P; Vanini, G, 2020) |
| "Hydroxychloroquine (HCQ) has been promoted as a potential treatment of coronavirus disease 2019 (COVID-19), but there are safety concerns." | 1.56 | Effects of hydroxychloroquine treatment on QT interval. ( Adabag, S; Bart, B; Hooks, M; Vardeny, O; Westanmo, A, 2020) |
| "Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7." | 1.56 | Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. ( Baettig, V; Bassetti, S; Battegay, M; Egli, A; Franzeck, F; Gebhard, CE; Geenen, J; Hirsch, HH; Hollinger, A; Khanna, N; Marzolini, C; Mueller, D; Osthoff, M; Sendi, P; Stader, F; Stoeckle, M; Tschudin-Sutter, S; Weisser, M, 2020) |
| "A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks." | 1.56 | Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. ( Cauda, R; Cingolani, A; Cipriani, MC; Fantoni, M; Gremese, E; Larosa, L; Liperoti, R; Montemurro, G; Murri, R; Pasciuto, G; Pirronti, T; Tummolo, AM, 2020) |
| "Hydroxychloroquine was prescribed in 79% of hospitalized patients." | 1.56 | Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. ( Aull, MJ; Craig-Schapiro, R; Dadhania, DM; Gingras, L; Hartono, C; Kapur, S; Kodiyanplakkal, RP; Lee, JB; Lee, JR; Lubetzky, M; Marku-Podvorica, J; Muthukumar, T; Saal, S; Salinas, T; Sultan, S; Suthanthiran, M, 2020) |
| "Axitinib (AXI) is a tyrosine kinase inhibitor, currently under investigation in an international phase II/III trial including thymic neuroendocrine tumors." | 1.56 | SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view. ( Fazio, N; Funicelli, L; Garcia-Carbonero, R; Gervaso, L; Laffi, A; Pellicori, S; Rubino, M; Spada, F; Zampino, G, 2020) |
| "Among 2,186 U." | 1.56 | Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. ( Arcobello, J; Bakouny, Z; Choueiri, TK; de Lima Lopes, G; Doroshow, DB; Egan, PC; Farmakiotis, D; Fecher, LA; Friese, CR; Galsky, MD; Goel, S; Grivas, P; Gupta, S; Halfdanarson, TR; Halmos, B; Hawley, JE; Hsu, CY; Khaki, AR; Kuderer, NM; Lee, BJ; Lemmon, CA; Lyman, GH; Mishra, S; Olszewski, AJ; Painter, CA; Panagiotou, OA; Pennell, NA; Peters, S; Puc, MM; Revankar, SG; Rini, BI; Rivera, DR; Rubinstein, SM; Schapira, L; Schmidt, A; Schwartz, GK; Shah, DP; Shah, SA; Shyr, Y; Thompson, MA; Warner, JL; Wu, JT; Xie, Z; Yeh, AC; Zhu, H, 2020) |
| "Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2, but clinical data supporting HCQ for coronavirus disease 2019 (COVID-19) are limited." | 1.56 | Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. ( Choi, JJ; Goyal, P; Gulick, RM; Kondo, M; Magleby, R; Maldarelli, GA; Pham, K; Rennert, H; Safford, MM; Satlin, MJ; Schenck, EJ; Westblade, LF, 2020) |
| "The evolving pandemic of Coronavirus Disease 2019 has posed a substantial health risk worldwide." | 1.56 | A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece. ( Argyraki, A; Boletis, I; Grigorakos, K; Lourida, P; Marinaki, S; Skalioti, C; Tsiakas, S, 2020) |
| "Key words: Coronavirus disease 2019 (COVID-19), Meningoencephalitis, Pneumonia." | 1.56 | A Case of 45-Year Man Who Succumbed to Coronavirus Disease 2019 (COVID-19). ( Khan, MA, 2020) |
| "Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties." | 1.56 | Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. ( Airó, P; Andreoli, L; Bertasi, V; Bianchi, M; Bottone, D; Brucato, A; Civelli, P; Colombo, E; Cotelli, MS; Damiolini, E; Franceschini, F; Furloni, R; Galbassini, G; Gatta, D; Ghirardelli, ML; Magri, R; Malamani, P; Mendeni, M; Miclini, M; Molinari, S; Morotti, A; Piantoni, S; Richini, D; Salada, L; Scarsi, M; Tincani, A; Turla, M; Vender, A, 2020) |
| "Among candidate drugs to treat coronavirus disease 2019 (COVID-19), the combination of hydroxychloroquine (HCQ) and azithromycin (AZ) has received intense worldwide attention." | 1.56 | Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection. ( Azria, P; Borie, MF; Guillerm, JC; Hubert, S; Lorc'h, EL; Mahé, A; Ménage, E; Mourad, JJ; Voisin, O, 2020) |
| "Hydroxychloroquine was prescribed as an antiviral in 90% of cases, both as monotherapy (11." | 1.56 | Inpatient Care during the COVID-19 Pandemic: A Survey of Italian Physicians. ( Attanasi, M; Caronni, A; Centanni, S; Chiarelli, F; Cimino, MM; Cipolla, G; Di Pillo, S; Faverio, P; Pasini, S; Pellegrino, GM; Sferrazza Papa, GF, 2020) |
| "Hilar lymphadenopathy is a rarely reported finding in the setting of COVID-19." | 1.56 | Hilar lymphadenopathy, a novel finding in the setting of coronavirus disease (COVID-19): a case report. ( Eng, MH; Kan, N; Mirza, H; Mughal, MS; Osman, R; Rehman, R, 2020) |
| "Hydroxychloroquine has been touted as a potential COVID-19 treatment." | 1.56 | Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. ( Asif, A; Balani, B; Barsky, C; Bednarz, U; Berry, DA; Berry, NS; Berry, SM; Biran, N; Cicogna, C; Go, RC; Goldberg, SL; Goy, AH; Hansen, E; Ip, A; Jacobs, LG; Korcak, J; Landolfi, JC; Marafelias, M; Mathura, S; Pecora, AL; Piwoz, JA; Rose, KM; Sawczuk, IS; Sebti, R; Sinclaire, BA; Sperber, S; Sugalski, G; Tank, L; Timmapuri, SL; Underwood, JP; Varga, DW; Zuckerman, J, 2020) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "Hydroxychloroquine/azithromycin treatment was associated with a lower ICU admission rate (P=0." | 1.56 | A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island. ( Allou, N; Allyn, J; André, M; Borsu, K; Bruneau, L; Coolen-Allou, N; Dibernardo, S; Dubernet, A; Foch, E; Gauzere, L; Jabot, J; Jaffar-Bandjee, MC; Lagrange-Xelot, M; Larsen, K; Maillot, A; Masse, L; Moreau, D; Raffray, L; Renaud, S; Thomas, V, 2020) |
| "The evolution to pulmonary fibrosis is frequent in older males and patients with comorbidities and bone marrow involvement." | 1.56 | First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution. ( Balzarini, L; Ferrozzi, F; Mancini, C; Marvisi, M; Ramponi, S; Uccelli, M, 2020) |
| "Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg." | 1.56 | Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. ( Bottieau, E; Catteau, L; Dauby, N; Duysburgh, E; Goetghebeur, E; Hautekiet, J; Montourcy, M; Van Beckhoven, D; van Ierssel, S; Van Oyen, H; Wyndham-Thomas, C, 2020) |
| "Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19." | 1.56 | Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. ( , 2020) |
| "We interpreted this as a viral exanthema likely caused by an immune response to SARS-CoV-2 nucleotides." | 1.56 | Viral exanthema as manifestation of SARS-CoV-2 infection: A case report. ( Birlutiu, V; Iancu, GM; Solomon, A, 2020) |
| "A chest CT scan showed an acute type B aortic dissection (ATBAD) and bilateral lung involvement with ground-glass opacity, compatible with interstitial pneumonia." | 1.56 | An infection-oriented approach for thoracic endovascular aortic repair in a SARS-CoV-2 positive patient. A case report. ( Ferrari, SA; Muzzarelli, L; Piconi, S; Rossi, G; Sommaruga, S, 2020) |
| " This position statement recommends dosage adjustment for these drugs in the context of renal impairment." | 1.56 | Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function. ( Andreoli, MCC; Bastos, K; D'Avila, R; Kraychete, A; Misael, AM; Moura-Neto, JA; Nascimento, MMD; Silva, DRD, 2020) |
| "However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2." | 1.56 | Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report. ( Antonelli, G; Bitossi, C; Borrazzo, C; Ceccarelli, G; d'Ettorre, G; Frasca, F; Innocenti, GP; Mastroianni, CM; Pinacchio, C; Recchia, G; Ridolfi, M; Santinelli, L; Scagnolari, C; Siccardi, G, 2020) |
| "Methemoglobinemia is a rare disorder of the blood in which there is an increase in methemoglobin, which occurs when hemoglobin is present in the oxidized form." | 1.56 | Unexplained Methemoglobinemia in Coronavirus Disease 2019: A Case Report. ( Bloom, A; Faisal, H; Gaber, AO, 2020) |
| " Some studies have shown that COVID-19 combined with diabetes is an independent risk factor for death or other adverse outcomes." | 1.56 | Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. ( Fu, X; Liu, Y; Xie, C, 2020) |
| "Hydroxychloroquine was used to treat both patients; the first patient was treated with it over a period of 14 days before showing signs of improvement." | 1.56 | Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report. ( Atef-Yekta, R; Jafary, M; Lamsehchi, A; Sadeghi, K; Sagheb, S, 2020) |
| "We have developed a population pharmacokinetic model for hydroxychloroquine in COVID-19 patients using prospectively collected pharmacokinetic data from patients either enrolled in a clinical trial or treated with hydroxychloroquine as part of standard of care in two tertiary Belgian hospitals." | 1.56 | Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ( Belkhir, L; Dauby, N; De Greef, J; Delongie, KA; Dogné, JM; Hamdani, J; Kiridis, S; Lescrainier, C; Musuamba, FT; Nasreddine, R; Thémans, P; Vandeputte, M; Verlinden, V; Wallemacq, P; Wittebole, X; Wuillaume, F; Yombi, JC, 2020) |
| "HCQ administration is safe for a short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths." | 1.56 | Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. ( Antinori, S; Bellia, A; Biffi, M; Busana, M; Casalini, G; Cogliati, CB; Duru, F; Fabbricatore, D; Forleo, GB; Galiè, N; Galli, M; Gasperetti, A; Lanfranchi, A; Lavalle, C; Mariani, MV; Mitacchione, G; Saguner, A; Salghetti, F; Schiavone, M; Tocci, M; Tondo, C; Viale, P; Ziacchi, M, 2020) |
| "To evaluate the impact of the coronavirus disease 2019 (COVID-19) pandemic on rheumatology practice." | 1.56 | The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. ( Abdulateef, N; Abutiban, F; Eissa, M; El Kibbi, L; El Rakawi, M; Halabi, H; Hamdi, W; Hmamouchi, I; Masri, B; Ziadé, N, 2020) |
| "Hydroxychloroquine was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI): 0." | 1.56 | The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. ( Ayerbe, L; Ayis, S; Risco-Risco, C, 2020) |
| " Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment." | 1.56 | Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19. ( Arthur, A; Dayton, F; Farragher, JP; Kavanagh, O; Mahoney, B; Marie Healy, A; O'Reilly, NJ; Robinson, S; Walker, G, 2020) |
| " We envision that MAT can be used to optimize the dosing regimen of HCQ by maximizing its bioavailability, while simultaneously minimizing the cytotoxic damage." | 1.56 | A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects. ( Kannan, R; Przekwas, A, 2020) |
| "Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial." | 1.56 | Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. ( Annie, FH; Broce, M; Frazier, KR; Lucas, BD; Sirbu, C, 2020) |
| "Since December 2019, Coronavirus Disease 2019 (COVID-19) has emerged as a global pandemic." | 1.56 | Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients. ( Gao, C; Jin, CC; Tong, YX; Xiao, AT; Zhang, S; Zhu, L, 2020) |
| "BACKGROUND Acute generalized exanthematous pustulosis (AGEP) is a rare exanthem characterized by the abrupt onset of numerous small, non-follicular, sterile pustules arising on an erythematous base." | 1.56 | Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine. ( Haraszti, S; Jensen, N; Sendil, S, 2020) |
| "Patients hospitalised with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2; coronavirus 2019 disease (COVID-19)] infection are frequently older with co-morbidities and receiving polypharmacy, all of which are known risk factors for drug-drug interactions (DDIs)." | 1.56 | Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. ( Antinori, S; Bradanini, L; Cattaneo, D; Covizzi, A; Gervasoni, C; Giacomelli, A; Maggioni, AP; Oreni, L; Pasina, L; Ridolfo, A; Schiuma, M, 2020) |
| " In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ." | 1.56 | Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. ( Abagyan, R; Cohen, IV; Issa, MA; Makunts, T; Moumedjian, T, 2020) |
| "Hydroxychloroquine (HCQ) has been tried against COVID-19 owing to its in vitro virucidal action against SARS-CoV-2, but the role of HCQ as post-exposure prophylaxis (PEP) remains inconclusive." | 1.56 | Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. ( Arora, N; Bhalla, A; Dhibar, DP; Kakkar, A; Medhi, B; Mohindra, R; Prakash, A; Pvm, L; Sharma, N; Singh, MP; Singla, N; Suri, V, 2020) |
| "The growing coronavirus disease 2019 (COVID-19) pandemic initially led to widespread use of hydroxychloroquine sulfate as an off-label experimental treatment of this disease." | 1.56 | Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report. ( Aguilar, J; Averbukh, Y, 2020) |
| "Hydroxychloroquine is an agent used as a treatment but also considered as a prophylaxis for SARS-CoV-2 infection." | 1.56 | [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease]. ( Bouchti, IE; Malek, SA, 2020) |
| "It may cause severe viral pneumonia with Acute Respiratory Distress Syndrome requiring critical care." | 1.56 | Very severe COVID-19 in the critically ill in Tunisia. ( Boussarsar, M; Ennouri, E; Jerbi, S; Mahmoud, J; Meddeb, K; Nachi, R; Saida, IB; Thabet, N, 2020) |
| "The pregnancy is still ongoing without any visible sequelae on the foetus so far." | 1.56 | COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report. ( Calès, P; Delaroche, L; Descamps, P; Dieli-Crimi, R; Guerin, A; Lamazou, F; Letouzey, V; Octernaud, S; Oger, P; Place, V, 2020) |
| "Hydroxychloroquine therapy was not associated with mortality in our study." | 1.56 | Clinical Characteristics and Outcomes of 905 COVID-19 Patients Admitted to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran. ( Aghili, SM; Allameh, SF; Amoozadeh, L; Ayoobi Yazdi, N; Beigmohammadi, MT; Dehghan Manshadi, SA; Edalatifard, M; Ghalehtaki, R; Hasannezhad, M; Jafarian, A; Kazemizadeh, H; Khajavirad, N; Khatami, SR; Mirfazaelian, H; Mohammadnejad, E; Nahvijou, A; Nasiri Toosi, M; Nemati, S; Radnia, M; Rashidian, L; Sadeghniiat-Haghighi, K; Salehi, M; Seyyedsalehi, MS; Yunesian, M; Zendehdel, K, 2020) |
| "Hydroxychloroquine (HCQ) has generated a lot of controversies whether it is effective in prevention and treatment of COVID-19." | 1.56 | Long-term application of hydroxychloroquine could not prevent the infection of COVID-19. ( Chen, Y; Ding, H; Fang, J; Gong, Y; Ke, C; Pan, A; Wang, B; Xu, L; Yu, B; Zhu, Y, 2020) |
| "Hydroxychloroquine was administered to 21 patients (11 %), favipiravir to 26 patients (13 %) and remdesivir to 13 patients (6 %)." | 1.56 | [Clinical progression of the first wave of novel coronavirus infection in Ostrava]. ( da Silva, S; Martinková, I; Petroušová, L; Rožnovský, L, 2020) |
| "Since the outbreak of 2019 novel coronavirus infection (2019-nCoV) in Morocco, a total of 145 COVID-19 confirmed cases have been reported in the Cheikh Khalifa's Hospital." | 1.56 | The epidemiological and clinical profile of COVID-19 in children: Moroccan experience of the Cheikh Khalifa University Center. ( Bahlaoui, A; Chekhlabi, N; Dini, N; El Kettani, C; Ettair, S; Haoudar, A; Mahi, M, 2020) |
| " Of the 13 institutions listing hydroxychloroquine dosing recommendations, 62% recommended maintenance dosing of 200 mg twice daily." | 1.56 | Open-source institutional guideline recommendations during the COVID-19 pandemic. ( Collins, CD; Huang, J; Potoski, BA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1379 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, DE | 1 |
| Jang, GM | 1 |
| Bouhaddou, M | 1 |
| Xu, J | 2 |
| Obernier, K | 1 |
| White, KM | 1 |
| O'Meara, MJ | 1 |
| Rezelj, VV | 1 |
| Guo, JZ | 1 |
| Swaney, DL | 1 |
| Tummino, TA | 1 |
| Hüttenhain, R | 1 |
| Kaake, RM | 1 |
| Richards, AL | 1 |
| Tutuncuoglu, B | 1 |
| Foussard, H | 1 |
| Batra, J | 1 |
| Haas, K | 1 |
| Modak, M | 1 |
| Kim, M | 2 |
| Haas, P | 1 |
| Polacco, BJ | 1 |
| Braberg, H | 1 |
| Fabius, JM | 1 |
| Eckhardt, M | 1 |
| Soucheray, M | 1 |
| Bennett, MJ | 1 |
| Cakir, M | 1 |
| McGregor, MJ | 1 |
| Li, Q | 1 |
| Meyer, B | 1 |
| Roesch, F | 1 |
| Vallet, T | 1 |
| Mac Kain, A | 1 |
| Miorin, L | 1 |
| Moreno, E | 1 |
| Naing, ZZC | 1 |
| Zhou, Y | 3 |
| Peng, S | 1 |
| Shi, Y | 2 |
| Zhang, Z | 4 |
| Shen, W | 1 |
| Kirby, IT | 1 |
| Melnyk, JE | 1 |
| Chorba, JS | 1 |
| Lou, K | 1 |
| Dai, SA | 1 |
| Barrio-Hernandez, I | 1 |
| Memon, D | 1 |
| Hernandez-Armenta, C | 1 |
| Lyu, J | 1 |
| Mathy, CJP | 1 |
| Perica, T | 1 |
| Pilla, KB | 1 |
| Ganesan, SJ | 1 |
| Saltzberg, DJ | 1 |
| Rakesh, R | 1 |
| Liu, X | 2 |
| Rosenthal, SB | 1 |
| Calviello, L | 1 |
| Venkataramanan, S | 1 |
| Liboy-Lugo, J | 1 |
| Lin, Y | 3 |
| Huang, XP | 1 |
| Liu, Y | 7 |
| Wankowicz, SA | 1 |
| Bohn, M | 1 |
| Safari, M | 1 |
| Ugur, FS | 1 |
| Koh, C | 1 |
| Savar, NS | 1 |
| Tran, QD | 1 |
| Shengjuler, D | 1 |
| Fletcher, SJ | 1 |
| O'Neal, MC | 1 |
| Cai, Y | 1 |
| Chang, JCJ | 1 |
| Broadhurst, DJ | 1 |
| Klippsten, S | 1 |
| Sharp, PP | 1 |
| Wenzell, NA | 1 |
| Kuzuoglu-Ozturk, D | 1 |
| Wang, HY | 1 |
| Trenker, R | 1 |
| Young, JM | 1 |
| Cavero, DA | 1 |
| Hiatt, J | 1 |
| Roth, TL | 1 |
| Rathore, U | 1 |
| Subramanian, A | 1 |
| Noack, J | 1 |
| Hubert, M | 1 |
| Stroud, RM | 1 |
| Frankel, AD | 1 |
| Rosenberg, OS | 1 |
| Verba, KA | 1 |
| Agard, DA | 1 |
| Ott, M | 1 |
| Emerman, M | 1 |
| Jura, N | 1 |
| von Zastrow, M | 1 |
| Verdin, E | 1 |
| Ashworth, A | 1 |
| Schwartz, O | 1 |
| d'Enfert, C | 1 |
| Mukherjee, S | 1 |
| Jacobson, M | 1 |
| Malik, HS | 1 |
| Fujimori, DG | 1 |
| Ideker, T | 1 |
| Craik, CS | 1 |
| Floor, SN | 1 |
| Fraser, JS | 1 |
| Gross, JD | 1 |
| Sali, A | 1 |
| Roth, BL | 1 |
| Ruggero, D | 1 |
| Taunton, J | 1 |
| Kortemme, T | 1 |
| Beltrao, P | 1 |
| Vignuzzi, M | 1 |
| García-Sastre, A | 1 |
| Shokat, KM | 1 |
| Shoichet, BK | 1 |
| Krogan, NJ | 1 |
| Choudhry, N | 1 |
| Zhao, X | 3 |
| Xu, D | 1 |
| Zanin, M | 1 |
| Chen, W | 3 |
| Yang, Z | 1 |
| Chen, J | 6 |
| Pillaiyar, T | 1 |
| Wendt, LL | 1 |
| Manickam, M | 1 |
| Easwaran, M | 1 |
| Sargin Altunok, E | 1 |
| Satici, C | 1 |
| Dinc, V | 1 |
| Kamat, S | 1 |
| Alkan, M | 1 |
| Demirkol, MA | 1 |
| Toprak, ID | 1 |
| Kostek, ME | 1 |
| Yazla, S | 1 |
| Esatoglu, SN | 1 |
| Liu, HH | 1 |
| Ezekowitz, MD | 1 |
| Columbo, M | 1 |
| Khan, O | 1 |
| Martin, J | 1 |
| Spahr, J | 1 |
| Yaron, D | 1 |
| Cushinotto, L | 1 |
| Kapelusznik, L | 1 |
| Civriz Bozdağ, S | 1 |
| Cengiz Seval, G | 1 |
| Yönal Hindilerden, İ | 1 |
| Hindilerden, F | 1 |
| Andıç, N | 1 |
| Baydar, M | 1 |
| Aydın Kaynar, L | 1 |
| Toprak, SK | 1 |
| Göksoy, HS | 1 |
| Balık Aydın, B | 1 |
| Demirci, U | 1 |
| Can, F | 1 |
| Özkocaman, V | 1 |
| Gündüz, E | 1 |
| Güven, ZT | 1 |
| Özkurt, ZN | 1 |
| Demircioğlu, S | 1 |
| Beksaç, M | 1 |
| İnce, İ | 1 |
| Yılmaz, U | 1 |
| Eroğlu Küçükdiler, H | 1 |
| Abishov, E | 1 |
| Yavuz, B | 1 |
| Ataş, Ü | 1 |
| Mutlu, YG | 1 |
| Baş, V | 1 |
| Özkalemkaş, F | 1 |
| Üsküdar Teke, H | 1 |
| Gürsoy, V | 1 |
| Çelik, S | 1 |
| Çiftçiler, R | 1 |
| Yağcı, M | 1 |
| Topçuoğlu, P | 1 |
| Çeneli, Ö | 1 |
| Abbasov, H | 1 |
| Selim, C | 1 |
| Ar, MC | 1 |
| Yücel, OK | 1 |
| Sadri, S | 2 |
| Albayrak, C | 1 |
| Demir, AM | 1 |
| Güler, N | 1 |
| Keklik, M | 1 |
| Terzi, H | 1 |
| Doğan, A | 1 |
| Yegin, ZA | 1 |
| Kurt Yüksel, M | 1 |
| Yavaşoğlu, İ | 2 |
| Beköz, HS | 1 |
| Aksu, T | 1 |
| Maral, S | 1 |
| Erol, V | 1 |
| Kaynar, L | 1 |
| İlhan, O | 1 |
| Bolaman, AZ | 1 |
| Sevindik, ÖG | 1 |
| Akyay, A | 1 |
| Özcan, M | 2 |
| Gürman, G | 1 |
| Ünal, Ş | 3 |
| Yavuz, Y | 1 |
| Diz Küçükkaya, R | 1 |
| Özsan, GH | 1 |
| Million, M | 6 |
| Lagier, JC | 13 |
| Tissot-Dupont, H | 1 |
| Ravaux, I | 1 |
| Dhiver, C | 1 |
| Tomei, C | 1 |
| Cassir, N | 1 |
| Delorme, L | 1 |
| Cortaredona, S | 1 |
| Amrane, S | 1 |
| Aubry, C | 1 |
| Bendamardji, K | 1 |
| Berenger, C | 1 |
| Doudier, B | 2 |
| Edouard, S | 1 |
| Hocquart, M | 1 |
| Mailhe, M | 2 |
| Porcheto, C | 1 |
| Seng, P | 1 |
| Triquet, C | 1 |
| Gentile, S | 2 |
| Jouve, E | 1 |
| Giraud-Gatineau, A | 1 |
| Chaudet, H | 2 |
| Camoin-Jau, L | 2 |
| Colson, P | 6 |
| Gautret, P | 13 |
| Fournier, PE | 1 |
| Maille, B | 1 |
| Deharo, JC | 2 |
| Habert, P | 1 |
| Gaubert, JY | 1 |
| Jacquier, A | 1 |
| Honore, S | 6 |
| Guillon-Lorvellec, K | 1 |
| Obadia, Y | 1 |
| Parola, P | 4 |
| Brouqui, P | 4 |
| Raoult, D | 18 |
| Cenac, C | 1 |
| Ducatez, MF | 1 |
| Guéry, JC | 1 |
| Hernandez-Cardenas, C | 1 |
| Thirion-Romero, I | 3 |
| Rodríguez-Llamazares, S | 2 |
| Rivera-Martinez, NE | 2 |
| Meza-Meneses, P | 2 |
| Remigio-Luna, A | 2 |
| Perez-Padilla, R | 3 |
| Cavanna, L | 3 |
| Cremona, G | 1 |
| Citterio, C | 2 |
| Nunzio, CD | 1 |
| Muroni, M | 1 |
| Andena, AM | 1 |
| Cattadori, E | 1 |
| Gubbelini, M | 1 |
| Muroni, L | 1 |
| Schiavo, R | 1 |
| Nolli, M | 1 |
| Codeluppi, M | 2 |
| Maniscalco, P | 1 |
| Pedrazzini, G | 1 |
| Pileggi, GS | 2 |
| Ferreira, GA | 3 |
| Reis, APMG | 2 |
| Reis-Neto, ET | 2 |
| Abreu, MM | 2 |
| Albuquerque, CP | 2 |
| Araújo, NC | 2 |
| Bacchiega, AB | 2 |
| Bianchi, DV | 2 |
| Bica, B | 2 |
| Bonfa, ED | 1 |
| Borba, EF | 3 |
| Brito, DCSE | 1 |
| Duarte, ÂLBP | 1 |
| Santo, RCE | 1 |
| Fernandes, PR | 2 |
| Guimarães, MP | 2 |
| Gomes, KWP | 1 |
| Kakehasi, AM | 3 |
| Klumb, EM | 2 |
| Lanna, CCD | 1 |
| Marques, CDL | 3 |
| Monticielo, OA | 2 |
| Mota, LMH | 2 |
| Munhoz, GA | 2 |
| Paiva, ES | 2 |
| Pereira, HLA | 2 |
| Provenza, JR | 3 |
| Ribeiro, SLE | 2 |
| Junior, LFR | 1 |
| Sampaio, CSJC | 1 |
| Sampaio, VS | 2 |
| Sato, EI | 3 |
| Skare, T | 2 |
| de Souza, VA | 2 |
| Valim, V | 2 |
| Lacerda, MVG | 2 |
| Xavier, RM | 3 |
| Pinheiro, MM | 2 |
| Altay, S | 1 |
| Mendoza-Pinto, C | 1 |
| García-Carrasco, M | 1 |
| Munguía Realpozo, P | 1 |
| Méndez-Martínez, S | 1 |
| Pérez-Belmonte, LM | 1 |
| Sanz-Cánovas, J | 1 |
| Salinas, A | 1 |
| Fornie, IS | 1 |
| Méndez-Bailón, M | 1 |
| Gómez-Huelgas, R | 1 |
| Nogrady, B | 1 |
| Boudesseul, J | 1 |
| Zerhouni, O | 1 |
| Harbert, A | 1 |
| Rubinos, C | 1 |
| Han, F | 1 |
| Mo, M | 1 |
| Wang, C | 3 |
| Yang, Y | 4 |
| Wu, J | 2 |
| Kahraman, ME | 1 |
| Yüksel, F | 1 |
| Özbuğday, Y | 1 |
| Perrella, A | 1 |
| Orlando, V | 1 |
| Trama, U | 1 |
| Bernardi, FF | 1 |
| Menditto, E | 1 |
| Coscioni, E | 1 |
| Jia, Q | 3 |
| Fu, J | 4 |
| Liang, P | 3 |
| Wang, S | 5 |
| Wang, Y | 9 |
| Zhang, X | 3 |
| Zhou, H | 3 |
| Zhang, L | 7 |
| Lv, Y | 3 |
| Han, S | 4 |
| Eryavuz Onmaz, D | 1 |
| Tezcan, D | 1 |
| Abusoglu, S | 1 |
| Yilmaz, S | 1 |
| Yerlikaya, FH | 1 |
| Onmaz, M | 1 |
| Abusoglu, G | 1 |
| Unlu, A | 1 |
| Di Castelnuovo, A | 2 |
| Costanzo, S | 2 |
| Gialluisi, A | 2 |
| Iacoviello, L | 2 |
| de Gaetano, G | 1 |
| Yogendrakumar, V | 1 |
| Dewar, B | 1 |
| McGuinty, M | 1 |
| Dowlatshahi, D | 1 |
| Dyason, C | 1 |
| Kwok, ES | 1 |
| Ramsay, T | 1 |
| Lund, H | 1 |
| Shamy, M | 1 |
| Zavala-Flores, E | 1 |
| Salcedo-Matienzo, J | 1 |
| Quiroz-Alva, A | 1 |
| Berrocal-Kasay, A | 1 |
| Lasco, G | 1 |
| Yu, VG | 1 |
| Moon, K | 1 |
| Hong, KW | 2 |
| Bae, IG | 2 |
| Ozcifci, G | 1 |
| Aydin, T | 1 |
| Atli, Z | 1 |
| Balkan, II | 1 |
| Tabak, F | 1 |
| Oztas, M | 1 |
| Ozguler, Y | 1 |
| Ugurlu, S | 1 |
| Hatemi, G | 1 |
| Melikoglu, M | 1 |
| Fresko, I | 1 |
| Hamuryudan, V | 1 |
| Seyahi, E | 1 |
| Yao, Y | 2 |
| Ma, D | 2 |
| Xu, Y | 1 |
| Yuan, XL | 1 |
| Liang, JJ | 1 |
| Chen, SL | 1 |
| Jhanji, V | 1 |
| Ng, TK | 1 |
| Ahmed, AS | 1 |
| Alotaibi, WS | 1 |
| Aldubayan, MA | 1 |
| Alhowail, AH | 1 |
| Al-Najjar, AH | 2 |
| Chigurupati, S | 1 |
| Elgharabawy, RM | 1 |
| Rao, A | 1 |
| Veluswamy, SK | 1 |
| Shankarappa, BG | 1 |
| Reddy, RM | 1 |
| Umesh, N | 1 |
| John, L | 1 |
| Mathew, L | 1 |
| Shetty, N | 1 |
| Duzgun, Z | 1 |
| Kural, BV | 1 |
| Orem, A | 1 |
| Yildiz, I | 1 |
| Fuentes-Gonzalez, MF | 1 |
| Ordinola Navarro, A | 1 |
| Carmona-Aguilera, Z | 1 |
| Hernández-Jimenez, CA | 1 |
| Benitez-Altamirano, GM | 1 |
| Beltran-Ontiveros, LD | 1 |
| Lopez-Vejar, C | 1 |
| Ramirez-Hinojosa, JP | 1 |
| Vera-Lastra, O | 1 |
| Lopez Luis, BA | 1 |
| Batiha, GE | 1 |
| Shaheen, HM | 1 |
| Al-Kuraishy, HM | 1 |
| Teibo, JO | 1 |
| Akinfe, OA | 1 |
| Al-Garbee, AI | 1 |
| Teibo, TKA | 1 |
| Kabrah, SM | 1 |
| Homme, RP | 1 |
| George, AK | 1 |
| Singh, M | 1 |
| Smolenkova, I | 1 |
| Zheng, Y | 1 |
| Pushpakumar, S | 1 |
| Tyagi, SC | 1 |
| McKinnon, JE | 5 |
| Wang, DD | 4 |
| Zervos, M | 4 |
| Saval, M | 1 |
| Marshall-Nightengale, L | 1 |
| Kilgore, P | 3 |
| Pabla, P | 1 |
| Szandzik, E | 1 |
| Maksimowicz-McKinnon, K | 1 |
| O'Neill, WW | 2 |
| Croci, S | 2 |
| Venneri, MA | 1 |
| Mantovani, S | 1 |
| Fallerini, C | 1 |
| Benetti, E | 1 |
| Picchiotti, N | 1 |
| Campolo, F | 1 |
| Imperatore, F | 1 |
| Palmieri, M | 1 |
| Daga, S | 1 |
| Gabbi, C | 1 |
| Montagnani, F | 1 |
| Beligni, G | 1 |
| Farias, TDJ | 1 |
| Carriero, ML | 1 |
| Di Sarno, L | 1 |
| Alaverdian, D | 1 |
| Aslaksen, S | 1 |
| Cubellis, MV | 1 |
| Spiga, O | 1 |
| Baldassarri, M | 1 |
| Fava, F | 1 |
| Norman, PJ | 1 |
| Frullanti, E | 1 |
| Isidori, AM | 1 |
| Amoroso, A | 1 |
| Mari, F | 1 |
| Furini, S | 1 |
| Mondelli, MU | 1 |
| Chiariello, M | 1 |
| Renieri, A | 1 |
| Meloni, I | 1 |
| Palacios-Rápalo, SN | 1 |
| De Jesús-González, LA | 1 |
| Cordero-Rivera, CD | 1 |
| Farfan-Morales, CN | 1 |
| Osuna-Ramos, JF | 1 |
| Martínez-Mier, G | 1 |
| Quistián-Galván, J | 1 |
| Muñoz-Pérez, A | 1 |
| Bernal-Dolores, V | 1 |
| Del Ángel, RM | 1 |
| Reyes-Ruiz, JM | 1 |
| Juneja, S | 1 |
| Rana, P | 1 |
| Chawla, P | 1 |
| Katoch, R | 1 |
| Singh, K | 1 |
| Rana, S | 1 |
| Mittal, T | 1 |
| Kaur, B | 1 |
| Kaur, S | 1 |
| Kolli, AR | 1 |
| Calvino-Martin, F | 1 |
| Hoeng, J | 1 |
| Mishra, A | 1 |
| Rathore, AS | 1 |
| Ferron, PJ | 1 |
| Le Daré, B | 1 |
| Bronsard, J | 1 |
| Steichen, C | 1 |
| Babina, E | 1 |
| Pelletier, R | 1 |
| Hauet, T | 1 |
| Morel, I | 1 |
| Tarte, K | 1 |
| Reizine, F | 1 |
| Clément, B | 1 |
| Fromenty, B | 1 |
| Gicquel, T | 1 |
| Mazaherpour, H | 1 |
| Sofian, M | 2 |
| Farahani, E | 1 |
| Abdi, A | 1 |
| Mazaherpour, S | 1 |
| Bavand, A | 1 |
| Ramezani, A | 2 |
| Watson, C | 1 |
| Zhu, X | 1 |
| Xiao, Y | 2 |
| Gao, Q | 2 |
| Gao, L | 1 |
| Zhang, W | 3 |
| Xin, X | 1 |
| Chen, K | 2 |
| Srivastava, U | 1 |
| Ginjupalli, VKM | 1 |
| Cupelli, M | 1 |
| Lazzerini, PE | 1 |
| Capecchi, PL | 1 |
| Chen, L | 2 |
| Boutjdir, M | 1 |
| Bosquet, A | 1 |
| Affo, C | 1 |
| Plaisance, L | 1 |
| Poenou, G | 1 |
| Mortier, E | 1 |
| Mahé, I | 1 |
| Bangdiwala, AS | 4 |
| Boulware, DR | 7 |
| Taccone, FS | 2 |
| Hites, M | 2 |
| Dauby, N | 4 |
| Friedman-Klabanoff, DJ | 1 |
| Fitzpatrick, MC | 1 |
| Deming, ME | 1 |
| Agrawal, V | 2 |
| Sitar, S | 1 |
| Schaafsma, T | 1 |
| Brown, E | 2 |
| Neuzil, KM | 3 |
| Barnabas, RV | 5 |
| Laufer, MK | 2 |
| Rojas-Serrano, J | 2 |
| Portillo-Vásquez, AM | 1 |
| Vázquez-Pérez, J | 1 |
| Mejía-Nepomuceno, F | 1 |
| Ramírez-Venegas, A | 1 |
| Pérez-Kawabe, KM | 1 |
| Boretti, A | 1 |
| Kepenekli, E | 1 |
| Yakut, N | 1 |
| Ergenc, Z | 1 |
| Aydıner, Ö | 1 |
| Sarınoğlu, RC | 1 |
| Karahasan, A | 1 |
| Karakoc-Aydıner, E | 1 |
| Memişoğlu, A | 1 |
| Gökdemir, Y | 1 |
| Eralp, EE | 1 |
| Ergenekon, P | 1 |
| Karadağ, B | 1 |
| Tezel, KG | 1 |
| Aydın, M | 1 |
| Şenyürek, B | 1 |
| Boran, P | 1 |
| Schiavone, M | 3 |
| Gasperetti, A | 3 |
| Gherbesi, E | 2 |
| Bergamaschi, L | 1 |
| Arosio, R | 1 |
| Mitacchione, G | 3 |
| Viecca, M | 2 |
| Forleo, GB | 3 |
| Beeraka, NM | 1 |
| Tulimilli, SV | 1 |
| Greeshma, MV | 1 |
| Dallavalasa, S | 1 |
| Zhang, Y | 7 |
| Xiao, W | 2 |
| Fan, R | 1 |
| Zhao, D | 2 |
| Bettadapura, ADS | 1 |
| Nataraj, SM | 1 |
| Madhunapantula, SV | 1 |
| Liu, J | 5 |
| S K, SR | 1 |
| P A, A | 1 |
| B, S | 1 |
| Kalala, KP | 1 |
| Pm, A | 1 |
| Sabarathinam, S | 1 |
| Kieliszek, M | 1 |
| Fu, XL | 1 |
| Qian, Y | 1 |
| Jin, XH | 1 |
| Yu, HR | 1 |
| Du, L | 1 |
| Wu, H | 2 |
| Chen, HL | 1 |
| Shi, YQ | 1 |
| Walbi, IA | 1 |
| Albarqi, HA | 1 |
| Alghanim, NS | 1 |
| Albadi, MA | 1 |
| Al Maimouni, HM | 1 |
| Alkahtani, SA | 1 |
| Alshabi, AM | 1 |
| Alali, AS | 1 |
| Alqahtani, F | 1 |
| Hazzazi, MA | 1 |
| Alanazi, DS | 1 |
| Sabei, AA | 1 |
| Alsaweed, OS | 1 |
| Alajra, RK | 1 |
| Alqhtani, H | 1 |
| Westhoff, WJ | 1 |
| Smith, LH | 1 |
| Wyszynski, DF | 1 |
| Hernandez-Diaz, S | 2 |
| Belmont, HM | 1 |
| Haj-Ali, M | 1 |
| Choi, MY | 1 |
| Weber, B | 1 |
| Stevens, E | 1 |
| Guan, H | 2 |
| Ellrodt, J | 1 |
| Oakes, E | 1 |
| Di Carli, M | 1 |
| Tedrow, U | 1 |
| Sauer, W | 1 |
| Costenbader, KH | 1 |
| Bajka, A | 1 |
| Toro, M | 1 |
| Kniestedt, C | 1 |
| Zweifel, S | 1 |
| Sainz-Gil, M | 2 |
| Merino Kolly, N | 1 |
| Velasco-González, V | 2 |
| Verde Rello, Z | 1 |
| Fernandez-Araque, AM | 1 |
| Sanz Fadrique, R | 1 |
| Martín Arias, LH | 1 |
| Tirupakuzhi Vijayaraghavan, BK | 2 |
| Jha, V | 2 |
| Rajbhandari, D | 2 |
| Myatra, SN | 2 |
| Ghosh, A | 3 |
| Bhattacharya, A | 1 |
| Arfin, S | 2 |
| Bassi, A | 2 |
| Donaldson, LH | 1 |
| Hammond, NE | 1 |
| John, O | 2 |
| Joshi, R | 2 |
| Kunigari, M | 2 |
| Amrutha, C | 1 |
| Husaini, SHM | 1 |
| Ghosh, S | 1 |
| Nag, SK | 1 |
| Selvaraj, HK | 1 |
| Kantroo, V | 1 |
| Shah, KD | 1 |
| Venkatesh, B | 2 |
| Schaffer, AL | 1 |
| Henry, D | 1 |
| Zoega, H | 1 |
| Elliott, JH | 1 |
| Pearson, SA | 1 |
| Casey, JD | 2 |
| Beskow, LM | 1 |
| Brown, J | 1 |
| Brown, SM | 3 |
| Gayat, É | 1 |
| Ng Gong, M | 2 |
| Harhay, MO | 1 |
| Jaber, S | 1 |
| Jentzer, JC | 1 |
| Laterre, PF | 1 |
| Marshall, JC | 3 |
| Matthay, MA | 1 |
| Rice, TW | 2 |
| Rosenberg, Y | 1 |
| Turnbull, AE | 1 |
| Ware, LB | 1 |
| Self, WH | 2 |
| Mebazaa, A | 1 |
| Collins, SP | 3 |
| Hui, LY | 1 |
| Mun, CS | 1 |
| Sing, LC | 1 |
| Rajak, H | 1 |
| Karunakaran, R | 1 |
| Ravichandran, V | 1 |
| Bruce, P | 1 |
| Ainscough, K | 1 |
| Hatter, L | 1 |
| Braithwaite, I | 1 |
| Berry, LR | 3 |
| Fitzgerald, M | 3 |
| Hills, T | 4 |
| Brickell, K | 1 |
| Cosgrave, D | 1 |
| Semprini, A | 1 |
| Morpeth, S | 2 |
| Berry, S | 3 |
| Doran, P | 2 |
| Young, P | 1 |
| Beasley, R | 1 |
| Nichol, A | 2 |
| Varol, F | 1 |
| Can, YY | 1 |
| Sahin, E | 2 |
| Durak, C | 1 |
| Kilic, A | 1 |
| Sahin, C | 1 |
| Gursoy, F | 1 |
| Akin, T | 1 |
| Singh, B | 2 |
| Ryan, H | 2 |
| Kredo, T | 2 |
| Chaplin, M | 2 |
| Fletcher, T | 2 |
| Luo, M | 1 |
| Wu, B | 1 |
| Li, Y | 6 |
| Wu, F | 1 |
| Gil-Vila, A | 1 |
| Ravichandran, N | 1 |
| Selva-O'Callaghan, A | 1 |
| Sen, P | 1 |
| Nune, A | 1 |
| Gaur, PS | 1 |
| Gonzalez, RA | 1 |
| Lilleker, JB | 1 |
| Joshi, M | 2 |
| Agarwal, V | 3 |
| Kardes, S | 2 |
| Day, J | 1 |
| Makol, A | 1 |
| Milchert, M | 1 |
| Gheita, T | 1 |
| Salim, B | 1 |
| Velikova, T | 1 |
| Gracia-Ramos, AE | 1 |
| Parodis, I | 1 |
| Nikiphorou, E | 1 |
| Tan, AL | 1 |
| Chatterjee, T | 1 |
| Cavagna, L | 4 |
| Saavedra, MA | 1 |
| Shinjo, SK | 1 |
| Ziade, N | 2 |
| Knitza, J | 1 |
| Kuwana, M | 1 |
| Distler, O | 1 |
| Chinoy, H | 1 |
| Aggarwal, R | 1 |
| Gupta, L | 2 |
| Griese, M | 1 |
| Kappler, M | 1 |
| Stehling, F | 1 |
| Schulze, J | 1 |
| Baden, W | 1 |
| Koerner-Rettberg, C | 1 |
| Carlens, J | 1 |
| Prenzel, F | 1 |
| Nährlich, L | 1 |
| Thalmeier, A | 1 |
| Sebah, D | 1 |
| Kronfeld, K | 1 |
| Rock, H | 1 |
| Ruckes, C | 1 |
| Wetzke, M | 1 |
| Seidl, E | 1 |
| Schwerk, N | 1 |
| Dal-Ré, R | 1 |
| Porcher, R | 1 |
| Ravaud, P | 3 |
| Resche-Rigon, M | 1 |
| Tharaux, PL | 1 |
| Mariette, X | 2 |
| Hermine, O | 1 |
| Hayden, KR | 1 |
| Jones, M | 1 |
| Elkin, KR | 1 |
| Shreve, MJ | 1 |
| Clees, WI | 1 |
| Clark, S | 1 |
| Mashtare, ML | 1 |
| Veith, TL | 1 |
| Elliott, HA | 1 |
| Watson, JE | 1 |
| Silverman, J | 1 |
| Richard, TL | 1 |
| Read, AF | 1 |
| Preisendanz, HE | 1 |
| Polo, R | 3 |
| García-Albéniz, X | 2 |
| Terán, C | 1 |
| Morales, M | 1 |
| Rial-Crestelo, D | 1 |
| Garcinuño, MA | 1 |
| García Del Toro, M | 1 |
| Hita, C | 1 |
| Gómez-Sirvent, JL | 1 |
| Buzón, L | 1 |
| Díaz de Santiago, A | 1 |
| Arellano, JP | 1 |
| Sanz, J | 1 |
| Bachiller, P | 1 |
| Alfaro, EM | 1 |
| Díaz-Brito, V | 1 |
| Masiá, M | 2 |
| Hernández-Torres, A | 1 |
| Guerra, JM | 1 |
| Santos, J | 1 |
| Arazo, P | 1 |
| Muñoz, L | 1 |
| Arribas, JR | 1 |
| Martínez de Salazar, P | 1 |
| Moreno, S | 1 |
| Hernán, MA | 2 |
| Del Amo, J | 2 |
| Kumbhakar, R | 1 |
| Neradilek, M | 1 |
| Stewart, J | 2 |
| Stankiewicz Karita, HC | 3 |
| Landovitz, RJ | 2 |
| Kissinger, PJ | 2 |
| Jerome, KR | 2 |
| Paasche-Orlow, MK | 3 |
| Bershteyn, A | 4 |
| Chu, HY | 2 |
| Greninger, AL | 2 |
| Luk, A | 2 |
| Wald, A | 3 |
| Brown, ER | 2 |
| Johnston, C | 4 |
| Morales-Asencio, JM | 1 |
| Pham, B | 1 |
| Rios, P | 1 |
| Radhakrishnan, A | 1 |
| Darvesh, N | 1 |
| Antony, J | 1 |
| Williams, C | 1 |
| Ramkissoon, N | 1 |
| Cormack, GV | 1 |
| Grossman, MR | 1 |
| Kampman, M | 1 |
| Patel, M | 5 |
| Yazdi, F | 1 |
| Robson, R | 1 |
| Ghassemi, M | 1 |
| Macdonald, E | 1 |
| Warren, R | 1 |
| Muller, MP | 1 |
| Straus, SE | 1 |
| Tricco, AC | 1 |
| Kanchibhotla, D | 1 |
| Harsora, P | 1 |
| Subramanian, S | 1 |
| Reddy, MRK | 1 |
| Venkatesh, HKR | 1 |
| Lyashchenko, AK | 1 |
| Yu, Y | 1 |
| McMahon, DJ | 1 |
| Bies, R | 1 |
| Yin, MT | 1 |
| Cremers, S | 1 |
| Bertello, M | 1 |
| Rubegni, G | 1 |
| Rubegni, P | 1 |
| Tognetti, L | 1 |
| Fairley, JL | 1 |
| Nikpour, M | 1 |
| Mack, HG | 1 |
| Brosnan, M | 1 |
| Saracino, AM | 1 |
| Pellegrini, M | 1 |
| Wicks, IP | 1 |
| Navar, AM | 1 |
| Cosmatos, I | 1 |
| Purinton, S | 1 |
| Ramsey, JL | 1 |
| Taylor, RJ | 1 |
| Sobel, RE | 1 |
| Barlow, G | 1 |
| Dieck, GS | 1 |
| Bulgrein, ML | 1 |
| Peterson, ED | 1 |
| Maguire, A | 1 |
| Persson, E | 1 |
| Västfjäll, D | 1 |
| Tinghög, G | 1 |
| Kukreja, RC | 1 |
| Wang, R | 1 |
| Koka, S | 1 |
| Das, A | 2 |
| Samidurai, A | 1 |
| Xi, L | 1 |
| Gentry, CA | 1 |
| Thind, SK | 1 |
| Williams, RJ | 1 |
| Hendrickson, SC | 1 |
| Kurdgelashvili, G | 1 |
| Humphrey, MB | 1 |
| Vititoe, SE | 1 |
| Easthausen, IJ | 1 |
| Lasky, T | 1 |
| Chakravarty, A | 1 |
| Bradley, MC | 1 |
| Roe, LM | 1 |
| Gatto, NM | 1 |
| Weckstein, AR | 1 |
| Garry, EM | 1 |
| Jiménez, S | 1 |
| Miró, Ò | 1 |
| Alquézar-Arbé, A | 1 |
| Piñera, P | 1 |
| Jacob, J | 1 |
| Llorens, P | 1 |
| García-Lamberechts, EJ | 1 |
| Martín-Sánchez, FJ | 1 |
| González Del Castillo, J | 1 |
| Burillo-Putze, G | 1 |
| Sandercock, PAG | 1 |
| Darbyshire, J | 1 |
| DeMets, D | 1 |
| Fowler, R | 1 |
| Lalloo, DG | 1 |
| Munavvar, M | 1 |
| Staplin, N | 2 |
| Warris, A | 1 |
| Wittes, J | 1 |
| Emberson, JR | 3 |
| Janeena, A | 1 |
| Jayaraman, N | 1 |
| Shanmugam, G | 1 |
| Easwaramoorthi, S | 1 |
| Ayyadurai, N | 1 |
| Diallo, M | 1 |
| Eyamamé, D | 1 |
| Pshenichnaya, NY | 1 |
| Kareva, EN | 1 |
| Leneva, IA | 1 |
| Bulgakova, VA | 1 |
| Kravchenko, IE | 1 |
| Nikolaeva, IV | 1 |
| Grekova, AI | 1 |
| Ivanova, AP | 1 |
| Puzyreva, LV | 1 |
| Khasanova, GM | 1 |
| Orlova, SN | 1 |
| Tikhonova, EP | 1 |
| Petrov, VA | 1 |
| Malinin, OV | 1 |
| Kolaeva, NV | 1 |
| Volchkova, EV | 1 |
| Kanshina, NN | 1 |
| Chulanov, VP | 1 |
| Zheng, YQ | 1 |
| Li, HJ | 1 |
| Lin, SP | 1 |
| Lu, D | 1 |
| Liu, D | 6 |
| Wang, X | 9 |
| Ren, R | 1 |
| Pang, G | 1 |
| Giardini, V | 1 |
| Ornaghi, S | 1 |
| Gambacorti-Passerini, C | 1 |
| Casati, M | 1 |
| Carrer, A | 1 |
| Acampora, E | 1 |
| Vasarri, MV | 1 |
| Arienti, F | 1 |
| Vergani, P | 1 |
| Yılmaz Çebi, A | 1 |
| Kılıçarslan, O | 1 |
| Uçar, D | 1 |
| Ho, M | 1 |
| Tadrous, M | 1 |
| Iacono, A | 1 |
| Suda, K | 1 |
| Gomes, T | 1 |
| Favre, G | 3 |
| Gerbier, E | 3 |
| Maisonneuve, E | 3 |
| Pomar, L | 3 |
| Winterfeld, U | 3 |
| Lepigeon, K | 3 |
| Bloemenkamp, KWM | 3 |
| de Bruin, O | 3 |
| Hurley, E | 3 |
| Nordeng, H | 3 |
| Siiskonen, SJ | 3 |
| Sturkenboom, MCJM | 3 |
| Baud, D | 3 |
| Panchaud, A | 3 |
| Alemu, A | 3 |
| Bitew, ZW | 3 |
| Seid, G | 3 |
| Diriba, G | 3 |
| Gashu, E | 3 |
| Berhe, N | 3 |
| Mariam, SH | 3 |
| Gumi, B | 3 |
| Navarro, R | 2 |
| Paredes, JL | 2 |
| Tucto, L | 2 |
| Medina, C | 2 |
| Angles-Yanqui, E | 2 |
| Nario, JC | 2 |
| Ruiz-Cabrejos, J | 2 |
| Quintana, JL | 3 |
| Turpo-Espinoza, K | 2 |
| Mejia-Cordero, F | 2 |
| Aphang-Lam, M | 2 |
| Florez, J | 2 |
| Carrasco-Escobar, G | 2 |
| Ochoa, TJ | 2 |
| Moraes, VY | 2 |
| Marra, AR | 2 |
| Matos, LL | 2 |
| Serpa Neto, A | 3 |
| Rizzo, LV | 3 |
| Cendoroglo Neto, M | 2 |
| Lenza, M | 2 |
| Higgins, AM | 2 |
| Lorenzi, E | 2 |
| Murthy, S | 6 |
| McQuilten, Z | 2 |
| Mouncey, PR | 2 |
| Al-Beidh, F | 2 |
| Annane, D | 2 |
| Arabi, YM | 4 |
| Beane, A | 3 |
| van Bentum-Puijk, W | 2 |
| Bhimani, Z | 2 |
| Bonten, MJM | 2 |
| Bradbury, CA | 2 |
| Brunkhorst, FM | 2 |
| Burrell, A | 2 |
| Buzgau, A | 2 |
| Buxton, M | 2 |
| Charles, WN | 2 |
| Cove, M | 2 |
| Detry, MA | 2 |
| Estcourt, LJ | 2 |
| Fagbodun, EO | 2 |
| Girard, TD | 2 |
| Goligher, EC | 2 |
| Goossens, H | 2 |
| Haniffa, R | 2 |
| Horvat, CM | 2 |
| Huang, DT | 2 |
| Ichihara, N | 2 |
| Lamontagne, F | 5 |
| McAuley, DF | 2 |
| McGlothlin, A | 2 |
| McGuinness, SP | 2 |
| McVerry, BJ | 3 |
| Neal, MD | 2 |
| Nichol, AD | 2 |
| Parke, RL | 2 |
| Parker, JC | 2 |
| Parry-Billings, K | 2 |
| Peters, SEC | 2 |
| Reyes, LF | 2 |
| Rowan, KM | 2 |
| Saito, H | 2 |
| Santos, MS | 2 |
| Saunders, CT | 2 |
| Serpa-Neto, A | 3 |
| Seymour, CW | 2 |
| Shankar-Hari, M | 3 |
| Stronach, LM | 2 |
| Turgeon, AF | 3 |
| Turner, AM | 2 |
| van de Veerdonk, FL | 2 |
| Zarychanski, R | 6 |
| Green, C | 2 |
| Lewis, RJ | 2 |
| Angus, DC | 3 |
| McArthur, CJ | 2 |
| Derde, LPG | 2 |
| Gordon, AC | 3 |
| Webb, SA | 3 |
| Lawler, PR | 2 |
| Kanashiro-Takeuchi, RM | 1 |
| Kazmierczak, K | 1 |
| Liang, J | 1 |
| Takeuchi, LM | 1 |
| Sitbon, YH | 1 |
| Szczesna-Cordary, D | 1 |
| Barrett, R | 2 |
| Lin, SX | 1 |
| Culliford, D | 1 |
| Fraser, S | 1 |
| Edwards, CJ | 1 |
| Hill, A | 2 |
| Mirchandani, M | 1 |
| Pinheiro, FO | 1 |
| Martins Carvalho, M | 1 |
| Madureira, P | 1 |
| Seabra Rato, M | 1 |
| Macedo, F | 1 |
| Costa, L | 3 |
| Mitjà, O | 2 |
| Reis, G | 2 |
| Spivak, AM | 1 |
| Sarwar, A | 1 |
| Webb, B | 2 |
| Hill, MD | 1 |
| Smith, D | 2 |
| Kremsner, P | 2 |
| Curran, M | 1 |
| Carter, D | 1 |
| Alexander, J | 1 |
| Corbacho, M | 1 |
| Lee, TC | 6 |
| Hullsiek, KH | 4 |
| McDonald, EG | 6 |
| Hess, R | 1 |
| Hughes, M | 1 |
| Baeten, JM | 3 |
| Schwartz, I | 2 |
| Metz, L | 1 |
| Richer, L | 1 |
| Chew, KW | 1 |
| Daar, E | 1 |
| Wohl, D | 1 |
| Dunne, M | 1 |
| Dhibar, DP | 3 |
| Arora, N | 2 |
| Chaudhary, D | 1 |
| Prakash, A | 4 |
| Medhi, B | 4 |
| Singla, N | 2 |
| Mohindra, R | 3 |
| Suri, V | 3 |
| Bhalla, A | 3 |
| Sharma, N | 3 |
| Singh, MP | 2 |
| Lakshmi, PVM | 1 |
| Goyal, K | 1 |
| Hossain, MI | 1 |
| Myers, M | 1 |
| Herath, D | 1 |
| Aldhumani, AH | 1 |
| Boesger, H | 1 |
| Hines, JV | 1 |
| Naggie, S | 3 |
| Milstone, A | 1 |
| Castro, M | 1 |
| Lakshmi, S | 1 |
| Anderson, DJ | 1 |
| Cahuayme-Zuniga, L | 1 |
| Turner, KB | 1 |
| Cohen, LW | 1 |
| Currier, J | 1 |
| Fraulo, E | 1 |
| Friedland, A | 2 |
| Garg, J | 1 |
| George, A | 2 |
| Mulder, H | 1 |
| Olson, RE | 1 |
| O'Brien, EC | 1 |
| Rothman, RL | 1 |
| Shenkman, E | 1 |
| Shostak, J | 1 |
| Woods, CW | 2 |
| Anstrom, KJ | 2 |
| Hernandez, AF | 3 |
| Damirchi, M | 1 |
| Aghaie, M | 1 |
| Sedighi, S | 1 |
| Tavassoli, S | 1 |
| Roshandel, G | 1 |
| Hassani, M | 1 |
| Abdolahi, N | 1 |
| Wang, SSY | 1 |
| Xu, C | 2 |
| Corrêa, BSG | 1 |
| de Barros, S | 1 |
| Vaz, JB | 1 |
| Peres, MA | 1 |
| Uchiyama, MK | 1 |
| da Silva, AA | 1 |
| Furukawa, LNS | 1 |
| Hu, LY | 1 |
| Yuan, Y | 2 |
| Wen, ZX | 1 |
| Hu, YY | 1 |
| Yin, MM | 1 |
| Hu, YJ | 1 |
| Llanos-Cuentas, A | 1 |
| Schwalb, A | 1 |
| Delfin, B | 1 |
| Alvarez, F | 1 |
| Ugarte-Gil, C | 1 |
| Guerra Gronerth, RI | 1 |
| Lucchetti, A | 1 |
| Grogl, M | 1 |
| Gotuzzo, E | 2 |
| Burdzhiev, NT | 1 |
| Hu, H | 1 |
| Li, J | 5 |
| Lozanova, VV | 1 |
| Kandinska, MI | 1 |
| Wang, M | 3 |
| Castro-Jiménez, A | 1 |
| Gratacós-Gómez, AR | 1 |
| Florido López, F | 1 |
| Al Muqarrab, F | 1 |
| Schwartz, RA | 2 |
| Almohssen, AA | 1 |
| Peretti, M | 1 |
| Rebaudet, S | 1 |
| Chiche, L | 1 |
| Pegliasco, H | 1 |
| Coquet, E | 1 |
| Tanaka, T | 1 |
| Okamoto, M | 1 |
| Matsuo, N | 1 |
| Naitou-Nishida, Y | 1 |
| Nouno, T | 1 |
| Kojima, T | 1 |
| Nishii, Y | 1 |
| Uchiyashiki, Y | 1 |
| Takeoka, H | 1 |
| Nagasaki, Y | 2 |
| Ejsmont, A | 1 |
| Warowicka, A | 1 |
| Broniarczyk, J | 1 |
| Goscianska, J | 1 |
| Learoyd, AE | 1 |
| Arnold, L | 1 |
| Reid, F | 1 |
| Beckley-Hoelscher, N | 1 |
| Casian, A | 1 |
| Sangle, S | 1 |
| Morton, N | 1 |
| Nel, L | 1 |
| Cape, A | 1 |
| John, S | 1 |
| Kim, S | 3 |
| Shivapatham, D | 1 |
| Luqmani, R | 1 |
| Jayne, D | 1 |
| Galloway, J | 1 |
| Douiri, A | 1 |
| D'Cruz, D | 1 |
| Lucchetta, R | 1 |
| Matuoka, JY | 1 |
| Oliveira Junior, HA | 1 |
| Oliveira, G | 1 |
| Cavalcanti, AB | 3 |
| Azevedo, L | 1 |
| Berwanger, O | 3 |
| Lopes, RD | 3 |
| Rosa, RG | 3 |
| Veiga, VC | 3 |
| Avezum, Á | 3 |
| Hempenius, M | 1 |
| Bots, SH | 1 |
| Groenwold, RHH | 1 |
| de Boer, A | 1 |
| Klungel, OH | 1 |
| Gardarsdottir, H | 1 |
| Vaz, ES | 1 |
| Vassiliades, SV | 1 |
| Giarolla, J | 1 |
| Polli, MC | 1 |
| Parise-Filho, R | 1 |
| Seydi, E | 1 |
| Hassani, MK | 1 |
| Naderpour, S | 1 |
| Arjmand, A | 1 |
| Pourahmad, J | 1 |
| Kilit, TP | 1 |
| Özyiğit, F | 1 |
| Erarslan, S | 1 |
| Onbaşı, K | 1 |
| Ertuğrul, A | 1 |
| Özkaya, D | 1 |
| Nazıroğlu, M | 1 |
| Sadeghizadeh, M | 1 |
| Asadollahi, E | 1 |
| Jahangiri, B | 1 |
| Yadollahzadeh, M | 1 |
| Mohajeri, M | 1 |
| Afsharpad, M | 1 |
| Najafi, F | 1 |
| Rezaie, N | 1 |
| Eskandari, M | 1 |
| Tavakoli-Ardakani, M | 1 |
| Feizabadi, F | 1 |
| Masjedi, MR | 1 |
| Steinbronn, C | 2 |
| Chhonker, YS | 2 |
| Leingang, H | 1 |
| Heller, KB | 1 |
| Krows, ML | 2 |
| Paasche-Orlow, M | 1 |
| Laufer, M | 1 |
| Landovitz, R | 1 |
| Wener, M | 3 |
| Murry, DJ | 2 |
| Arnold, SLM | 2 |
| Feng, Y | 2 |
| Liu, S | 2 |
| Pan, S | 1 |
| Wei, L | 1 |
| Ma, Y | 1 |
| Liu, Z | 4 |
| Xing, Y | 1 |
| Wang, J | 4 |
| Cui, Q | 1 |
| Wang, T | 1 |
| Cai, C | 1 |
| Marques, RZ | 1 |
| Kochi, LY | 1 |
| Guzman-Tordecilla, M | 1 |
| Malage, L | 1 |
| Juneau, P | 1 |
| Gomes, MP | 1 |
| Hourdain, J | 1 |
| Franceschi, F | 1 |
| Mercier, N | 1 |
| Belhadi, D | 1 |
| DeChanet, A | 1 |
| Delmas, C | 1 |
| Saillard, J | 1 |
| Dumousseaux, M | 1 |
| Le Mestre, S | 1 |
| Fougerou-Leurent, C | 1 |
| Ferrane, A | 1 |
| Burdet, C | 1 |
| Espérou, H | 1 |
| Ader, F | 5 |
| Peiffer-Smadja, N | 7 |
| Poissy, J | 1 |
| Andrejak, C | 2 |
| Paiva, JA | 1 |
| Tacconelli, E | 2 |
| Staub, T | 1 |
| Greil, R | 1 |
| Costagliola, D | 2 |
| Mentre, F | 3 |
| Yazdanpanah, Y | 3 |
| Diallo, A | 1 |
| Hong, H | 1 |
| Hu, M | 1 |
| Halabi, S | 1 |
| Amaravadi, R | 1 |
| Abella, BS | 3 |
| Portillo-Vázquez, AM | 1 |
| Rajasingham, R | 6 |
| Hayes, KN | 1 |
| Riester, MR | 1 |
| Silva, JBB | 1 |
| Cupp, MA | 1 |
| Lee, Y | 1 |
| Zullo, AR | 1 |
| El-Sayed, A | 1 |
| Elmansi, HM | 1 |
| Shalan, S | 1 |
| Eid, M | 1 |
| Morin, C | 1 |
| Padki, A | 1 |
| Wong, A | 2 |
| Miano, T | 1 |
| Kane-Gill, SL | 1 |
| Cozzi, G | 1 |
| Deveau, R | 1 |
| Rathod, D | 2 |
| Kargirwar, K | 1 |
| Kumar, V | 1 |
| Shalia, K | 1 |
| Singhal, P | 1 |
| Aït Moussa, L | 1 |
| Tebaa, A | 1 |
| Alj, L | 1 |
| Sefiani, H | 1 |
| Meski, FZ | 1 |
| Khattabi, A | 1 |
| Soulaymani Bencheikh, R | 1 |
| Finkelstein, J | 1 |
| Huo, X | 1 |
| Abdelmageed, N | 1 |
| Twafik, WA | 1 |
| Morad, OA | 1 |
| Haridy, M | 1 |
| Hassan, R | 1 |
| Ahmed, M | 1 |
| El-Zorba, HY | 1 |
| El-Banna, HA | 1 |
| Seddek, AL | 1 |
| Ghallab, A | 1 |
| Morad, SAF | 1 |
| Silva, IF | 1 |
| Enes, KP | 1 |
| Rocha, GM | 1 |
| Varotti, FP | 1 |
| Barbosa, LA | 1 |
| Thomé, RG | 1 |
| Santos, HBD | 1 |
| Delen, LA | 1 |
| Gok, A | 1 |
| Kasapoglu, US | 1 |
| Cagasar, O | 1 |
| Gok, Z | 1 |
| Berber, N | 1 |
| Derya, S | 1 |
| Tetik, B | 1 |
| Alruwaili, M | 2 |
| Jarrar, B | 1 |
| Jarrar, Q | 1 |
| Goh, KW | 1 |
| Moshawih, S | 1 |
| Ardianto, C | 1 |
| Ming, LC | 1 |
| Kowatsch, MM | 1 |
| Lajoie, J | 1 |
| Mwangi, L | 1 |
| Omollo, K | 1 |
| Oyugi, J | 1 |
| Hollett, N | 1 |
| Kimani, J | 1 |
| Fowke, KR | 1 |
| Chaudhary, S | 1 |
| Joshi, A | 1 |
| Sesham, K | 1 |
| Rai, P | 1 |
| Kumar, S | 7 |
| Mridha, AR | 1 |
| Baitha, U | 2 |
| Nag, TC | 1 |
| Yadav, SC | 1 |
| Barbosa, AN | 1 |
| Chebabo, A | 1 |
| Starling, C | 1 |
| Pérez, C | 1 |
| Cunha, CA | 1 |
| de Luna, D | 1 |
| Nunes, EP | 2 |
| Zambrano, G | 1 |
| Ferreira, JC | 1 |
| Croda, J | 1 |
| Falavigna, M | 2 |
| Gomes-da-Silva, MM | 1 |
| Thormann, M | 1 |
| Cimerman, S | 1 |
| Parahiba, SM | 1 |
| Tanni, S | 1 |
| Bernardo, WM | 1 |
| Rodriguez-Morales, AJ | 1 |
| Klebanov, N | 1 |
| Pahalyants, V | 1 |
| Said, JT | 1 |
| Murphy, WS | 1 |
| Theodosakis, N | 1 |
| Scarry, J | 1 |
| Duey, S | 1 |
| Klevens, M | 1 |
| Lilly, E | 1 |
| Semenov, YR | 1 |
| Alsmadi, MM | 1 |
| Jaradat, MM | 1 |
| Obaidat, RM | 1 |
| Alnaief, M | 1 |
| Tayyem, R | 1 |
| Idkaidek, N | 1 |
| Kabore, Y | 1 |
| Vatrinet, R | 1 |
| Guindo, O | 1 |
| Moussa, SH | 1 |
| Schilling, WHK | 1 |
| Grais, RF | 1 |
| Zhou, G | 1 |
| Verweij, S | 1 |
| Bijlsma, MJ | 1 |
| de Vos, S | 1 |
| Oude Rengerink, K | 1 |
| Pasmooij, AMG | 1 |
| van Baarle, D | 1 |
| Niesters, HGM | 1 |
| Mol, P | 1 |
| Vonk, JM | 1 |
| Hak, E | 1 |
| Lee, E | 1 |
| Lee, SY | 1 |
| Jeong, J | 1 |
| Bang, J | 1 |
| Oh, J | 1 |
| Shin, SD | 1 |
| Kim, NJ | 2 |
| Choe, PG | 2 |
| Oh, MD | 2 |
| Perlis, RH | 1 |
| Lunz Trujillo, K | 1 |
| Green, J | 1 |
| Safarpour, A | 1 |
| Druckman, JN | 1 |
| Santillana, M | 1 |
| Ognyanova, K | 1 |
| Lazer, D | 1 |
| Aldhafiri, WN | 1 |
| Soni, D | 1 |
| Trivedi, N | 2 |
| Johnson, C | 1 |
| Karita, HCS | 1 |
| Barnabas, R | 1 |
| Arnold, SL | 1 |
| Souza-Silva, MVR | 1 |
| Pereira, DN | 1 |
| Pires, MC | 1 |
| Vasconcelos, IM | 1 |
| Schwarzbold, AV | 1 |
| Vasconcelos, DH | 1 |
| Pereira, EC | 1 |
| Manenti, ERF | 1 |
| Costa, FR | 1 |
| Aguiar, FC | 1 |
| Anschau, F | 1 |
| Bartolazzi, F | 1 |
| Nascimento, GF | 1 |
| Vianna, HR | 1 |
| Batista, JDL | 1 |
| Machado-Rugolo, J | 1 |
| Ruschel, KB | 1 |
| Ferreira, MAP | 1 |
| Oliveira, LS | 1 |
| Menezes, LSM | 1 |
| Ziegelmann, PK | 1 |
| Tofani, MGT | 1 |
| Bicalho, MAC | 1 |
| Nogueira, MCA | 1 |
| Guimarães-Júnior, MH | 1 |
| Aguiar, RLO | 1 |
| Rios, DRA | 1 |
| Polanczyk, CA | 1 |
| Marcolino, MS | 1 |
| Aiello, F | 1 |
| Balzano, F | 1 |
| Uccello Barretta, G | 1 |
| D'Acquarica, I | 2 |
| Mazzoccanti, G | 1 |
| Agranat, I | 2 |
| Aina, OO | 1 |
| Busari, AA | 1 |
| Oladele, DA | 1 |
| Esezobor, C | 1 |
| Akase, IE | 1 |
| Okwuraiwe, AP | 1 |
| Okoyenta, CO | 1 |
| Otrofanowei, E | 1 |
| James, AB | 1 |
| Bamidele, TA | 1 |
| Olopade, OB | 1 |
| Ajibaye, O | 1 |
| Musa, AZ | 1 |
| Salako, AO | 1 |
| Agabi, OP | 1 |
| Olakiigbe, AK | 1 |
| Akintan, PE | 1 |
| Amoo, OS | 1 |
| Ima-Edomwonyi, E | 1 |
| Raheem, TY | 1 |
| David, AN | 1 |
| Akinbode, GO | 1 |
| Nmadu, N | 1 |
| Osuolale, KA | 1 |
| Fadipe, B | 1 |
| Abiola, A | 1 |
| Tade, T | 1 |
| Audu, RA | 1 |
| Adeyemo, WL | 1 |
| Ezechi, OC | 1 |
| Bode, C | 1 |
| Salako, BL | 1 |
| Vieux, N | 1 |
| Perrier, Q | 1 |
| Bedouch, P | 1 |
| Epaulard, O | 1 |
| Atefi, N | 1 |
| Goodarzi, A | 2 |
| Riahi, T | 1 |
| Khodabandehloo, N | 1 |
| Talebi Taher, M | 1 |
| Najar Nobari, N | 2 |
| Seirafianpour, F | 2 |
| Mahdi, Z | 1 |
| Baghestani, A | 1 |
| Valizadeh, R | 1 |
| Song, R | 1 |
| Chen, X | 2 |
| Li, B | 1 |
| Ni, J | 1 |
| Zhang, H | 1 |
| Liang, X | 1 |
| Zou, L | 3 |
| Yang, F | 1 |
| Li, G | 1 |
| Guo, X | 1 |
| Mao, F | 1 |
| Lei, C | 1 |
| Sui, J | 1 |
| Li, W | 3 |
| Jin, R | 2 |
| Rolain, JM | 3 |
| Touret, F | 2 |
| de Lamballerie, X | 2 |
| Yao, X | 2 |
| Ye, F | 1 |
| Zhang, M | 3 |
| Cui, C | 2 |
| Huang, B | 1 |
| Niu, P | 1 |
| Zhao, L | 2 |
| Dong, E | 1 |
| Song, C | 2 |
| Zhan, S | 1 |
| Lu, R | 1 |
| Li, H | 6 |
| Tan, W | 1 |
| Sahraei, Z | 1 |
| Shabani, M | 1 |
| Shokouhi, S | 2 |
| Saffaei, A | 2 |
| Zhou, D | 1 |
| Dai, SM | 1 |
| Tong, Q | 1 |
| Duan, Y | 1 |
| Zhu, HL | 1 |
| Zhou, C | 1 |
| Hu, TY | 1 |
| Frieman, M | 1 |
| Wolfram, J | 1 |
| Hoang, VT | 7 |
| Meddeb, L | 1 |
| Courjon, J | 2 |
| Giordanengo, V | 1 |
| Vieira, VE | 1 |
| Tissot Dupont, H | 1 |
| Chabrière, E | 2 |
| La Scola, B | 3 |
| Pagliano, P | 1 |
| Piazza, O | 1 |
| De Caro, F | 1 |
| Ascione, T | 1 |
| Filippelli, A | 1 |
| Guastalegname, M | 1 |
| Vallone, A | 1 |
| Atluri, S | 1 |
| Manchikanti, L | 1 |
| Hirsch, JA | 1 |
| Kupferschmidt, K | 4 |
| Cohen, J | 1 |
| Zhao, Y | 2 |
| Zhang, F | 1 |
| Wang, Q | 2 |
| Li, T | 2 |
| Qin, Y | 1 |
| Yan, X | 1 |
| Zeng, X | 1 |
| Zhang, S | 3 |
| Kim, AHJ | 5 |
| Sparks, JA | 8 |
| Liew, JW | 7 |
| Putman, MS | 3 |
| Berenbaum, F | 4 |
| Duarte-García, A | 4 |
| Graef, ER | 7 |
| Korsten, P | 4 |
| Sattui, SE | 5 |
| Sirotich, E | 3 |
| Ugarte-Gil, MF | 3 |
| Webb, K | 2 |
| Grainger, R | 3 |
| Sargiacomo, C | 1 |
| Sotgia, F | 1 |
| Lisanti, MP | 1 |
| Agrawal, S | 1 |
| Goel, AD | 1 |
| Gupta, N | 3 |
| Yazdany, J | 2 |
| Gandolfini, I | 1 |
| Delsante, M | 1 |
| Fiaccadori, E | 1 |
| Zaza, G | 1 |
| Manenti, L | 1 |
| Degli Antoni, A | 1 |
| Peruzzi, L | 1 |
| Riella, LV | 1 |
| Cravedi, P | 1 |
| Maggiore, U | 1 |
| Ye, Q | 1 |
| Wang, B | 3 |
| Mao, J | 1 |
| Shang, S | 1 |
| Shu, Q | 1 |
| Zhang, T | 1 |
| Molina, JM | 2 |
| Delaugerre, C | 2 |
| Le Goff, J | 2 |
| Mela-Lima, B | 1 |
| Ponscarme, D | 1 |
| Goldwirt, L | 1 |
| de Castro, N | 1 |
| Scuccimarri, R | 1 |
| Sutton, E | 1 |
| Fitzcharles, MA | 1 |
| Lu, CC | 1 |
| Chen, MY | 1 |
| Lee, WS | 1 |
| Chang, YL | 2 |
| Keshtkar-Jahromi, M | 1 |
| Bavari, S | 1 |
| Marmor, MF | 2 |
| Marotto, D | 1 |
| Sarzi-Puttini, P | 2 |
| Fantini, J | 4 |
| Di Scala, C | 1 |
| Chahinian, H | 4 |
| Yahi, N | 4 |
| Janniger, CK | 1 |
| Barlow, A | 1 |
| Landolf, KM | 1 |
| Barlow, B | 1 |
| Yeung, SYA | 1 |
| Heavner, JJ | 1 |
| Claassen, CW | 1 |
| Heavner, MS | 1 |
| Al-Tawfiq, JA | 1 |
| Memish, ZA | 2 |
| Kutlu, Ö | 1 |
| Metin, A | 1 |
| Lodise, TP | 1 |
| Rybak, MJ | 1 |
| Roden, DM | 4 |
| Harrington, RA | 2 |
| Poppas, A | 2 |
| Russo, AM | 2 |
| Buckner, F | 1 |
| Juurlink, DN | 1 |
| Ferner, RE | 1 |
| Aronson, JK | 1 |
| Peschken, CA | 1 |
| Jakhar, D | 1 |
| Kaur, I | 1 |
| Nau, JY | 4 |
| Yousefzadegan, S | 1 |
| Rezaei, N | 1 |
| Spezzani, V | 1 |
| Piunno, A | 1 |
| Iselin, HU | 1 |
| Jaffe, S | 1 |
| Serafin, MB | 1 |
| Bottega, A | 1 |
| Foletto, VS | 1 |
| da Rosa, TF | 1 |
| Hörner, A | 1 |
| Hörner, R | 1 |
| Bartiromo, M | 1 |
| Borchi, B | 1 |
| Botta, A | 2 |
| Bagalà, A | 1 |
| Lugli, G | 1 |
| Tilli, M | 1 |
| Cavallo, A | 1 |
| Xhaferi, B | 1 |
| Cutruzzulà, R | 1 |
| Vaglio, A | 2 |
| Bresci, S | 1 |
| Larti, A | 1 |
| Bartoloni, A | 1 |
| Cirami, C | 1 |
| Hillaker, E | 1 |
| Belfer, JJ | 1 |
| Bondici, A | 1 |
| Murad, H | 1 |
| Dumkow, LE | 1 |
| Shah, S | 1 |
| Das, S | 5 |
| Jain, A | 1 |
| Misra, DP | 3 |
| Negi, VS | 1 |
| Pereira, BB | 1 |
| Gao, J | 2 |
| Hu, S | 2 |
| Sanders, JM | 1 |
| Monogue, ML | 1 |
| Jodlowski, TZ | 1 |
| Cutrell, JB | 1 |
| De Luna, G | 1 |
| Habibi, A | 1 |
| Deux, JF | 1 |
| Colard, M | 1 |
| Pham Hung d'Alexandry d'Orengiani, AL | 1 |
| Schlemmer, F | 3 |
| Joher, N | 1 |
| Kassasseya, C | 1 |
| Pawlotsky, JM | 2 |
| Ourghanlian, C | 2 |
| Michel, M | 3 |
| Mekontso-Dessap, A | 1 |
| Bartolucci, P | 1 |
| Boyarsky, BJ | 1 |
| Po-Yu Chiang, T | 1 |
| Werbel, WA | 1 |
| Durand, CM | 1 |
| Avery, RK | 2 |
| Getsin, SN | 1 |
| Jackson, KR | 1 |
| Kernodle, AB | 1 |
| Van Pilsum Rasmussen, SE | 1 |
| Massie, AB | 1 |
| Segev, DL | 1 |
| Garonzik-Wang, JM | 1 |
| Patrì, A | 2 |
| Fabbrocini, G | 2 |
| Alia, E | 1 |
| Grant-Kels, JM | 2 |
| Guidon, AC | 1 |
| Amato, AA | 1 |
| Rome, BN | 1 |
| Avorn, J | 1 |
| Stevens, RW | 1 |
| Estes, L | 1 |
| Rivera, C | 1 |
| Breslin, N | 2 |
| Baptiste, C | 2 |
| Gyamfi-Bannerman, C | 2 |
| Miller, R | 2 |
| Martinez, R | 1 |
| Bernstein, K | 1 |
| Ring, L | 1 |
| Landau, R | 1 |
| Purisch, S | 1 |
| Friedman, AM | 1 |
| Fuchs, K | 2 |
| Sutton, D | 1 |
| Andrikopoulou, M | 1 |
| Rupley, D | 1 |
| Sheen, JJ | 1 |
| Aubey, J | 1 |
| Zork, N | 1 |
| Moroz, L | 1 |
| Mourad, M | 1 |
| Wapner, R | 1 |
| Simpson, LL | 1 |
| D'Alton, ME | 1 |
| Goffman, D | 2 |
| Brufsky, A | 1 |
| Şimşek Yavuz, S | 1 |
| Gendrot, M | 1 |
| Javelle, E | 1 |
| Clerc, A | 1 |
| Savini, H | 1 |
| Pradines, B | 1 |
| Simard, JF | 1 |
| Harrison, C | 2 |
| Konig, MF | 3 |
| Proulx, L | 1 |
| Richards, DP | 1 |
| Robinson, PC | 4 |
| Young, KJ | 2 |
| Kim, AH | 4 |
| Joob, B | 2 |
| Wiwanitkit, V | 2 |
| Heldwein, FL | 1 |
| Calado, A | 1 |
| Sinha, N | 1 |
| Balayla, G | 1 |
| LaCourse, S | 1 |
| John-Stewart, G | 1 |
| Adams Waldorf, KM | 1 |
| Costanzo, M | 1 |
| De Giglio, MAR | 1 |
| Roviello, GN | 1 |
| Oldenburg, CE | 1 |
| Doan, T | 1 |
| Sarma, P | 2 |
| Kaur, H | 2 |
| Kumar, H | 1 |
| Mahendru, D | 1 |
| Avti, P | 1 |
| Bhattacharyya, A | 2 |
| Prajapat, M | 2 |
| Shekhar, N | 1 |
| Singh, R | 3 |
| Singh, A | 3 |
| Sapp, JL | 1 |
| Alqarawi, W | 1 |
| MacIntyre, CJ | 1 |
| Tadros, R | 1 |
| Steinberg, C | 1 |
| Roberts, JD | 1 |
| Laksman, Z | 1 |
| Healey, JS | 1 |
| Krahn, AD | 1 |
| Fernández-Ruiz, M | 3 |
| Andrés, A | 2 |
| Loinaz, C | 2 |
| Delgado, JF | 1 |
| López-Medrano, F | 2 |
| San Juan, R | 2 |
| González, E | 2 |
| Polanco, N | 1 |
| Folgueira, MD | 2 |
| Lalueza, A | 1 |
| Lumbreras, C | 2 |
| Aguado, JM | 3 |
| Wander, P | 1 |
| Epstein, M | 1 |
| Bernstein, D | 1 |
| El Boussadani, B | 1 |
| Benajiba, C | 1 |
| Aajal, A | 1 |
| Ait Brik, A | 1 |
| Ammour, O | 1 |
| El Hangouch, J | 1 |
| Oussama, O | 1 |
| Oussama, B | 1 |
| Tahiri, N | 1 |
| Raissuni, Z | 1 |
| Chabner, BA | 1 |
| Elens, L | 2 |
| Langman, LJ | 1 |
| Hesselink, DA | 1 |
| Bergan, S | 1 |
| Moes, DJAR | 1 |
| Molinaro, M | 1 |
| Venkataramanan, R | 1 |
| Lemaitre, F | 3 |
| Gorham, J | 1 |
| Vincent, JL | 1 |
| Mahmoudjafari, Z | 1 |
| Alexander, M | 1 |
| Roddy, J | 1 |
| Shaw, R | 1 |
| Shigle, TL | 1 |
| Timlin, C | 1 |
| Culos, K | 1 |
| Lee, SH | 1 |
| Son, H | 1 |
| Peck, KR | 2 |
| Zhao, M | 1 |
| Jean, SS | 1 |
| Lee, PI | 1 |
| Hsueh, PR | 1 |
| Principi, N | 1 |
| Esposito, S | 1 |
| Rathi, S | 1 |
| Ish, P | 1 |
| Kalantri, A | 1 |
| Kalantri, S | 1 |
| Lipworth, B | 2 |
| Chan, R | 2 |
| Lipworth, S | 1 |
| RuiWen Kuo, C | 1 |
| Alpern, JD | 1 |
| Gertner, E | 1 |
| Song, J | 1 |
| Kang, S | 1 |
| Choi, SW | 2 |
| Seo, KW | 1 |
| Lee, S | 3 |
| So, MW | 1 |
| Lim, DH | 1 |
| Aminian, A | 1 |
| Kermansaravi, M | 1 |
| Azizi, S | 1 |
| Alibeigi, P | 1 |
| Safamanesh, S | 1 |
| Mousavimaleki, A | 1 |
| Rezaei, MT | 1 |
| Faridi, M | 1 |
| Mokhber, S | 1 |
| Pazouki, A | 1 |
| Safari, S | 1 |
| Falcão, MB | 1 |
| Pamplona de Góes Cavalcanti, L | 1 |
| Filgueiras Filho, NM | 1 |
| Antunes de Brito, CA | 1 |
| Khaddour, K | 1 |
| Sikora, A | 1 |
| Tahir, N | 1 |
| Nepomuceno, D | 1 |
| Huang, T | 1 |
| Hussain, FA | 1 |
| Njoku, FU | 1 |
| Saraf, SL | 1 |
| Molokie, RE | 1 |
| Gordeuk, VR | 2 |
| Han, J | 1 |
| Hsu, JJ | 1 |
| Gaynor, P | 1 |
| Kamath, M | 1 |
| Fan, A | 1 |
| Al-Saffar, F | 1 |
| Cruz, D | 1 |
| Nsair, A | 1 |
| Lentini, G | 1 |
| Cavalluzzi, MM | 1 |
| Habtemariam, S | 1 |
| Perricone, C | 1 |
| Triggianese, P | 1 |
| Bartoloni, E | 1 |
| Cafaro, G | 1 |
| Bonifacio, AF | 1 |
| Bursi, R | 1 |
| Perricone, R | 1 |
| Gerli, R | 1 |
| Moiseev, S | 1 |
| Avdeev, S | 1 |
| Brovko, M | 1 |
| Novikov, P | 1 |
| Fomin, V | 1 |
| Xie, W | 1 |
| Soresina, A | 1 |
| Moratto, D | 1 |
| Chiarini, M | 1 |
| Paolillo, C | 1 |
| Baresi, G | 1 |
| Focà, E | 2 |
| Bezzi, M | 1 |
| Baronio, B | 1 |
| Giacomelli, M | 1 |
| Badolato, R | 1 |
| Khunti, S | 1 |
| Khunti, N | 1 |
| Seidu, S | 1 |
| Khunti, K | 1 |
| Mathies, D | 1 |
| Rauschning, D | 1 |
| Wagner, U | 1 |
| Mueller, F | 1 |
| Maibaum, M | 1 |
| Binnemann, C | 1 |
| Waldeck, S | 1 |
| Thinnes, K | 1 |
| Braun, M | 1 |
| Schmidbauer, W | 1 |
| Hagen, RM | 1 |
| Bickel, C | 1 |
| Dondorp, AM | 1 |
| Hayat, M | 1 |
| Aryal, D | 1 |
| Schultz, MJ | 1 |
| Licciardi, F | 1 |
| Giani, T | 1 |
| Baldini, L | 1 |
| Favalli, EG | 3 |
| Caporali, R | 4 |
| Cimaz, R | 1 |
| Parperis, K | 1 |
| Abena, PM | 1 |
| Decloedt, EH | 2 |
| Bottieau, E | 3 |
| Suleman, F | 1 |
| Adejumo, P | 1 |
| Sam-Agudu, NA | 1 |
| Muyembe TamFum, JJ | 1 |
| Seydi, M | 1 |
| Eholie, SP | 1 |
| Mills, EJ | 3 |
| Kallay, O | 1 |
| Zumla, A | 1 |
| Nachega, JB | 2 |
| Beauverd, Y | 1 |
| Adam, Y | 1 |
| Assouline, B | 1 |
| Samii, K | 2 |
| Fontana, F | 1 |
| Alfano, G | 1 |
| Mori, G | 1 |
| Amurri, A | 1 |
| Tei, L | 1 |
| Ballestri, M | 1 |
| Leonelli, M | 1 |
| Facchini, F | 1 |
| Damiano, F | 1 |
| Magistroni, R | 1 |
| Cappelli, G | 1 |
| Tomcsányi, J | 1 |
| Tomcsányi, K | 1 |
| Al-Abdi, S | 1 |
| Al-Aamri, M | 1 |
| Manning, TJ | 1 |
| Thomas-Richardson, J | 1 |
| Cowan, M | 1 |
| Beard, T | 1 |
| Sarayani, A | 1 |
| Cicali, B | 1 |
| Henriksen, CH | 1 |
| Brown, JD | 1 |
| Goyal, M | 2 |
| Monti, S | 2 |
| Montecucco, C | 5 |
| London, AJ | 1 |
| Kimmelman, J | 1 |
| Fihn, SD | 1 |
| Perencevich, E | 1 |
| Bradley, SM | 2 |
| Tripathy, JP | 1 |
| Pereira, MR | 1 |
| Mohan, S | 1 |
| Cohen, DJ | 1 |
| Husain, SA | 1 |
| Dube, GK | 1 |
| Ratner, LE | 1 |
| Arcasoy, S | 1 |
| Aversa, MM | 1 |
| Benvenuto, LJ | 1 |
| Dadhania, DM | 2 |
| Kapur, S | 2 |
| Dove, LM | 1 |
| Brown, RS | 2 |
| Rosenblatt, RE | 1 |
| Samstein, B | 1 |
| Uriel, N | 5 |
| Farr, MA | 2 |
| Satlin, M | 1 |
| Small, CB | 1 |
| Walsh, TJ | 1 |
| Kodiyanplakkal, RP | 2 |
| Miko, BA | 1 |
| Aaron, JG | 1 |
| Tsapepas, DS | 1 |
| Emond, JC | 1 |
| Verna, EC | 1 |
| Alexander, PE | 2 |
| Debono, VB | 1 |
| Mammen, MJ | 2 |
| Iorio, A | 1 |
| Aryal, K | 1 |
| Deng, D | 1 |
| Brocard, E | 1 |
| Alhazzani, W | 3 |
| Chang, D | 3 |
| Saleh, M | 3 |
| Gabriels, J | 3 |
| Ismail, H | 2 |
| Goldner, B | 2 |
| Willner, J | 2 |
| Beldner, S | 2 |
| Mitra, R | 2 |
| John, R | 3 |
| Epstein, LM | 3 |
| Funck-Brentano, C | 3 |
| Salem, JE | 2 |
| Nguyen, LS | 3 |
| Drici, MD | 2 |
| Mathian, A | 8 |
| Mahevas, M | 2 |
| Rohmer, J | 1 |
| Roumier, M | 2 |
| Cohen-Aubart, F | 1 |
| Amador-Borrero, B | 1 |
| Barrelet, A | 1 |
| Chauvet, C | 1 |
| Chazal, T | 1 |
| Delahousse, M | 1 |
| Devaux, M | 1 |
| Euvrard, R | 1 |
| Fadlallah, J | 1 |
| Florens, N | 1 |
| Haroche, J | 1 |
| Hié, M | 1 |
| Juillard, L | 1 |
| Lhote, R | 1 |
| Maillet, T | 1 |
| Richard-Colmant, G | 1 |
| Palluy, JB | 1 |
| Pha, M | 1 |
| Perard, L | 1 |
| Remy, P | 1 |
| Rivière, E | 1 |
| Sène, D | 1 |
| Sève, P | 1 |
| Morélot-Panzini, C | 1 |
| Viallard, JF | 1 |
| Virot, JS | 1 |
| Benameur, N | 1 |
| Zahr, N | 1 |
| Yssel, H | 1 |
| Godeau, B | 2 |
| Amoura, Z | 8 |
| Sawalha, AH | 1 |
| Zhang, J | 2 |
| Xie, B | 1 |
| Hashimoto, K | 1 |
| Iyer, M | 1 |
| Jayaramayya, K | 1 |
| Subramaniam, MD | 1 |
| Lee, SB | 1 |
| Dayem, AA | 1 |
| Cho, SG | 1 |
| Vellingiri, B | 1 |
| Mehta, N | 1 |
| Mazer-Amirshahi, M | 1 |
| Alkindi, N | 1 |
| Pourmand, A | 1 |
| Ahsan, W | 1 |
| Javed, S | 1 |
| Bratty, MA | 1 |
| Alhazmi, HA | 1 |
| Najmi, A | 1 |
| Kim, Y | 1 |
| Kwon, O | 1 |
| Paek, JH | 1 |
| Park, WY | 1 |
| Jin, K | 1 |
| Hyun, M | 1 |
| Lee, JY | 1 |
| Kim, HA | 1 |
| Sun, X | 1 |
| Ni, Y | 1 |
| Becker, RC | 1 |
| Sankar, J | 2 |
| Dhochak, N | 1 |
| Kabra, SK | 1 |
| Lodha, R | 1 |
| Ardura, M | 1 |
| Hartley, D | 1 |
| Dandoy, C | 1 |
| Lehmann, L | 1 |
| Jaglowski, S | 1 |
| Auletta, JJ | 1 |
| Yakoub-Agha, I | 1 |
| Askanase, AD | 1 |
| Khalili, L | 1 |
| Buyon, JP | 1 |
| Parisi, S | 2 |
| Ditto, MC | 2 |
| Finucci, A | 2 |
| Fusaro, E | 2 |
| Radbel, J | 1 |
| Narayanan, N | 1 |
| Bhatt, PJ | 1 |
| Andreani, J | 1 |
| Le Bideau, M | 1 |
| Duflot, I | 1 |
| Jardot, P | 1 |
| Rolland, C | 1 |
| Boxberger, M | 1 |
| Wurtz, N | 1 |
| Sargin, G | 1 |
| Yavaşoğlu, Sİ | 1 |
| Al-Kofahi, M | 2 |
| Jacobson, P | 1 |
| Matas, A | 1 |
| Kandaswamy, R | 1 |
| Jaber, MM | 1 |
| Young, JH | 1 |
| Nicol, MR | 3 |
| Ingraham, NE | 1 |
| Boulware, D | 1 |
| Sparks, MA | 1 |
| Schacker, T | 1 |
| Benson, B | 1 |
| Murray, T | 1 |
| Connett, J | 1 |
| Chipman, JG | 1 |
| Charles, A | 1 |
| Tignanelli, CJ | 1 |
| Spinelli, FR | 2 |
| Ceccarelli, F | 2 |
| Di Franco, M | 3 |
| Conti, F | 4 |
| Soo Kim, B | 1 |
| Mansoor, A | 1 |
| Mahmood, E | 1 |
| Makker, P | 1 |
| Chinitz, J | 1 |
| Skipitaris, N | 1 |
| Mountantonakis, S | 1 |
| DeJong, C | 1 |
| Wachter, RM | 1 |
| Liu, M | 1 |
| Caputi, TL | 1 |
| Dredze, M | 1 |
| Kesselheim, AS | 2 |
| Ayers, JW | 1 |
| Jeevaratnam, K | 1 |
| Intson, K | 1 |
| Neckles, R | 1 |
| Leung, C | 1 |
| Jawaid, A | 1 |
| Standing, JF | 1 |
| Pascarella, G | 1 |
| Strumia, A | 1 |
| Piliego, C | 1 |
| Bruno, F | 1 |
| Del Buono, R | 1 |
| Costa, F | 1 |
| Scarlata, S | 1 |
| Agrò, FE | 1 |
| Sachdeva, M | 3 |
| Shah, M | 2 |
| Ziv, M | 1 |
| Leshem, E | 1 |
| Dodiuk-Gad, RP | 2 |
| Mikuls, TR | 1 |
| Johnson, SR | 2 |
| Fraenkel, L | 1 |
| Arasaratnam, RJ | 1 |
| Baden, LR | 7 |
| Bermas, BL | 1 |
| Chatham, W | 1 |
| Cohen, S | 1 |
| Costenbader, K | 1 |
| Gravallese, EM | 1 |
| Kalil, AC | 1 |
| Weinblatt, ME | 1 |
| Winthrop, K | 1 |
| Mudano, AS | 1 |
| Turner, A | 1 |
| Saag, KG | 2 |
| Javelot, H | 1 |
| El-Hage, W | 1 |
| Meyer, G | 1 |
| Becker, G | 1 |
| Michel, B | 1 |
| Hingray, C | 1 |
| Meyerowitz, EA | 1 |
| Vannier, AGL | 1 |
| Friesen, MGN | 1 |
| Schoenfeld, S | 1 |
| Gelfand, JA | 1 |
| Callahan, MV | 1 |
| Kim, AY | 1 |
| Reeves, PM | 1 |
| Poznansky, MC | 1 |
| Bekci, T | 1 |
| Felsenstein, S | 1 |
| Herbert, JA | 1 |
| McNamara, PS | 1 |
| Hedrich, CM | 1 |
| Solé, G | 1 |
| Salort-Campana, E | 1 |
| Pereon, Y | 1 |
| Stojkovic, T | 1 |
| Wahbi, K | 1 |
| Cintas, P | 1 |
| Adams, D | 1 |
| Laforet, P | 1 |
| Tiffreau, V | 1 |
| Desguerre, I | 1 |
| Pisella, LI | 1 |
| Molon, A | 1 |
| Attarian, S | 1 |
| Kang, Y | 2 |
| Chen, T | 1 |
| Mui, D | 1 |
| Ferrari, V | 1 |
| Jagasia, D | 1 |
| Scherrer-Crosbie, M | 1 |
| Chen, Y | 5 |
| Han, Y | 1 |
| Chary, MA | 1 |
| Barbuto, AF | 1 |
| Izadmehr, S | 1 |
| Hayes, BD | 2 |
| Burns, MM | 1 |
| Monzani, A | 1 |
| Genoni, G | 1 |
| Scopinaro, A | 1 |
| Pistis, G | 1 |
| Kozel, D | 1 |
| Secco, GG | 1 |
| Dinkin, M | 1 |
| Gao, V | 1 |
| Kahan, J | 1 |
| Bobker, S | 1 |
| Simonetto, M | 1 |
| Wechsler, P | 1 |
| Harpe, J | 1 |
| Greer, C | 1 |
| Mints, G | 1 |
| Salama, G | 1 |
| Tsiouris, AJ | 1 |
| Leifer, D | 1 |
| Tapia, L | 1 |
| Chowdhury, MS | 1 |
| Rathod, J | 1 |
| Gernsheimer, J | 1 |
| Hammami, MB | 1 |
| Garibaldi, B | 1 |
| Shah, P | 1 |
| Liu, G | 1 |
| Jain, T | 1 |
| Chen, PH | 1 |
| Kim, AK | 1 |
| Avdic, E | 1 |
| Petty, B | 1 |
| Strout, S | 1 |
| Fine, DM | 1 |
| Niranjan-Azadi, A | 1 |
| Garneau, WM | 1 |
| Cameron, AM | 1 |
| Monroy Trujillo, JM | 1 |
| Gurakar, A | 1 |
| Avery, R | 1 |
| Giudicessi, JR | 1 |
| Noseworthy, PA | 1 |
| Friedman, PA | 1 |
| Ackerman, MJ | 1 |
| Ceriello, A | 2 |
| Vastarella, M | 1 |
| Annunziata, MC | 1 |
| Cantelli, M | 1 |
| Nappa, P | 1 |
| Tasso, M | 1 |
| Caso, F | 1 |
| Fung, KL | 1 |
| Chan, PL | 1 |
| Richardson, PJ | 1 |
| Ottaviani, S | 1 |
| Prelle, A | 1 |
| Stebbing, J | 1 |
| Casalini, G | 2 |
| Corbellino, M | 1 |
| Grandolfo, M | 1 |
| Romita, P | 1 |
| Bonamonte, D | 1 |
| Cazzato, G | 1 |
| Hansel, K | 1 |
| Stingeni, L | 1 |
| Conforti, C | 1 |
| Giuffrida, R | 1 |
| Foti, C | 1 |
| Shader, RI | 1 |
| Boyer, L | 1 |
| Auquier, P | 1 |
| Fond, G | 1 |
| Juusela, A | 1 |
| Nazir, M | 1 |
| Gimovsky, M | 1 |
| Svensson, M | 1 |
| Seftel, MD | 1 |
| Ballout, RA | 1 |
| Sviridov, D | 1 |
| Bukrinsky, MI | 1 |
| Remaley, AT | 1 |
| Hope, AA | 1 |
| Munro, CL | 1 |
| Sieni, E | 1 |
| Pegoraro, F | 1 |
| Casini, T | 1 |
| Tondo, A | 1 |
| Bortone, B | 1 |
| Moriondo, M | 1 |
| Azzari, C | 1 |
| Galli, L | 1 |
| Favre, C | 1 |
| Uvais, NA | 1 |
| Nath, KA | 1 |
| Rahmanzade, R | 1 |
| Rahmanzadeh, R | 1 |
| Hashemian, SM | 2 |
| Naksuk, N | 1 |
| Lazar, S | 1 |
| Peeraphatdit, TB | 1 |
| Meo, SA | 1 |
| Klonoff, DC | 1 |
| Akram, J | 3 |
| Lucchino, B | 1 |
| Emmi, G | 1 |
| Bettiol, A | 1 |
| Mattioli, I | 1 |
| Silvestri, E | 1 |
| Di Scala, G | 1 |
| Urban, ML | 1 |
| Prisco, D | 1 |
| Kronbichler, A | 1 |
| Effenberger, M | 1 |
| Eisenhut, M | 1 |
| Lee, KH | 3 |
| Shin, JI | 2 |
| Aouba, A | 1 |
| Baldolli, A | 1 |
| Geffray, L | 1 |
| Verdon, R | 1 |
| Bergot, E | 1 |
| Martin-Silva, N | 1 |
| Justet, A | 1 |
| O'Kelly, B | 1 |
| McGettrick, P | 1 |
| Angelov, D | 1 |
| Fay, M | 1 |
| McGinty, T | 1 |
| Cotter, AG | 1 |
| Sheehan, G | 1 |
| Lambert, JS | 1 |
| Martín-Moro, F | 1 |
| Marquet, J | 1 |
| Piris, M | 1 |
| Michael, BM | 1 |
| Sáez, AJ | 1 |
| Corona, M | 1 |
| Jiménez, C | 1 |
| Astibia, B | 1 |
| García, I | 1 |
| Rodríguez, E | 1 |
| García-Hoz, C | 1 |
| Fortún-Abete, J | 1 |
| Herrera, P | 1 |
| López-Jiménez, J | 1 |
| Rubin, EJ | 5 |
| Harrington, DP | 1 |
| Hogan, JW | 1 |
| Gatsonis, C | 1 |
| Hamel, MB | 1 |
| Morrissey, S | 4 |
| Geleris, J | 1 |
| Sun, Y | 1 |
| Platt, J | 1 |
| Zucker, J | 2 |
| Baldwin, M | 1 |
| Hripcsak, G | 2 |
| Labella, A | 1 |
| Manson, DK | 1 |
| Kubin, C | 1 |
| Barr, RG | 1 |
| Sobieszczyk, ME | 2 |
| Schluger, NW | 2 |
| Gendelman, O | 1 |
| Amital, H | 1 |
| Bragazzi, NL | 1 |
| Watad, A | 1 |
| Chodick, G | 1 |
| Scheetz, MH | 1 |
| Simard, J | 1 |
| Machado, PM | 2 |
| Gianfrancesco, M | 1 |
| Langguth, D | 1 |
| Lother, SA | 3 |
| Abassi, M | 3 |
| Agostinis, A | 1 |
| Cheng, MP | 3 |
| Drobot, G | 3 |
| Engen, N | 1 |
| Kelly, LE | 3 |
| Lofgren, SM | 3 |
| MacKenzie, LJ | 3 |
| Marten, N | 2 |
| Okafor, EC | 4 |
| Pastick, KA | 4 |
| Pullen, MF | 3 |
| Skipper, CP | 3 |
| Asli, R | 2 |
| Abdullah, MS | 2 |
| Chong, PL | 2 |
| Metussin, D | 2 |
| Momin, RN | 2 |
| Mani, BI | 2 |
| Chong, VH | 2 |
| de Rojas, T | 1 |
| Pérez-Martínez, A | 1 |
| Cela, E | 1 |
| Baragaño, M | 1 |
| Galán, V | 1 |
| Mata, C | 1 |
| Peretó, A | 1 |
| Madero, L | 1 |
| Douedi, S | 1 |
| Miskoff, J | 1 |
| Romano, MR | 1 |
| Raimondi, R | 1 |
| Montericcio, A | 1 |
| Allegrini, D | 1 |
| Jimenez-Cauhe, J | 2 |
| Ortega-Quijano, D | 1 |
| Carretero-Barrio, I | 1 |
| Suarez-Valle, A | 2 |
| Saceda-Corralo, D | 1 |
| Moreno-Garcia Del Real, C | 1 |
| Fernandez-Nieto, D | 2 |
| Robustelli Test, E | 1 |
| Vezzoli, P | 1 |
| Carugno, A | 1 |
| Raponi, F | 1 |
| Gianatti, A | 1 |
| Rongioletti, F | 1 |
| Sena, P | 1 |
| Piszczatoski, CR | 1 |
| Powell, J | 1 |
| Derendorf, H | 1 |
| Ravioli, S | 1 |
| Ochsner, H | 1 |
| Lindner, G | 1 |
| Hong, KS | 1 |
| Chung, JH | 1 |
| Shin, KC | 1 |
| Choi, EY | 1 |
| Jin, HJ | 1 |
| Jang, JG | 1 |
| Lee, W | 2 |
| Ahn, JH | 1 |
| Liu, L | 3 |
| Liu, P | 2 |
| Xu, Q | 2 |
| Xia, L | 2 |
| Ling, Y | 1 |
| Huang, D | 1 |
| Song, S | 1 |
| Zhang, D | 2 |
| Qian, Z | 1 |
| Shen, Y | 2 |
| Lu, H | 2 |
| Rosenberg, ES | 2 |
| Dufort, EM | 1 |
| Udo, T | 2 |
| Wilberschied, LA | 1 |
| Kumar, J | 2 |
| Tesoriero, J | 1 |
| Weinberg, P | 1 |
| Kirkwood, J | 1 |
| Muse, A | 1 |
| DeHovitz, J | 1 |
| Blog, DS | 1 |
| Hutton, B | 1 |
| Holtgrave, DR | 2 |
| Zucker, HA | 1 |
| Annangi, S | 1 |
| Hachfi, W | 1 |
| Ben Lasfar, N | 1 |
| Valderrama, EV | 1 |
| Humbert, K | 1 |
| Lord, A | 1 |
| Frontera, J | 1 |
| Yaghi, S | 2 |
| Besutti, G | 1 |
| Bonacini, R | 1 |
| Iotti, V | 1 |
| Marini, G | 1 |
| Riva, N | 1 |
| Dolci, G | 1 |
| Maiorana, M | 1 |
| Spaggiari, L | 1 |
| Monelli, F | 1 |
| Ligabue, G | 1 |
| Guaraldi, G | 2 |
| Rossi, PG | 1 |
| Pattacini, P | 1 |
| Massari, M | 2 |
| Bozzalla Cassione, E | 2 |
| Zanframundo, G | 2 |
| Biglia, A | 2 |
| Codullo, V | 2 |
| Gadebusch Bondio, M | 1 |
| Marloth, M | 1 |
| Anastasiou, IA | 1 |
| Eleftheriadou, I | 1 |
| Tentolouris, A | 1 |
| Tsilingiris, D | 1 |
| Tentolouris, N | 1 |
| Troldborg, A | 1 |
| Bartels, LE | 1 |
| Deleuran, B | 1 |
| Bygbjerg, IC | 1 |
| Xia, T | 1 |
| Infante, M | 2 |
| Ricordi, C | 2 |
| Fabbri, A | 2 |
| Litaiem, N | 1 |
| Hajlaoui, K | 1 |
| Karray, M | 1 |
| Slouma, M | 1 |
| Zeglaoui, F | 1 |
| Palmeira, VA | 1 |
| Costa, LB | 1 |
| Perez, LG | 1 |
| Ribeiro, VT | 1 |
| Lanza, K | 1 |
| Silva, ACSE | 1 |
| Latif, F | 1 |
| Clerkin, KJ | 1 |
| Habal, MV | 1 |
| Takeda, K | 3 |
| Naka, Y | 2 |
| Restaino, S | 1 |
| Sayer, G | 3 |
| Klimke, A | 1 |
| Hefner, G | 1 |
| Will, B | 1 |
| Voss, U | 1 |
| Stroppa, EM | 1 |
| Toscani, I | 1 |
| Anselmi, E | 1 |
| Zaffignani, E | 1 |
| Romão, VC | 2 |
| Cruz-Machado, AR | 2 |
| Fonseca, JE | 2 |
| Okour, M | 1 |
| Austin, D | 1 |
| Gollob, MH | 2 |
| Chorin, E | 2 |
| Wadhwani, L | 2 |
| Magnani, S | 1 |
| Dai, M | 2 |
| Shulman, E | 2 |
| Nadeau-Routhier, C | 1 |
| Knotts, R | 1 |
| Bar-Cohen, R | 2 |
| Kogan, E | 1 |
| Barbhaiya, C | 2 |
| Aizer, A | 2 |
| Holmes, D | 2 |
| Bernstein, S | 2 |
| Spinelli, M | 2 |
| Park, DS | 2 |
| Stefano, C | 1 |
| Chinitz, LA | 3 |
| Jankelson, L | 3 |
| Derwand, R | 1 |
| Scholz, M | 1 |
| Vouri, SM | 1 |
| Thai, TN | 1 |
| Winterstein, AG | 1 |
| Dariya, B | 1 |
| Nagaraju, GP | 1 |
| Gegúndez-Fernández, JA | 1 |
| Zarranz-Ventura, J | 1 |
| Garay-Aramburu, G | 1 |
| Muñoz-Negrete, FJ | 1 |
| Mendicute Del Barrio, J | 1 |
| Pablo-Júlvez, L | 1 |
| García-Delpech, S | 1 |
| López-Alemany, A | 1 |
| Arnalich-Montiel, F | 1 |
| Cordero-Coma, M | 1 |
| Cárceles, JA | 1 |
| Tran, VT | 1 |
| Chabrol, A | 1 |
| Paule, R | 1 |
| Guillaud, C | 1 |
| Fois, E | 1 |
| Lepeule, R | 1 |
| Szwebel, TA | 1 |
| Lescure, FX | 1 |
| Matignon, M | 1 |
| Khellaf, M | 1 |
| Crickx, E | 1 |
| Terrier, B | 1 |
| Morbieu, C | 1 |
| Legendre, P | 1 |
| Dang, J | 1 |
| Schoindre, Y | 1 |
| Perrodeau, E | 1 |
| Carlier, N | 1 |
| Roche, N | 1 |
| de Lastours, V | 1 |
| Kerneis, S | 1 |
| Ménager, P | 1 |
| Mouthon, L | 1 |
| Audureau, E | 1 |
| Gallien, S | 1 |
| Costedoat-Chalumeau, N | 1 |
| Tang, W | 2 |
| Cao, Z | 1 |
| Han, M | 1 |
| Wang, Z | 2 |
| Sun, W | 3 |
| Wu, Y | 2 |
| Chen, E | 1 |
| Yang, J | 1 |
| Lin, J | 1 |
| Zhao, Q | 1 |
| Yan, Y | 1 |
| Xie, Z | 3 |
| Li, D | 1 |
| Qu, J | 1 |
| Ning, G | 1 |
| Shi, G | 1 |
| Xie, Q | 1 |
| Ledford, H | 3 |
| Naymagon, L | 1 |
| Berwick, S | 1 |
| Kessler, A | 1 |
| Lancman, G | 1 |
| Gidwani, U | 1 |
| Troy, K | 1 |
| Chaumont, H | 1 |
| Etienne, P | 1 |
| Roze, E | 1 |
| Couratier, C | 1 |
| Roger, PM | 1 |
| Lannuzel, A | 1 |
| Pahan, P | 1 |
| Pahan, K | 1 |
| Everaert, BR | 1 |
| Muylle, J | 1 |
| Bartholomeus Twickler, T | 1 |
| Lahouati, M | 2 |
| Mériglier, E | 2 |
| Martin, L | 1 |
| Bouchet, S | 3 |
| Desclaux, A | 1 |
| Bonnet, F | 2 |
| Yu, B | 2 |
| Li, C | 4 |
| Chen, P | 1 |
| Zhou, N | 1 |
| Wang, L | 3 |
| Jiang, H | 1 |
| Wang, DW | 1 |
| Asensio, E | 1 |
| Acunzo, R | 1 |
| Uribe, W | 1 |
| Saad, EB | 1 |
| Sáenz, LC | 1 |
| Durante-Mangoni, E | 1 |
| Andini, R | 1 |
| Bertolino, L | 1 |
| Mele, F | 1 |
| Florio, LL | 1 |
| Murino, P | 1 |
| Corcione, A | 1 |
| Zampino, R | 1 |
| Pilotto, A | 1 |
| Odolini, S | 1 |
| Masciocchi, S | 1 |
| Comelli, A | 1 |
| Volonghi, I | 1 |
| Gazzina, S | 1 |
| Nocivelli, S | 1 |
| Pezzini, A | 1 |
| Caruso, A | 1 |
| Leonardi, M | 1 |
| Pasolini, MP | 1 |
| Gasparotti, R | 1 |
| Castelli, F | 2 |
| Ashton, NJ | 1 |
| Blennow, K | 1 |
| Zetterberg, H | 1 |
| Padovani, A | 1 |
| Patil, VM | 1 |
| Singhal, S | 1 |
| Masand, N | 1 |
| Nawar, T | 1 |
| Morjaria, S | 1 |
| Kaltsas, A | 1 |
| Patel, D | 1 |
| Perez-Johnston, R | 1 |
| Daniyan, AF | 1 |
| Mailankody, S | 1 |
| Parameswaran, R | 1 |
| Gevers, S | 1 |
| Kwa, MSG | 1 |
| Wijnans, E | 1 |
| van Nieuwkoop, C | 1 |
| Krouse, HJ | 1 |
| Yekedüz, E | 1 |
| Dursun, B | 1 |
| Aydın, GÇ | 1 |
| Yazgan, SC | 1 |
| Öztürk, HH | 1 |
| Azap, A | 1 |
| Utkan, G | 1 |
| Ürün, Y | 1 |
| Estella, Á | 1 |
| Garnacho-Montero, J | 1 |
| Erre, GL | 1 |
| Ferraccioli, ES | 2 |
| Piga, M | 1 |
| Mangoni, A | 1 |
| Passiu, G | 1 |
| Gremese, E | 3 |
| Ferraccioli, G | 2 |
| Peltan, ID | 1 |
| Kumar, N | 1 |
| Starr, N | 1 |
| Grissom, C | 1 |
| Buckel, WR | 1 |
| Srivastava, R | 1 |
| Harris, ES | 1 |
| Leither, LM | 2 |
| Johnson, SA | 1 |
| Paine, R | 1 |
| Greene, T | 1 |
| Marto, N | 1 |
| Monteiro, EC | 1 |
| Aggarwal, G | 1 |
| Henry, BM | 1 |
| Aggarwal, S | 1 |
| Bangalore, S | 1 |
| Cairoli, E | 1 |
| Espinosa, G | 1 |
| Kajani, R | 1 |
| Apramian, A | 1 |
| Vega, A | 1 |
| Ubhayakar, N | 1 |
| Xu, P | 1 |
| Liu, A | 1 |
| Kucharz, EJ | 1 |
| Zhai, MZ | 1 |
| Lye, CT | 1 |
| Sattar, Y | 1 |
| Connerney, M | 1 |
| Rauf, H | 1 |
| Saini, M | 1 |
| Ullah, W | 2 |
| Mamtani, S | 1 |
| Syed, U | 1 |
| Luddington, S | 1 |
| Walfish, A | 1 |
| Quiros Roldan, E | 1 |
| Biasiotto, G | 1 |
| Magro, P | 1 |
| Zanella, I | 1 |
| Vicenzi, M | 1 |
| Di Cosola, R | 1 |
| Ruscica, M | 1 |
| Ratti, A | 1 |
| Rota, I | 1 |
| Rota, F | 1 |
| Bollati, V | 1 |
| Aliberti, S | 2 |
| Blasi, F | 2 |
| Vinetz, JM | 1 |
| Su, YB | 1 |
| Kuo, MJ | 1 |
| Lin, TY | 1 |
| Chien, CS | 2 |
| Yang, YP | 2 |
| Chou, SJ | 1 |
| Leu, HB | 1 |
| Baumann, T | 1 |
| Delgado, J | 1 |
| Montserrat, E | 1 |
| Mégarbane, B | 4 |
| Scherrmann, JM | 3 |
| Addeo, A | 1 |
| Obeid, M | 1 |
| Friedlaender, A | 1 |
| Melgosa, M | 1 |
| Madrid, A | 1 |
| Alvárez, O | 1 |
| Lumbreras, J | 1 |
| Nieto, F | 1 |
| Parada, E | 1 |
| Perez-Beltrán, V | 1 |
| Ozaras, R | 1 |
| Berk, A | 1 |
| Ucar, DH | 1 |
| Duman, H | 1 |
| Kaya, F | 1 |
| Mutlu, H | 1 |
| Oren, O | 1 |
| Yang, EH | 1 |
| Gluckman, TJ | 2 |
| Michos, ED | 1 |
| Blumenthal, RS | 1 |
| Gersh, BJ | 1 |
| Edelstein, CL | 1 |
| Venkatachalam, MA | 1 |
| Dong, Z | 1 |
| Alberici, F | 1 |
| Delbarba, E | 1 |
| Manenti, C | 1 |
| Econimo, L | 1 |
| Valerio, F | 1 |
| Pola, A | 1 |
| Maffei, C | 1 |
| Possenti, S | 1 |
| Lucca, B | 1 |
| Cortinovis, R | 1 |
| Terlizzi, V | 1 |
| Zappa, M | 1 |
| Saccà, C | 1 |
| Pezzini, E | 1 |
| Calcaterra, E | 1 |
| Piarulli, P | 1 |
| Guerini, A | 1 |
| Boni, F | 1 |
| Gallico, A | 1 |
| Mucchetti, A | 1 |
| Affatato, S | 1 |
| Bove, S | 1 |
| Bracchi, M | 1 |
| Costantino, EM | 1 |
| Zubani, R | 1 |
| Camerini, C | 1 |
| Gaggia, P | 1 |
| Movilli, E | 1 |
| Bossini, N | 1 |
| Gaggiotti, M | 1 |
| Scolari, F | 1 |
| Karam, G | 1 |
| Becker, ML | 1 |
| Tsai, MC | 1 |
| Cipriani, A | 1 |
| Zorzi, A | 1 |
| Ceccato, D | 1 |
| Capone, F | 1 |
| Parolin, M | 1 |
| Donato, F | 1 |
| Fioretto, P | 1 |
| Pesavento, R | 2 |
| Previato, L | 1 |
| Maffei, P | 1 |
| Saller, A | 1 |
| Avogaro, A | 1 |
| Sarais, C | 1 |
| Gregori, D | 1 |
| Iliceto, S | 1 |
| Vettor, R | 2 |
| Yahya, AS | 1 |
| Khawaja, S | 1 |
| Chukwuma, J | 1 |
| Merino, JL | 1 |
| Martínez-Cossiani, M | 1 |
| Iniesta, A | 1 |
| Escobar, C | 1 |
| Rey, JR | 1 |
| Castrejón-Castrejón, S | 1 |
| Ross, SB | 1 |
| Wilson, MG | 1 |
| Papillon-Ferland, L | 1 |
| Elsayed, S | 1 |
| Wu, PE | 1 |
| Battu, K | 1 |
| Porter, S | 1 |
| Rashidi, B | 1 |
| Tamblyn, R | 1 |
| Pilote, L | 1 |
| Downar, J | 1 |
| Bonnici, A | 1 |
| Huang, A | 1 |
| Dolladille, C | 1 |
| Fenioux, C | 2 |
| Alexandre, J | 1 |
| Mira, JP | 1 |
| Moslehi, JJ | 1 |
| Mufti, A | 1 |
| Maliyar, K | 1 |
| Lytvyn, Y | 1 |
| Yeung, J | 1 |
| Zaidel, EJ | 2 |
| Wyss Quintana, FS | 2 |
| Sosa Liprandi, Á | 2 |
| Mendoza, I | 2 |
| Márquez, MF | 2 |
| Nuñez, E | 2 |
| Barbosa, M | 2 |
| Baranchuk, A | 2 |
| Park, SJ | 2 |
| Yu, KM | 1 |
| Kim, YI | 1 |
| Kim, SM | 1 |
| Kim, EH | 1 |
| Kim, SG | 1 |
| Kim, EJ | 2 |
| Casel, MAB | 1 |
| Rollon, R | 1 |
| Jang, SG | 1 |
| Lee, MH | 1 |
| Chang, JH | 1 |
| Song, MS | 1 |
| Jeong, HW | 1 |
| Choi, Y | 1 |
| Shin, WJ | 1 |
| Jung, JU | 1 |
| Choi, YK | 1 |
| Atzrodt, CL | 1 |
| Maknojia, I | 1 |
| McCarthy, RDP | 1 |
| Oldfield, TM | 1 |
| Po, J | 1 |
| Ta, KTL | 1 |
| Stepp, HE | 1 |
| Clements, TP | 1 |
| Gazendam, A | 1 |
| Nucci, N | 1 |
| Ekhtiari, S | 1 |
| Gohal, C | 1 |
| Zhu, M | 1 |
| Payne, A | 1 |
| Bhandari, M | 1 |
| Pianta, L | 1 |
| Vinciguerra, A | 1 |
| Bertazzoni, G | 1 |
| Morello, R | 1 |
| Mangiatordi, F | 1 |
| Lund, VJ | 1 |
| Trimarchi, M | 1 |
| Rogado, J | 3 |
| Obispo, B | 3 |
| Pangua, C | 2 |
| Serrano-Montero, G | 2 |
| Martín Marino, A | 1 |
| Pérez-Pérez, M | 2 |
| López-Alfonso, A | 2 |
| Gullón, P | 3 |
| Lara, MÁ | 3 |
| Lauterio, A | 1 |
| Valsecchi, M | 1 |
| Santambrogio, S | 1 |
| De Carlis, R | 1 |
| Merli, M | 2 |
| Calini, A | 1 |
| Centonze, L | 1 |
| Buscemi, V | 1 |
| Bottiroli, M | 1 |
| Puoti, M | 2 |
| Fumagalli, R | 1 |
| De Carlis, L | 1 |
| Tilangi, P | 1 |
| Desai, D | 1 |
| Khan, A | 3 |
| Soneja, M | 1 |
| Tripathy, S | 1 |
| Dassarma, B | 1 |
| Roy, S | 1 |
| Chabalala, H | 1 |
| Matsabisa, MG | 1 |
| Feeney, E | 1 |
| Wallace, D | 1 |
| Cotter, A | 1 |
| Tinago, W | 1 |
| McCarthy, C | 1 |
| Keane, D | 1 |
| Hussain, R | 1 |
| Alvarez Barco, E | 1 |
| Mallon, P | 1 |
| Defoort-Dhellemmes, S | 1 |
| Tahiri Joutei Hassani, R | 1 |
| Bennis, A | 1 |
| Gerosa, M | 2 |
| Murgo, A | 1 |
| Balevic, SJ | 3 |
| Hornik, CP | 3 |
| Green, TP | 1 |
| Clowse, MEB | 1 |
| Gonzalez, D | 2 |
| Maharaj, AR | 2 |
| Schanberg, LE | 2 |
| Eudy, AM | 1 |
| Swamy, GK | 1 |
| Hughes, BL | 1 |
| Cohen-Wolkowiez, M | 3 |
| Sturley, SL | 1 |
| Rajakumar, T | 1 |
| Hammond, N | 3 |
| Higaki, K | 1 |
| Márka, Z | 1 |
| Márka, S | 1 |
| Munkacsi, AB | 1 |
| Tadolini, M | 1 |
| Codecasa, LR | 1 |
| García-García, JM | 1 |
| Blanc, FX | 1 |
| Borisov, S | 1 |
| Alffenaar, JW | 1 |
| Bachez, P | 1 |
| Bart, PA | 1 |
| Belilovski, E | 1 |
| Cardoso-Landivar, J | 1 |
| Centis, R | 1 |
| D'Ambrosio, L | 1 |
| Luiza De Souza-Galvão, M | 1 |
| Dominguez-Castellano, A | 1 |
| Dourmane, S | 1 |
| Fréchet Jachym, M | 1 |
| Froissart, A | 1 |
| Giacomet, V | 1 |
| Goletti, D | 1 |
| Grard, S | 1 |
| Gualano, G | 1 |
| Izadifar, A | 1 |
| Le Du, D | 1 |
| Marín Royo, M | 1 |
| Mazza-Stalder, J | 1 |
| Motta, I | 1 |
| Ong, CWM | 1 |
| Palmieri, F | 1 |
| Rivière, F | 1 |
| Rodrigo, T | 1 |
| Silva, DR | 1 |
| Sánchez-Montalvá, A | 2 |
| Saporiti, M | 1 |
| Scarpellini, P | 1 |
| Spanevello, A | 1 |
| Sumarokova, E | 1 |
| Tabernero, E | 1 |
| Tambyah, PA | 2 |
| Tiberi, S | 1 |
| Torre, A | 1 |
| Visca, D | 1 |
| Zabaleta Murguiondo, M | 1 |
| Sotgiu, G | 1 |
| Migliori, GB | 2 |
| Kauv, J | 1 |
| Lê, MP | 3 |
| Veyrier, M | 1 |
| Le Hingrat, Q | 1 |
| Visseaux, B | 1 |
| Massias, L | 1 |
| Chauveheid, MP | 1 |
| Descamps, D | 1 |
| Ghosn, J | 1 |
| Peytavin, G | 3 |
| Risch, HA | 3 |
| Hernandez, AV | 5 |
| Roman, YM | 3 |
| Pasupuleti, V | 3 |
| Barboza, JJ | 3 |
| White, CM | 4 |
| Habibzadeh, P | 1 |
| Moghadami, M | 1 |
| Lankarani, KB | 1 |
| Hodkinson, B | 1 |
| Singh, P | 1 |
| Gcelu, A | 1 |
| Bautista-Molano, W | 1 |
| Pons-Estel, G | 1 |
| Alpízar-Rodríguez, D | 1 |
| Kamp, TJ | 1 |
| Hamdan, MH | 1 |
| January, CT | 1 |
| Ramireddy, A | 1 |
| Chugh, H | 1 |
| Reinier, K | 1 |
| Ebinger, J | 1 |
| Park, E | 1 |
| Thompson, M | 1 |
| Cingolani, E | 1 |
| Cheng, S | 1 |
| Marban, E | 1 |
| Albert, CM | 1 |
| Chugh, SS | 1 |
| Vaduganathan, M | 1 |
| van Meijgaard, J | 1 |
| Mehra, MR | 1 |
| Joseph, J | 1 |
| O'Donnell, CJ | 1 |
| Warraich, HJ | 1 |
| Afshar, H | 1 |
| Yassin, Z | 2 |
| Kalantari, S | 2 |
| Aloosh, O | 1 |
| Lotfi, T | 1 |
| Moghaddasi, M | 1 |
| Sadeghipour, A | 1 |
| Emamikhah, M | 2 |
| Ramachandran, V | 1 |
| Marimuthu, RR | 1 |
| Chinnambedu, RS | 1 |
| Bhowmick, S | 1 |
| Tiwari, S | 1 |
| Sen, S | 1 |
| Ridgway, JP | 1 |
| Farley, B | 1 |
| Benoit, JL | 1 |
| Frohne, C | 1 |
| Hazra, A | 1 |
| Pettit, N | 1 |
| Pho, M | 1 |
| Pursell, K | 1 |
| Saltzman, J | 1 |
| Schmitt, J | 1 |
| Uvin, AZ | 1 |
| Pitrak, D | 1 |
| McNulty, M | 1 |
| Rodrigo, C | 1 |
| Fernando, SD | 1 |
| Rajapakse, S | 1 |
| Guedj, J | 3 |
| Néant, N | 2 |
| Kuderer, NM | 2 |
| Choueiri, TK | 2 |
| Shah, DP | 2 |
| Shyr, Y | 2 |
| Rubinstein, SM | 2 |
| Rivera, DR | 2 |
| Shete, S | 1 |
| Hsu, CY | 2 |
| Desai, A | 1 |
| de Lima Lopes, G | 2 |
| Grivas, P | 2 |
| Painter, CA | 2 |
| Peters, S | 3 |
| Thompson, MA | 2 |
| Bakouny, Z | 2 |
| Batist, G | 1 |
| Bekaii-Saab, T | 1 |
| Bilen, MA | 1 |
| Bouganim, N | 1 |
| Larroya, MB | 1 |
| Castellano, D | 1 |
| Del Prete, SA | 1 |
| Doroshow, DB | 2 |
| Egan, PC | 2 |
| Elkrief, A | 1 |
| Farmakiotis, D | 2 |
| Flora, D | 1 |
| Galsky, MD | 2 |
| Glover, MJ | 1 |
| Griffiths, EA | 1 |
| Gulati, AP | 1 |
| Gupta, S | 4 |
| Hafez, N | 1 |
| Halfdanarson, TR | 2 |
| Hawley, JE | 2 |
| Hsu, E | 1 |
| Kasi, A | 1 |
| Khaki, AR | 2 |
| Lemmon, CA | 2 |
| Lewis, C | 1 |
| Logan, B | 1 |
| Masters, T | 1 |
| McKay, RR | 1 |
| Mesa, RA | 1 |
| Morgans, AK | 1 |
| Mulcahy, MF | 1 |
| Panagiotou, OA | 2 |
| Peddi, P | 1 |
| Pennell, NA | 3 |
| Reynolds, K | 1 |
| Rosen, LR | 1 |
| Rosovsky, R | 1 |
| Salazar, M | 1 |
| Schmidt, A | 2 |
| Shah, SA | 2 |
| Shaya, JA | 1 |
| Steinharter, J | 1 |
| Stockerl-Goldstein, KE | 1 |
| Subbiah, S | 1 |
| Vinh, DC | 1 |
| Wehbe, FH | 1 |
| Weissmann, LB | 1 |
| Wu, JT | 2 |
| Wulff-Burchfield, E | 1 |
| Yeh, A | 1 |
| Yu, PP | 1 |
| Zhou, AY | 1 |
| Zubiri, L | 1 |
| Mishra, S | 2 |
| Lyman, GH | 2 |
| Rini, BI | 2 |
| Warner, JL | 2 |
| Frigerio, M | 1 |
| Hor, CP | 1 |
| Hussin, N | 1 |
| Nalliah, S | 1 |
| Ooi, WT | 1 |
| Tang, XY | 1 |
| Zachariah, S | 1 |
| Jugindar Singh, GPS | 1 |
| Abdul Rani, R | 1 |
| Perumal, K | 1 |
| Cheah, WK | 1 |
| Bonzano, L | 1 |
| Cassone, G | 2 |
| Tarallo, L | 1 |
| Pellacani, G | 1 |
| Alanagreh, L | 1 |
| Alzoughool, F | 1 |
| Atoum, M | 1 |
| Fanin, A | 1 |
| Calegari, J | 1 |
| Beverina, A | 1 |
| Tiraboschi, S | 1 |
| Weehuizen, JM | 2 |
| Hoepelman, AIM | 2 |
| Carlsson, H | 1 |
| Hjorton, K | 1 |
| Abujrais, S | 1 |
| Rönnblom, L | 1 |
| Åkerfeldt, T | 1 |
| Kultima, K | 1 |
| Wallace, B | 1 |
| Washer, L | 1 |
| Marder, W | 1 |
| Kahlenberg, JM | 1 |
| Gemcioglu, E | 1 |
| Davutoglu, M | 1 |
| Ozdemir, EE | 1 |
| Erden, A | 1 |
| Maraj, I | 2 |
| Hummel, JP | 3 |
| Taoutel, R | 2 |
| Chamoun, R | 2 |
| Workman, V | 1 |
| Tran, L | 2 |
| DelVecchio, A | 2 |
| Howes, C | 1 |
| Akar, JG | 3 |
| Nagaraja, BS | 1 |
| Ramesh, KN | 1 |
| Dhar, D | 1 |
| Mondal, MS | 1 |
| Dey, T | 1 |
| Saha, S | 2 |
| Khan, MA | 3 |
| Rutul, SD | 1 |
| Pratik, K | 1 |
| Manjula, J | 1 |
| Sangeeth, TA | 1 |
| Singh, V | 2 |
| Medetalibeyoğlu, A | 1 |
| Şenkal, N | 1 |
| Çapar, G | 1 |
| Köse, M | 1 |
| Tükek, T | 1 |
| Nascene, AA | 2 |
| Engen, NW | 2 |
| LaBar, D | 1 |
| Schwartz, IS | 2 |
| Cohen, MS | 1 |
| Johnson, NJ | 1 |
| Semler, MW | 1 |
| Aggarwal, NR | 1 |
| Brower, RG | 1 |
| Chang, SY | 1 |
| Eppensteiner, J | 1 |
| Filbin, M | 1 |
| Gibbs, KW | 1 |
| Ginde, AA | 1 |
| Gong, MN | 1 |
| Harrell, F | 1 |
| Hayden, DL | 1 |
| Hough, CL | 1 |
| Moss, M | 1 |
| Oldmixon, CF | 1 |
| Park, PK | 1 |
| Reineck, LA | 1 |
| Ringwood, NJ | 1 |
| Robinson, BRH | 1 |
| Schoenfeld, DA | 1 |
| Shapiro, NI | 1 |
| Steingrub, JS | 1 |
| Torr, DK | 1 |
| Weissman, A | 1 |
| Lindsell, CJ | 1 |
| Thompson, BT | 1 |
| Pirjani, R | 1 |
| Soori, T | 1 |
| Dehpour, AR | 1 |
| Sepidarkish, M | 1 |
| Moini, A | 1 |
| Shizarpour, A | 1 |
| Mohammad Jafari, R | 1 |
| Irvani, SSN | 1 |
| Golmohammadi, M | 1 |
| Pourhoseingholi, MA | 1 |
| Darazam, IA | 2 |
| Miller, RS | 1 |
| Celum, C | 2 |
| Chu, H | 1 |
| Wesche, D | 2 |
| Cuadrado-Lavín, A | 1 |
| Olmos, JM | 1 |
| Cifrian, JM | 1 |
| Gimenez, T | 1 |
| Gandarillas, MA | 1 |
| García-Saiz, M | 1 |
| Rebollo, MH | 1 |
| Martínez-Taboada, V | 1 |
| López-Hoyos, M | 1 |
| Fariñas, MC | 1 |
| Crespo, J | 1 |
| Liu, W | 2 |
| Zhou, P | 1 |
| Ye, Z | 1 |
| Liu, F | 1 |
| Li, X | 5 |
| He, N | 1 |
| Wu, Z | 1 |
| Zhang, Q | 3 |
| Gong, X | 1 |
| Tang, Q | 1 |
| Du, X | 1 |
| Ying, Y | 1 |
| Xu, X | 3 |
| Shen, N | 1 |
| Couban, RJ | 1 |
| Ibrahim, QI | 1 |
| Guyatt, G | 2 |
| Zhai, S | 1 |
| Montastruc, JL | 1 |
| Toutain, PL | 1 |
| Ibáñez, S | 1 |
| Martínez, O | 1 |
| Valenzuela, F | 1 |
| Silva, F | 2 |
| Valenzuela, O | 1 |
| Novara, E | 1 |
| Molinaro, E | 1 |
| Benedetti, I | 1 |
| Bonometti, R | 1 |
| Lauritano, EC | 1 |
| Boverio, R | 1 |
| Nina, PB | 1 |
| Dash, AP | 1 |
| Oymak, Y | 1 |
| Karapinar, TH | 1 |
| Devrim, İ | 1 |
| Carvalho, A | 2 |
| Alqusairi, R | 1 |
| Adams, A | 2 |
| Paul, M | 1 |
| Kothari, N | 1 |
| DeBenedet, AT | 1 |
| Sun, J | 3 |
| Fan, X | 1 |
| Han, Q | 1 |
| Maillart, E | 1 |
| Leemans, S | 1 |
| Van Noten, H | 1 |
| Vandergraesen, T | 1 |
| Mahadeb, B | 1 |
| Salaouatchi, MT | 1 |
| De Bels, D | 1 |
| Clevenbergh, P | 1 |
| Lang, JP | 1 |
| Moura, FA | 1 |
| Siddiqi, HK | 1 |
| Morrow, DA | 1 |
| Bohula, EA | 1 |
| Mvumbi, DM | 1 |
| Gouveia, CC | 1 |
| Campos, L | 2 |
| Servick, K | 1 |
| Enserink, M | 1 |
| Afra, TP | 3 |
| Vasudevan Nampoothiri, R | 1 |
| Razmi T, M | 2 |
| Modi, AR | 1 |
| Koval, CE | 1 |
| Taege, AJ | 1 |
| Modaresi Esfeh, J | 1 |
| Eghtesad, B | 1 |
| Narayanan Menon, KV | 1 |
| Quintini, C | 1 |
| Miller, C | 1 |
| Ranard, LS | 1 |
| Fried, JA | 1 |
| Abdalla, M | 1 |
| Anstey, DE | 1 |
| Givens, RC | 1 |
| Kumaraiah, D | 1 |
| Kodali, SK | 1 |
| Karmpaliotis, D | 1 |
| Rabbani, LE | 1 |
| Kirtane, AJ | 1 |
| Leon, MB | 1 |
| Schwartz, A | 2 |
| Masoumi, A | 1 |
| Mella, A | 1 |
| Mingozzi, S | 1 |
| Gallo, E | 1 |
| Lavacca, A | 1 |
| Rossetti, M | 1 |
| Clari, R | 1 |
| Randone, O | 1 |
| Maffei, S | 1 |
| Salomone, M | 1 |
| Imperiale, D | 1 |
| Biancone, L | 1 |
| Patrono, D | 1 |
| Lupo, F | 1 |
| Canta, F | 1 |
| Mazza, E | 1 |
| Mirabella, S | 1 |
| Corcione, S | 2 |
| Tandoi, F | 1 |
| De Rosa, FG | 2 |
| Romagnoli, R | 1 |
| Hornik, CD | 1 |
| Smith, PB | 1 |
| Zimmerman, KO | 1 |
| Benjamin, DK | 1 |
| Mazzanti, A | 1 |
| Briani, M | 1 |
| Kukavica, D | 1 |
| Bulian, F | 1 |
| Marelli, S | 1 |
| Trancuccio, A | 1 |
| Monteforte, N | 1 |
| Manciulli, T | 1 |
| Morini, M | 1 |
| Carlucci, A | 1 |
| Viggiani, G | 1 |
| Cannata, F | 2 |
| Negri, S | 1 |
| Bloise, R | 1 |
| Memmi, M | 1 |
| Gambelli, P | 1 |
| Carbone, A | 1 |
| Molteni, M | 1 |
| Bianchini, R | 1 |
| Salgarello, R | 1 |
| Sozzi, S | 1 |
| De Cata, P | 1 |
| Fanfulla, F | 1 |
| Ceriana, P | 1 |
| Locatelli, C | 1 |
| Napolitano, C | 1 |
| Chiovato, L | 1 |
| Tomasi, L | 1 |
| Stefanini, GG | 1 |
| Condorelli, G | 1 |
| Priori, SG | 1 |
| Di Giambenedetto, S | 1 |
| Del Giacomo, P | 1 |
| Ciccullo, A | 3 |
| Porfidia, A | 1 |
| De Matteis, G | 1 |
| Cianci, R | 1 |
| De Vito, F | 1 |
| Dusina, A | 1 |
| Borghetti, A | 1 |
| Tumbarello, M | 1 |
| Shih, RD | 1 |
| Johnson, HM | 1 |
| Maki, DG | 1 |
| Hennekens, CH | 2 |
| Lyngbakken, MN | 3 |
| Berdal, JE | 2 |
| Eskesen, A | 2 |
| Kvale, D | 2 |
| Olsen, IC | 3 |
| Rangberg, A | 2 |
| Jonassen, CM | 2 |
| Omland, T | 2 |
| Røsjø, H | 3 |
| Dalgard, O | 4 |
| Sanchez-Piedra, C | 1 |
| Diaz-Torne, C | 2 |
| Manero, J | 1 |
| Pego-Reigosa, JM | 1 |
| Rúa-Figueroa, Í | 1 |
| Gonzalez-Gay, MA | 2 |
| Gomez-Reino, J | 1 |
| Alvaro-Gracia, JM | 2 |
| Asfuroglu Kalkan, E | 1 |
| Ates, I | 1 |
| Marino, AM | 1 |
| Morlacchi, LC | 1 |
| Rossetti, V | 1 |
| Gigli, L | 1 |
| Amati, F | 1 |
| Rosso, L | 1 |
| Nosotti, M | 1 |
| Hossri, S | 1 |
| Shadi, M | 1 |
| Hamarsha, Z | 1 |
| Schneider, R | 1 |
| El-Sayegh, D | 1 |
| Calderón, JM | 1 |
| Zerón, HM | 1 |
| Padmanabhan, S | 2 |
| Holubar, J | 1 |
| Le Quintrec, M | 1 |
| Letaief, H | 1 |
| Faillie, JL | 1 |
| Pers, YM | 2 |
| Jorgensen, C | 1 |
| Danion, F | 1 |
| Ruch, Y | 1 |
| Fourtage, M | 1 |
| Kaeuffer, C | 1 |
| Greigert, V | 1 |
| Lefebvre, N | 1 |
| Muller, J | 1 |
| Nai, T | 1 |
| Hansmann, Y | 1 |
| Painvin, B | 1 |
| Guillot, P | 1 |
| Verdier, MC | 1 |
| Gacouin, A | 1 |
| Maamar, A | 1 |
| Chai, PR | 1 |
| Ferro, EG | 1 |
| Kirshenbaum, JM | 1 |
| Culbreth, SE | 1 |
| Boyer, EW | 1 |
| Erickson, TB | 1 |
| Liu, XH | 1 |
| Lu, SH | 1 |
| Yang, ZG | 1 |
| Charles, S | 1 |
| Lu, HZ | 1 |
| Dos Reis Neto, ET | 1 |
| de Medeiros Pinheiro, M | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| D'Alton, M | 1 |
| Patel, TK | 1 |
| Barvaliya, M | 1 |
| Kevadiya, BD | 1 |
| Patel, PB | 1 |
| Bhalla, HL | 1 |
| Tu, S | 1 |
| En, VSJ | 1 |
| Brest, P | 1 |
| Benzaquen, J | 1 |
| Klionsky, DJ | 3 |
| Hofman, P | 1 |
| Mograbi, B | 1 |
| Bonam, SR | 1 |
| Muller, S | 1 |
| Bayry, J | 1 |
| Sivapalan, P | 2 |
| Ulrik, CS | 2 |
| Bojesen, RD | 1 |
| Lapperre, TS | 1 |
| Eklöf, JV | 2 |
| Håkansson, KEJ | 1 |
| Browatzki, A | 2 |
| Tidemansen, C | 1 |
| Wilcke, JT | 1 |
| Janner, J | 1 |
| Gottlieb, V | 1 |
| Meteran, H | 1 |
| Porsbjerg, C | 1 |
| Madsen, BL | 1 |
| Moberg, M | 1 |
| Pedersen, L | 1 |
| Benfield, TL | 2 |
| Lundgren, JD | 2 |
| Knop, FK | 2 |
| Biering-Sørensen, T | 2 |
| Ghanizada, M | 1 |
| Sonne, TP | 1 |
| Bødtger, UCS | 2 |
| Jensen, SG | 1 |
| Rasmussen, DB | 1 |
| Brøndum, E | 1 |
| Tupper, OD | 1 |
| Sørensen, SW | 1 |
| Alstrup, G | 1 |
| Laursen, CB | 2 |
| Møller, UW | 1 |
| Sverrild, A | 1 |
| Jensen, JS | 2 |
| Monte Serrano, J | 1 |
| Cruañes Monferrer, J | 1 |
| García-García, M | 1 |
| García-Gil, MF | 1 |
| Medeiros-Domingo, A | 1 |
| Carrasco, OF | 1 |
| Berni-Betancourt, A | 1 |
| Delaleu, J | 1 |
| Deniau, B | 1 |
| Battistella, M | 1 |
| de Masson, A | 1 |
| Bensaid, B | 1 |
| Jachiet, M | 1 |
| Lazaridou, I | 1 |
| Bagot, M | 1 |
| Bouaziz, JD | 1 |
| Rossi, E | 1 |
| Lasagni, C | 1 |
| Trakatelli, M | 1 |
| Wertzberger Rowan, S | 1 |
| Magnoni, C | 1 |
| Yang, A | 1 |
| Yang, C | 1 |
| Yang, B | 1 |
| Rowland Yeo, K | 1 |
| Pan, X | 2 |
| Ban Ke, A | 1 |
| Jones, HM | 1 |
| Almond, LM | 1 |
| Di Perri, G | 1 |
| Viale, P | 6 |
| Bartoletti, M | 3 |
| Wang, YL | 1 |
| Wang, SH | 1 |
| Yang, AY | 1 |
| Alonso-Herreros, JM | 1 |
| Berisa-Prado, S | 1 |
| Cañete-Ramírez, C | 1 |
| Dávila-Pousa, C | 1 |
| Flox-Benítez, MDP | 1 |
| Ladrón de Guevara-García, M | 1 |
| López-Cabezas, C | 1 |
| Martín de Rosales-Cabrera, AM | 1 |
| Ramos-Martínez, B | 1 |
| Pani, A | 2 |
| Lauriola, M | 2 |
| Romandini, A | 1 |
| Scaglione, F | 2 |
| Guillan, M | 1 |
| Villacieros-Alvarez, J | 1 |
| Bellido, S | 1 |
| Perez-Jorge Peremarch, C | 1 |
| Suarez-Vega, VM | 1 |
| Aragones-Garcia, M | 1 |
| Cabrera-Rojo, C | 1 |
| Fernandez-Ferro, J | 1 |
| Medina, MT | 2 |
| Moncada, SS | 1 |
| Kim, JW | 2 |
| Kwon, HH | 1 |
| Jung, CY | 1 |
| Kim, KC | 1 |
| Choe, JY | 2 |
| Hong, HL | 1 |
| Santillán-García, A | 1 |
| Bravo-Jeria, R | 1 |
| Verdugo-Paiva, F | 1 |
| Rada, G | 2 |
| Alsuliman, T | 1 |
| Alasadi, L | 1 |
| Alkharat, B | 1 |
| Srour, M | 1 |
| Alrstom, A | 1 |
| Kadono, Y | 1 |
| Nakamura, Y | 1 |
| Ogawa, Y | 1 |
| Yamamoto, S | 1 |
| Kajikawa, R | 1 |
| Nakajima, Y | 1 |
| Matsumoto, M | 1 |
| Kishima, H | 1 |
| Harrigan, JJ | 1 |
| Hubbard, RA | 1 |
| Thomas, S | 1 |
| Riello, RJ | 1 |
| Bange, E | 1 |
| Mamtani, M | 1 |
| Mamtani, R | 1 |
| Enos, T | 1 |
| Jeong, HS | 1 |
| Vandergriff, T | 1 |
| Jacobe, HT | 1 |
| Chong, BF | 1 |
| Stojkovic-Filipovic, J | 1 |
| Bosic, M | 1 |
| Melian-Olivera, A | 1 |
| Dominguez-Santas, M | 1 |
| Diaz-Guimaraens, B | 1 |
| Garcia Del Real, CM | 1 |
| Waters, L | 1 |
| Rockstroh, JK | 1 |
| Hong, SI | 1 |
| Ryu, BH | 1 |
| Chong, YP | 1 |
| Kim, HC | 1 |
| Cho, OH | 1 |
| Dastan, F | 1 |
| Nadji, SA | 1 |
| Marjani, M | 1 |
| Moniri, A | 1 |
| Jamaati, H | 1 |
| Baghaei, P | 1 |
| Abedini, A | 1 |
| Varahram, M | 1 |
| Yousefian, S | 1 |
| Tabarsi, P | 1 |
| Qaseem, A | 2 |
| Yost, J | 2 |
| Etxeandia-Ikobaltzeta, I | 2 |
| Miller, MC | 1 |
| Abraham, GM | 1 |
| Obley, AJ | 1 |
| Forciea, MA | 1 |
| Jokela, JA | 1 |
| Humphrey, LL | 2 |
| Al-Bari, AA | 1 |
| Paliani, U | 2 |
| Cardona, A | 2 |
| García-Moguel, I | 1 |
| Díaz Campos, R | 1 |
| Alonso Charterina, S | 1 |
| Fernández Rodríguez, C | 1 |
| Fernández Crespo, J | 1 |
| Cavalcanti, DD | 1 |
| Raz, E | 1 |
| Shapiro, M | 1 |
| Dehkharghani, S | 1 |
| Lillemoe, K | 1 |
| Nossek, E | 1 |
| Torres, J | 1 |
| Jain, R | 2 |
| Riina, HA | 1 |
| Radmanesh, A | 1 |
| Nelson, PK | 1 |
| Di Pasquale, G | 1 |
| Maggioni, AP | 2 |
| Kuroki, Y | 1 |
| Hiyama, K | 1 |
| Minami, J | 1 |
| Takeuchi, M | 1 |
| Shojima, M | 1 |
| Matsueda, S | 1 |
| Nagae, H | 1 |
| Nakano, T | 1 |
| Facheris, P | 1 |
| Valenti, M | 1 |
| Pavia, G | 1 |
| Gargiulo, L | 1 |
| Narcisi, A | 1 |
| Costanzo, A | 1 |
| Borroni, RG | 1 |
| Chee, YJ | 1 |
| Tan, SK | 1 |
| Yeoh, E | 1 |
| Heinz, N | 1 |
| Griesemer, A | 1 |
| Kinney, J | 1 |
| Vittorio, J | 1 |
| Lagana, SM | 1 |
| Goldner, D | 1 |
| Velasco, M | 1 |
| Kato, T | 1 |
| Lobritto, S | 1 |
| Martinez, M | 2 |
| T, MR | 1 |
| Bishnoi, A | 1 |
| Hafi, NB | 1 |
| Pati, S | 1 |
| Houston, T | 1 |
| Xu, TM | 1 |
| Lin, B | 1 |
| Chen, C | 2 |
| Liu, LG | 1 |
| Xue, Y | 1 |
| Kuraitis, D | 2 |
| Murina, A | 2 |
| Luo, J | 1 |
| Rizvi, H | 1 |
| Preeshagul, IR | 1 |
| Egger, JV | 1 |
| Hoyos, D | 1 |
| Bandlamudi, C | 1 |
| McCarthy, CG | 1 |
| Falcon, CJ | 1 |
| Schoenfeld, AJ | 1 |
| Arbour, KC | 1 |
| Chaft, JE | 1 |
| Daly, RM | 1 |
| Drilon, A | 1 |
| Eng, J | 1 |
| Iqbal, A | 1 |
| Lai, WV | 1 |
| Li, BT | 1 |
| Lito, P | 1 |
| Namakydoust, A | 1 |
| Ng, K | 1 |
| Offin, M | 1 |
| Paik, PK | 1 |
| Riely, GJ | 1 |
| Rudin, CM | 1 |
| Yu, HA | 1 |
| Zauderer, MG | 1 |
| Donoghue, MTA | 1 |
| Łuksza, M | 1 |
| Greenbaum, BD | 1 |
| Kris, MG | 1 |
| Hellmann, MD | 1 |
| De Lucia, O | 1 |
| Biggioggero, M | 1 |
| Del Papa, N | 1 |
| Cai, S | 2 |
| Li, M | 2 |
| Dong, L | 2 |
| Vahedi, E | 1 |
| Ghanei, M | 1 |
| Ghazvini, A | 1 |
| Azadi, H | 1 |
| Izadi, M | 1 |
| Panahi, Y | 1 |
| Fathi, S | 1 |
| Salesi, M | 1 |
| Saadat, SH | 1 |
| Ghazale, AH | 1 |
| Rezapour, M | 1 |
| Mozafari, A | 1 |
| Zand, N | 1 |
| Parsaei, MR | 1 |
| Ranjkesh, MH | 1 |
| Jafari, R | 1 |
| Movaseghi, F | 1 |
| Darabi, E | 1 |
| Fassihi, SC | 1 |
| Nabar, NR | 1 |
| Fassihi, R | 1 |
| Marcacuzco, A | 1 |
| Caso, O | 1 |
| Cambra, F | 1 |
| Justo, I | 1 |
| Calvo, J | 1 |
| García-Sesma, A | 1 |
| Manrique, A | 1 |
| Pérez-Jacoiste Asín, MA | 1 |
| Jacquet-Lagrèze, M | 1 |
| Riad, Z | 1 |
| Hugon-Vallet, E | 1 |
| Ferraris, A | 1 |
| Fellahi, JL | 1 |
| Abrams-Downey, A | 1 |
| Saabiye, J | 1 |
| Vidaurrazaga, M | 1 |
| Dirim, AB | 1 |
| Demir, E | 1 |
| Ucar, AR | 1 |
| Garayeva, N | 1 |
| Safak, S | 1 |
| Oto, OA | 1 |
| Yazici, H | 1 |
| Alibeyoglu, AM | 1 |
| Orhun, G | 1 |
| Cagatay, AA | 1 |
| Turkmen, A | 1 |
| De Gottardi, A | 1 |
| Fratila, C | 1 |
| Bertoli, R | 1 |
| Cerny, A | 1 |
| Magenta, L | 1 |
| Gianella, P | 1 |
| Majno-Hurst, P | 1 |
| Ceschi, A | 1 |
| Vanini, G | 1 |
| Bernasconi, E | 1 |
| Ahn, BY | 1 |
| Kang, CK | 1 |
| Seo, JD | 1 |
| Song, SH | 1 |
| Park, WB | 1 |
| Park, SW | 1 |
| Mukhtyar, C | 1 |
| Kuo, CR | 1 |
| Magro, G | 1 |
| Gamboa-Alonso, CM | 1 |
| Figueroa-Parra, G | 1 |
| Galarza-Delgado, DA | 2 |
| Timerbulatov, SV | 1 |
| Timerbulstov, MV | 1 |
| Gainullina, EN | 1 |
| Gafarova, AR | 1 |
| Timerbulatov, VM | 1 |
| Chen, TY | 1 |
| Farghaly, S | 1 |
| Cham, S | 1 |
| Tatem, LL | 1 |
| Sin, JH | 1 |
| Rauda, R | 1 |
| Ribisi, M | 1 |
| Sumrani, N | 1 |
| Maritati, F | 1 |
| Cerutti, E | 1 |
| Zuccatosta, L | 1 |
| Fiorentini, A | 1 |
| Finale, C | 1 |
| Ficosecco, M | 1 |
| Cristiano, F | 1 |
| Capestro, A | 1 |
| Balestra, E | 1 |
| Taruscia, D | 1 |
| Vivarelli, M | 1 |
| Donati, A | 1 |
| Perna, GP | 1 |
| Giacometti, A | 1 |
| Tavio, M | 1 |
| Onesta, M | 1 |
| Di Sante, L | 1 |
| Ranghino, A | 1 |
| Mattioli, M | 1 |
| Fustini, E | 1 |
| Gennarini, S | 1 |
| Dadkhahfar, S | 2 |
| Araghi, F | 1 |
| Tabary, M | 1 |
| Moravvej, H | 1 |
| Mary, A | 1 |
| Hénaut, L | 1 |
| Schmit, JL | 1 |
| Lanoix, JP | 1 |
| Brazier, M | 1 |
| Gómez-Enjuto, S | 1 |
| Hernando-Requejo, V | 1 |
| Lapeña-Motilva, J | 1 |
| Ogando-Durán, G | 1 |
| Fouz-Ruiz, D | 1 |
| Domingo-García, J | 1 |
| Rodríguez-García, E | 1 |
| Cemillán-Fernández, CA | 1 |
| Pineda-Sic, RA | 1 |
| Serna-Peña, G | 1 |
| Castillo-Torres, SA | 1 |
| Flores-Alvarado, DE | 1 |
| Esquivel-Valerio, JA | 1 |
| Hernández-Galarza, IJ | 1 |
| Mehta, SA | 1 |
| Leonard, J | 1 |
| Labella, P | 1 |
| Cartiera, K | 1 |
| Soomro, I | 1 |
| Neumann, H | 1 |
| Montgomery, RA | 1 |
| Ali, NM | 1 |
| Wu, L | 1 |
| O'Kane, AM | 1 |
| Peng, H | 1 |
| Bi, Y | 1 |
| Motriuk-Smith, D | 1 |
| Ren, J | 1 |
| Nasir, N | 1 |
| Farooqi, J | 1 |
| Mahmood, SF | 1 |
| Jabeen, K | 1 |
| Allahyari, A | 1 |
| Rahimi, H | 1 |
| Khadem-Rezaiyan, M | 1 |
| Mozaheb, Z | 1 |
| Seddigh-Shamsi, M | 1 |
| Bary, A | 1 |
| Kamandi, M | 1 |
| Azimi, SA | 1 |
| HasanAbadi, SE | 1 |
| Noferesti, A | 1 |
| Shariatmaghani, SS | 1 |
| Rafatpanah, H | 1 |
| Khatami, S | 1 |
| Imani, AJ | 1 |
| Mortazi, H | 1 |
| Nodeh, MM | 1 |
| Valente-Acosta, B | 1 |
| Moreno-Sanchez, F | 1 |
| Fueyo-Rodriguez, O | 1 |
| Palomar-Lever, A | 1 |
| Bun, SS | 2 |
| Taghji, P | 1 |
| Squara, F | 1 |
| Scarlatti, D | 1 |
| Theodore, G | 1 |
| Baudouy, D | 1 |
| Sartre, B | 1 |
| Labbaoui, M | 1 |
| Dellamonica, J | 1 |
| Doyen, D | 1 |
| Marquette, CH | 1 |
| Levraut, J | 1 |
| Esnault, V | 1 |
| Ferrari, E | 1 |
| Millá Griñó, E | 1 |
| Muniesa Royo, MJ | 1 |
| Pazos López, M | 1 |
| Coskun Benlidayi, I | 1 |
| Kurtaran, B | 1 |
| Tirasci, E | 1 |
| Guzel, R | 1 |
| Stoian, AP | 1 |
| Catrinoiu, D | 1 |
| Rizzo, M | 1 |
| Bailly, C | 1 |
| Vergoten, G | 1 |
| Ren, L | 1 |
| Davis, JS | 1 |
| Ferreira, D | 1 |
| Denholm, JT | 2 |
| Tong, SY | 1 |
| Cipriano, A | 1 |
| Cruz, H | 1 |
| Tavares, J | 1 |
| Fragoso, J | 1 |
| Malheiro, J | 1 |
| Almeida, M | 1 |
| Martins, S | 1 |
| Abreu, M | 1 |
| Pedroso, S | 1 |
| Dias, L | 1 |
| Henriques, AC | 1 |
| Brandt, N | 1 |
| Chou, J | 1 |
| Morales-Ortega, A | 1 |
| Bernal-Bello, D | 1 |
| Llarena-Barroso, C | 1 |
| Frutos-Pérez, B | 1 |
| Duarte-Millán, MÁ | 1 |
| García de Viedma-García, V | 1 |
| Farfán-Sedano, AI | 1 |
| Canalejo-Castrillero, E | 1 |
| Ruiz-Giardín, JM | 1 |
| Ruiz-Ruiz, J | 1 |
| San Martín-López, JV | 1 |
| Iannaccone, G | 1 |
| Scacciavillani, R | 1 |
| Del Buono, MG | 1 |
| Camilli, M | 1 |
| Ronco, C | 1 |
| Lavie, CJ | 1 |
| Abbate, A | 1 |
| Crea, F | 1 |
| Massetti, M | 1 |
| Aspromonte, N | 1 |
| Stoll, F | 1 |
| Blank, A | 1 |
| Mikus, G | 1 |
| Czock, D | 1 |
| Foerster, KI | 1 |
| Hermann, S | 1 |
| Häußler, K | 1 |
| Muhareb, A | 1 |
| Hummler, S | 1 |
| Weiss, J | 1 |
| Burhenne, J | 1 |
| Haefeli, WE | 1 |
| Roussel, Y | 4 |
| Cirino, G | 1 |
| Ahluwalia, A | 1 |
| Solas, C | 6 |
| Grégoire, M | 1 |
| Lagarce, L | 1 |
| Polard, E | 1 |
| Saint-Salvi, B | 1 |
| Sommet, A | 1 |
| Tod, M | 1 |
| Barin-Le Guellec, C | 1 |
| Davoodi, L | 1 |
| Abedi, SM | 1 |
| Salehifar, E | 1 |
| Alizadeh-Navaei, R | 2 |
| Rouhanizadeh, H | 1 |
| Khorasani, G | 1 |
| Hosseinimehr, SJ | 1 |
| Nittari, G | 1 |
| Pallotta, G | 1 |
| Amenta, F | 1 |
| Tayebati, SK | 1 |
| Györfi, AH | 1 |
| Kopp, M | 1 |
| May, M | 1 |
| Vetter, M | 1 |
| Uder, M | 1 |
| Kremer, AE | 1 |
| Schett, G | 1 |
| Harrer, T | 1 |
| Distler, JHW | 1 |
| Nuño, L | 1 |
| Novella Navarro, M | 1 |
| Bonilla, G | 1 |
| Franco-Gómez, K | 1 |
| Aguado, P | 1 |
| Peiteado, D | 1 |
| Monjo, I | 1 |
| Tornero, C | 1 |
| Villalba, A | 1 |
| Miranda-Carus, ME | 1 |
| De Miguel, E | 1 |
| Bogas, P | 1 |
| Castilla-Plaza, A | 1 |
| Bernad-Pineda, M | 1 |
| García-Lorenzo, E | 1 |
| Rodríguez-Araya, T | 1 |
| Balsa, A | 1 |
| Bénézit, F | 1 |
| Le Bot, A | 1 |
| Jouneau, S | 1 |
| Pronier, C | 1 |
| Lentz, PA | 1 |
| Patrat-Delon, S | 1 |
| Revest, M | 1 |
| Thibault, V | 1 |
| Tattevin, P | 1 |
| Hooks, M | 1 |
| Bart, B | 1 |
| Vardeny, O | 1 |
| Westanmo, A | 1 |
| Adabag, S | 1 |
| Gougis, P | 1 |
| Veyri, M | 1 |
| Gligorov, J | 1 |
| Spano, JP | 1 |
| Bhandari, S | 2 |
| Sharma, R | 2 |
| Rankawat, G | 1 |
| Banerjee, S | 1 |
| Gupta, V | 1 |
| Dube, A | 1 |
| Kakkar, S | 1 |
| Sharma, S | 4 |
| Keswani, P | 1 |
| Agrawal, A | 1 |
| Tak, A | 1 |
| Nawal, CL | 1 |
| Udwadia, ZF | 1 |
| Malu, KN | 1 |
| Rana, D | 1 |
| Joshi, SR | 1 |
| Akintayo, RO | 1 |
| Akpabio, A | 1 |
| Kalla, A | 1 |
| Dey, D | 1 |
| Migowa, A | 1 |
| Olaosebikan, H | 1 |
| Bahiri, R | 1 |
| El Miedany, Y | 1 |
| Hadef, D | 1 |
| Hamdi, W | 2 |
| Oyoo, O | 1 |
| Slimani, S | 1 |
| Yerima, A | 1 |
| Taha, Y | 1 |
| Adebajo, A | 1 |
| Adelowo, O | 1 |
| Tikly, M | 1 |
| Ghozlani, I | 1 |
| Abdelghani, KB | 1 |
| Fouad, NA | 1 |
| Mosad, D | 1 |
| El Mikkawy, D | 1 |
| Abu-Zaid, MH | 1 |
| Abdel-Magied, RA | 1 |
| Varghese, GM | 1 |
| Manesh, A | 1 |
| Karthik, R | 1 |
| Abraham, OC | 1 |
| Chatterjee, P | 1 |
| Anand, T | 1 |
| Singh, KJ | 1 |
| Rasaily, R | 1 |
| Singh, H | 4 |
| Praharaj, I | 1 |
| Gangakhedkar, RR | 1 |
| Bhargava, B | 1 |
| Panda, S | 1 |
| González, R | 1 |
| García-Otero, L | 1 |
| Pons-Duran, C | 1 |
| Marbán-Castro, E | 1 |
| Goncé, A | 1 |
| Llurba, E | 1 |
| Gil, MDM | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Chen, H | 2 |
| Ramírez, M | 1 |
| Bardají, A | 1 |
| Menendez, C | 1 |
| McEniery, CM | 1 |
| Fisk, M | 1 |
| Miles, K | 1 |
| Kaloyirou, F | 1 |
| Hubsch, A | 1 |
| Smith, J | 1 |
| Wilkinson, IB | 1 |
| Cheriyan, J | 1 |
| Howard, L | 1 |
| Baombe, J | 1 |
| Reynard, C | 1 |
| Salacup, G | 1 |
| Lo, KB | 2 |
| Gul, F | 2 |
| Peterson, E | 1 |
| De Joy, R | 1 |
| Bhargav, R | 1 |
| Pelayo, J | 1 |
| Albano, J | 2 |
| Azmaiparashvili, Z | 2 |
| Benzaquen, S | 1 |
| Patarroyo-Aponte, G | 1 |
| Rangaswami, J | 1 |
| Coler-Reilly, A | 1 |
| Samuel, S | 1 |
| Friedman, RA | 1 |
| Sharma, C | 1 |
| Ganigara, M | 1 |
| Mitchell, E | 1 |
| Schleien, C | 1 |
| Blaufox, AD | 1 |
| Azmy, V | 1 |
| Benson, J | 1 |
| Love, K | 1 |
| Steele, R | 1 |
| Parra-Lara, LG | 2 |
| Martínez-Arboleda, JJ | 2 |
| Rosso, F | 2 |
| Offerhaus, JA | 1 |
| Wilde, AAM | 1 |
| Remme, CA | 1 |
| Arshad, S | 2 |
| Chaudhry, ZS | 2 |
| Jacobsen, G | 2 |
| Huitsing, K | 2 |
| Brar, I | 2 |
| Alangaden, GJ | 2 |
| Ramesh, MS | 2 |
| O'Neill, W | 2 |
| Guzman-Prado, Y | 1 |
| Im, JH | 1 |
| Nahm, CH | 1 |
| Baek, JH | 1 |
| Kwon, HY | 1 |
| Lee, JS | 2 |
| Shehab, N | 1 |
| Lovegrove, M | 1 |
| Budnitz, DS | 1 |
| Oscanoa, TJ | 1 |
| Romero-Ortuno, R | 1 |
| Carvajal, A | 1 |
| Savarino, A | 2 |
| Geiger, JD | 1 |
| Chang, R | 1 |
| Sun, WZ | 1 |
| Allison, D | 1 |
| Campbell-Lee, S | 1 |
| Crane, J | 1 |
| Vidanovic, V | 1 |
| Webb, S | 1 |
| Fraidenburg, D | 1 |
| Hussain, F | 1 |
| Naghipour, S | 1 |
| Ghodousi, M | 1 |
| Rahsepar, S | 1 |
| Elyasi, S | 1 |
| Martinez, MA | 1 |
| Procacci, P | 1 |
| Macchiagodena, M | 1 |
| Pagliai, M | 1 |
| Guarnieri, G | 2 |
| Iannone, F | 1 |
| Mathioudakis, AG | 1 |
| Fally, M | 1 |
| Hashad, R | 1 |
| Knight, S | 1 |
| Felton, T | 2 |
| Vestbo, J | 1 |
| Martinez, GP | 1 |
| Zabaleta, ME | 1 |
| Di Giulio, C | 1 |
| Charris, JE | 1 |
| Mijares, MR | 1 |
| Firouzabadi, FD | 1 |
| Firouzabadi, MD | 1 |
| Ghalehbaghi, B | 1 |
| Jahandideh, H | 1 |
| Roomiani, M | 1 |
| Goudarzi, S | 1 |
| Biguetti, C | 1 |
| Marrelli, MT | 1 |
| Brotto, M | 1 |
| Wu, TC | 1 |
| Sacilotto, L | 1 |
| Darrieux, FCDC | 1 |
| Pisani, CF | 1 |
| Melo, SL | 1 |
| Hachul, DT | 1 |
| Scanavacca, M | 1 |
| Watson, JA | 3 |
| Tarning, J | 3 |
| Hoglund, RM | 2 |
| Baud, FJ | 1 |
| Clemessy, JL | 1 |
| White, NJ | 4 |
| Duška, F | 1 |
| Waldauf, P | 1 |
| Halačová, M | 1 |
| Zvoníček, V | 1 |
| Bala, J | 1 |
| Balík, M | 1 |
| Beneš, J | 1 |
| Klementová, O | 1 |
| Kozáková, I | 1 |
| Kubricht, V | 1 |
| Le Roy, A | 1 |
| Vymazal, T | 1 |
| Řehořová, V | 1 |
| Černý, V | 1 |
| Marzolini, C | 2 |
| Stader, F | 1 |
| Stoeckle, M | 1 |
| Franzeck, F | 1 |
| Egli, A | 1 |
| Bassetti, S | 1 |
| Hollinger, A | 1 |
| Osthoff, M | 1 |
| Weisser, M | 1 |
| Gebhard, CE | 1 |
| Baettig, V | 1 |
| Geenen, J | 1 |
| Khanna, N | 1 |
| Tschudin-Sutter, S | 1 |
| Mueller, D | 1 |
| Hirsch, HH | 1 |
| Battegay, M | 1 |
| Sendi, P | 1 |
| Agostinis, P | 2 |
| Rabson, A | 1 |
| Melino, G | 1 |
| Carafoli, E | 2 |
| Sun, E | 1 |
| Cingolani, A | 2 |
| Tummolo, AM | 1 |
| Montemurro, G | 1 |
| Larosa, L | 1 |
| Cipriani, MC | 1 |
| Pasciuto, G | 1 |
| Liperoti, R | 1 |
| Murri, R | 1 |
| Pirronti, T | 1 |
| Cauda, R | 2 |
| Fantoni, M | 2 |
| Ferreira, A | 1 |
| Oliveira-E-Silva, A | 1 |
| Bettencourt, P | 1 |
| Giovane, RA | 1 |
| Rezai, S | 1 |
| Cleland, E | 1 |
| Henderson, CE | 1 |
| Alivernini, S | 1 |
| Tolusso, B | 1 |
| Parrotta, E | 1 |
| Kister, I | 1 |
| Charvet, L | 1 |
| Sammarco, C | 1 |
| Saha, V | 1 |
| Charlson, RE | 1 |
| Howard, J | 1 |
| Gutman, JM | 1 |
| Gottesman, M | 1 |
| Abou-Fayssal, N | 1 |
| Wolintz, R | 1 |
| Keilson, M | 1 |
| Fernandez-Carbonell, C | 1 |
| Krupp, LB | 1 |
| Zhovtis Ryerson, L | 1 |
| Santos-Moreno, P | 1 |
| Buitrago-Garcia, D | 1 |
| Villarreal, L | 1 |
| Aza, A | 1 |
| Cabrera, M | 1 |
| Rivero, W | 1 |
| Rojas-Villarraga, A | 1 |
| Aquino, YSJ | 1 |
| Cabrera, N | 1 |
| Massabeti, R | 1 |
| Cipriani, MS | 1 |
| Valenti, I | 1 |
| Göpel, S | 1 |
| Bethge, W | 1 |
| Martus, P | 1 |
| Kreth, F | 1 |
| Iftner, T | 1 |
| Joos, S | 1 |
| Döbele, S | 1 |
| Mordmüller, B | 1 |
| Ettrich, T | 1 |
| Seufferlein, T | 1 |
| Bitzer, M | 1 |
| Malek, N | 1 |
| Nampoothiri, RV | 1 |
| Hafi, NAB | 1 |
| Gajurel, K | 1 |
| Lecronier, M | 1 |
| Beurton, A | 1 |
| Burrel, S | 1 |
| Haudebourg, L | 1 |
| Deleris, R | 1 |
| Le Marec, J | 1 |
| Virolle, S | 1 |
| Nemlaghi, S | 1 |
| Bureau, C | 1 |
| Mora, P | 1 |
| De Sarcus, M | 1 |
| Clovet, O | 1 |
| Duceau, B | 1 |
| Grisot, PH | 1 |
| Pari, MH | 1 |
| Arzoine, J | 1 |
| Clarac, U | 1 |
| Boutolleau, D | 1 |
| Raux, M | 1 |
| Delemazure, J | 1 |
| Faure, M | 1 |
| Decavele, M | 1 |
| Morawiec, E | 1 |
| Mayaux, J | 1 |
| Demoule, A | 1 |
| Dres, M | 1 |
| Hsia, BC | 1 |
| Greige, N | 1 |
| Quiroz, JA | 1 |
| Khokhar, AS | 1 |
| Daily, J | 1 |
| Di Biase, L | 1 |
| Ferrick, KJ | 1 |
| Fisher, JD | 1 |
| Krumerman, A | 1 |
| Osama El-Gendy, A | 1 |
| Saeed, H | 1 |
| Ali, AMA | 1 |
| Zawbaa, HM | 1 |
| Gomaa, D | 1 |
| Harb, HS | 1 |
| Madney, YM | 1 |
| Osama, H | 1 |
| Abdelrahman, MA | 1 |
| Abdelrahim, MEA | 1 |
| Colafrancesco, S | 1 |
| Scrivo, R | 1 |
| Barbati, C | 1 |
| Priori, R | 1 |
| Reuter, H | 1 |
| Allwood, B | 1 |
| Parker, A | 1 |
| Koegelenberg, CFN | 1 |
| Blockman, M | 1 |
| Taljaard, J | 1 |
| Kouzy, R | 1 |
| Abi Jaoude, J | 1 |
| Garcia Garcia, CJ | 1 |
| El Alam, MB | 1 |
| Taniguchi, CM | 1 |
| Ludmir, EB | 1 |
| Bozzo, R | 1 |
| Ibelli, F | 1 |
| Scublinsky, D | 1 |
| Davoudi-Monfared, E | 2 |
| Rahmani, H | 2 |
| Khalili, H | 3 |
| Hajiabdolbaghi, M | 2 |
| Salehi, M | 3 |
| Abbasian, L | 2 |
| Kazemzadeh, H | 1 |
| Yekaninejad, MS | 2 |
| Saxena, A | 1 |
| Torres-Costa, S | 1 |
| Lima-Fontes, M | 1 |
| Falcão-Reis, F | 1 |
| Falcão, M | 2 |
| Hiedra, R | 1 |
| Elbashabsheh, M | 1 |
| Wright, RM | 1 |
| Patarroyo Aponte, G | 1 |
| Ghodsizad, A | 1 |
| Grant, AA | 1 |
| Mirsaeidi, M | 1 |
| Sneij, WC | 1 |
| Khalid, L | 1 |
| Delazerda, D | 1 |
| Auerbach, JS | 1 |
| Alvarez, RA | 1 |
| de Marchena, EJ | 1 |
| Hare, J | 1 |
| Guerra, G | 1 |
| Vianna, R | 1 |
| Loebe, M | 1 |
| Wright, JK | 1 |
| Tan, DHS | 1 |
| Walmsley, SL | 1 |
| Hulme, J | 1 |
| O'Connor, E | 1 |
| Snider, C | 1 |
| Cheng, I | 1 |
| Chan, AK | 1 |
| Borgundvaag, B | 1 |
| McLeod, S | 1 |
| Clarke, RJ | 1 |
| Dresser, L | 1 |
| Haji, F | 1 |
| Mazzulli, T | 1 |
| Mubareka, S | 1 |
| Jüni, P | 1 |
| Lee, D | 1 |
| Tomlinson, G | 2 |
| Kain, KC | 1 |
| Landes, M | 1 |
| Davis, J | 1 |
| Paterson, D | 1 |
| Roberts, J | 1 |
| Snelling, T | 1 |
| Zentner, D | 1 |
| Rees, M | 1 |
| O'Sullivan, M | 1 |
| Price, D | 1 |
| Bowen, A | 1 |
| Tong, SYC | 1 |
| Thoguluva Chandrasekar, V | 1 |
| Venkatesalu, B | 1 |
| Patel, HK | 1 |
| Spadaccini, M | 1 |
| Manteuffel, J | 1 |
| Ramesh, M | 1 |
| Avidan, MS | 1 |
| Dehbi, HM | 1 |
| Delany-Moretlwe, S | 1 |
| Tekwani, BL | 1 |
| Khan, MS | 1 |
| Butler, J | 1 |
| Patil, P | 1 |
| Pathak, H | 1 |
| Santhanam, S | 1 |
| Goel, A | 1 |
| Sharma, V | 1 |
| Pandey, A | 1 |
| Akerkar, S | 1 |
| Das, P | 1 |
| Dudam, R | 1 |
| Mendiratta, N | 1 |
| Pandey, BD | 1 |
| Cb, M | 1 |
| Singh, BK | 1 |
| Nolkha, N | 1 |
| Jain, S | 5 |
| Sharma, A | 1 |
| Marouf, BH | 1 |
| Dizaye, K | 1 |
| Fu, C | 1 |
| Bai, Y | 1 |
| Bae, KT | 1 |
| Shao, F | 1 |
| Meylan, P | 1 |
| Williams, DA | 1 |
| Luke, D | 1 |
| McDonald, R | 1 |
| Rosendaal, FR | 1 |
| Machiels, JD | 2 |
| Bleeker-Rovers, CP | 1 |
| Ter Heine, R | 1 |
| Rahamat-Langendoen, J | 1 |
| de Mast, Q | 1 |
| Ten Oever, J | 2 |
| Bousema, T | 1 |
| van Crevel, R | 1 |
| Wertheim, HF | 1 |
| Oliva, M | 1 |
| Hsu, K | 1 |
| Alsamarai, S | 1 |
| Chavez, V | 1 |
| Ferrara, L | 1 |
| Chattopadhyay, A | 1 |
| Chaudhuri, K | 1 |
| Schrezenmeier, EV | 1 |
| Burmester, GR | 1 |
| Eckardt, KU | 1 |
| Dörner, T | 1 |
| Moschini, L | 1 |
| Loffi, M | 2 |
| Regazzoni, V | 2 |
| Di Tano, G | 2 |
| Danzi, GB | 3 |
| Lubetzky, M | 1 |
| Aull, MJ | 1 |
| Craig-Schapiro, R | 1 |
| Lee, JR | 1 |
| Marku-Podvorica, J | 1 |
| Salinas, T | 1 |
| Gingras, L | 1 |
| Lee, JB | 1 |
| Sultan, S | 1 |
| Hartono, C | 1 |
| Saal, S | 1 |
| Muthukumar, T | 1 |
| Suthanthiran, M | 1 |
| Taştemur, Ş | 1 |
| Ataseven, H | 1 |
| Spada, F | 1 |
| Pellicori, S | 1 |
| Zampino, G | 1 |
| Funicelli, L | 1 |
| Gervaso, L | 1 |
| Laffi, A | 1 |
| Rubino, M | 1 |
| Garcia-Carbonero, R | 1 |
| Fazio, N | 1 |
| Tanriverdİ, E | 1 |
| Çörtük, M | 1 |
| Yildirim, BZ | 1 |
| Uğur Chousein, EG | 1 |
| Turan, D | 1 |
| Çinarka, H | 1 |
| Özgül, MA | 1 |
| Çetinkaya, E | 1 |
| Cortegiani, A | 1 |
| Ippolito, M | 1 |
| Ingoglia, G | 1 |
| Iozzo, P | 1 |
| Giarratano, A | 1 |
| Einav, S | 1 |
| Wang, D | 1 |
| Li, Z | 2 |
| Fleury, V | 1 |
| Tuncer, T | 1 |
| Karaci, M | 1 |
| Boga, A | 1 |
| Durmaz, H | 1 |
| Guven, S | 1 |
| Jankowska, EA | 1 |
| Sierpiński, R | 1 |
| Tkaczyszyn, M | 1 |
| Drozd, M | 1 |
| Szachniewicz, J | 1 |
| Duda-Sikuła, M | 1 |
| Knysz, B | 1 |
| Simon, K | 1 |
| Szenborn, L | 1 |
| Ponikowski, P | 1 |
| Kelly, M | 1 |
| O'Connor, R | 1 |
| Townsend, L | 1 |
| Coghlan, M | 1 |
| Relihan, E | 1 |
| Moriarty, M | 1 |
| Carr, B | 1 |
| Melanophy, G | 1 |
| Doyle, C | 1 |
| Bannan, C | 1 |
| O'Riordan, R | 1 |
| Merry, C | 1 |
| Clarke, S | 1 |
| Bergin, C | 1 |
| Foo, R | 1 |
| Thum, T | 1 |
| Khuroo, MS | 1 |
| Diotallevi, F | 1 |
| Campanati, A | 1 |
| Radi, G | 1 |
| Luchetti, MM | 1 |
| Benfaremo, D | 1 |
| Tagliati, C | 1 |
| Simonetti, O | 1 |
| Offidani, A | 1 |
| Alejandro, R | 1 |
| Caprio, M | 1 |
| Mehta, B | 1 |
| Moezinia, CJ | 1 |
| Jannat-Khah, D | 1 |
| Gibofsky, A | 1 |
| Tornberg, H | 1 |
| Pearce-Fisher, D | 1 |
| Goodman, SM | 1 |
| Salmon, JE | 1 |
| Ibrahim, S | 2 |
| Maisonnasse, P | 2 |
| Contreras, V | 1 |
| Behillil, S | 1 |
| Marlin, R | 1 |
| Naninck, T | 1 |
| Pizzorno, A | 1 |
| Lemaitre, J | 1 |
| Gonçalves, A | 1 |
| Kahlaoui, N | 1 |
| Terrier, O | 1 |
| Fang, RHT | 1 |
| Enouf, V | 1 |
| Dereuddre-Bosquet, N | 1 |
| Brisebarre, A | 1 |
| Chapon, C | 1 |
| Hoen, B | 1 |
| Lina, B | 1 |
| Calatrava, MR | 1 |
| van der Werf, S | 1 |
| Le Grand, R | 2 |
| Lee, BJ | 1 |
| Arcobello, J | 1 |
| Fecher, LA | 1 |
| Friese, CR | 1 |
| Goel, S | 1 |
| Halmos, B | 1 |
| Olszewski, AJ | 1 |
| Puc, MM | 1 |
| Revankar, SG | 1 |
| Schapira, L | 1 |
| Schwartz, GK | 1 |
| Yeh, AC | 1 |
| Zhu, H | 2 |
| Stremmel, C | 1 |
| Kellnar, A | 1 |
| Massberg, S | 1 |
| Kääb, S | 1 |
| Satlin, MJ | 1 |
| Goyal, P | 1 |
| Magleby, R | 1 |
| Maldarelli, GA | 1 |
| Pham, K | 1 |
| Kondo, M | 1 |
| Schenck, EJ | 1 |
| Rennert, H | 1 |
| Westblade, LF | 1 |
| Choi, JJ | 1 |
| Safford, MM | 1 |
| Gulick, RM | 1 |
| Arıkan, F | 1 |
| Yıldız, Y | 1 |
| Ercan, T | 1 |
| Oruç, Ö | 1 |
| Akçay, S | 1 |
| Yılmaz, F | 1 |
| Toptaş, T | 1 |
| Tuğlular, T | 1 |
| Taramasso, L | 3 |
| Di Biagio, A | 3 |
| Mikulska, M | 2 |
| Giacobbe, DR | 3 |
| Vena, A | 3 |
| Dentone, C | 2 |
| De Maria, A | 2 |
| Delfino, E | 2 |
| Berruti, M | 2 |
| Russo, C | 2 |
| Orsi, A | 2 |
| Bruzzone, B | 2 |
| Bassetti, M | 4 |
| Zampieri, FG | 4 |
| Azevedo, LCP | 2 |
| Damiani, LP | 1 |
| Marcadenti, A | 1 |
| Kawano-Dourado, L | 3 |
| Lisboa, T | 2 |
| Junqueira, DLM | 1 |
| de Barros E Silva, PGM | 1 |
| Tramujas, L | 1 |
| Abreu-Silva, EO | 1 |
| Laranjeira, LN | 1 |
| Soares, AT | 1 |
| Echenique, LS | 1 |
| Pereira, AJ | 2 |
| Freitas, FGR | 1 |
| Gebara, OCE | 2 |
| Dantas, VCS | 2 |
| Furtado, RHM | 2 |
| Milan, EP | 2 |
| Golin, NA | 1 |
| Cardoso, FF | 1 |
| Maia, IS | 1 |
| Hoffmann Filho, CR | 1 |
| Kormann, APM | 1 |
| Amazonas, RB | 2 |
| Bocchi de Oliveira, MF | 1 |
| Machado, FR | 3 |
| Ibrahim, H | 1 |
| Perl, A | 1 |
| Lewis, T | 1 |
| Kon, Z | 1 |
| Goldenberg, R | 1 |
| Yarta, K | 1 |
| Staniloae, C | 1 |
| Williams, M | 1 |
| Marinaki, S | 1 |
| Tsiakas, S | 1 |
| Skalioti, C | 1 |
| Lourida, P | 1 |
| Argyraki, A | 1 |
| Grigorakos, K | 1 |
| Boletis, I | 1 |
| Gheita, TA | 1 |
| Salem, MN | 1 |
| Eesa, NN | 1 |
| Khalil, NM | 1 |
| Gamal, NM | 1 |
| Noor, RA | 1 |
| Moshrif, AH | 1 |
| Shereef, RE | 1 |
| Ismail, F | 1 |
| Noshy, N | 1 |
| Fawzy, RM | 1 |
| Elshebini, E | 1 |
| Khalifa, I | 1 |
| Saadany, HE | 1 |
| Tharwat, S | 1 |
| El-Najjar, A | 1 |
| Fattah, YA | 1 |
| Sallam, R | 1 |
| El-Bahnasawy, AS | 1 |
| Gharbia, O | 1 |
| Hassan, E | 1 |
| ElShanawany, A | 1 |
| Mohamed, EF | 1 |
| Senara, S | 1 |
| Ismail, M | 2 |
| Nasef, SI | 1 |
| Abdalla, AM | 1 |
| Elessawi, D | 1 |
| Fawzy, SM | 1 |
| Alfadl, EA | 1 |
| Khalifa, A | 1 |
| Abaza, NM | 1 |
| Silva Arouche, TD | 1 |
| Reis, AF | 1 |
| Martins, AY | 1 |
| S Costa, JF | 1 |
| Carvalho Junior, RN | 1 |
| J C Neto, AM | 1 |
| Dabestani, A | 1 |
| DeAngelo, D | 1 |
| Chhay, SR | 1 |
| Larson, BJ | 1 |
| Ganio, MC | 1 |
| Tang, D | 1 |
| Zhang, R | 2 |
| Kang, R | 1 |
| Drożdżal, S | 1 |
| Rosik, J | 1 |
| Lechowicz, K | 1 |
| Machaj, F | 1 |
| Kotfis, K | 1 |
| Ghavami, S | 1 |
| Łos, MJ | 1 |
| Santos, CS | 1 |
| Morales, CM | 1 |
| Álvarez, ED | 1 |
| Castro, CÁ | 1 |
| Robles, AL | 1 |
| Sandoval, TP | 1 |
| Khan, S | 1 |
| Ahmad, Z | 1 |
| Khan, F | 1 |
| Asif, H | 1 |
| Zia-Ur-Rahman, A | 1 |
| Gurkan, O | 1 |
| Yilmaz, A | 1 |
| Cengel, F | 1 |
| Altunok, ES | 1 |
| Ekin, EE | 1 |
| Saseedharan, S | 1 |
| Kadam, V | 1 |
| Karanam, R | 1 |
| Baghel, P | 1 |
| Islam, M | 1 |
| Figliozzi, S | 1 |
| Rizzo, S | 1 |
| De Gaspari, M | 1 |
| Tarantini, G | 1 |
| He, F | 2 |
| Luo, Q | 1 |
| Lei, M | 1 |
| Fan, L | 1 |
| Shao, X | 1 |
| Hu, K | 1 |
| Qin, S | 1 |
| Yu, N | 1 |
| Cao, J | 1 |
| Yang, L | 1 |
| Lebin, JA | 2 |
| LeSaint, KT | 2 |
| Grau-Pujol, B | 1 |
| Camprubí, D | 1 |
| Marti-Soler, H | 1 |
| Fernández-Pardos, M | 1 |
| Guinovart, C | 1 |
| Muñoz, J | 1 |
| Rein, N | 1 |
| Haham, N | 1 |
| Orenbuch-Harroch, E | 1 |
| Romain, M | 1 |
| Argov, Z | 1 |
| Vaknin-Dembinsky, A | 1 |
| Gotkine, M | 1 |
| Siemieniuk, RA | 1 |
| Bartoszko, JJ | 2 |
| Zeraatkar, D | 3 |
| Kum, E | 3 |
| Qasim, A | 3 |
| Martinez, JPD | 2 |
| Izcovich, A | 2 |
| Han, MA | 1 |
| Agarwal, A | 3 |
| Agoritsas, T | 5 |
| Azab, M | 2 |
| Bravo, G | 1 |
| Chu, DK | 2 |
| Couban, R | 2 |
| Devji, T | 2 |
| Escamilla, Z | 1 |
| Foroutan, F | 2 |
| Gao, Y | 1 |
| Ge, L | 1 |
| Ghadimi, M | 2 |
| Heels-Ansdell, D | 1 |
| Honarmand, K | 2 |
| Hou, L | 1 |
| Ibrahim, Q | 1 |
| Khamis, A | 2 |
| Lam, B | 1 |
| Mansilla, C | 1 |
| Loeb, M | 3 |
| Miroshnychenko, A | 1 |
| Marcucci, M | 1 |
| McLeod, SL | 2 |
| Motaghi, S | 2 |
| Mustafa, RA | 2 |
| Pardo-Hernandez, H | 1 |
| Rizwan, Y | 1 |
| Saadat, P | 1 |
| Switzer, C | 2 |
| Thabane, L | 3 |
| Vandvik, PO | 3 |
| Vernooij, RW | 1 |
| Viteri-García, A | 1 |
| Yao, L | 2 |
| Guyatt, GH | 2 |
| Brignardello-Petersen, R | 3 |
| Scarsi, M | 1 |
| Piantoni, S | 1 |
| Colombo, E | 1 |
| Airó, P | 1 |
| Richini, D | 1 |
| Miclini, M | 1 |
| Bertasi, V | 1 |
| Bianchi, M | 1 |
| Bottone, D | 1 |
| Civelli, P | 1 |
| Cotelli, MS | 1 |
| Damiolini, E | 1 |
| Galbassini, G | 1 |
| Gatta, D | 1 |
| Ghirardelli, ML | 1 |
| Magri, R | 1 |
| Malamani, P | 1 |
| Mendeni, M | 1 |
| Molinari, S | 1 |
| Morotti, A | 1 |
| Salada, L | 1 |
| Turla, M | 1 |
| Vender, A | 1 |
| Tincani, A | 1 |
| Brucato, A | 1 |
| Franceschini, F | 1 |
| Furloni, R | 1 |
| Andreoli, L | 1 |
| Torequl Islam, M | 1 |
| Nasiruddin, M | 1 |
| Khan, IN | 1 |
| Mishra, SK | 2 |
| Kudrat-E-Zahan, M | 1 |
| Alam Riaz, T | 1 |
| Ali, ES | 1 |
| Rahman, MS | 1 |
| Mubarak, MS | 1 |
| Martorell, M | 1 |
| Cho, WC | 1 |
| Calina, D | 1 |
| Docea, AO | 1 |
| Sharifi-Rad, J | 1 |
| Gates, LE | 1 |
| Hamed, AA | 1 |
| Nanni, O | 1 |
| Vertogen, B | 1 |
| Lilli, C | 1 |
| Zingaretti, C | 1 |
| Donati, C | 1 |
| Masini, C | 1 |
| Monti, M | 1 |
| Serra, P | 1 |
| Vespignani, R | 1 |
| Grossi, V | 1 |
| Biggeri, A | 1 |
| Scarpi, E | 1 |
| Galardi, F | 1 |
| Bertoni, L | 1 |
| Colamartini, A | 1 |
| Falcini, F | 1 |
| Altini, M | 1 |
| Massa, I | 1 |
| Gaggeri, R | 1 |
| Martinelli, G | 1 |
| Braz, HLB | 1 |
| Silveira, JAM | 1 |
| Marinho, AD | 1 |
| de Moraes, MEA | 1 |
| Moraes Filho, MO | 1 |
| Monteiro, HSA | 1 |
| Jorge, RJB | 1 |
| Kara, E | 1 |
| Demirkan, K | 1 |
| Malviya, A | 1 |
| Atkinson, JG | 1 |
| d'Arminio Monforte, A | 1 |
| Tavelli, A | 1 |
| Bai, F | 1 |
| Marchetti, G | 1 |
| Cozzi-Lepri, A | 1 |
| Pahlajani, D | 1 |
| Capucci, A | 1 |
| Santarelli, A | 1 |
| Bartolomei, M | 1 |
| Paolizzi, C | 1 |
| Biagetti, C | 1 |
| Dappozzo, A | 1 |
| Piovaccari, G | 1 |
| Dai, L | 1 |
| Putman, M | 1 |
| Chock, YPE | 1 |
| Tam, H | 1 |
| Danila, MI | 1 |
| Sanchez-Alvarez, C | 1 |
| Coates, LC | 1 |
| Palmerlee, C | 1 |
| Peirce, A | 1 |
| Jayatilleke, A | 1 |
| Kilian, A | 1 |
| Liew, J | 1 |
| Prokop, LJ | 1 |
| Murad, MH | 2 |
| Wallace, ZS | 2 |
| Choi, NH | 1 |
| Silver, ES | 1 |
| Fremed, M | 2 |
| Liberman, L | 1 |
| Grabbe, S | 1 |
| Beissert, S | 1 |
| Enk, A | 1 |
| Guharoy, R | 2 |
| Krenzelok, E | 1 |
| Saniasiaya, J | 1 |
| Kulasegarah, J | 1 |
| Saitz, R | 1 |
| Schwitzer, G | 1 |
| Vollaard, A | 1 |
| Gieling, EM | 2 |
| van der Linden, PD | 2 |
| Sinha, B | 1 |
| de Boer, MGJ | 2 |
| Siddiqui, AJ | 1 |
| Jahan, S | 1 |
| Ashraf, SA | 1 |
| Alreshidi, M | 1 |
| Ashraf, MS | 1 |
| Snoussi, M | 1 |
| Adnan, M | 2 |
| Voisin, O | 1 |
| Lorc'h, EL | 1 |
| Mahé, A | 1 |
| Azria, P | 1 |
| Borie, MF | 1 |
| Hubert, S | 1 |
| Ménage, E | 1 |
| Guillerm, JC | 1 |
| Mourad, JJ | 1 |
| Lalabekyan, B | 1 |
| Kunst, G | 1 |
| Skelton, VA | 1 |
| D'Andrea, S | 1 |
| Berardicurti, O | 1 |
| Berardicurti, A | 1 |
| Felzani, G | 1 |
| Francavilla, F | 1 |
| Francavilla, S | 1 |
| Giacomelli, R | 1 |
| Barbonetti, A | 1 |
| Tang, Y | 1 |
| Xu, Z | 1 |
| Ji, J | 1 |
| Wen, C | 1 |
| Attanasi, M | 1 |
| Pasini, S | 1 |
| Caronni, A | 1 |
| Pellegrino, GM | 1 |
| Faverio, P | 1 |
| Di Pillo, S | 1 |
| Cimino, MM | 1 |
| Cipolla, G | 1 |
| Chiarelli, F | 1 |
| Centanni, S | 1 |
| Sferrazza Papa, GF | 1 |
| Winthrop, KL | 1 |
| Brunton, AE | 1 |
| Beekmann, S | 1 |
| Polgreen, P | 1 |
| Baddley, J | 1 |
| Calabrese, C | 1 |
| Calabrese, L | 1 |
| Curtis, JR | 1 |
| Harsch, IA | 1 |
| Skiba, M | 1 |
| Lopatta, E | 1 |
| Konturek, PC | 1 |
| Miao, H | 1 |
| Wu, M | 1 |
| Lu, C | 1 |
| Tian, M | 1 |
| Luo, P | 1 |
| Gu, J | 1 |
| Yuan, B | 1 |
| Gan, W | 1 |
| de la Cruz-Benito, B | 1 |
| Lázaro-Del Campo, P | 1 |
| Ramírez-López, A | 1 |
| de Soto-Álvarez, T | 1 |
| Sánchez-Vadillo, I | 1 |
| García-Pérez, E | 1 |
| Dos Santos-Ortas, A | 1 |
| Humala-Barbier, K | 1 |
| López-de la Guía, A | 1 |
| Casado-Abad, G | 1 |
| Jiménez-Yuste, V | 1 |
| Canales-Albendea, M | 1 |
| Kalligeros, M | 1 |
| Shehadeh, F | 1 |
| Atalla, E | 1 |
| Mylona, EK | 1 |
| Aung, S | 1 |
| Pandita, A | 1 |
| Larkin, J | 1 |
| Sanchez, M | 1 |
| Touzard-Romo, F | 1 |
| Brotherton, A | 1 |
| Shah, R | 1 |
| Cunha, CB | 1 |
| Mylonakis, E | 2 |
| Norinder, U | 1 |
| Tuck, A | 1 |
| Norgren, K | 1 |
| Munic Kos, V | 1 |
| Dar, SA | 1 |
| Wahid, M | 1 |
| Haque, S | 1 |
| Almalki, SS | 1 |
| Akhter, N | 1 |
| Salvarani, C | 2 |
| Mancuso, P | 2 |
| Gradellini, F | 1 |
| Viani, N | 1 |
| Pandolfi, P | 1 |
| Reta, M | 1 |
| Carrozzi, G | 1 |
| Sandri, G | 1 |
| Bajocchi, G | 1 |
| Galli, E | 1 |
| Muratore, F | 1 |
| Boiardi, L | 1 |
| Pipitone, N | 1 |
| Marata, AM | 1 |
| Costantini, M | 1 |
| Giorgi Rossi, P | 2 |
| Wiseman, DM | 1 |
| Brito-Azevedo, A | 1 |
| Molina-Iturritza, E | 1 |
| San-José-Muñiz, I | 1 |
| Ganchegui-Aguirre, M | 1 |
| Balerdi-Sarasola, L | 1 |
| Ortiz-de-Zárate-Ibarra, Z | 1 |
| Gainzarain-Arana, JC | 1 |
| Portu-Zapirain, J | 1 |
| Lolachi, S | 1 |
| Morin, S | 1 |
| Coen, M | 1 |
| Calmy, A | 3 |
| Serratrice, J | 1 |
| Maiti, S | 1 |
| Banerjee, A | 1 |
| Azhar, S | 2 |
| Shahzad, M | 2 |
| Latif, W | 1 |
| Khan, KS | 2 |
| Mughal, MS | 1 |
| Rehman, R | 1 |
| Osman, R | 1 |
| Kan, N | 1 |
| Mirza, H | 1 |
| Eng, MH | 1 |
| Varisco, TJ | 1 |
| Johnson, ML | 1 |
| Thornton, D | 1 |
| Akula, SM | 2 |
| McCubrey, JA | 2 |
| Abrams, SL | 1 |
| Steelman, LS | 1 |
| Candido, S | 1 |
| Libra, M | 1 |
| Lerpiriyapong, K | 1 |
| Cocco, L | 1 |
| Ramazzotti, G | 1 |
| Ratti, S | 1 |
| Follo, MY | 1 |
| Martelli, AM | 1 |
| Blalock, WL | 1 |
| Piazzi, M | 1 |
| Montalto, G | 1 |
| Cervello, M | 1 |
| Notarbartolo, M | 1 |
| Basecke, J | 1 |
| Rivera-Izquierdo, M | 1 |
| Valero-Ubierna, MDC | 1 |
| R-delAmo, JL | 1 |
| Fernández-García, MÁ | 1 |
| Martínez-Diz, S | 1 |
| Tahery-Mahmoud, A | 1 |
| Rodríguez-Camacho, M | 1 |
| Gámiz-Molina, AB | 1 |
| Barba-Gyengo, N | 1 |
| Gámez-Baeza, P | 1 |
| Cabrero-Rodríguez, C | 1 |
| Guirado-Ruiz, PA | 1 |
| Martín-Romero, DT | 1 |
| Láinez-Ramos-Bossini, AJ | 1 |
| Sánchez-Pérez, MR | 1 |
| Mancera-Romero, J | 1 |
| García-Martín, M | 1 |
| Martín-delosReyes, LM | 1 |
| Martínez-Ruiz, V | 1 |
| Jiménez-Mejías, E | 1 |
| Lopez, A | 1 |
| Duclos, G | 1 |
| Pastene, B | 1 |
| Bezulier, K | 1 |
| Guilhaumou, R | 3 |
| Zieleskiewicz, L | 1 |
| Leone, M | 1 |
| Mehta, S | 2 |
| Shamim, S | 1 |
| Khan, M | 1 |
| Kharaba, ZJ | 1 |
| Ijaz, M | 1 |
| Murtaza, G | 1 |
| Kabeerdoss, J | 1 |
| Danda, D | 1 |
| Garini, A | 1 |
| Sil, A | 1 |
| Tarek, M | 1 |
| Roomi, S | 1 |
| Ahmed, F | 1 |
| Farooq, S | 1 |
| Sadiq, U | 1 |
| Chohan, A | 1 |
| Jafar, M | 1 |
| Saddique, M | 1 |
| Khanal, S | 1 |
| Watson, R | 1 |
| Boigon, M | 1 |
| Calò, LA | 1 |
| Davis, PA | 1 |
| Burgos-Blasco, B | 1 |
| Güemes-Villahoz, N | 1 |
| Vidal-Villegas, B | 1 |
| Donate-Lopez, J | 1 |
| Garcia-Feijoo, J | 1 |
| Faden, YA | 1 |
| Alghilan, NA | 1 |
| Alawami, SH | 1 |
| Alsulmi, ES | 1 |
| Alsum, HA | 1 |
| Katib, YA | 1 |
| Sabr, YS | 1 |
| Tahir, FH | 1 |
| Bondagji, NS | 1 |
| Bhargava, S | 1 |
| Singh, AK | 1 |
| Rokde, R | 1 |
| Ip, A | 2 |
| Berry, DA | 1 |
| Hansen, E | 2 |
| Goy, AH | 2 |
| Pecora, AL | 2 |
| Sinclaire, BA | 2 |
| Bednarz, U | 2 |
| Marafelias, M | 2 |
| Berry, SM | 1 |
| Berry, NS | 1 |
| Mathura, S | 1 |
| Sawczuk, IS | 2 |
| Biran, N | 1 |
| Go, RC | 1 |
| Sperber, S | 1 |
| Piwoz, JA | 1 |
| Balani, B | 1 |
| Cicogna, C | 1 |
| Sebti, R | 1 |
| Zuckerman, J | 1 |
| Rose, KM | 1 |
| Tank, L | 1 |
| Jacobs, LG | 1 |
| Korcak, J | 1 |
| Timmapuri, SL | 1 |
| Underwood, JP | 2 |
| Sugalski, G | 1 |
| Barsky, C | 1 |
| Varga, DW | 1 |
| Asif, A | 1 |
| Landolfi, JC | 1 |
| Goldberg, SL | 2 |
| Kittleson, MM | 1 |
| Lin, C | 1 |
| Xia, X | 1 |
| Montero, F | 1 |
| Martínez-Barrio, J | 1 |
| Serrano-Benavente, B | 1 |
| González, T | 1 |
| Rivera, J | 1 |
| Molina Collada, J | 1 |
| Castrejón, I | 2 |
| Álvaro-Gracia, J | 1 |
| Sirakaya, E | 1 |
| Sahiner, M | 1 |
| Aslan Sirakaya, H | 1 |
| Pablos, JL | 1 |
| Galindo, M | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Blanco, R | 1 |
| Martinez-Lopez, D | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Fernandez-Nebro, A | 1 |
| Ricci, E | 1 |
| Calza, L | 2 |
| Squillace, N | 1 |
| Menzaghi, B | 1 |
| Rusconi, S | 1 |
| Orofino, G | 1 |
| Bargiacchi, O | 1 |
| Molteni, C | 1 |
| Valsecchi, L | 1 |
| Cenderello, G | 1 |
| Ferrara, S | 1 |
| Saracino, A | 2 |
| Maggi, P | 1 |
| Falasca, K | 2 |
| Bonfanti, P | 3 |
| Michelson, M | 1 |
| Chow, T | 1 |
| Martin, NA | 1 |
| Ross, M | 1 |
| Tee Qiao Ying, A | 1 |
| Minton, S | 1 |
| Burry, LD | 1 |
| Barletta, JF | 1 |
| Williamson, D | 1 |
| Kanji, S | 1 |
| Maves, RC | 1 |
| Dichter, J | 1 |
| Christian, MD | 1 |
| Geiling, J | 1 |
| Erstad, BL | 1 |
| Subramanian, K | 1 |
| Nalli, A | 1 |
| Senthil, V | 1 |
| Nayak, A | 1 |
| Bhat, A | 1 |
| Farooqi, FI | 1 |
| Morgan, RC | 1 |
| Dhawan, N | 1 |
| Dinh, J | 1 |
| Yatzkan, G | 1 |
| Michel, G | 1 |
| Bagheri, M | 1 |
| Rashe, Z | 1 |
| Ahur, MH | 1 |
| Eidizadeh, M | 1 |
| Sauvat, A | 1 |
| Ciccosanti, F | 1 |
| Colavita, F | 1 |
| Di Rienzo, M | 1 |
| Castilletti, C | 1 |
| Capobianchi, MR | 1 |
| Kepp, O | 2 |
| Zitvogel, L | 2 |
| Fimia, GM | 1 |
| Piacentini, M | 1 |
| Kroemer, G | 2 |
| Rivas, N | 1 |
| Espinoza, M | 1 |
| Loban, A | 1 |
| Luque, O | 1 |
| Jurado, J | 1 |
| Henry-Hurtado, N | 1 |
| Goodridge, A | 2 |
| Del Castillo, R | 1 |
| Martinez, D | 1 |
| Sarria, GJ | 1 |
| Pinillos, L | 1 |
| Garcia, B | 1 |
| Castillo, L | 1 |
| Carhuactocto, A | 1 |
| Giordano, FA | 1 |
| Sarria, GR | 1 |
| Stevenson, A | 1 |
| Kirresh, A | 1 |
| Conway, S | 1 |
| White, L | 1 |
| Ahmad, M | 1 |
| Little, C | 1 |
| Karlsen, APH | 1 |
| Wiberg, S | 1 |
| Laigaard, J | 1 |
| Pedersen, C | 1 |
| Rokamp, KZ | 1 |
| Mathiesen, O | 1 |
| Nicolini, LA | 1 |
| Signori, A | 1 |
| Sepulcri, C | 1 |
| Dettori, S | 2 |
| Sormani, MP | 1 |
| Mirabella, M | 1 |
| Magnasco, L | 1 |
| Mora, S | 1 |
| Toscanini, F | 1 |
| Balletto, E | 1 |
| Alessandrini, AI | 1 |
| Baldi, F | 1 |
| Briano, F | 1 |
| Camera, M | 1 |
| Dodi, F | 1 |
| Ferrazin, A | 1 |
| Labate, L | 1 |
| Mazzarello, G | 1 |
| Pincino, R | 1 |
| Portunato, F | 1 |
| Tutino, S | 1 |
| Barisione, E | 1 |
| Schenone, E | 1 |
| Rosseti, N | 1 |
| Sasso, E | 1 |
| Da Rin, G | 1 |
| Pelosi, P | 1 |
| Beltramini, S | 1 |
| Giacomini, M | 1 |
| Icardi, G | 1 |
| Gratarola, A | 1 |
| De Franceschi, L | 1 |
| Costa, E | 1 |
| Dima, F | 1 |
| Morandi, M | 1 |
| Olivieri, O | 1 |
| Gentile, D | 1 |
| Fuochi, V | 1 |
| Rescifina, A | 1 |
| Furneri, PM | 1 |
| Abd-Elsalam, S | 2 |
| Esmail, ES | 1 |
| Khalaf, M | 1 |
| Abdo, EF | 2 |
| Medhat, MA | 1 |
| Abd El Ghafar, MS | 1 |
| Ahmed, OA | 1 |
| Soliman, S | 2 |
| Serangawy, GN | 1 |
| Alboraie, M | 1 |
| Dubernet, A | 1 |
| Larsen, K | 1 |
| Masse, L | 1 |
| Allyn, J | 1 |
| Foch, E | 1 |
| Bruneau, L | 1 |
| Maillot, A | 1 |
| Lagrange-Xelot, M | 1 |
| Thomas, V | 1 |
| Jaffar-Bandjee, MC | 1 |
| Gauzere, L | 1 |
| Raffray, L | 1 |
| Borsu, K | 1 |
| Dibernardo, S | 1 |
| Renaud, S | 1 |
| André, M | 1 |
| Moreau, D | 1 |
| Jabot, J | 1 |
| Coolen-Allou, N | 1 |
| Allou, N | 1 |
| Taşlıdere, B | 1 |
| Mehmetaj, L | 1 |
| Özcan, AB | 1 |
| Gülen, B | 1 |
| Taşlıdere, N | 1 |
| Guerra, I | 1 |
| Algaba, A | 1 |
| Jiménez, L | 1 |
| Mar Aller, M | 1 |
| Garza, D | 1 |
| Bonillo, D | 1 |
| Molina Esteban, LM | 1 |
| Bermejo, F | 1 |
| Dajti, E | 1 |
| Cristini, F | 2 |
| Tamanini, G | 1 |
| Cescon, M | 1 |
| Bazzoli, F | 1 |
| Tamè, M | 1 |
| Tanriverdi, O | 1 |
| Koc, G | 1 |
| Odabasi, Z | 1 |
| Tan, E | 1 |
| Carbillon, L | 1 |
| Benbara, A | 1 |
| Boujenah, J | 1 |
| Halm, MA | 1 |
| Sergi, CM | 1 |
| Chiu, B | 1 |
| Marvisi, M | 2 |
| Ferrozzi, F | 1 |
| Balzarini, L | 2 |
| Mancini, C | 2 |
| Ramponi, S | 2 |
| Uccelli, M | 1 |
| Giaime, P | 1 |
| Guenoun, M | 1 |
| Pedinielli, N | 1 |
| Narbonne, H | 1 |
| Bergounioux, JP | 1 |
| Sampol, J | 1 |
| Ollier, J | 1 |
| Sichez, H | 1 |
| Serveaux, M | 1 |
| Brunner, F | 1 |
| Bataille, S | 1 |
| Fujii, H | 1 |
| Tsuji, T | 1 |
| Yuba, T | 1 |
| Tanaka, S | 1 |
| Suga, Y | 1 |
| Matsuyama, A | 1 |
| Omura, A | 1 |
| Shiotsu, S | 1 |
| Takumi, C | 1 |
| Ono, S | 1 |
| Horiguchi, M | 1 |
| Hiraoka, N | 1 |
| Gangemi, A | 1 |
| Marron, R | 1 |
| Chowdhury, J | 1 |
| Yousef, I | 1 |
| Zheng, M | 1 |
| Mills, N | 1 |
| Tragesser, L | 1 |
| Giurintano, J | 1 |
| Gupta, R | 2 |
| Gordon, M | 1 |
| Rali, P | 1 |
| D'Alonso, G | 1 |
| Fleece, D | 1 |
| Zhao, H | 1 |
| Patlakh, N | 1 |
| Criner, G | 1 |
| Funnell, SGP | 1 |
| Dowling, WE | 1 |
| Muñoz-Fontela, C | 1 |
| Gsell, PS | 1 |
| Ingber, DE | 1 |
| Hamilton, GA | 1 |
| Delang, L | 1 |
| Rocha-Pereira, J | 1 |
| Kaptein, S | 1 |
| Dallmeier, KH | 1 |
| Neyts, J | 1 |
| Rosenke, K | 2 |
| de Wit, E | 2 |
| Feldmann, H | 2 |
| Frieman, MB | 1 |
| Coleman, CM | 1 |
| de Miranda Santos, IKF | 1 |
| Costa, CHN | 1 |
| Cheng, G | 1 |
| Sekhavati, E | 1 |
| Jafari, F | 1 |
| SeyedAlinaghi, S | 1 |
| Jamalimoghadamsiahkali, S | 1 |
| Sadr, S | 1 |
| Tabarestani, M | 1 |
| Pirhayati, M | 1 |
| Zendehdel, A | 1 |
| Manafi, N | 1 |
| Ahmadinejad, Z | 1 |
| Kouchak, HE | 1 |
| Jafari, S | 1 |
| Seifi, A | 2 |
| Golestan, FS | 1 |
| Ghiasvand, F | 2 |
| Catteau, L | 2 |
| Montourcy, M | 2 |
| Hautekiet, J | 2 |
| Goetghebeur, E | 2 |
| van Ierssel, S | 1 |
| Duysburgh, E | 1 |
| Van Oyen, H | 1 |
| Wyndham-Thomas, C | 1 |
| Van Beckhoven, D | 2 |
| Padilla, S | 1 |
| Telenti, G | 1 |
| Guillén, L | 1 |
| García, JA | 1 |
| García-Abellán, J | 1 |
| Ding, C | 1 |
| Mora, A | 1 |
| García-Pachón, E | 1 |
| Gutiérrez, F | 1 |
| Niriella, MA | 1 |
| Ediriweera, DS | 1 |
| De Silva, AP | 1 |
| Premarathne, R | 1 |
| Balasooriya, P | 1 |
| Duminda, KD | 1 |
| Malavige, NG | 1 |
| Wanigasuriya, K | 1 |
| Lekamwasam, S | 1 |
| Kularathne, SA | 1 |
| Siribaddana, S | 1 |
| de Silva, HJ | 1 |
| Jayasinghe, S | 1 |
| Díaz, E | 1 |
| Amézaga Menéndez, R | 1 |
| Vidal Cortés, P | 1 |
| Escapa, MG | 1 |
| Suberviola, B | 1 |
| Serrano Lázaro, A | 1 |
| Marcos Neira, P | 1 |
| Quintana Díaz, M | 1 |
| Catalán González, M | 1 |
| Fried, MW | 1 |
| Crawford, JM | 1 |
| Mospan, AR | 1 |
| Watkins, SE | 1 |
| Munoz, B | 1 |
| Zink, RC | 1 |
| Elliott, S | 1 |
| Burleson, K | 1 |
| Landis, C | 1 |
| Reddy, KR | 1 |
| Al-Makki, A | 1 |
| Taber, T | 1 |
| Bellan, M | 1 |
| Stobbione, P | 1 |
| Pedrinelli, AR | 1 |
| Rizzi, E | 1 |
| Casciaro, GF | 1 |
| Vassia, V | 1 |
| Landi, R | 1 |
| Cittone, MG | 1 |
| Rigamonti, C | 1 |
| Patrucco, F | 1 |
| Realmuto, C | 1 |
| Todoerti, M | 1 |
| Parodi, M | 1 |
| Rossi, P | 1 |
| Pirisi, M | 1 |
| Sainaghi, PP | 2 |
| Nourian, A | 1 |
| Nabiee, M | 1 |
| Sadeghi, S | 1 |
| Hasannezhad, M | 2 |
| Ghaderkhani, S | 1 |
| Mohammadi, M | 1 |
| Sbidian, E | 1 |
| Penso, L | 1 |
| Herlemont, P | 1 |
| Botton, J | 1 |
| Baricault, B | 1 |
| Semenzato, L | 1 |
| Drouin, J | 1 |
| Weill, A | 1 |
| Dray-Spira, R | 1 |
| Zureik, M | 1 |
| Fiolet, T | 2 |
| Guihur, A | 2 |
| Rebeaud, ME | 2 |
| Mulot, M | 2 |
| Mahamat-Saleh, Y | 2 |
| Oliveira J E Silva, L | 1 |
| Vidor, MV | 1 |
| Zarpellon de Araújo, V | 1 |
| Bellolio, F | 1 |
| Sadasivam, B | 1 |
| Atal, S | 1 |
| Ray, A | 1 |
| Uzunova, K | 1 |
| Filipova, E | 1 |
| Pavlova, V | 1 |
| Vekov, T | 1 |
| Cura Yayla, BC | 1 |
| Özsürekçi, Y | 2 |
| Aykaç, K | 2 |
| Derin Oygar, P | 1 |
| Laçinel Gürlevik, S | 1 |
| İlbay, S | 1 |
| Kukul, MG | 1 |
| Karahan, S | 1 |
| Cengiz, AB | 1 |
| Ceyhan, M | 2 |
| Donaldson, L | 1 |
| Riva, E | 1 |
| Turriziani, O | 1 |
| Antonelli, G | 2 |
| Patti, G | 2 |
| Hodgson, C | 1 |
| Thomson, K | 1 |
| Nachlis, H | 1 |
| Lopez-Medina, AI | 1 |
| Campos-Staffico, AM | 1 |
| Luzum, JA | 1 |
| Montrone, M | 1 |
| Catino, A | 1 |
| Palmieri, VO | 1 |
| Longo, V | 1 |
| Galetta, D | 1 |
| Iancu, GM | 1 |
| Solomon, A | 1 |
| Birlutiu, V | 1 |
| Redondo-Sendino, Á | 1 |
| González Sánchez, IC | 1 |
| de Victoria Fernández, B | 1 |
| Rossi, G | 1 |
| Ferrari, SA | 1 |
| Sommaruga, S | 1 |
| Muzzarelli, L | 1 |
| Piconi, S | 1 |
| García-Saavedra, MB | 1 |
| Rosales-Gutiérrez, RR | 1 |
| Valverde, E | 1 |
| Chumbes-Aguirre, M | 1 |
| Alvarado, R | 1 |
| Azañero, R | 1 |
| Chávez, C | 1 |
| Moura-Neto, JA | 1 |
| Misael, AM | 1 |
| Silva, DRD | 1 |
| D'Avila, R | 1 |
| Andreoli, MCC | 1 |
| Kraychete, A | 1 |
| Bastos, K | 1 |
| Nascimento, MMD | 1 |
| Gasparyan, AY | 1 |
| Zimba, O | 1 |
| Nasiri, S | 2 |
| Abasifar, H | 1 |
| Mortazavi, N | 1 |
| Gheisari, M | 1 |
| Fatima, U | 2 |
| Rizvi, SSA | 2 |
| Fatima, S | 2 |
| Hassan, MI | 2 |
| Chan, XHS | 1 |
| Cheah, PY | 1 |
| Inama, G | 1 |
| Dodi, C | 1 |
| Provini, M | 1 |
| Bossoni, E | 1 |
| Inama, L | 1 |
| Sharma, P | 1 |
| Chen, V | 1 |
| Fung, CM | 1 |
| Troost, JP | 1 |
| Patel, VN | 1 |
| Combs, M | 1 |
| Norman, S | 1 |
| Garg, P | 1 |
| Colvin, M | 1 |
| Aaronson, K | 1 |
| Sonnenday, CJ | 1 |
| Golob, JL | 1 |
| Somers, EC | 1 |
| Doshi, MM | 1 |
| Sher, DJ | 1 |
| Zang, Y | 1 |
| Han, X | 1 |
| He, M | 1 |
| Shi, J | 1 |
| Iwasaka, S | 1 |
| Shono, Y | 1 |
| Tokuda, K | 1 |
| Nakashima, K | 1 |
| Yamamoto, Y | 1 |
| Maki, J | 1 |
| Shimono, N | 1 |
| Akahoshi, T | 1 |
| Taguchi, T | 1 |
| Chang, MC | 2 |
| Hur, J | 1 |
| Park, D | 2 |
| Simpson, I | 1 |
| Fonseca, HA | 1 |
| Corrêa, TD | 1 |
| Ferraz, LR | 1 |
| Lapa, MG | 1 |
| Manoel, ALO | 1 |
| Piza, FMT | 1 |
| Martins, PA | 1 |
| Lisboa, TC | 1 |
| Olivato, GB | 1 |
| Oliveira, MB | 1 |
| Soares, RVP | 1 |
| Moia, DDF | 1 |
| Piano, LPA | 1 |
| Castilho, K | 1 |
| Momesso, RGRAP | 1 |
| Schettino, GPP | 1 |
| Neto, AS | 1 |
| Cegolon, L | 1 |
| Javanbakht, M | 1 |
| Mastrangelo, G | 1 |
| d'Ettorre, G | 1 |
| Recchia, G | 1 |
| Ridolfi, M | 1 |
| Siccardi, G | 1 |
| Pinacchio, C | 1 |
| Innocenti, GP | 1 |
| Santinelli, L | 1 |
| Frasca, F | 1 |
| Bitossi, C | 1 |
| Ceccarelli, G | 1 |
| Borrazzo, C | 1 |
| Scagnolari, C | 1 |
| Mastroianni, CM | 1 |
| Kirenga, B | 1 |
| Muttamba, W | 1 |
| Kayongo, A | 1 |
| Nsereko, C | 1 |
| Siddharthan, T | 1 |
| Lusiba, J | 1 |
| Mugenyi, L | 1 |
| Byanyima, RK | 1 |
| Worodria, W | 1 |
| Nakwagala, F | 1 |
| Nantanda, R | 1 |
| Kimuli, I | 1 |
| Katagira, W | 1 |
| Bagaya, BS | 1 |
| Nasinghe, E | 1 |
| Aanyu-Tukamuhebwa, H | 1 |
| Amuge, B | 1 |
| Sekibira, R | 1 |
| Buregyeya, E | 1 |
| Kiwanuka, N | 1 |
| Muwanga, M | 1 |
| Kalungi, S | 1 |
| Joloba, ML | 1 |
| Kateete, DP | 1 |
| Byarugaba, B | 1 |
| Kamya, MR | 1 |
| Mwebesa, H | 1 |
| Bazeyo, W | 1 |
| Burrage, DR | 1 |
| Koushesh, S | 1 |
| Sofat, N | 1 |
| Yang, S | 1 |
| Ni, R | 1 |
| Lu, Y | 1 |
| Xie, F | 1 |
| Zhang, C | 1 |
| Lu, L | 1 |
| Sgubbi, P | 1 |
| Savoia, F | 1 |
| Calderoni, O | 1 |
| Longo, R | 1 |
| Stinchi, C | 1 |
| Tabanelli, M | 1 |
| Faisal, H | 1 |
| Bloom, A | 1 |
| Gaber, AO | 1 |
| Croft, A | 1 |
| Bucca, A | 1 |
| Jansen, JH | 1 |
| Motzkus, C | 1 |
| Herbert, A | 1 |
| Wang, A | 2 |
| Hunter, BR | 1 |
| Danjuma, MI | 1 |
| Sinha, U | 1 |
| Fatima, H | 1 |
| Mohamed, MFH | 1 |
| Nathoe, H | 1 |
| Baralić, K | 1 |
| Jorgovanović, D | 1 |
| Živančević, K | 1 |
| Antonijević Miljaković, E | 1 |
| Antonijević, B | 1 |
| Buha Djordjevic, A | 1 |
| Ćurčić, M | 1 |
| Đukić-Ćosić, D | 1 |
| Wang, N | 1 |
| Liu, R | 2 |
| Meng, L | 1 |
| He, H | 1 |
| Ding, Y | 2 |
| Hou, Y | 1 |
| Lu, W | 1 |
| Ma, W | 1 |
| Zhan, Y | 1 |
| Dai, B | 1 |
| Ge, S | 1 |
| Hu, T | 1 |
| Lu, J | 1 |
| Ta, W | 1 |
| Lu, S | 1 |
| He, L | 1 |
| Chow, R | 1 |
| Simone, CB | 1 |
| Lock, M | 1 |
| Wang, H | 1 |
| Ran, Q | 1 |
| Wei, J | 1 |
| Ferrere, G | 1 |
| Alves-Costa-Silva, C | 1 |
| Ly, P | 1 |
| Wu, Q | 1 |
| Tian, AL | 1 |
| Derosa, L | 1 |
| Fu, X | 1 |
| Xie, C | 1 |
| Ippoliti, G | 1 |
| Mortara, A | 1 |
| Milighetti, S | 1 |
| Mazen, M | 1 |
| Perseghin, G | 1 |
| Pastori, D | 1 |
| Grosso, P | 1 |
| Ramirez, GA | 1 |
| Beretta, L | 1 |
| Bellocchi, C | 1 |
| Argolini, LM | 1 |
| Moroni, L | 1 |
| Della Torre, E | 1 |
| Artusi, C | 1 |
| Nicolosi, S | 1 |
| Bozzolo, EP | 1 |
| Dagna, L | 2 |
| Zhong, J | 1 |
| Carlucci, PM | 1 |
| Ahuja, T | 1 |
| Petrilli, C | 1 |
| Rajagopalan, H | 1 |
| Jones, S | 1 |
| Rahimian, J | 1 |
| Workman, VK | 1 |
| Abboud, JM | 1 |
| Afif, C | 1 |
| Chouairi, S | 1 |
| Howes, CJ | 1 |
| Enriquez, AD | 1 |
| Mercuro, NJ | 1 |
| Yen, CF | 2 |
| Shim, DJ | 2 |
| Maher, TR | 1 |
| McCoy, CM | 1 |
| Zimetbaum, PJ | 1 |
| Gold, HS | 2 |
| Bonow, RO | 1 |
| Turakhia, M | 1 |
| Bessière, F | 1 |
| Roccia, H | 1 |
| Delinière, A | 1 |
| Charrière, R | 1 |
| Chevalier, P | 1 |
| Argaud, L | 1 |
| Cour, M | 1 |
| de Barros, CM | 1 |
| Almeida, CAF | 1 |
| Pereira, B | 1 |
| Costa, KCM | 1 |
| Pinheiro, FA | 1 |
| Maia, LDB | 1 |
| Trindade, CM | 1 |
| Garcia, RCT | 1 |
| Torres, LH | 1 |
| Diwan, S | 1 |
| Boralli, VB | 1 |
| Nicolò, M | 1 |
| Ferro Desideri, L | 1 |
| Traverso, CE | 1 |
| Yang, TH | 1 |
| Chou, CY | 1 |
| Yang, YF | 1 |
| Yarmishyn, AA | 1 |
| Yang, TY | 1 |
| Liu, CH | 1 |
| Chang, KJ | 1 |
| Jones, CW | 1 |
| Woodford, AL | 1 |
| Platts-Mills, TF | 1 |
| Caron, P | 1 |
| Baicus, C | 1 |
| Pinte, L | 1 |
| Stoichitoiu, LE | 1 |
| Badea, C | 1 |
| Bernardini, A | 1 |
| Ciconte, G | 1 |
| Negro, G | 1 |
| Rondine, R | 1 |
| Mecarocci, V | 1 |
| Viva, T | 1 |
| Santini, F | 1 |
| de Innocentiis, C | 1 |
| Giannelli, L | 1 |
| Witkowska, E | 1 |
| Locati, ET | 1 |
| Castelvecchio, S | 1 |
| Marrocco-Trischitta, MM | 1 |
| Vicedomini, G | 1 |
| Menicanti, L | 2 |
| Pappone, C | 1 |
| Sobol, I | 1 |
| Yuzefpolskaya, M | 1 |
| Roth, Z | 1 |
| Colombo, PC | 1 |
| Horn, E | 1 |
| Sagheb, S | 1 |
| Lamsehchi, A | 1 |
| Jafary, M | 1 |
| Atef-Yekta, R | 1 |
| Sadeghi, K | 1 |
| Wu, T | 1 |
| Zuo, Z | 1 |
| You, Y | 1 |
| Yang, X | 1 |
| Pan, L | 1 |
| Hu, Y | 1 |
| Luo, X | 1 |
| Jiang, L | 1 |
| Xia, Z | 1 |
| Deng, M | 1 |
| Achutha, AS | 1 |
| Pushpa, VL | 1 |
| Suchitra, S | 1 |
| Huybrechts, KF | 1 |
| Bateman, BT | 1 |
| Zhu, Y | 2 |
| Straub, L | 1 |
| Mogun, H | 1 |
| Kim, SC | 1 |
| Desai, RJ | 1 |
| Gupta, SP | 1 |
| Berling, I | 1 |
| King, JD | 1 |
| Shepherd, G | 1 |
| Hoffman, RS | 1 |
| Alhatali, B | 1 |
| Lavergne, V | 1 |
| Roberts, DM | 1 |
| Gosselin, S | 1 |
| Wilson, G | 1 |
| Nolin, TD | 1 |
| Ghannoum, M | 1 |
| Goldman, A | 1 |
| Bomze, D | 1 |
| Dankner, R | 1 |
| Hod, H | 1 |
| Meirson, T | 1 |
| Boursi, B | 1 |
| Maor, E | 1 |
| Sheha, D | 1 |
| El-Shayeb, M | 1 |
| Eid, Y | 1 |
| Amin, M | 1 |
| Saeed, A | 1 |
| Abdou, D | 1 |
| Aly, T | 1 |
| Samy, S | 1 |
| Elziaty, R | 1 |
| Aboelyazed, S | 1 |
| Osman, A | 1 |
| Sheha, A | 1 |
| Chiricozzi, A | 1 |
| Garcovich, S | 1 |
| Malvaso, D | 1 |
| Giovanardi, G | 1 |
| Peris, K | 1 |
| Thémans, P | 1 |
| Belkhir, L | 3 |
| Yombi, JC | 2 |
| De Greef, J | 2 |
| Delongie, KA | 1 |
| Vandeputte, M | 1 |
| Nasreddine, R | 1 |
| Wittebole, X | 1 |
| Wuillaume, F | 1 |
| Lescrainier, C | 1 |
| Verlinden, V | 1 |
| Kiridis, S | 1 |
| Dogné, JM | 1 |
| Hamdani, J | 1 |
| Wallemacq, P | 1 |
| Musuamba, FT | 1 |
| Marconi, L | 1 |
| Scudeller, L | 1 |
| Pancaldi, L | 1 |
| Tedeschi, S | 2 |
| Giannella, M | 1 |
| Rinaldi, M | 1 |
| Bussini, L | 1 |
| Valentini, I | 1 |
| Ferravante, AF | 1 |
| Potalivo, A | 1 |
| Marchionni, E | 1 |
| Fornaro, G | 1 |
| Pascale, R | 1 |
| Pasquini, Z | 1 |
| Barchiesi, F | 1 |
| Volpato, F | 1 |
| Rubin, A | 1 |
| Tonetti, T | 2 |
| Gaibani, P | 2 |
| Ranieri, VM | 2 |
| Biffi, M | 1 |
| Duru, F | 1 |
| Ziacchi, M | 1 |
| Lavalle, C | 1 |
| Saguner, A | 1 |
| Lanfranchi, A | 1 |
| Tocci, M | 1 |
| Fabbricatore, D | 1 |
| Salghetti, F | 1 |
| Mariani, MV | 1 |
| Busana, M | 1 |
| Bellia, A | 1 |
| Cogliati, CB | 1 |
| Antinori, S | 2 |
| Galli, M | 2 |
| Galiè, N | 1 |
| Tondo, C | 2 |
| Hasbal, NB | 1 |
| Zurita, MF | 1 |
| Iglesias Arreaga, A | 1 |
| Luzuriaga Chavez, AA | 1 |
| Zurita, L | 1 |
| Shah, RR | 1 |
| Agarwal, M | 1 |
| Ranjan, P | 1 |
| Mittal, A | 1 |
| Vitte, J | 1 |
| Mezouar, S | 1 |
| Diallo, AB | 1 |
| Boumaza, A | 1 |
| Mege, JL | 2 |
| Desnues, B | 1 |
| Lacout, A | 1 |
| Marcy, PY | 1 |
| Perronne, C | 1 |
| Hmamouchi, I | 1 |
| El Kibbi, L | 1 |
| Abdulateef, N | 1 |
| Halabi, H | 1 |
| Abutiban, F | 1 |
| El Rakawi, M | 1 |
| Eissa, M | 1 |
| Masri, B | 1 |
| Ayerbe, L | 1 |
| Risco-Risco, C | 1 |
| Ayis, S | 1 |
| Allam, MF | 1 |
| Andraous, F | 1 |
| Padern, G | 1 |
| Jolkovsky, EL | 1 |
| Biney, BT | 1 |
| Uspal, JE | 1 |
| Hyman, MC | 1 |
| Frank, I | 1 |
| Hensley, SE | 1 |
| Gill, S | 1 |
| Vogl, DT | 1 |
| Maillard, I | 1 |
| Babushok, DV | 1 |
| Huang, AC | 1 |
| Nasta, SD | 1 |
| Walsh, JC | 1 |
| Wiletyo, EP | 1 |
| Gimotty, PA | 1 |
| Milone, MC | 1 |
| Amaravadi, RK | 2 |
| Fishbein, J | 1 |
| Qiu, M | 1 |
| Mountantonakis, SE | 1 |
| Zuchelkowski, BE | 1 |
| Gingras, S | 1 |
| Yang, M | 1 |
| Triulzi, D | 1 |
| Page, GP | 1 |
| Kim-Shapiro, DB | 1 |
| Gladwin, MT | 1 |
| Lammers, AJJ | 1 |
| Brohet, RM | 1 |
| Theunissen, REP | 1 |
| Koster, C | 1 |
| Rood, R | 1 |
| Verhagen, DWM | 1 |
| Brinkman, K | 1 |
| Hassing, RJ | 1 |
| Dofferhoff, A | 1 |
| El Moussaoui, R | 1 |
| Hermanides, G | 1 |
| Ellerbroek, J | 1 |
| Bokhizzou, N | 1 |
| Visser, H | 1 |
| van den Berge, M | 1 |
| Bax, H | 1 |
| Postma, DF | 1 |
| Groeneveld, PHP | 1 |
| Kow, CS | 1 |
| Hasan, SS | 1 |
| Gautam, SS | 1 |
| Gautam, CS | 1 |
| Garg, VK | 1 |
| Al Sarkhi, AK | 1 |
| Kavanagh, O | 1 |
| Marie Healy, A | 1 |
| Dayton, F | 1 |
| Robinson, S | 1 |
| O'Reilly, NJ | 1 |
| Mahoney, B | 1 |
| Arthur, A | 1 |
| Walker, G | 1 |
| Farragher, JP | 1 |
| Quintana-Ortega, C | 1 |
| Remesal, A | 1 |
| Ruiz de Valbuena, M | 1 |
| de la Serna, O | 1 |
| Laplaza-González, M | 1 |
| Álvarez-Rojas, E | 1 |
| Udaondo, C | 1 |
| Alcobendas, R | 1 |
| Murias, S | 1 |
| Rodriguez-Garcia, JL | 1 |
| Sanchez-Nievas, G | 1 |
| Arevalo-Serrano, J | 1 |
| Garcia-Gomez, C | 1 |
| Jimenez-Vizuete, JM | 1 |
| Martinez-Alfaro, E | 1 |
| Colombi, D | 1 |
| Bodini, FC | 1 |
| Morelli, N | 1 |
| Silva, M | 1 |
| Milanese, G | 1 |
| Michieletti, E | 1 |
| Mosconi, G | 1 |
| Spazzoli, A | 1 |
| Bruno, PF | 1 |
| Angelini, ML | 1 |
| Cristino, S | 1 |
| Lifrieri, MF | 1 |
| Americo, C | 1 |
| De Fabritiis, M | 1 |
| Ambri, K | 1 |
| Dirani, G | 1 |
| Semprini, S | 1 |
| Sambri, V | 1 |
| Zambianchi, L | 1 |
| Kannan, R | 1 |
| Przekwas, A | 1 |
| Kashour, Z | 2 |
| Riaz, M | 1 |
| Garbati, MA | 1 |
| AlDosary, O | 1 |
| Tlayjeh, H | 1 |
| Gerberi, D | 2 |
| Sohail, MR | 1 |
| Kashour, T | 2 |
| Tleyjeh, IM | 2 |
| Horby, P | 1 |
| Mafham, M | 1 |
| Linsell, L | 1 |
| Bell, JL | 1 |
| Wiselka, M | 1 |
| Ustianowski, A | 1 |
| Elmahi, E | 1 |
| Prudon, B | 1 |
| Whitehouse, T | 1 |
| Williams, J | 1 |
| Faccenda, J | 1 |
| Underwood, J | 1 |
| Baillie, JK | 1 |
| Chappell, LC | 1 |
| Faust, SN | 1 |
| Jaki, T | 1 |
| Jeffery, K | 1 |
| Lim, WS | 1 |
| Montgomery, A | 1 |
| Rowan, K | 1 |
| Juszczak, E | 1 |
| Haynes, R | 1 |
| Landray, MJ | 1 |
| Murt, A | 1 |
| Dincer, MT | 1 |
| Karaca, C | 1 |
| Brusasco, C | 1 |
| Corradi, F | 1 |
| Di Domenico, A | 1 |
| Raggi, F | 1 |
| Timossi, G | 1 |
| Santori, G | 1 |
| Brusasco, V | 1 |
| Yayla, BCC | 1 |
| Morris, G | 1 |
| Athan, E | 1 |
| Walder, K | 1 |
| Bortolasci, CC | 1 |
| O'Neil, A | 1 |
| Marx, W | 1 |
| Berk, M | 1 |
| Carvalho, AF | 1 |
| Maes, M | 1 |
| Puri, BK | 1 |
| Choo, SY | 1 |
| Mamishi, S | 1 |
| Navaeian, A | 1 |
| Shabanian, R | 1 |
| Baroutjian, A | 1 |
| Sanchez, C | 1 |
| Boneva, D | 1 |
| McKenney, M | 1 |
| Elkbuli, A | 2 |
| Malaty, M | 1 |
| Kayes, T | 1 |
| Amarasekera, AT | 1 |
| Kodsi, M | 1 |
| MacIntyre, CR | 1 |
| Tan, TC | 1 |
| Annie, FH | 1 |
| Sirbu, C | 1 |
| Frazier, KR | 1 |
| Broce, M | 1 |
| Lucas, BD | 1 |
| Ortega-Peña, M | 1 |
| González-Cuevas, R | 1 |
| Hoang, BX | 1 |
| Han, B | 1 |
| Kim, JY | 1 |
| Kim, JM | 1 |
| Junqueira, DR | 1 |
| Rowe, BH | 1 |
| Duvignaud, A | 1 |
| Lhomme, E | 1 |
| Pistone, T | 1 |
| Onaisi, R | 1 |
| Sitta, R | 1 |
| Journot, V | 1 |
| Nguyen, D | 1 |
| Crémer, A | 1 |
| Darnaud, T | 1 |
| Poitrenaud, D | 1 |
| Piroth, L | 1 |
| Binquet, C | 1 |
| Michel, JF | 1 |
| Lefèvre, B | 1 |
| Lebeaux, D | 1 |
| Lebel, J | 1 |
| Dupouy, J | 1 |
| Roussillon, C | 1 |
| Gimbert, A | 1 |
| Wittkop, L | 1 |
| Thiébaut, R | 1 |
| Orne-Gliemann, J | 1 |
| Joseph, JP | 1 |
| Richert, L | 1 |
| Anglaret, X | 1 |
| Malvy, D | 1 |
| Huang, YY | 1 |
| Zhou, L | 1 |
| Wu, D | 1 |
| Liu, H | 1 |
| Yu, K | 1 |
| Cui, J | 1 |
| Zhan, CG | 1 |
| Luo, HB | 1 |
| Mori, N | 1 |
| Katayama, M | 1 |
| Nukaga, S | 1 |
| Giampreti, A | 1 |
| Eleftheriou, G | 1 |
| Gallo, M | 1 |
| Butera, R | 1 |
| Contessa, G | 1 |
| Faraoni, L | 1 |
| Sangiovanni, A | 1 |
| Negri, G | 1 |
| Falchi, G | 1 |
| Bacis, G | 1 |
| Micallef, S | 1 |
| Piscopo, TV | 1 |
| Casha, R | 1 |
| Borg, D | 1 |
| Vella, C | 1 |
| Zammit, MA | 1 |
| Borg, J | 1 |
| Mallia, D | 1 |
| Farrugia, J | 1 |
| Vella, SM | 1 |
| Xerri, T | 1 |
| Portelli, A | 1 |
| Fenech, M | 1 |
| Fsadni, C | 1 |
| Mallia Azzopardi, C | 1 |
| Fram, G | 1 |
| Malette, K | 1 |
| Villablanca, P | 1 |
| Kang, G | 1 |
| So, K | 1 |
| Basir, MB | 1 |
| Thorp, HH | 1 |
| Sosa-García, JO | 1 |
| Gutiérrez-Villaseñor, AO | 1 |
| García-Briones, A | 1 |
| Romero-González, JP | 1 |
| Juárez-Hernández, E | 1 |
| González-Chon, O | 1 |
| Batu, ED | 1 |
| Lamot, L | 1 |
| Sag, E | 1 |
| Ozen, S | 1 |
| Uziel, Y | 1 |
| Ewers, M | 1 |
| Ioannidis, JPA | 2 |
| Plesnila, N | 1 |
| Peters, EJ | 1 |
| Collard, D | 1 |
| Van Assen, S | 1 |
| Beudel, M | 1 |
| Bomers, MK | 1 |
| Buijs, J | 1 |
| De Haan, LR | 1 |
| De Ruijter, W | 1 |
| Douma, RA | 1 |
| Elbers, PW | 1 |
| Goorhuis, A | 1 |
| Gritters van den Oever, NC | 1 |
| Knarren, LG | 1 |
| Moeniralam, HS | 1 |
| Mostard, RL | 1 |
| Quanjel, MJ | 1 |
| Reidinga, AC | 1 |
| Renckens, R | 1 |
| Van Den Bergh, JP | 1 |
| Vlasveld, IN | 1 |
| Sikkens, JJ | 1 |
| Gao, C | 1 |
| Zhu, L | 1 |
| Jin, CC | 1 |
| Tong, YX | 1 |
| Xiao, AT | 1 |
| Di Mascio, D | 1 |
| D'Antonio, F | 1 |
| Bonanad, C | 1 |
| Díez-Villanueva, P | 1 |
| García-Blas, S | 1 |
| Martínez-Sellés, M | 1 |
| Vlachogianni, G | 1 |
| Hassapopoulou-Matamis, H | 1 |
| Politis, C | 1 |
| Fylaki, E | 1 |
| Mentis, A | 1 |
| Gómez-Rial, J | 1 |
| Currás-Tuala, MJ | 1 |
| Rivero-Calle, I | 1 |
| Gómez-Carballa, A | 1 |
| Cebey-López, M | 1 |
| Rodríguez-Tenreiro, C | 1 |
| Dacosta-Urbieta, A | 1 |
| Rivero-Velasco, C | 1 |
| Rodríguez-Núñez, N | 2 |
| Trastoy-Pena, R | 1 |
| Rodríguez-García, J | 1 |
| Salas, A | 1 |
| Martinón-Torres, F | 1 |
| Gagliotti, C | 1 |
| Buttazzi, R | 1 |
| Ricchizzi, E | 1 |
| Di Mario, S | 1 |
| Moro, ML | 1 |
| Shao, SC | 1 |
| Lai, EC | 1 |
| Chen, YH | 1 |
| Chan, YY | 1 |
| Chen, HY | 1 |
| Sonpar, A | 1 |
| García-Fernández, A | 1 |
| Ramos-Ruiz, P | 1 |
| Ibáñez-Criado, A | 1 |
| Moreno-Pérez, Ó | 1 |
| Cambra-Poveda, C | 1 |
| Martínez-Martínez, JG | 1 |
| Lappere, TS | 1 |
| Shaker, SB | 1 |
| Meyer, CN | 1 |
| Weinreich, UM | 1 |
| Panda, PK | 2 |
| Bandyopadhyay, A | 1 |
| Singh, BC | 1 |
| Moirangthem, B | 1 |
| Chikara, G | 1 |
| Bahurupi, YA | 1 |
| Rueegg, CS | 1 |
| Bugatti, S | 1 |
| De Stefano, L | 1 |
| Bobbio-Pallavicini, F | 1 |
| Jarvis, MA | 1 |
| Feldmann, F | 1 |
| Schwarz, B | 1 |
| Okumura, A | 1 |
| Lovaglio, J | 1 |
| Saturday, G | 1 |
| Hanley, PW | 1 |
| Meade-White, K | 1 |
| Williamson, BN | 1 |
| Hansen, F | 1 |
| Perez-Perez, L | 1 |
| Leventhal, S | 1 |
| Tang-Huau, TL | 1 |
| Callison, J | 1 |
| Haddock, E | 1 |
| Stromberg, KA | 1 |
| Scott, D | 1 |
| Sewell, G | 1 |
| Bosio, CM | 1 |
| Hawman, D | 1 |
| Shin, JS | 1 |
| Jung, E | 1 |
| Park, YG | 1 |
| Lee, J | 2 |
| Kim, SJ | 1 |
| Park, HJ | 1 |
| Lee, JH | 1 |
| Park, SM | 1 |
| Moon, SH | 1 |
| Ban, K | 1 |
| Go, YY | 1 |
| Bansal, P | 1 |
| Goyal, A | 1 |
| Cusick, A | 1 |
| Lahan, S | 1 |
| Dhaliwal, HS | 1 |
| Bhyan, P | 1 |
| Bhattad, PB | 1 |
| Aslam, F | 1 |
| Ranka, S | 1 |
| Dalia, T | 1 |
| Chhabra, L | 1 |
| Sanghavi, D | 1 |
| Sonani, B | 1 |
| Davis, JM | 1 |
| Nguyen, VT | 1 |
| Rivière, P | 1 |
| Ripoll, P | 1 |
| Barnier, J | 1 |
| Vuillemot, R | 1 |
| Ferrand, G | 1 |
| Cohen-Boulakia, S | 1 |
| Boutron, I | 1 |
| Haraszti, S | 1 |
| Sendil, S | 1 |
| Jensen, N | 1 |
| Khan, AA | 2 |
| Khan, Z | 1 |
| Krenzelok, EP | 1 |
| Slopovský, J | 1 |
| Šálek, T | 1 |
| Pazderová, N | 1 |
| Zomborská, E | 1 |
| Makovník, M | 1 |
| Palacka, P | 1 |
| Horniczká, K | 1 |
| Stankovič, I | 1 |
| Pörsök, Š | 1 |
| Mallhi, TH | 2 |
| Ahmad, A | 1 |
| Butt, MH | 1 |
| Misbah, S | 1 |
| Khan, YH | 2 |
| Alotaibi, NH | 2 |
| Gallus, S | 1 |
| Clavenna, A | 1 |
| Lugo, A | 1 |
| Choi, MJ | 1 |
| Kang, M | 2 |
| Shin, SY | 1 |
| Noh, JY | 1 |
| Cheong, HJ | 1 |
| Kim, WJ | 2 |
| Jung, J | 2 |
| Song, JY | 1 |
| Gavriatopoulou, M | 1 |
| Ntanasis-Stathopoulos, I | 1 |
| Korompoki, E | 1 |
| Fotiou, D | 1 |
| Migkou, M | 1 |
| Tzanninis, IG | 1 |
| Psaltopoulou, T | 1 |
| Kastritis, E | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 1 |
| Bosaeed, M | 1 |
| Mahmoud, E | 1 |
| Hussein, M | 1 |
| Alharbi, A | 1 |
| Alsaedy, A | 1 |
| Alothman, A | 1 |
| Aljeraisy, M | 1 |
| Alqahtani, H | 1 |
| Nashabat, M | 1 |
| Almutairi, B | 1 |
| Almaghaslah, M | 1 |
| Aldibasi, O | 1 |
| AlJohani, S | 1 |
| Bouchama, A | 1 |
| Arabi, Y | 1 |
| Alaskar, A | 1 |
| Cismaru, CA | 1 |
| Cismaru, GL | 1 |
| Seyed Nabavi, F | 1 |
| Seyed Nabavi, M | 1 |
| Berindan-Neagoe, I | 1 |
| Kuzu, AS | 1 |
| Pakhchanian, H | 1 |
| Raiker, R | 1 |
| Karagülle, M | 1 |
| Cavalli, G | 1 |
| Coleman, I | 1 |
| Ruiz, G | 1 |
| Brahmbhatt, S | 1 |
| Ackerman, L | 1 |
| Cattaneo, D | 1 |
| Pasina, L | 1 |
| Giacomelli, A | 1 |
| Oreni, L | 1 |
| Covizzi, A | 1 |
| Bradanini, L | 1 |
| Schiuma, M | 1 |
| Ridolfo, A | 1 |
| Gervasoni, C | 1 |
| Niburski, K | 1 |
| Niburski, O | 1 |
| Pimentel, J | 1 |
| Andersson, N | 1 |
| Chauhan, P | 1 |
| Kakkar, AK | 2 |
| Cohen, IV | 1 |
| Makunts, T | 1 |
| Moumedjian, T | 1 |
| Issa, MA | 1 |
| Abagyan, R | 1 |
| Murray, K | 1 |
| Quinn, S | 1 |
| Turk, M | 1 |
| O'Rourke, A | 1 |
| Molloy, E | 1 |
| O'Neill, L | 1 |
| Mongey, AB | 1 |
| Fearon, U | 1 |
| Veale, DJ | 1 |
| Gunay, S | 1 |
| Caliskan, S | 1 |
| Sigirli, D | 1 |
| Doudka, N | 1 |
| Giocanti, M | 1 |
| Basso, M | 1 |
| Ugdonne, R | 1 |
| Barthelemy, K | 1 |
| Lacarelle, B | 1 |
| Blin, O | 1 |
| Kakkar, A | 1 |
| Pvm, L | 1 |
| Vaidyanathan, G | 1 |
| García-Rodríguez, D | 1 |
| Remior, P | 1 |
| García-Izquierdo, E | 1 |
| Toquero, J | 1 |
| Castro, V | 1 |
| Fernández Lozano, I | 1 |
| Chen, PL | 1 |
| Hsiao, YH | 1 |
| Chuang, C | 1 |
| Feng, JY | 1 |
| Ho, HL | 1 |
| Lin, YT | 1 |
| Chen, SJ | 1 |
| Huang, SF | 1 |
| Chen, HP | 1 |
| Chou, TY | 1 |
| Chen, YM | 1 |
| Wang, FD | 1 |
| Khamis, F | 1 |
| Al Naabi, H | 1 |
| Al Lawati, A | 1 |
| Ambusaidi, Z | 1 |
| Al Sharji, M | 1 |
| Al Barwani, U | 1 |
| Pandak, N | 1 |
| Al Balushi, Z | 1 |
| Al Bahrani, M | 1 |
| Al Salmi, I | 1 |
| Al-Zakwani, I | 1 |
| Orbak, Z | 1 |
| Laloglu, F | 1 |
| Akat, H | 1 |
| Aguilar, J | 1 |
| Averbukh, Y | 1 |
| McLaughlin, M | 1 |
| Trujillo, H | 1 |
| Gutiérrez, E | 1 |
| Sevillano, Á | 1 |
| Caravaca-Fontán, F | 1 |
| Morales, E | 1 |
| Praga, M | 1 |
| Friedrich, S | 1 |
| Friede, T | 1 |
| Ly, TDA | 2 |
| Zanini, D | 1 |
| Laforge, V | 1 |
| Arlotto, S | 1 |
| Mendizabal, H | 1 |
| Finaud, M | 1 |
| Morel, D | 1 |
| Quenette, O | 1 |
| Malfuson-Clot-Faybesse, P | 1 |
| Midejean, A | 1 |
| Le-Dinh, P | 1 |
| Daher, G | 1 |
| Labarriere, B | 1 |
| Morel-Roux, AM | 1 |
| Coquet, A | 1 |
| Augier, P | 1 |
| Emani, VR | 1 |
| Goswami, S | 1 |
| Nandanoor, D | 1 |
| Emani, SR | 1 |
| Reddy, NK | 1 |
| Reddy, R | 1 |
| Malek, SA | 1 |
| Bouchti, IE | 1 |
| Saida, IB | 1 |
| Ennouri, E | 1 |
| Nachi, R | 1 |
| Meddeb, K | 1 |
| Mahmoud, J | 1 |
| Thabet, N | 1 |
| Jerbi, S | 1 |
| Boussarsar, M | 1 |
| Lewis, MJ | 1 |
| Anderson, BR | 1 |
| Argenio, M | 1 |
| Krishnan, U | 1 |
| Weller, R | 1 |
| Levasseur, S | 1 |
| Sommer, R | 1 |
| Lytrivi, ID | 1 |
| Bacha, EA | 1 |
| Vincent, J | 1 |
| Chung, WK | 1 |
| Rosenzweig, EB | 1 |
| Starc, TJ | 1 |
| Rosenbaum, M | 1 |
| Lamazou, F | 1 |
| Oger, P | 1 |
| Dieli-Crimi, R | 1 |
| Guerin, A | 1 |
| Letouzey, V | 1 |
| Octernaud, S | 1 |
| Place, V | 1 |
| Calès, P | 1 |
| Descamps, P | 1 |
| Delaroche, L | 1 |
| Pandolfi, L | 1 |
| Fossali, T | 1 |
| Frangipane, V | 1 |
| Bozzini, S | 1 |
| Morosini, M | 1 |
| D'Amato, M | 1 |
| Lettieri, S | 1 |
| Urtis, M | 1 |
| Di Toro, A | 1 |
| Saracino, L | 1 |
| Percivalle, E | 1 |
| Tomaselli, S | 1 |
| Cova, E | 1 |
| Mojoli, F | 1 |
| Bergomi, P | 1 |
| Ottolina, D | 1 |
| Lilleri, D | 1 |
| Corsico, AG | 1 |
| Arbustini, E | 1 |
| Colombo, R | 1 |
| Meloni, F | 1 |
| Boari, GEM | 1 |
| Chiarini, G | 1 |
| Bonetti, S | 1 |
| Malerba, P | 1 |
| Bianco, G | 1 |
| Faustini, C | 1 |
| Braglia-Orlandini, F | 1 |
| Turini, D | 1 |
| Guarinoni, V | 1 |
| Saottini, M | 1 |
| Viola, S | 1 |
| Ferrari-Toninelli, G | 1 |
| Pasini, G | 1 |
| Mascadri, C | 1 |
| Bonzi, B | 1 |
| Desenzani, P | 1 |
| Tusi, C | 1 |
| Zanotti, E | 1 |
| Nardin, M | 1 |
| Rizzoni, D | 1 |
| Faraone, I | 1 |
| Labanca, F | 1 |
| Ponticelli, M | 1 |
| De Tommasi, N | 1 |
| Milella, L | 1 |
| Kumar, G | 1 |
| Hererra, M | 1 |
| Rojas, ER | 1 |
| Sakhuja, A | 1 |
| Meersman, M | 1 |
| Dalton, D | 1 |
| Kethireddy, S | 1 |
| Nanchal, R | 1 |
| Guddati, AK | 1 |
| Berlivet, L | 1 |
| Löwy, I | 1 |
| Mamontov, E | 1 |
| Cheng, Y | 1 |
| Daemen, LL | 1 |
| Kolesnikov, AI | 1 |
| Ramirez-Cuesta, AJ | 1 |
| Ryder, MR | 1 |
| Stone, MB | 1 |
| Revollo, B | 1 |
| Tebe, C | 2 |
| Peñafiel, J | 2 |
| Blanco, I | 1 |
| Perez-Alvarez, N | 1 |
| Lopez, R | 1 |
| Rodriguez, L | 1 |
| Ferrer, J | 1 |
| Ricart, P | 1 |
| Moret, E | 1 |
| Tural, C | 1 |
| Carreres, A | 1 |
| Matllo, J | 1 |
| Videla, S | 1 |
| Clotet, B | 2 |
| Llibre, JM | 1 |
| Allameh, SF | 1 |
| Nemati, S | 1 |
| Ghalehtaki, R | 1 |
| Mohammadnejad, E | 1 |
| Aghili, SM | 1 |
| Khajavirad, N | 1 |
| Beigmohammadi, MT | 1 |
| Mirfazaelian, H | 1 |
| Edalatifard, M | 1 |
| Kazemizadeh, H | 1 |
| Dehghan Manshadi, SA | 1 |
| Amoozadeh, L | 1 |
| Radnia, M | 1 |
| Khatami, SR | 1 |
| Nahvijou, A | 1 |
| Seyyedsalehi, MS | 1 |
| Rashidian, L | 1 |
| Ayoobi Yazdi, N | 1 |
| Nasiri Toosi, M | 1 |
| Sadeghniiat-Haghighi, K | 1 |
| Jafarian, A | 1 |
| Yunesian, M | 1 |
| Zendehdel, K | 1 |
| Rivoisy, C | 1 |
| Hessamfar, M | 1 |
| Bernard, N | 1 |
| Aureau, I | 1 |
| Lapoirie, J | 1 |
| Contis, A | 1 |
| Sacher, F | 1 |
| Sacristan, B | 1 |
| Pedeboscq, S | 1 |
| Vandenhende, MA | 1 |
| Pilla Reddy, V | 1 |
| El-Khateeb, E | 1 |
| Jo, H | 1 |
| Giovino, N | 1 |
| Lythgoe, E | 1 |
| Jamei, M | 1 |
| Rastomi-Hodjegan, A | 1 |
| Kumar, M | 1 |
| Madan, J | 1 |
| Sodhi, RK | 1 |
| Singh, SB | 1 |
| Katyal, A | 1 |
| Bakadia, BM | 1 |
| Souho, T | 1 |
| Lamboni, L | 1 |
| Ullah, MW | 1 |
| Boni, BO | 1 |
| Ahmed, AAQ | 1 |
| Mukole, BM | 1 |
| Yang, G | 1 |
| Abers, MS | 1 |
| Delmonte, OM | 1 |
| Ricotta, EE | 1 |
| Fintzi, J | 1 |
| Fink, DL | 1 |
| de Jesus, AAA | 1 |
| Zarember, KA | 1 |
| Alehashemi, S | 1 |
| Oikonomou, V | 1 |
| Desai, JV | 1 |
| Canna, SW | 1 |
| Shakoory, B | 1 |
| Dobbs, K | 1 |
| Imberti, L | 1 |
| Sottini, A | 1 |
| Quiros-Roldan, E | 1 |
| Rossi, C | 1 |
| Brugnoni, D | 1 |
| Biondi, A | 1 |
| Bettini, LR | 1 |
| D'Angio', M | 1 |
| Castagnoli, R | 1 |
| Montagna, D | 1 |
| Licari, A | 1 |
| Marseglia, GL | 1 |
| Gliniewicz, EF | 1 |
| Shaw, E | 1 |
| Kahle, DE | 1 |
| Rastegar, AT | 1 |
| Stack, M | 1 |
| Myint-Hpu, K | 1 |
| Levinson, SL | 1 |
| DiNubile, MJ | 1 |
| Chertow, DW | 1 |
| Burbelo, PD | 1 |
| Cohen, JI | 1 |
| Calvo, KR | 1 |
| Tsang, JS | 1 |
| Su, HC | 1 |
| Gallin, JI | 1 |
| Kuhns, DB | 1 |
| Goldbach-Mansky, R | 1 |
| Lionakis, MS | 1 |
| Notarangelo, LD | 1 |
| Torres-Atencio, I | 1 |
| Vega, S | 1 |
| Lee, Z | 1 |
| Rayner, CR | 1 |
| Forrest, JI | 2 |
| Senchaudhuri, E | 1 |
| Raina, N | 1 |
| Rahman, S | 1 |
| Kamal, MA | 1 |
| Horby, PW | 1 |
| Maraolo, AE | 1 |
| Grossi, A | 1 |
| Heras, E | 1 |
| Garibaldi, P | 1 |
| Boix, M | 1 |
| Valero, O | 1 |
| Castillo, J | 1 |
| Curbelo, Y | 1 |
| Mendoza, O | 1 |
| Anglada, M | 1 |
| Miralles, JC | 1 |
| Llull, P | 1 |
| Llovera, R | 1 |
| Piqué, JM | 1 |
| Kim, MG | 1 |
| Stein, AA | 1 |
| Overby, P | 1 |
| Kleinman, G | 1 |
| Nuoman, R | 1 |
| Gulko, E | 1 |
| Al-Mufti, F | 1 |
| Pisapia, JM | 1 |
| Muh, CR | 1 |
| Bavdekar, SB | 1 |
| Chandrasekaran, A | 1 |
| Govindarajan, RP | 1 |
| Malik, S | 1 |
| Bajaj, S | 1 |
| Javeri, Y | 1 |
| Niranjan, V | 1 |
| Tripathi, T | 1 |
| Rodriguez-Gonzalez, CG | 1 |
| Chamorro-de-Vega, E | 1 |
| Valerio, M | 1 |
| Amor-Garcia, MA | 1 |
| Tejerina, F | 1 |
| Sancho-Gonzalez, M | 1 |
| Narrillos-Moraza, A | 1 |
| Gimenez-Manzorro, A | 1 |
| Manrique-Rodriguez, S | 1 |
| Machado, M | 1 |
| Olmedo, M | 1 |
| Escudero-Vilaplana, V | 1 |
| Villanueva-Bueno, C | 1 |
| Torroba-Sanz, B | 1 |
| Melgarejo-Ortuño, A | 1 |
| Vicente-Valor, J | 1 |
| Herranz, A | 1 |
| Bouza, E | 1 |
| Muñoz, P | 1 |
| Sanjurjo, M | 1 |
| De Schryver, N | 1 |
| Serck, N | 1 |
| Vinetti, M | 1 |
| Gérard, L | 2 |
| Riou, M | 1 |
| Marcot, C | 1 |
| Canuet, M | 1 |
| Renaud-Picard, B | 1 |
| Chatron, E | 1 |
| Porzio, M | 1 |
| Dégot, T | 1 |
| Hirschi, S | 1 |
| Metz-Favre, C | 1 |
| Kassegne, L | 1 |
| Ederle, C | 1 |
| Khayath, N | 1 |
| Labani, A | 1 |
| Leyendecker, P | 1 |
| De Blay, F | 1 |
| Kessler, R | 1 |
| Pan, H | 1 |
| Peto, R | 1 |
| Henao-Restrepo, AM | 1 |
| Preziosi, MP | 1 |
| Sathiyamoorthy, V | 1 |
| Abdool Karim, Q | 1 |
| Alejandria, MM | 1 |
| Hernández García, C | 1 |
| Kieny, MP | 1 |
| Malekzadeh, R | 1 |
| Reddy, KS | 1 |
| Roses Periago, M | 1 |
| Abi Hanna, P | 1 |
| Al-Bader, AM | 1 |
| Alhasawi, A | 1 |
| Allum, E | 1 |
| Alotaibi, A | 1 |
| Alvarez-Moreno, CA | 1 |
| Appadoo, S | 1 |
| Asiri, A | 1 |
| Aukrust, P | 2 |
| Barratt-Due, A | 2 |
| Bellani, S | 1 |
| Branca, M | 1 |
| Cappel-Porter, HBC | 1 |
| Cerrato, N | 1 |
| Chow, TS | 1 |
| Como, N | 1 |
| Eustace, J | 1 |
| García, PJ | 1 |
| Godbole, S | 1 |
| Griskevicius, L | 1 |
| Hamra, R | 1 |
| Hassan, M | 1 |
| Hassany, M | 1 |
| Hutton, D | 1 |
| Irmansyah, I | 1 |
| Jancoriene, L | 1 |
| Kirwan, J | 1 |
| Lennon, P | 1 |
| Lopardo, G | 1 |
| Lydon, P | 1 |
| Magrini, N | 1 |
| Maguire, T | 1 |
| Manevska, S | 1 |
| Manuel, O | 1 |
| McGinty, S | 1 |
| Mesa Rubio, ML | 1 |
| Miranda-Montoya, MC | 1 |
| Nel, J | 1 |
| Perola, M | 1 |
| Portolés, A | 1 |
| Rasmin, MR | 1 |
| Raza, A | 1 |
| Rees, H | 1 |
| Reges, PPS | 1 |
| Rogers, CA | 1 |
| Salami, K | 1 |
| Salvadori, MI | 1 |
| Sinani, N | 1 |
| Sterne, JAC | 1 |
| Stevanovikj, M | 1 |
| Tikkinen, KAO | 1 |
| Trelle, S | 1 |
| Zaid, H | 1 |
| Røttingen, JA | 1 |
| Swaminathan, S | 1 |
| Alkasir, A | 1 |
| Lippmann, S | 1 |
| Khan, MSI | 1 |
| Nabeka, H | 1 |
| Akbar, SMF | 1 |
| Al Mahtab, M | 1 |
| Shimokawa, T | 1 |
| Islam, F | 1 |
| Matsuda, S | 1 |
| Alsharif, MH | 1 |
| Alsharif, YH | 1 |
| Albreem, MA | 1 |
| Jahid, A | 1 |
| Solyman, AAA | 1 |
| Yahya, K | 1 |
| Alomari, OA | 1 |
| Hossain, MS | 1 |
| Wood, WA | 1 |
| Neuberg, DS | 1 |
| Thompson, JC | 1 |
| Tallman, MS | 1 |
| Sekeres, MA | 1 |
| Sehn, LH | 1 |
| Anderson, KC | 1 |
| Goldberg, AD | 1 |
| Niemeyer, CM | 1 |
| Tucker, E | 1 |
| Hewitt, K | 1 |
| Plovnick, RM | 1 |
| Hicks, LK | 1 |
| Özdemir, İH | 1 |
| Özlek, B | 1 |
| Özen, MB | 1 |
| Gündüz, R | 1 |
| Çetin, N | 2 |
| Bilge, AR | 1 |
| Benouna, ME | 1 |
| Ech-Chenbouli, A | 1 |
| Shamshirian, A | 2 |
| Hessami, A | 1 |
| Heydari, K | 1 |
| Navaei, RA | 1 |
| Ebrahimzadeh, MA | 1 |
| Yip, GW | 1 |
| Ghasemian, R | 1 |
| Sedaghat, M | 1 |
| Baradaran, H | 1 |
| Yazdi, SM | 1 |
| Aboufazeli, E | 1 |
| Jafarpour, H | 1 |
| Dadgostar, E | 1 |
| Tirandazi, B | 1 |
| Sadeghnezhad, R | 1 |
| Karimifar, K | 1 |
| Eftekhari, A | 1 |
| Shamshirian, D | 1 |
| Thorpe, LE | 1 |
| Kottkamp, A | 1 |
| Deming, M | 1 |
| Paolino, K | 1 |
| Hoffman, R | 1 |
| Schaafsma, TT | 1 |
| Thomas, KK | 1 |
| Morrison, S | 1 |
| Haugen, HS | 1 |
| Kidoguchi, L | 1 |
| Huang, ML | 1 |
| Corbacho-Monné, M | 1 |
| Ubals, M | 1 |
| Alemany, A | 1 |
| Suñer, C | 1 |
| Tobias, A | 1 |
| Ballana, E | 1 |
| Pérez, CA | 1 |
| Admella, P | 1 |
| Riera-Martí, N | 1 |
| Laporte, P | 1 |
| Mitjà, J | 1 |
| Clua, M | 1 |
| Bertran, L | 1 |
| Sarquella, M | 1 |
| Gavilán, S | 1 |
| Ara, J | 1 |
| Argimon, JM | 1 |
| Cuatrecasas, G | 1 |
| Cañadas, P | 1 |
| Elizalde-Torrent, A | 1 |
| Fabregat, R | 1 |
| Farré, M | 1 |
| Forcada, A | 1 |
| Flores-Mateo, G | 1 |
| López, C | 1 |
| Muntada, E | 1 |
| Nadal, N | 1 |
| Narejos, S | 1 |
| Nieto, A | 1 |
| Prat, N | 1 |
| Puig, J | 1 |
| Quiñones, C | 1 |
| Ramírez-Viaplana, F | 1 |
| Reyes-Urueña, J | 1 |
| Riveira-Muñoz, E | 1 |
| Ruiz, L | 1 |
| Sanz, S | 1 |
| Sentís, A | 1 |
| Sierra, A | 1 |
| Velasco, C | 1 |
| Vivanco-Hidalgo, RM | 2 |
| Zamora, J | 1 |
| Casabona, J | 1 |
| Vall-Mayans, M | 1 |
| González-Beiras, C | 1 |
| Seyhan, AU | 1 |
| Doganay, F | 1 |
| Yilmaz, E | 1 |
| Topal, NP | 1 |
| Ak, R | 1 |
| Gürsoy, C | 1 |
| Tapan, ÖO | 1 |
| Dogan, E | 1 |
| Togan, T | 1 |
| Demirbilek, SG | 1 |
| Rendic, S | 1 |
| Guengerich, FP | 1 |
| Mondal, S | 1 |
| De, N | 1 |
| Pal, A | 1 |
| Gao, W | 1 |
| Zlámal, M | 1 |
| Štěchovská, K | 1 |
| Holub, M | 1 |
| Mashayekhi, F | 1 |
| Holvoet, W | 1 |
| van Soest, K | 1 |
| Havenith, T | 1 |
| Lorusso, R | 1 |
| van Mook, WNKA | 1 |
| Delnoij, T | 1 |
| Miller-Handley, H | 1 |
| Luckett, K | 1 |
| Govil, A | 1 |
| Tejada Cifuentes, F | 1 |
| Lloret Callejo, Á | 1 |
| Tirado Peláez, MJ | 1 |
| Rubio Pulido, O | 1 |
| Ruiz-Morote Aragón, M | 1 |
| Fernández Urrusuno, R | 1 |
| Muñoz Carreras, MI | 1 |
| Méndez Esteban, MI | 1 |
| Maestre Sánchez, V | 1 |
| García Bonilla, A | 1 |
| Paredero Dominguez, JM | 1 |
| Arroyo Pineda, V | 1 |
| Marco Tejón, E | 1 |
| Romero Candel, G | 1 |
| Fernández Marchante, AI | 1 |
| Marco Del Rio, J | 1 |
| Ortiz Martín, T | 1 |
| López Sánchez, P | 1 |
| Bakheet, N | 1 |
| Fouad, R | 1 |
| Kassem, AM | 1 |
| Hussin, W | 1 |
| El-Shazly, M | 1 |
| Velayati, AA | 1 |
| Banifazl, M | 1 |
| Fotouhi, F | 1 |
| Sadat Larijani, M | 1 |
| Afzali, N | 1 |
| Nadeem, U | 1 |
| Raafey, M | 1 |
| Kim, G | 1 |
| Treger, J | 1 |
| Pytel, P | 1 |
| N Husain, A | 1 |
| Schulte, JJ | 1 |
| Jung, SY | 1 |
| Kim, MS | 3 |
| Kim, MC | 1 |
| Choi, SH | 1 |
| Chung, JW | 1 |
| Choi, ST | 1 |
| Herth, FJF | 1 |
| Sakoulas, G | 1 |
| Haddad, F | 2 |
| Tosato, M | 1 |
| Varone, F | 1 |
| Calvani, R | 1 |
| Moschese, D | 1 |
| Potenza, A | 1 |
| Siciliano, M | 1 |
| Sinha, BNM | 1 |
| Vollaard, AM | 1 |
| McMahon, JH | 1 |
| Lydeamore, MJ | 1 |
| Stewardson, AJ | 1 |
| Ter Avest, M | 1 |
| Kramers, C | 1 |
| Tan, J | 1 |
| Bilgin, ZD | 1 |
| Evcil, I | 1 |
| Yazgi, D | 1 |
| Binay, G | 1 |
| Okuyucu Genc, C | 1 |
| Gulsen, B | 1 |
| Huseynova, A | 1 |
| Ozdemir, AZ | 1 |
| Ozmen, E | 1 |
| Usta, Y | 1 |
| Ustun, S | 1 |
| Caglar Andac, S | 1 |
| Marra, F | 1 |
| Smolders, EJ | 1 |
| El-Sherif, O | 1 |
| Boyle, A | 1 |
| Davidson, K | 1 |
| Sommerville, AJ | 1 |
| Siccardi, M | 1 |
| Burger, D | 1 |
| Gibbons, S | 1 |
| Khoo, S | 1 |
| Back, D | 1 |
| Verma, A | 1 |
| Kumar, D | 1 |
| Matangila, JR | 1 |
| Nyembu, RK | 1 |
| Telo, GM | 1 |
| Ngoy, CD | 1 |
| Sakobo, TM | 1 |
| Massolo, JM | 1 |
| Muyembe, BM | 1 |
| Mvwala, RK | 1 |
| Ilunga, CK | 1 |
| Limbole, EB | 1 |
| Ntalaja, JM | 1 |
| Kongo, RM | 1 |
| Roozbeh, F | 1 |
| Saeedi, M | 1 |
| Hedayatizadeh-Omran, A | 1 |
| Merat, S | 1 |
| Wentzel, H | 1 |
| Levi, J | 1 |
| Smoke, SM | 1 |
| Raja, K | 1 |
| Hilden, P | 1 |
| Daniel, NM | 1 |
| Pelle, MC | 1 |
| Tassone, B | 1 |
| Ricchio, M | 1 |
| Mazzitelli, M | 1 |
| Davoli, C | 1 |
| Procopio, G | 1 |
| Cancelliere, A | 1 |
| La Gamba, V | 1 |
| Lio, E | 1 |
| Matera, G | 1 |
| Quirino, A | 1 |
| Barreca, GS | 1 |
| Trecarichi, EM | 2 |
| Torti, C | 2 |
| Chopra, D | 1 |
| Boparai, JK | 1 |
| Bhandari, B | 1 |
| Srivastava, A | 1 |
| Zequn, Z | 1 |
| Yujia, W | 1 |
| Dingding, Q | 1 |
| Jiangfang, L | 1 |
| Huh, K | 1 |
| Ji, W | 1 |
| Hong, J | 1 |
| Bae, GH | 1 |
| Lee, R | 1 |
| Na, Y | 1 |
| Pamphlett, R | 1 |
| Wang, MX | 1 |
| Chan, RC | 1 |
| Hussein, MIH | 1 |
| Albashir, AAD | 1 |
| Elawad, OAMA | 1 |
| Homeida, A | 1 |
| Sands, K | 1 |
| Wenzel, R | 1 |
| McLean, L | 1 |
| Korwek, K | 1 |
| Roach, J | 1 |
| Miller, K | 1 |
| Poland, RE | 1 |
| Burgess, LH | 1 |
| Jackson, E | 1 |
| Perlin, JB | 1 |
| Devarajan, A | 1 |
| Vaseghi, M | 1 |
| Gomes, CP | 1 |
| Fernandes, DE | 1 |
| Casimiro, F | 1 |
| da Mata, GF | 1 |
| Passos, MT | 1 |
| Varela, P | 1 |
| Mastroianni-Kirsztajn, G | 1 |
| Pesquero, JB | 1 |
| Mondal, R | 1 |
| Ganguly, U | 1 |
| Deb, S | 1 |
| Shome, G | 1 |
| Pramanik, S | 1 |
| Bandyopadhyay, D | 1 |
| Lahiri, D | 1 |
| Zhou, B | 1 |
| Kojima, S | 1 |
| Kawamoto, A | 1 |
| Fukushima, M | 1 |
| Martínez-López-de-Castro, N | 1 |
| Samartín-Ucha, M | 1 |
| Paradela-Carreiro, A | 1 |
| Pérez-Landeiro, A | 1 |
| Inaraja-Bobo, MT | 1 |
| Álvarez-Payero, M | 1 |
| Castro-Núñez, I | 1 |
| García-Beloso, N | 1 |
| Robles-Torres, D | 1 |
| López-López, A | 1 |
| González-Costas, S | 1 |
| Leboreiro-Enríquez, B | 1 |
| Otero-Millán, L | 1 |
| Yaiza Romero-Ventosa, E | 1 |
| Casanova-Martínez, C | 1 |
| Lorenzo-Lorenzo, K | 1 |
| Regueira-Arcay, AM | 1 |
| Vázquez-López, C | 1 |
| Martínez-Reglero, C | 1 |
| Piñeiro-Corrales, G | 1 |
| Won, JH | 1 |
| Lee, H | 2 |
| Giglia, M | 1 |
| Beci, G | 1 |
| Rosselli Del Turco, E | 1 |
| Guardigni, V | 1 |
| Amedeo, A | 1 |
| Cucchetto, G | 1 |
| Verucchi, G | 1 |
| Cipolli, M | 1 |
| Rother, N | 1 |
| Yanginlar, C | 1 |
| Lindeboom, RGH | 1 |
| Bekkering, S | 1 |
| van Leent, MMT | 1 |
| Buijsers, B | 1 |
| Jonkman, I | 1 |
| de Graaf, M | 1 |
| Baltissen, M | 1 |
| Lamers, LA | 1 |
| Riksen, NP | 1 |
| Fayad, ZA | 1 |
| Mulder, WJM | 1 |
| Hilbrands, LB | 1 |
| Joosten, LAB | 1 |
| Netea, MG | 1 |
| Vermeulen, M | 1 |
| van der Vlag, J | 1 |
| Duivenvoorden, R | 1 |
| Kim, JS | 1 |
| Hong, SH | 1 |
| Seong, D | 1 |
| Choi, YR | 1 |
| Ahn, YT | 1 |
| Kim, KS | 1 |
| Kim, SE | 1 |
| Sim, W | 1 |
| Kim, D | 1 |
| Jun, B | 1 |
| Yang, JW | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Dragioti, E | 1 |
| Jacob, L | 1 |
| Koyanagi, A | 1 |
| Abou Ghayda, R | 1 |
| Smith, L | 1 |
| Gong, Y | 1 |
| Pan, A | 1 |
| Ding, H | 1 |
| Fang, J | 2 |
| Ke, C | 1 |
| Xu, L | 1 |
| An, MH | 1 |
| Hwang, TH | 1 |
| Vernaz, N | 1 |
| Gayet-Ageron, A | 1 |
| Gold, G | 1 |
| Perrier, A | 1 |
| Picard, F | 1 |
| Prendki, V | 1 |
| Reny, JL | 2 |
| Samer, C | 2 |
| Stirnemann, J | 2 |
| Vetter, P | 1 |
| Zanella, MC | 1 |
| Zekry, D | 1 |
| Baggio, S | 1 |
| Re, MC | 1 |
| Raza, HA | 1 |
| Tariq, J | 1 |
| Manchanda, K | 1 |
| Singh, J | 1 |
| Bhagat, R | 1 |
| Tiwana, IK | 1 |
| Procter, BC | 1 |
| Ross, C | 1 |
| Pickard, V | 1 |
| Smith, E | 1 |
| Hanson, C | 1 |
| McCullough, PA | 3 |
| Jindal, V | 1 |
| Mittal, S | 1 |
| Kaur, T | 1 |
| Bansal, AS | 1 |
| Kaur, P | 1 |
| Kaur, G | 1 |
| Sati, HC | 1 |
| Garg, A | 1 |
| Hosseini, FS | 1 |
| Malektojari, A | 1 |
| Ghazizadeh, S | 1 |
| Hassaniazad, M | 1 |
| Davoodian, P | 1 |
| Dadvand, H | 1 |
| Nikpoor, AR | 1 |
| Nikoofal-Sahlabadi, S | 1 |
| Kahoori, S | 1 |
| Sepandi, M | 1 |
| Hassanipour, S | 1 |
| Fathalipour, M | 1 |
| Lewis, K | 2 |
| Chaudhuri, D | 1 |
| Alshamsi, F | 2 |
| Carayannopoulos, L | 1 |
| Dearness, K | 1 |
| Chagla, Z | 1 |
| Malek, AE | 1 |
| Granwehr, BP | 1 |
| Isaza-Pierotti, DF | 1 |
| Yin, L | 1 |
| Dos Santos, MR | 1 |
| Saad, MO | 1 |
| El Bakkouri, K | 1 |
| Goldman, JD | 1 |
| Diaz, G | 1 |
| Urba, WJ | 1 |
| Wambier, CG | 1 |
| Nguyen, TV | 1 |
| Shan, G | 1 |
| Wang, W | 1 |
| Petroušová, L | 1 |
| da Silva, S | 1 |
| Rožnovský, L | 1 |
| Martinková, I | 1 |
| More, SA | 1 |
| Patil, AS | 1 |
| Sakle, NS | 1 |
| Mokale, SN | 1 |
| Mohanta, TK | 1 |
| Arina, P | 1 |
| Defilippi, P | 1 |
| Karthika, C | 1 |
| Sureshkumar, R | 1 |
| Printz, C | 1 |
| Youssef, JG | 1 |
| Zahiruddin, F | 1 |
| Youssef, G | 1 |
| Ensor, J | 1 |
| Pingali, SR | 1 |
| Zu, Y | 1 |
| Sahay, S | 1 |
| Iyer, SP | 1 |
| Yadav, AK | 1 |
| Wen, S | 1 |
| Yu, L | 1 |
| Ahn, J | 1 |
| Walker, DM | 1 |
| Prasad, R | 1 |
| Sweeney, RL | 1 |
| Ponce, MG | 1 |
| La Capra, S | 1 |
| Cunningham, FJ | 1 |
| Calise, AG | 1 |
| Pulver, BL | 1 |
| Ruocco, D | 1 |
| Mojares, GE | 1 |
| Eagan, MP | 1 |
| Ziontz, KL | 1 |
| Mastrokyriakos, P | 1 |
| Knowlson, C | 2 |
| Torgerson, DJ | 2 |
| Ortiz Molina, E | 1 |
| Hernandez Pailos, R | 1 |
| Pola Guillen, M | 1 |
| Pascual Pedreno, A | 1 |
| Rodriguez Rodriguez, E | 1 |
| Hernandez Martinez, A | 1 |
| Nakabo, S | 1 |
| Chu, J | 1 |
| Hasni, S | 1 |
| Kaplan, MJ | 1 |
| Falcão, F | 1 |
| Viegas, E | 1 |
| Carmo, I | 1 |
| Soares, J | 1 |
| Solano, M | 1 |
| Cavaco, P | 1 |
| Mendes, D | 1 |
| Rijo, J | 1 |
| Povoa, P | 1 |
| Pais Martins, A | 1 |
| Carmo, E | 1 |
| Mansinho, K | 1 |
| Fonseca, C | 1 |
| Mirco, A | 1 |
| Farinha, H | 1 |
| Aldir, I | 1 |
| Correia, J | 1 |
| Rigo-Bonnin, R | 1 |
| Canalias, F | 1 |
| Veraldi, S | 1 |
| Romagnuolo, M | 1 |
| Benzecry, V | 1 |
| MacGowan, A | 1 |
| Hamilton, F | 1 |
| Bayliss, M | 1 |
| Read, L | 1 |
| Attwood, M | 1 |
| Noel, A | 1 |
| Grier, S | 1 |
| Morley, A | 1 |
| Arnold, D | 1 |
| Maskell, N | 1 |
| Anton-Vazquez, V | 1 |
| Clivillé, R | 1 |
| Imani-Saber, Z | 1 |
| Vaseghi, H | 1 |
| Mahdian, M | 1 |
| Safari, F | 1 |
| Ghadami, M | 1 |
| Kheirabadi, D | 1 |
| Mousavi-Roknabadi, RS | 1 |
| Rezaeisadrabadi, M | 1 |
| Dehghan, H | 1 |
| Fazlzadeh, A | 1 |
| Ou, T | 1 |
| Mou, H | 1 |
| Ojha, A | 1 |
| Choe, H | 1 |
| Farzan, M | 1 |
| Di Penta, M | 1 |
| Ucciferri, C | 1 |
| Auricchio, A | 1 |
| Di Nicola, M | 1 |
| Marchioni, M | 1 |
| Celletti, E | 1 |
| Sabatini, E | 1 |
| Cipollone, F | 2 |
| Vecchiet, J | 1 |
| Tchana-Sato, V | 1 |
| Ancion, A | 1 |
| Tridetti, J | 1 |
| Sakalihasan, N | 1 |
| Hayette, MP | 1 |
| Detry, O | 1 |
| Delvenne, P | 1 |
| Amabili, P | 1 |
| Senard, M | 1 |
| Hougrand, O | 1 |
| Szecel, D | 1 |
| Lavigne, JP | 1 |
| Minga Lowampa, E | 1 |
| Ponte, C | 1 |
| Maquoi, I | 1 |
| Morimont, P | 1 |
| Van Den Bulck, M | 1 |
| Delbouille, MH | 1 |
| Defraigne, JO | 1 |
| Lancellotti, P | 1 |
| Smit, M | 1 |
| Marinosci, A | 1 |
| O'Connell, TF | 1 |
| Bradley, CJ | 1 |
| Abbas, AE | 1 |
| Williamson, BD | 1 |
| Rusia, A | 1 |
| Tawney, AM | 1 |
| Gaines, R | 1 |
| Schott, J | 1 |
| Dmitrienko, A | 1 |
| Haines, DE | 1 |
| Rakedzon, S | 1 |
| Neuberger, A | 1 |
| Domb, AJ | 1 |
| Petersiel, N | 1 |
| Schwartz, E | 1 |
| Babadi, M | 1 |
| Mehrabani, M | 1 |
| Jalili, M | 1 |
| Pouranian, M | 1 |
| Daraie, P | 1 |
| Mohaghegh, F | 1 |
| Aghavali, S | 1 |
| Zaribafian, M | 1 |
| Rohani, M | 1 |
| Daou, F | 1 |
| Abou-Sleymane, G | 1 |
| Badro, DA | 1 |
| Khanafer, N | 1 |
| Tobaiqy, M | 1 |
| Al Faraj, A | 1 |
| Devaux, CA | 1 |
| Vianello, V | 1 |
| Dereani, E | 1 |
| Caruso, G | 1 |
| Montessoro, B | 1 |
| Taurian, M | 1 |
| Di Chiara, A | 1 |
| Patruno, V | 1 |
| Cavallin, F | 1 |
| Fadini, GP | 1 |
| Aldovini, A | 1 |
| Baritussio, A | 2 |
| Curcio, F | 1 |
| Tascini, C | 1 |
| Koch, M | 1 |
| Komissarov, A | 1 |
| Molodtsov, I | 1 |
| Ivanova, O | 1 |
| Maryukhnich, E | 1 |
| Kudryavtseva, S | 1 |
| Mazus, A | 1 |
| Nikonov, E | 1 |
| Vasilieva, E | 1 |
| Duverger, E | 1 |
| Herlem, G | 1 |
| Picaud, F | 1 |
| Ortonobes Roig, S | 1 |
| Soler-Blanco, N | 1 |
| Torrente Jiménez, I | 1 |
| Van den Eynde Otero, E | 1 |
| Moreno-Ariño, M | 1 |
| Gómez-Valent, M | 1 |
| Sisti, G | 1 |
| Schiattarella, A | 1 |
| Sisti, A | 1 |
| Badraoui, R | 1 |
| Bardakci, F | 1 |
| Alreshidi, MM | 1 |
| Simani, L | 1 |
| Ramezani, M | 1 |
| Sagharichi, M | 1 |
| Aalipour, MA | 1 |
| Ghorbani, F | 1 |
| Pakdaman, H | 1 |
| Mitrasinovic, PM | 1 |
| Onodi, F | 1 |
| Bonnet-Madin, L | 1 |
| Meertens, L | 1 |
| Karpf, L | 1 |
| Poirot, J | 1 |
| Zhang, SY | 1 |
| Picard, C | 1 |
| Puel, A | 1 |
| Jouanguy, E | 1 |
| Casanova, JL | 1 |
| Amara, A | 1 |
| Soumelis, V | 1 |
| Arora, K | 1 |
| Balmant, BD | 1 |
| Torrinhas, RS | 1 |
| Rocha, IM | 1 |
| Fonseca, DC | 1 |
| Formiga, FFC | 1 |
| Bonfá, ESDO | 1 |
| Waitzberg, DL | 1 |
| Bahl, A | 1 |
| Johnson, S | 1 |
| Chen, NW | 1 |
| Habler, K | 1 |
| Brügel, M | 1 |
| Teupser, D | 1 |
| Liebchen, U | 1 |
| Scharf, C | 1 |
| Schönermarck, U | 1 |
| Vogeser, M | 1 |
| Paal, M | 1 |
| Berkman, SA | 1 |
| Tapson, VF | 1 |
| Ehrlich, H | 1 |
| Raj, CTD | 1 |
| Kandaswamy, DK | 1 |
| Danduga, RCSR | 1 |
| Rajasabapathy, R | 1 |
| James, RA | 1 |
| Evans, L | 1 |
| Møller, MH | 1 |
| Ostermann, M | 1 |
| Prescott, HC | 1 |
| Fan, E | 1 |
| Oczkowski, S | 1 |
| Levy, MM | 1 |
| Derde, L | 2 |
| Dzierba, A | 1 |
| Du, B | 2 |
| Machado, F | 1 |
| Wunsch, H | 1 |
| Crowther, M | 1 |
| Cecconi, M | 2 |
| Koh, Y | 1 |
| Burry, L | 1 |
| Chertow, DS | 1 |
| Szczeklik, W | 1 |
| Belley-Cote, E | 1 |
| Greco, M | 1 |
| Bala, M | 1 |
| Kesecioglu, J | 1 |
| McGeer, A | 1 |
| Mermel, L | 1 |
| Nainan Myatra, S | 1 |
| Arrington, A | 1 |
| Kleinpell, R | 1 |
| Citerio, G | 1 |
| Bridges, E | 1 |
| Hayden, FG | 1 |
| Alshahrani, M | 1 |
| Al Duhailib, Z | 1 |
| Martin, GS | 1 |
| Kaplan, LJ | 1 |
| Coopersmith, CM | 1 |
| Antonelli, M | 1 |
| Rhodes, A | 1 |
| Gyselinck, I | 1 |
| Liesenborghs, L | 1 |
| Landeloos, E | 1 |
| Belmans, A | 1 |
| Verbeke, G | 1 |
| Verhamme, P | 1 |
| Vos, R | 1 |
| Janssens, W | 1 |
| Bignardi, PR | 1 |
| Vengrus, CS | 1 |
| Aquino, BM | 1 |
| Cerci Neto, A | 1 |
| Lutaud, R | 1 |
| Scronias, D | 1 |
| Ward, J | 1 |
| Verger, P | 1 |
| Alunno, A | 1 |
| Najm, A | 1 |
| De Marco, G | 1 |
| Emmel, J | 1 |
| Mason, L | 1 |
| McGonagle, DG | 1 |
| Uslu, S | 1 |
| Perillat, L | 1 |
| Baigrie, BS | 1 |
| Younis, NK | 1 |
| Zareef, RO | 1 |
| Maktabi, MAN | 1 |
| Mahfouz, R | 1 |
| Awad, N | 1 |
| Schiller, DS | 1 |
| Fulman, M | 1 |
| Chak, A | 1 |
| Hulme, OJ | 1 |
| Wagenmakers, EJ | 1 |
| Damkier, P | 1 |
| Madelung, CF | 1 |
| Siebner, HR | 1 |
| Helweg-Larsen, J | 1 |
| Gronau, QF | 1 |
| Madsen, KH | 1 |
| Ruíz-Quiñonez, JA | 1 |
| Guzmán-Priego, CG | 1 |
| Nolasco-Rosales, GA | 1 |
| Tovilla-Zarate, CA | 1 |
| Flores-Barrientos, OI | 1 |
| Narváez-Osorio, V | 1 |
| Baeza-Flores, GDC | 1 |
| Gonzalez-Castro, TB | 1 |
| López-Brito, CR | 1 |
| Denis-García, CA | 1 |
| Pérez-García, A | 1 |
| Juárez-Rojop, IE | 1 |
| Onori, ME | 1 |
| Ricciardi Tenore, C | 1 |
| Urbani, A | 1 |
| Minucci, A | 1 |
| Chekhlabi, N | 1 |
| El Kettani, C | 1 |
| Haoudar, A | 1 |
| Bahlaoui, A | 1 |
| Mahi, M | 1 |
| Ettair, S | 1 |
| Dini, N | 1 |
| Mainoli, B | 1 |
| Machado, T | 1 |
| Duarte, GS | 1 |
| Prada, L | 1 |
| Gonçalves, N | 1 |
| Ferreira, JJ | 1 |
| Costa, J | 1 |
| Eleni, M | 1 |
| Evangelia, M | 1 |
| Eleftheria, K | 1 |
| Vasilios, V | 1 |
| Vana, S | 1 |
| Vissaria, S | 1 |
| Evangelos, B | 1 |
| Ioannis, K | 1 |
| Aminimoghaddam, S | 1 |
| Afrooz, N | 1 |
| Motaghi Nejad, O | 1 |
| Mahmoudzadeh, F | 1 |
| Stegemann, M | 2 |
| Siemieniuk, R | 1 |
| Rochwerg, B | 3 |
| Bartoszko, J | 1 |
| Askie, L | 1 |
| Macdonald, H | 1 |
| Al-Maslamani, M | 1 |
| Amin, W | 1 |
| Da Silva, ARA | 1 |
| Barragan, FAJ | 1 |
| Bausch, FJ | 1 |
| Burhan, E | 1 |
| Chacko, B | 1 |
| Chanda, D | 1 |
| Dat, VQ | 1 |
| Geduld, H | 1 |
| Gee, P | 1 |
| Haider, M | 1 |
| Nerina, H | 1 |
| Hashimi, M | 1 |
| Jehan, F | 1 |
| Hui, D | 1 |
| Hunt, BJ | 1 |
| Kabra, S | 1 |
| Kanda, S | 1 |
| Kim, YJ | 2 |
| Kissoon, N | 1 |
| Krishna, S | 1 |
| Kwizera, A | 1 |
| Leo, YS | 1 |
| Mahaka, I | 1 |
| Hela, M | 1 |
| Mino, G | 1 |
| Nsutebu, E | 1 |
| Pshenichnaya, N | 1 |
| Qadir, N | 2 |
| Ranganathan, SS | 1 |
| Sabzwari, S | 1 |
| Sarin, R | 1 |
| Sharland, M | 1 |
| Souza, JP | 1 |
| Tshokey, T | 1 |
| Ugarte, S | 1 |
| Uyeki, T | 1 |
| Venkatapuram, S | 1 |
| Wachinou, AP | 1 |
| Wijewickrama, A | 1 |
| Vuyiseka, D | 1 |
| Preller, J | 1 |
| Owen, A | 1 |
| Lytvyn, L | 1 |
| Jacobs, M | 1 |
| Diaz, J | 1 |
| Dörks, M | 1 |
| Jobski, K | 1 |
| Hoffmann, F | 1 |
| Douros, A | 1 |
| Molina, I | 1 |
| Martinez, E | 1 |
| Roman-Viñas, R | 1 |
| Fibla, J | 1 |
| Pontes, C | 1 |
| Velasco Muñoz, C | 1 |
| Blaess, M | 1 |
| Kaiser, L | 1 |
| Sommerfeld, O | 1 |
| Csuk, R | 1 |
| Deigner, HP | 1 |
| Bae, S | 1 |
| Ghang, B | 1 |
| Lim, JS | 1 |
| Yun, SC | 1 |
| Kim, YG | 1 |
| Lee, SO | 1 |
| Kim, SH | 1 |
| Szendrey, M | 1 |
| Guo, J | 1 |
| Yang, T | 1 |
| Ginns, EI | 1 |
| Ryan, E | 1 |
| Sidransky, E | 1 |
| Meena, J | 1 |
| Yadav, A | 1 |
| Galan, LEB | 1 |
| Santos, NMD | 1 |
| Asato, MS | 1 |
| Araújo, JV | 1 |
| de Lima Moreira, A | 1 |
| Araújo, AMM | 1 |
| Paiva, ADP | 1 |
| Portella, DGS | 1 |
| Marques, FSS | 1 |
| Silva, GMA | 1 |
| de Sousa Resende, J | 1 |
| Tizolim, MR | 1 |
| Santos, PL | 1 |
| Buttenbender, SF | 1 |
| de Andrade, SB | 1 |
| Carbonell, RCC | 1 |
| Da Rocha, JG | 1 |
| de Souza, RGS | 1 |
| da Fonseca, AJ | 1 |
| Myasnikov, AL | 1 |
| Berns, SA | 1 |
| Talyzin, PA | 1 |
| Ershov, FI | 1 |
| Cruciani, F | 1 |
| Amato, L | 1 |
| De Crescenzo, F | 1 |
| Mitrova, Z | 1 |
| Saulle, R | 1 |
| Vecchi, S | 1 |
| Davoli, M | 1 |
| Uğurlu Ilgın, B | 1 |
| Akbulut Koyuncu, İM | 1 |
| Kızıltunç, E | 1 |
| Altulea, D | 1 |
| Maassen, S | 1 |
| Baranov, MV | 1 |
| van den Bogaart, G | 1 |
| Cui, X | 1 |
| Minkove, SJ | 1 |
| Cooper, D | 1 |
| Couse, Z | 1 |
| Eichacker, PQ | 1 |
| Torabi-Parizi, P | 1 |
| Kwak, SG | 1 |
| Kim, SK | 1 |
| Park, SH | 1 |
| Meena, JP | 1 |
| Kumar Gupta, A | 1 |
| Tanwar, P | 1 |
| Ram Jat, K | 1 |
| Mohan Pandey, R | 1 |
| Seth, R | 1 |
| Bokharee, N | 1 |
| Khokhar, A | 1 |
| Rasheed, M | 1 |
| Joshi, G | 1 |
| Thakur, S | 1 |
| Poduri, R | 1 |
| Serrano, G | 1 |
| Kastali, M | 1 |
| Kada, AY | 1 |
| Ounnas, S | 1 |
| Yee, SW | 1 |
| Vora, B | 1 |
| Oskotsky, T | 1 |
| Jakobsen, S | 1 |
| Enogieru, OJ | 1 |
| Koleske, ML | 1 |
| Kosti, I | 1 |
| Rödin, M | 1 |
| Sirota, M | 1 |
| Giacomini, KM | 1 |
| Dubey, P | 1 |
| Thakur, B | 1 |
| Reddy, S | 1 |
| Martinez, CA | 1 |
| Nurunnabi, M | 1 |
| Manuel, SL | 1 |
| Chheda, S | 1 |
| Bracamontes, C | 1 |
| Dwivedi, AK | 1 |
| Dev, N | 1 |
| Meena, RC | 1 |
| Gupta, DK | 1 |
| Strub-Wourgaft, N | 1 |
| Faiz, A | 1 |
| Guerin, PJ | 1 |
| Choi, BJ | 1 |
| Koo, Y | 1 |
| Kim, TY | 1 |
| Chung, WY | 1 |
| Jung, YJ | 1 |
| Park, JE | 1 |
| Lim, HS | 1 |
| Park, B | 1 |
| Yoon, D | 1 |
| Rahimzadeh, H | 1 |
| Keykhaei, M | 1 |
| Razeghi, E | 1 |
| Zivari, E | 1 |
| Mansouri, ES | 1 |
| Diaz-Arocutipa, C | 1 |
| Brañez-Condorena, A | 1 |
| Kumar-M, P | 1 |
| Shafiq, N | 1 |
| Kumari, D | 1 |
| Pandey, AK | 1 |
| Gupta, A | 1 |
| Gupta, PC | 1 |
| Patil, A | 1 |
| Malhotra, S | 1 |
| Choudhuri, AH | 1 |
| Duggal, S | 1 |
| Ahuja, B | 1 |
| Biswas, PS | 1 |
| Pérez-González, B | 1 |
| Thomas-Lora, FC | 1 |
| Hoyo, I | 1 |
| Flores-García, NC | 1 |
| Rodríguez-Aguilar, EF | 1 |
| Páez-Zayas, VM | 1 |
| Márquez-Guillén, E | 1 |
| Visag-Castillo, V | 1 |
| García-Juárez, I | 1 |
| Contreras, AG | 1 |
| Dabbous, HM | 1 |
| El-Sayed, MH | 1 |
| El Assal, G | 1 |
| Elghazaly, H | 1 |
| Ebeid, FFS | 1 |
| Sherief, AF | 1 |
| Elgaafary, M | 1 |
| Fawzy, E | 1 |
| Hassany, SM | 1 |
| Riad, AR | 1 |
| TagelDin, MA | 1 |
| Akhtar, Z | 1 |
| Gallagher, MM | 1 |
| Yap, YG | 1 |
| Leung, LWM | 1 |
| Elbatran, AI | 1 |
| Madden, B | 1 |
| Ewasiuk, V | 1 |
| Gregory, L | 1 |
| Breathnach, A | 1 |
| Chen, Z | 2 |
| Fluck, DS | 1 |
| Dubée, V | 2 |
| Roy, PM | 1 |
| Vielle, B | 1 |
| Parot-Schinkel, E | 1 |
| Blanchet, O | 1 |
| Darsonval, A | 1 |
| Lefeuvre, C | 1 |
| Abbara, C | 1 |
| Boucher, S | 1 |
| Devaud, E | 1 |
| Robineau, O | 1 |
| Rispal, P | 1 |
| Guimard, T | 1 |
| d'Anglejean, E | 1 |
| Diamantis, S | 1 |
| Custaud, MA | 1 |
| Pellier, I | 1 |
| Mercat, A | 1 |
| Macías, J | 2 |
| González-Moreno, P | 1 |
| Sánchez-García, E | 1 |
| Morillo-Verdugo, R | 2 |
| Pérez-Venegas, JJ | 1 |
| Pinilla, A | 1 |
| Macho, M | 1 |
| González-Serna, A | 1 |
| Corma, A | 1 |
| Real, LM | 1 |
| Pineda, JA | 2 |
| Skalafouris, C | 1 |
| Grosgurin, O | 1 |
| Eggimann, F | 1 |
| Grauser, D | 1 |
| Bonnabry, P | 1 |
| Guignard, B | 1 |
| Ogah, OS | 1 |
| Umuerri, EM | 1 |
| Adebiyi, A | 1 |
| Orimolade, OA | 1 |
| Sani, MU | 1 |
| Ojji, DB | 1 |
| Mbakwem, AC | 1 |
| Stewart, S | 1 |
| Sliwa, K | 1 |
| Xiong, X | 1 |
| Wang, K | 1 |
| Tang, T | 1 |
| Schicchi, A | 1 |
| Spila Alegiani, S | 1 |
| Crisafulli, S | 1 |
| Atzeni, F | 1 |
| Gini, R | 1 |
| Kirchmayer, U | 1 |
| Belleudi, V | 1 |
| Kurotschka, PK | 1 |
| Leoni, O | 1 |
| Ludergnani, M | 1 |
| Ferroni, E | 1 |
| Baracco, S | 1 |
| Trifirò, G | 1 |
| Khatri, A | 1 |
| Chang, KM | 1 |
| Berlinrut, I | 1 |
| Wallach, F | 1 |
| Axfors, C | 1 |
| Schmitt, AM | 1 |
| Janiaud, P | 1 |
| Van't Hooft, J | 1 |
| Baker, AW | 1 |
| Benfield, T | 1 |
| Berrevoets, MAH | 1 |
| Chen, CP | 1 |
| Chen, TC | 1 |
| Cheng, SH | 1 |
| Cheng, CY | 1 |
| Chung, WS | 1 |
| Cohen, YZ | 1 |
| Cowan, LN | 1 |
| de Almeida E Val, FF | 1 |
| de Lacerda, MVG | 1 |
| de Melo, GC | 1 |
| Elfakir, A | 1 |
| Hernandez-Cardenas, CM | 1 |
| Huang, YW | 1 |
| Igau, B | 1 |
| Jurado-Camacho, F | 1 |
| Kremsner, PG | 1 |
| Kreuels, B | 1 |
| Kuo, CY | 1 |
| Le, T | 1 |
| Lin, YC | 1 |
| Lin, WP | 1 |
| Lin, TH | 1 |
| McArthur, C | 1 |
| Monteiro, WM | 1 |
| Morpeth, SC | 1 |
| Mourad, A | 1 |
| Mulligan, MJ | 1 |
| Narayanasamy, S | 1 |
| Novack, LA | 1 |
| O'Brien, SM | 1 |
| Okeke, NL | 1 |
| Perez, L | 1 |
| Perrin, L | 1 |
| Rockhold, FW | 1 |
| Rolfe, R | 1 |
| Rosa, R | 1 |
| Seto, TB | 1 |
| Stout, JE | 1 |
| Troxel, AB | 1 |
| Tseng, TY | 1 |
| Turner, NA | 1 |
| Ulrich, RJ | 1 |
| Walsh, SR | 1 |
| Velinova, M | 1 |
| Wong, HL | 1 |
| Wrenn, R | 1 |
| Zhong, W | 1 |
| Moher, D | 1 |
| Goodman, SN | 1 |
| Hemkens, LG | 1 |
| Makri, A | 1 |
| Ramatillah, DL | 1 |
| Isnaini, S | 1 |
| Seet, RCS | 1 |
| Quek, AML | 1 |
| Ooi, DSQ | 1 |
| Sengupta, S | 1 |
| Lakshminarasappa, SR | 1 |
| Koo, CY | 1 |
| So, JBY | 1 |
| Goh, BC | 1 |
| Loh, KS | 1 |
| Fisher, D | 1 |
| Teoh, HL | 1 |
| Cook, AR | 1 |
| Hartman, M | 1 |
| Cornet, A | 1 |
| Andersen, J | 1 |
| Tani, C | 1 |
| Mosca, M | 1 |
| Qiu, R | 1 |
| Gao, Z | 1 |
| Weng, Y | 1 |
| Gong, H | 1 |
| Martelli Júnior, H | 1 |
| Marques, NP | 1 |
| Marques, NCT | 1 |
| Gomes de Lucena, E | 1 |
| Martelli, DRB | 1 |
| Oliveira, EA | 1 |
| Moreira Silva, EADS | 1 |
| Medeiros Silva, DC | 1 |
| Singh, G | 1 |
| Park, JJH | 1 |
| Harari, O | 1 |
| Quirino Dos Santos, CV | 1 |
| Guimarães de Almeida, APF | 1 |
| Figueiredo Neto, AD | 1 |
| Savassi, LCM | 1 |
| Milagres, AC | 1 |
| Teixeira, MM | 1 |
| Simplicio, MIC | 1 |
| Ribeiro, LB | 1 |
| Oliveira, R | 1 |
| Dale, M | 1 |
| Sogawa, H | 1 |
| Seyedsaadat, SM | 1 |
| Wolf, DC | 1 |
| Bodin, R | 1 |
| Partiula, B | 1 |
| Nog, R | 1 |
| Latifi, R | 1 |
| John, D | 1 |
| Veillette, G | 1 |
| Diflo, T | 1 |
| Nishida, S | 1 |
| Rubin, GA | 1 |
| Desai, AD | 1 |
| Chai, Z | 1 |
| Chen, Q | 1 |
| Wang, AS | 1 |
| Kemal, C | 1 |
| Baksh, H | 1 |
| Biviano, A | 1 |
| Dizon, JM | 1 |
| Yarmohammadi, H | 1 |
| Ehlert, F | 1 |
| Saluja, D | 1 |
| Rubin, DA | 1 |
| Morrow, JP | 1 |
| Avula, UMR | 1 |
| Berman, JP | 1 |
| Kushnir, A | 1 |
| Abrams, MP | 1 |
| Hennessey, JA | 1 |
| Elias, P | 1 |
| Poterucha, TJ | 1 |
| Kubin, CJ | 1 |
| LaSota, E | 1 |
| Garan, H | 1 |
| Waase, MP | 1 |
| Wan, EY | 1 |
| Alser, O | 2 |
| Mokhtari, A | 1 |
| Naar, L | 1 |
| Langeveld, K | 1 |
| Breen, KA | 1 |
| El Moheb, M | 1 |
| Kapoen, C | 1 |
| Gaitanidis, A | 1 |
| Christensen, MA | 1 |
| Maurer, LR | 1 |
| Mashbari, H | 1 |
| Bankhead-Kendall, B | 1 |
| Parks, J | 1 |
| Fawley, J | 1 |
| Saillant, N | 1 |
| Mendoza, A | 1 |
| Paranjape, C | 1 |
| Fagenholz, P | 1 |
| King, D | 1 |
| Farhat, MR | 1 |
| Velmahos, GC | 1 |
| Kaafarani, HMA | 1 |
| Panovska-Stavridis, I | 1 |
| Ridova, N | 1 |
| Stojanoska, T | 1 |
| Demiri, I | 1 |
| Stevanovic, M | 1 |
| Stojanovska, S | 1 |
| Ristevska, T | 1 |
| Dimkovski, A | 1 |
| Filipce, V | 1 |
| Dimovski, A | 1 |
| Grozdanova, A | 1 |
| Sirijatuphat, R | 1 |
| Suputtamongkol, Y | 1 |
| Angkasekwinai, N | 1 |
| Horthongkham, N | 1 |
| Chayakulkeeree, M | 1 |
| Rattanaumpawan, P | 1 |
| Koomanachai, P | 1 |
| Assanasen, S | 1 |
| Rongrungruang, Y | 1 |
| Chierakul, N | 1 |
| Ratanarat, R | 1 |
| Jitmuang, A | 1 |
| Wangchinda, W | 1 |
| Kantakamalakul, W | 1 |
| Siemieniuk, RAC | 1 |
| Soto, GB | 1 |
| Roldan, Y | 1 |
| Vernooij, RWM | 1 |
| Réa-Neto, Á | 1 |
| Bernardelli, RS | 1 |
| Câmara, BMD | 1 |
| Reese, FB | 1 |
| Queiroga, MVO | 1 |
| Oliveira, MC | 1 |
| Li, MX | 1 |
| Lu, GD | 1 |
| Shen, HM | 1 |
| Zhou, J | 1 |
| Best, JH | 1 |
| Kong, AM | 1 |
| Kaplan-Lewis, E | 1 |
| Brawley, OW | 1 |
| Baden, R | 1 |
| Zazzali, JL | 1 |
| Miller, KS | 1 |
| Loveless, J | 1 |
| Jariwala-Parikh, K | 1 |
| Mohan, SV | 1 |
| Große, M | 1 |
| Ruetalo, N | 1 |
| Layer, M | 1 |
| Hu, D | 1 |
| Businger, R | 1 |
| Rheber, S | 1 |
| Setz, C | 1 |
| Rauch, P | 1 |
| Auth, J | 1 |
| Fröba, M | 1 |
| Brysch, E | 1 |
| Schindler, M | 1 |
| Schubert, U | 1 |
| Anedda, L | 1 |
| Bianchini, L | 1 |
| Cuzzolin, L | 1 |
| Finco, G | 1 |
| Fanos, V | 1 |
| Marcialis, MA | 1 |
| Budhathoki, P | 1 |
| Shrestha, DB | 1 |
| Khadka, S | 1 |
| Rawal, E | 1 |
| Scala, E | 1 |
| Fania, L | 1 |
| Bernardini, F | 1 |
| Calarco, R | 1 |
| Chiloiro, S | 1 |
| Di Campli, C | 1 |
| Erculei, S | 1 |
| Giani, M | 1 |
| Giordano, M | 1 |
| Panebianco, A | 1 |
| Passarelli, F | 1 |
| Trovè, A | 1 |
| Verkhovskaia, S | 1 |
| Russo, G | 1 |
| Sgadari, A | 1 |
| Didona, B | 1 |
| Abeni, D | 1 |
| Scohy, A | 1 |
| Zech, F | 1 |
| Aboubakar, F | 1 |
| Pilette, C | 1 |
| Pothen, L | 1 |
| Yildiz, H | 1 |
| Okumuş, N | 1 |
| Demirtürk, N | 1 |
| Çetinkaya, RA | 1 |
| Güner, R | 1 |
| Avcı, İY | 1 |
| Orhan, S | 1 |
| Konya, P | 1 |
| Şaylan, B | 1 |
| Karalezli, A | 1 |
| Yamanel, L | 1 |
| Kayaaslan, B | 1 |
| Yılmaz, G | 2 |
| Savaşçı, Ü | 1 |
| Eser, F | 1 |
| Taşkın, G | 1 |
| Khokhar, D | 1 |
| Gupta, B | 1 |
| Saxena, P | 1 |
| Ghosh, KK | 1 |
| Geda, AK | 1 |
| Kuca, K | 1 |
| Manganotti, P | 1 |
| Bellavita, G | 1 |
| Tommasini, V | 1 |
| D Acunto, L | 1 |
| Fabris, M | 1 |
| Cecotti, L | 1 |
| Furlanis, G | 1 |
| Sartori, A | 1 |
| Bonzi, L | 1 |
| Buoite Stella, A | 1 |
| Pesavento, V | 1 |
| de Souza, R | 1 |
| Mhatre, S | 1 |
| Qayyumi, B | 1 |
| Chitkara, G | 1 |
| Madke, T | 1 |
| Bharmal, R | 1 |
| Asgaonkar, DS | 1 |
| Lakhani, P | 1 |
| Chaturvedi, P | 1 |
| Dikshit, R | 1 |
| Badwe, R | 1 |
| Lombardi, A | 1 |
| Lupia, T | 1 |
| Gori, A | 1 |
| Randell, RL | 1 |
| Singler, L | 1 |
| Cunningham, A | 1 |
| Smith, EM | 1 |
| Sammartino, D | 1 |
| Jafri, F | 1 |
| Cook, B | 1 |
| La, L | 1 |
| Kim, H | 1 |
| Cardasis, J | 1 |
| Raff, J | 1 |
| Ioannou, GN | 1 |
| O'Hare, AM | 1 |
| Berry, K | 1 |
| Fan, VS | 1 |
| Crothers, K | 1 |
| Eastment, MC | 1 |
| Locke, E | 1 |
| Green, P | 1 |
| Shah, JA | 1 |
| Dominitz, JA | 1 |
| Schneider, J | 1 |
| Jaenigen, B | 1 |
| Wagner, D | 1 |
| Rieg, S | 1 |
| Hornuss, D | 1 |
| Biever, PM | 1 |
| Kern, WV | 1 |
| Walz, G | 1 |
| Prats-Uribe, A | 1 |
| Sena, AG | 1 |
| Lai, LYH | 1 |
| Ahmed, WU | 1 |
| Alghoul, H | 1 |
| Alshammari, TM | 1 |
| Areia, C | 1 |
| Carter, W | 1 |
| Casajust, P | 1 |
| Dawoud, D | 1 |
| Golozar, A | 1 |
| Jonnagaddala, J | 1 |
| Mehta, PP | 1 |
| Gong, M | 1 |
| Morales, DR | 1 |
| Nyberg, F | 1 |
| Posada, JD | 1 |
| Recalde, M | 1 |
| Roel, E | 1 |
| Shah, K | 1 |
| Shah, NH | 1 |
| Schilling, LM | 1 |
| Subbian, V | 1 |
| Vizcaya, D | 1 |
| Cho, J | 1 |
| Lynch, KE | 1 |
| Matheny, ME | 1 |
| You, SC | 1 |
| Rijnbeek, PR | 1 |
| Lane, JC | 1 |
| Burn, E | 1 |
| Reich, C | 1 |
| Suchard, MA | 1 |
| Duarte-Salles, T | 1 |
| Kostka, K | 1 |
| Ryan, PB | 1 |
| Prieto-Alhambra, D | 1 |
| Gutiérrez Gabriel, S | 1 |
| Domínguez García, MJ | 1 |
| Pérez Mañas, G | 1 |
| Moreno García, N | 1 |
| Silvan Domínguez, M | 1 |
| Andrés, EM | 1 |
| Pearson, H | 1 |
| Shoaibi, A | 1 |
| Fortin, SP | 1 |
| Weinstein, R | 1 |
| Berlin, JA | 1 |
| Ryan, P | 1 |
| Sahu, KK | 1 |
| Mishra, AK | 1 |
| Mishra, K | 1 |
| Fernández-Araque, A | 1 |
| Jimeno, N | 1 |
| Martín, LH | 1 |
| Verde, Z | 1 |
| Watanabe, JH | 1 |
| Kwon, J | 1 |
| Nan, B | 1 |
| Abeles, SR | 1 |
| Jia, S | 1 |
| Mehta, SR | 1 |
| Stroehlein, JK | 1 |
| Wallqvist, J | 1 |
| Iannizzi, C | 1 |
| Mikolajewska, A | 1 |
| Metzendorf, MI | 1 |
| Benstoem, C | 1 |
| Meybohm, P | 1 |
| Becker, M | 1 |
| Skoetz, N | 1 |
| Piechotta, V | 1 |
| Tascioglu, D | 1 |
| Akkaya, E | 1 |
| Genc, S | 1 |
| de Almeida, DC | 1 |
| Franco, MDCP | 1 |
| Dos Santos, DRP | 1 |
| Santos, MC | 1 |
| Maltoni, IS | 1 |
| Mascotte, F | 1 |
| de Souza, AA | 1 |
| Pietrobom, PM | 1 |
| Medeiros, EA | 1 |
| Ferreira, PRA | 1 |
| Goes, MA | 1 |
| Ben Hadda, T | 1 |
| Berredjem, M | 1 |
| Almalki, FA | 1 |
| Rastija, V | 1 |
| Jamalis, J | 1 |
| Emran, TB | 1 |
| Abu-Izneid, T | 1 |
| Esharkawy, E | 1 |
| Rodriguez, LC | 1 |
| Alqahtani, AM | 1 |
| Ucan, A | 1 |
| Cerci, P | 1 |
| Efe, S | 1 |
| Akgun, H | 1 |
| Ozmen, A | 1 |
| Yagmuroglu, A | 1 |
| Bilgin, M | 1 |
| Avci, D | 1 |
| Ahmed, W | 1 |
| Al Obaidli, AAK | 1 |
| Joseph, P | 1 |
| Smith, ER | 1 |
| Anwar, S | 1 |
| Chandrasekar, T | 1 |
| Al Madani, AK | 1 |
| Dastoor, HD | 1 |
| Zahid, I | 1 |
| Costales, FA | 1 |
| Boobes, YAR | 1 |
| Al Kindi, F | 1 |
| Issa, SEK | 1 |
| Hassan, MH | 1 |
| Holt, SG | 1 |
| Potschka, H | 1 |
| Chandra, PP | 1 |
| Tripathi, M | 1 |
| Vohora, D | 1 |
| M'bodj, K | 1 |
| Abid, H | 2 |
| Adil, N | 1 |
| Abkari, ME | 1 |
| Aqodad, N | 1 |
| Amani, B | 2 |
| Khanijahani, A | 1 |
| Hashemi, P | 1 |
| Garmendia-Prieto, B | 1 |
| Carrillo-García, P | 1 |
| Gómez-Pavón, J | 1 |
| Alkan, G | 1 |
| Artac, H | 1 |
| Oz, SKT | 1 |
| Emiroglu, M | 1 |
| Voit, K | 1 |
| Timmermann, C | 1 |
| Steger, F | 1 |
| Shepshelovich, D | 1 |
| Yahav, D | 1 |
| Ben Ami, R | 1 |
| Goldvaser, H | 1 |
| Tau, N | 1 |
| Adetuyi, BO | 1 |
| Olajide, PA | 1 |
| Awoyelu, EH | 1 |
| Adetuyi, OA | 1 |
| Adebisi, OA | 1 |
| Oloke, JK | 1 |
| Chadli, A | 1 |
| Haraj, NE | 1 |
| El Aziz, S | 1 |
| Laidi, S | 1 |
| Mounir, A | 1 |
| Bensbaa, S | 1 |
| Mjabber, A | 1 |
| Barrou, L | 1 |
| El Kettani El Hamidi, C | 1 |
| Nsiri, A | 1 |
| Al Harrar, R | 1 |
| Ezzouine, H | 1 |
| Charra, B | 1 |
| Kamal, N | 1 |
| Soussi Abdallaoui, M | 1 |
| Bennouna, GM | 1 |
| Marhoum El Filali, K | 1 |
| Mchichi Alami, K | 1 |
| Agoub, M | 1 |
| El Mdaghri, N | 1 |
| Ramdani, B | 1 |
| Benghanem Gharbi, M | 1 |
| Afif, MH | 1 |
| Asseri, AA | 1 |
| AlHelali, I | 1 |
| Elbastawisi, E | 1 |
| Ali, AS | 1 |
| Al-Qahtani, SM | 1 |
| Shati, AA | 1 |
| Awadalla, NJ | 1 |
| Patel, PA | 1 |
| Lapp, SA | 1 |
| Grubbs, G | 1 |
| Edara, VV | 1 |
| Rostad, CA | 1 |
| Stokes, CL | 1 |
| Pauly, MG | 1 |
| Anderson, EJ | 1 |
| Piantadosi, A | 1 |
| Suthar, MS | 1 |
| Khurana, S | 1 |
| Sabnis, HS | 1 |
| Kim, TU | 1 |
| Corominas, H | 1 |
| Castellví, I | 1 |
| Matas, L | 1 |
| de la Rosa, D | 1 |
| Mangues, MA | 1 |
| Moya, P | 1 |
| Pomar, V | 1 |
| Benito, N | 1 |
| Moga, E | 1 |
| Sosa, NH | 1 |
| Casademont, J | 1 |
| Domingo, P | 1 |
| Saib, A | 1 |
| Amara, W | 1 |
| Wang, P | 1 |
| Cattan, S | 1 |
| Dellal, A | 1 |
| Regaieg, K | 1 |
| Nahon, S | 1 |
| Nallet, O | 1 |
| Hetta, HF | 1 |
| Muhammad, K | 1 |
| Algammal, AM | 1 |
| Ramadan, H | 1 |
| Abdel-Rahman, MS | 1 |
| Mabrok, M | 1 |
| Koneru, G | 1 |
| Elkady, AA | 1 |
| El-Saber Batiha, G | 1 |
| Waheed, Y | 1 |
| Munawar, N | 1 |
| Farghaly, HSM | 1 |
| Coppock, D | 1 |
| Baram, M | 1 |
| Chang, AM | 1 |
| Henwood, P | 1 |
| Kubey, A | 1 |
| Summer, R | 1 |
| Zurlo, J | 1 |
| Hess, B | 1 |
| Cantudo-Cuenca, MD | 1 |
| Gutiérrez-Pizarraya, A | 1 |
| Pinilla-Fernández, A | 1 |
| Contreras-Macías, E | 1 |
| Fernández-Fuertes, M | 1 |
| Lao-Domínguez, FA | 1 |
| Rincón, P | 1 |
| Armstrong, R | 1 |
| Fareed, G | 1 |
| Lotus, J | 1 |
| Oskoui, R | 1 |
| Prodromos, C | 1 |
| Tenenbaum, HC | 1 |
| Wax, CM | 1 |
| Dara, P | 1 |
| Gill, KK | 1 |
| Miatmoko, A | 1 |
| Hendrianto, E | 1 |
| Karsari, D | 1 |
| Dinaryanti, A | 1 |
| Ertanti, N | 1 |
| Ihsan, IS | 1 |
| Purnama, DS | 1 |
| Asmarawati, TP | 1 |
| Marfiani, E | 1 |
| Rosyid, AN | 1 |
| Wulaningrum, PA | 1 |
| Setiawan, HW | 1 |
| Siswanto, I | 1 |
| Tri Puspaningsih, NN | 1 |
| Hayward, G | 1 |
| Butler, CC | 1 |
| Yu, LM | 1 |
| Saville, BR | 1 |
| Berry, N | 1 |
| Dorward, J | 1 |
| Gbinigie, O | 1 |
| van Hecke, O | 1 |
| Ogburn, E | 1 |
| Swayze, H | 1 |
| Bongard, E | 1 |
| Allen, J | 1 |
| Tonner, S | 1 |
| Rutter, H | 1 |
| Tonkin-Crine, S | 1 |
| Borek, A | 1 |
| Judge, D | 1 |
| Grabey, J | 1 |
| de Lusignan, S | 1 |
| Thomas, NPB | 1 |
| Evans, PH | 1 |
| Andersson, MI | 1 |
| Llewelyn, M | 1 |
| Hopkins, S | 1 |
| Hobbs, FDR | 1 |
| Pérez-de-Llano, L | 1 |
| Romay-Lema, EM | 1 |
| Baloira-Villar, A | 1 |
| Anchorena, C | 1 |
| Torres-Durán, ML | 1 |
| Sousa, A | 1 |
| Corbacho-Abelaira, D | 1 |
| Paz-Ferrin, J | 1 |
| Diego-Roza, C | 1 |
| Vilariño-Maneiro, L | 1 |
| Marcos, PJ | 1 |
| Montero-Martínez, C | 1 |
| de la Iglesia-Martínez, F | 1 |
| Riveiro-Blanco, V | 1 |
| Abal-Arca, J | 1 |
| Bustillo-Casado, M | 1 |
| Golpe, R | 1 |
| Gerlovin, H | 1 |
| Posner, DC | 1 |
| Ho, YL | 1 |
| Rentsch, CT | 1 |
| Tate, JP | 1 |
| King, JT | 1 |
| Kurgansky, KE | 1 |
| Danciu, I | 1 |
| Linares, FA | 1 |
| Goethert, ID | 1 |
| Jacobson, DA | 1 |
| Freiberg, MS | 1 |
| Begoli, E | 1 |
| Muralidhar, S | 1 |
| Ramoni, RB | 1 |
| Tourassi, G | 1 |
| Gaziano, JM | 1 |
| Justice, AC | 1 |
| Gagnon, DR | 1 |
| Cho, K | 1 |
| Ömeroğlu, ŞK | 1 |
| Temel, F | 1 |
| Altun, D | 1 |
| Öztop, B | 1 |
| Ozyurtlu, F | 1 |
| Yavuz, V | 1 |
| Sulis, G | 1 |
| Batomen, B | 1 |
| Kotwani, A | 1 |
| Pai, M | 1 |
| Gandra, S | 1 |
| Zhang, P | 1 |
| Bu, Y | 1 |
| Jiang, P | 1 |
| Shi, X | 1 |
| Lun, B | 1 |
| Syafiandini, AF | 1 |
| Song, M | 1 |
| Grygiel-Górniak, B | 1 |
| Irani, AH | 1 |
| Steyn-Ross, DA | 1 |
| Steyn-Ross, ML | 1 |
| Voss, L | 1 |
| Sleigh, J | 1 |
| Gomides Reis, APM | 1 |
| Bonfa, E | 1 |
| Egypto Brito, DCS | 1 |
| Calderaro, DC | 1 |
| Pinto Duarte, ÂLB | 1 |
| Espírito Santo, RC | 1 |
| Poti Gomes, KW | 1 |
| Faustino Ilana, GG | 1 |
| Guedes de Melo, AK | 1 |
| Rocha, LF | 1 |
| Nezvalova-Henriksen, K | 1 |
| Kåsine, T | 1 |
| Lund-Johansen, F | 1 |
| Hoel, H | 1 |
| Holten, AR | 1 |
| Tveita, A | 1 |
| Mathiessen, A | 1 |
| Haugli, M | 1 |
| Eiken, R | 1 |
| Kildal, AB | 1 |
| Berg, Å | 1 |
| Johannessen, A | 1 |
| Heggelund, L | 1 |
| Dahl, TB | 1 |
| Skåra, KH | 1 |
| Mielnik, P | 1 |
| Le, LAK | 1 |
| Thoresen, L | 1 |
| Ernst, G | 1 |
| Hoff, DAL | 1 |
| Skudal, H | 1 |
| Kittang, BR | 1 |
| Olsen, RB | 1 |
| Tholin, B | 1 |
| Ystrøm, CM | 1 |
| Skei, NV | 1 |
| Tran, T | 1 |
| Dudman, S | 1 |
| Andersen, JT | 1 |
| Hannula, R | 1 |
| Finbråten, AK | 1 |
| Tonby, K | 1 |
| Blomberg, B | 1 |
| Aballi, S | 1 |
| Fladeby, C | 1 |
| Steffensen, A | 1 |
| Müller, F | 1 |
| Dyrhol-Riise, AM | 1 |
| Trøseid, M | 1 |
| Prabhakara, C | 1 |
| Godbole, R | 1 |
| Sil, P | 1 |
| Jahnavi, S | 1 |
| Gulzar, SE | 1 |
| van Zanten, TS | 1 |
| Sheth, D | 1 |
| Subhash, N | 1 |
| Chandra, A | 1 |
| Shivaraj, A | 1 |
| Panikulam, P | 1 |
| U, I | 1 |
| Nuthakki, VK | 1 |
| Puthiyapurayil, TP | 1 |
| Ahmed, R | 1 |
| Najar, AH | 1 |
| Lingamallu, SM | 1 |
| Mahajan, B | 1 |
| Vemula, P | 1 |
| Bharate, SB | 1 |
| Singh, PP | 1 |
| Vishwakarma, R | 1 |
| Guha, A | 1 |
| Sundaramurthy, V | 1 |
| Mayor, S | 1 |
| Fard, SR | 1 |
| Maleki, D | 1 |
| Taher, MT | 1 |
| Alimohamadi, Y | 1 |
| Minaeian, S | 1 |
| Ding, J | 1 |
| Bao, Y | 1 |
| Zhou, Z | 1 |
| Collins, CD | 1 |
| Huang, J | 1 |
| Potoski, BA | 1 |
| Emmons-Bell, S | 1 |
| Mutharasan, RK | 1 |
| Rodriguez, F | 1 |
| Gupta, D | 1 |
| Roth, G | 1 |
| Shah, RU | 1 |
| Wang, TY | 1 |
| Khera, R | 1 |
| Peterson, PN | 1 |
| da Rocha, JEB | 1 |
| Othman, H | 1 |
| Tiemessen, CT | 1 |
| Botha, G | 1 |
| Ramsay, M | 1 |
| Masimirembwa, C | 1 |
| Adebamowo, C | 1 |
| Choudhury, A | 1 |
| Brandenburg, JT | 1 |
| Matshaba, M | 1 |
| Simo, G | 1 |
| Gamo, FJ | 1 |
| Hazelhurst, S | 1 |
| Antinori, A | 1 |
| Berselli, N | 1 |
| Blandi, L | 1 |
| Bonaccio, M | 1 |
| Bruno, R | 1 |
| Mennuni, M | 1 |
| My, I | 1 |
| Parruti, G | 1 |
| Perlini, S | 2 |
| Santilli, F | 1 |
| Signorelli, C | 1 |
| Stefanini, G | 1 |
| Vergori, A | 1 |
| Ageno, W | 1 |
| Agodi, A | 1 |
| Agostoni, P | 1 |
| Aiello, L | 1 |
| Al Moghazi, S | 1 |
| Arboretti, R | 1 |
| Aucella, F | 1 |
| Barbieri, G | 1 |
| Barchitta, M | 1 |
| Cacciatore, F | 1 |
| Caiano, L | 1 |
| Carrozzi, L | 1 |
| Cascio, A | 1 |
| Castiglione, G | 1 |
| Colomba, C | 1 |
| Colombo, C | 1 |
| Crisetti, A | 1 |
| Crosta, F | 1 |
| D'Ardes, D | 1 |
| de Gaetano Donati, K | 1 |
| Di Gennaro, F | 1 |
| D'Offizi, G | 1 |
| Fusco, FM | 1 |
| Gaudiosi, C | 1 |
| Gentile, I | 1 |
| Gianfagna, F | 1 |
| Giuliano, G | 1 |
| Graziani, E | 1 |
| Langella, V | 1 |
| Larizza, G | 1 |
| Leone, A | 1 |
| Maccagni, G | 1 |
| Magni, F | 1 |
| Maitan, S | 1 |
| Mancarella, S | 1 |
| Manuele, R | 1 |
| Mapelli, M | 1 |
| Maragna, R | 1 |
| Marcucci, R | 1 |
| Maresca, G | 1 |
| Marongiu, S | 1 |
| Marotta, C | 1 |
| Marra, L | 1 |
| Mastroianni, F | 1 |
| Mengozzi, A | 1 |
| Meschiari, M | 1 |
| Milic, J | 1 |
| Minutolo, F | 1 |
| Mussinelli, R | 1 |
| Mussini, C | 1 |
| Musso, M | 1 |
| Odone, A | 1 |
| Olivieri, M | 1 |
| Palimodde, A | 1 |
| Pasi, E | 1 |
| Petri, F | 1 |
| Pivato, CA | 1 |
| Poletti, V | 1 |
| Ravaglia, C | 1 |
| Righetti, G | 1 |
| Rognoni, A | 1 |
| Rossato, M | 1 |
| Rossi, I | 1 |
| Rossi, M | 1 |
| Sabena, A | 1 |
| Salinaro, F | 1 |
| Sangiovanni, V | 1 |
| Sanrocco, C | 1 |
| Schiano Moriello, N | 1 |
| Scorzolini, L | 1 |
| Sgariglia, R | 1 |
| Simeone, PG | 1 |
| Spinicci, M | 1 |
| Tamburrini, E | 1 |
| Vianello, A | 1 |
| Vinceti, M | 1 |
| Virdis, A | 1 |
| De Caterina, R | 1 |
| Senecal, J | 1 |
| Hsu, JM | 1 |
| Baldi, E | 1 |
| Rordorf, R | 1 |
| Masiello, L | 1 |
| D'Amore, S | 1 |
| Ghio, S | 1 |
| Seminari, EM | 1 |
| Melazzini, F | 1 |
| Fraolini, E | 1 |
| Tavazzi, G | 1 |
| Vicentini, A | 1 |
| Atmani, I | 1 |
| Lahmidani, N | 1 |
| El Yousfi, M | 1 |
| Benajah, DA | 1 |
| Ibrahimi, SA | 1 |
| El Abkari, M | 1 |
| Ebru, O | 1 |
| Ibrahim, B | 1 |
| Ulkem, C | 1 |
| Prasanth, DSNBK | 1 |
| Murahari, M | 1 |
| Chandramohan, V | 1 |
| Guntupalli, C | 1 |
| Atmakuri, LR | 1 |
| Mehta, HB | 1 |
| An, H | 1 |
| Andersen, KM | 1 |
| Mansour, O | 1 |
| Madhira, V | 1 |
| Rashidi, ES | 1 |
| Bates, B | 1 |
| Setoguchi, S | 1 |
| Joseph, C | 1 |
| Kocis, PT | 1 |
| Moffitt, R | 1 |
| Bennett, TD | 1 |
| Chute, CG | 1 |
| Garibaldi, BT | 1 |
| Alexander, GC | 1 |
| Demir Önder, K | 1 |
| Seremet Keskin, A | 1 |
| Berk, H | 1 |
| Seyman, D | 1 |
| Öztoprak, N | 1 |
| Chopra, A | 1 |
| Srikanth, N | 1 |
| Patwardhan, B | 1 |
| Rane, M | 1 |
| Solano, J | 1 |
| Alter, S | 1 |
| Johnson, H | 1 |
| Krishnaswamy, S | 1 |
| Shih, R | 1 |
| Maki, D | 1 |
| DeMets, DL | 1 |
| Rodrigues, C | 1 |
| Freitas-Santos, RS | 1 |
| Levi, JE | 1 |
| Senerchia, AA | 1 |
| Lopes, ATA | 1 |
| Santos, SR | 1 |
| Siciliano, RF | 1 |
| Pierrotti, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883] | Phase 2 | 301 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts[NCT04652648] | Phase 4 | 54 participants (Actual) | Interventional | 2020-05-27 | Completed | ||
| Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial[NCT04418128] | Phase 2/Phase 3 | 84 participants (Anticipated) | Interventional | 2020-06-10 | Not yet recruiting | ||
| Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)[NCT02615938] | Phase 2 | 80 participants (Anticipated) | Interventional | 2015-04-30 | Suspended (stopped due to Correction of inspection findings) | ||
| Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients[NCT04324047] | 1,000 participants (Anticipated) | Observational | 2020-03-27 | Recruiting | |||
| Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults[NCT04315948] | Phase 3 | 1,552 participants (Actual) | Interventional | 2020-03-22 | Completed | ||
| "Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament ACAR en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes"[NCT04501965] | Phase 2 | 231 participants (Actual) | Interventional | 2020-06-01 | Enrolling by invitation | ||
| An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults[NCT05808231] | 100 participants (Anticipated) | Interventional | 2021-04-26 | Recruiting | |||
| Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial[NCT04339816] | Phase 3 | 3 participants (Actual) | Interventional | 2020-05-13 | Terminated (stopped due to Steering Committee decision in accordance with stopping rule 1: Emergence of new data) | ||
| Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725] | 80 participants (Anticipated) | Observational | 2020-03-20 | Active, not recruiting | |||
| A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2020-04-17 | Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias) | ||
| Évaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications[NCT04502342] | Phase 2 | 30 participants (Actual) | Interventional | 2020-06-01 | Enrolling by invitation | ||
| Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment[NCT04334967] | Phase 4 | 13 participants (Actual) | Interventional | 2020-03-30 | Suspended (stopped due to suspected unfavorable risk/benefit assessment) | ||
| A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh[NCT04434144] | 116 participants (Actual) | Observational [Patient Registry] | 2020-05-02 | Completed | |||
| Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441] | Phase 2 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Not started) | ||
| Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial[NCT04359095] | Phase 2/Phase 3 | 650 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study[NCT04341441] | Phase 3 | 624 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.) | ||
| Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467] | Phase 2 | 3,217 participants (Actual) | Interventional | 2020-03-28 | Completed | ||
| Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine in Colombia[NCT04654416] | 301 participants (Actual) | Observational | 2020-03-20 | Completed | |||
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial[NCT04491994] | Phase 3 | 540 participants (Actual) | Interventional | 2020-04-10 | Completed | ||
| Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study[NCT04380870] | 500 participants (Anticipated) | Observational | 2020-05-11 | Recruiting | |||
| Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial[NCT04345289] | Phase 3 | 147 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to DSMB advise due to high probability of futility) | ||
| A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting[NCT04370782] | Phase 4 | 18 participants (Actual) | Interventional | 2020-04-28 | Completed | ||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| Observational Study of COVID-19 Treatment Efficacy[NCT04369989] | 250 participants (Actual) | Observational | 2020-04-14 | Terminated (stopped due to Review of data revealed poor correlation with hypothesis and data quality challenges.) | |||
| Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial[NCT04397328] | Phase 3 | 336 participants (Anticipated) | Interventional | 2020-05-19 | Not yet recruiting | ||
| Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment[NCT04981379] | Phase 3 | 1,120 participants (Actual) | Interventional | 2020-11-16 | Completed | ||
| Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial[NCT04387760] | Phase 2 | 150 participants (Actual) | Interventional | 2020-08-11 | Completed | ||
| Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm[NCT04355247] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-04-14 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection[NCT04334512] | Phase 2 | 600 participants (Anticipated) | Interventional | 2020-06-22 | Recruiting | ||
| Observational Cohort of COVID-19 Patients at Raymond-Poincare[NCT04364698] | 500 participants (Anticipated) | Observational | 2020-05-07 | Recruiting | |||
| COVID-19 - Quality of Life After Infection[NCT04377464] | 200 participants (Anticipated) | Observational | 2020-05-05 | Not yet recruiting | |||
| Azitromycin Use in COVID-19 Positive Pediatric Patients; Effect on Ventricle Repolarization[NCT04699097] | 105 participants (Actual) | Observational | 2020-07-01 | Completed | |||
| Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20[NCT04673214] | Phase 3 | 114 participants (Actual) | Interventional | 2020-12-16 | Completed | ||
| The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19[NCT04891250] | Phase 4 | 0 participants (Actual) | Interventional | 2021-10-31 | Withdrawn (stopped due to Insufficient funding) | ||
| A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment[NCT04384380] | 33 participants (Actual) | Interventional | 2020-04-01 | Completed | |||
| A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization[NCT04365582] | Phase 3 | 0 participants (Actual) | Interventional | 2020-05-07 | Withdrawn (stopped due to The PI decided.) | ||
| Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19[NCT04349592] | 456 participants (Actual) | Interventional | 2020-04-14 | Completed | |||
| The Role of the Bacillus Calmette-Guérin Vaccine (BCG) in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) Vaccines[NCT05507671] | Phase 3 | 556 participants (Anticipated) | Interventional | 2021-05-27 | Active, not recruiting | ||
| Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial[NCT04344951] | Phase 2 | 29 participants (Actual) | Interventional | 2020-04-06 | Terminated (stopped due to No clinical efficacy against SARS-CoV-2 recorded) | ||
| Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)[NCT04400019] | Phase 2/Phase 3 | 1,930 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial[NCT04356534] | 40 participants (Actual) | Interventional | 2020-04-19 | Completed | |||
| Efficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 Patients[NCT04443270] | Phase 1 | 200 participants (Anticipated) | Interventional | 2020-07-27 | Not yet recruiting | ||
| Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial[NCT04391127] | Phase 3 | 108 participants (Actual) | Interventional | 2020-05-04 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection[NCT04335084] | Phase 2 | 600 participants (Anticipated) | Interventional | 2020-06-22 | Recruiting | ||
| Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19[NCT05132972] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2021-01-17 | Recruiting | ||
| Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients[NCT04437823] | Phase 2 | 5 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist[NCT04594356] | 120 participants (Actual) | Observational | 2020-11-19 | Completed | |||
| Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic[NCT04540926] | Phase 1/Phase 2 | 200 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience[NCT04447144] | 200 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| Evaluation of Independent Clinical- Laboratory Predictors of Clinical Outcomes in Hospitalized Positive SARS-CoV2 Patients (Outcomes SARS-CoV2)[NCT05162534] | 1,800 participants (Actual) | Observational | 2020-05-29 | Completed | |||
| Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis[NCT04920851] | 23 participants (Anticipated) | Observational | 2021-06-10 | Recruiting | |||
| A Randomized Double-blinded Placebo-controlled Outpatient Clinical Trial in High Risk Population Confirmed COVID-19 Patients Using Ivermectin and Doxycycline to Prevent COVID-19 Illness-related Hospitalization (COVIVER-OUT PLUS)[NCT04729140] | Phase 4 | 150 participants (Anticipated) | Interventional | 2020-12-28 | Recruiting | ||
| Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact[NCT04358614] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2020-03-16 | Completed | ||
| The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.[NCT04480593] | Phase 2/Phase 3 | 120 participants (Actual) | Interventional | 2020-06-02 | Completed | ||
| Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients[NCT04472585] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2020-11-14 | Recruiting | ||
| Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Therapeutic Safety of Ivermectin Versus Placebo Associated With Standard of Care Treatment in the Early Phase of Coronavirus Infection (COVID19).[NCT04836299] | Phase 2 | 90 participants (Anticipated) | Interventional | 2021-05-08 | Not yet recruiting | ||
| A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men[NCT04365127] | Phase 1 | 40 participants (Actual) | Interventional | 2020-04-27 | Completed | ||
| Valuation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19[NCT04598347] | 225 participants (Anticipated) | Observational [Patient Registry] | 2020-08-08 | Recruiting | |||
| Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial[NCT04392713] | 100 participants (Anticipated) | Interventional | 2020-04-15 | Recruiting | |||
| Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients.[NCT05045937] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2022-05-01 | Recruiting | |||
| Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled[NCT04529525] | Phase 2/Phase 3 | 501 participants (Actual) | Interventional | 2020-08-19 | Completed | ||
| Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19[NCT04372628] | Phase 2 | 452 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients: A Pragmatic Clinical Trial[NCT04896866] | 833 participants (Actual) | Interventional | 2021-03-01 | Completed | |||
| Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation (Lung and / or Liver) Adult Recipients[NCT05116748] | 200 participants (Anticipated) | Observational | 2021-10-01 | Active, not recruiting | |||
| The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management[NCT04646109] | Phase 3 | 66 participants (Actual) | Interventional | 2020-05-11 | Completed | ||
| Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection[NCT04513158] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-08-14 | Recruiting | ||
| Incidence of COVID-19 Test Conversion in Post-surgical Patients[NCT04392323] | 111 participants (Actual) | Interventional | 2020-05-13 | Completed | |||
| Study on the Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases Subject to Chronic Transfusion Support.[NCT04526405] | 63 participants (Actual) | Observational | 2020-07-14 | Completed | |||
| A Longitudinal Survey Study on Living With Sickle Cell Disease in the COVID-19 Pandemic[NCT04417673] | 500 participants (Actual) | Observational | 2020-06-15 | Completed | |||
| Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study[NCT04375202] | Phase 2 | 227 participants (Actual) | Interventional | 2020-04-18 | Terminated (stopped due to Insufficient rate of patient accrual and newly available scientific evidence) | ||
| Evaluation of Awake Prone Positioning Effectiveness in Moderate to Severe COVID-19[NCT05083130] | 93 participants (Actual) | Interventional | 2022-03-08 | Completed | |||
| Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe[NCT04397237] | 3,100 participants (Actual) | Observational | 2020-06-10 | Active, not recruiting | |||
| Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow[NCT05062681] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-09-15 | Recruiting | ||
| Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19[NCT04560205] | Phase 1 | 50 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | ||
| Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial[NCT04308668] | Phase 3 | 1,312 participants (Actual) | Interventional | 2020-03-17 | Completed | ||
| "Review of Barotrauma in Admitted Covid-19 Cases - A Single Center Retrospective Study From March 2020 Till April 2021."[NCT05216523] | 251 participants (Actual) | Observational | 2021-06-24 | Completed | |||
| Evaluation of Immune Cell Subgroups in Covid 19 Patients[NCT04531319] | 50 participants (Actual) | Observational | 2020-08-15 | Completed | |||
| Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS[NCT04754698] | Phase 4 | 2,067 participants (Anticipated) | Interventional | 2021-02-09 | Active, not recruiting | ||
| A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease[NCT04533347] | Phase 2 | 86 participants (Actual) | Interventional | 2021-02-19 | Completed | ||
| A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19[NCT04724720] | Phase 2 | 56 participants (Actual) | Interventional | 2021-01-19 | Active, not recruiting | ||
| A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults[NCT04370262] | Phase 3 | 233 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)[NCT04421664] | Phase 3 | 70 participants (Actual) | Interventional | 2020-03-25 | Terminated (stopped due to Request of Health Canada after publication of https://doi.org/10.7326/M20-4207) | ||
| Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19[NCT04261517] | Phase 3 | 30 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| The Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases: a Randomized Double Blind Placebo Controlled Trial[NCT04551755] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Long-term Neurocognitive and Psychiatric Consequences of COVID-19 in Patients Discharged From Critical Care Units. A Cohort Study of the Advance Interdisciplinary Rehabilitation Register (AIRR) Covid-19 Working Group.[NCT05019300] | 80 participants (Anticipated) | Observational | 2021-05-24 | Recruiting | |||
| Evaluation of a New Score Incorporating Endothelial Dysfunction for the Assessment of Coronary Heart Disease Risk in Patients With Rheumatoid Arthritis: a 3-year Prospective Study.[NCT02341066] | 3,000 participants (Anticipated) | Observational | 2015-07-31 | Recruiting | |||
| Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial[NCT04329832] | Phase 2 | 85 participants (Actual) | Interventional | 2020-03-30 | Completed | ||
| Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409] | 231 participants (Actual) | Interventional | 2020-04-24 | Completed | |||
| Intraoperative Lung Mechanics, Postoperative Complications, and Functional Evaluation in Post COVID-19 Patients Undergoing Thoracic Surgery[NCT05851807] | 120 participants (Anticipated) | Observational [Patient Registry] | 2022-05-12 | Recruiting | |||
| Long Term Immunological Responses of COVID-19 Vaccination in Cancer Patients on Chemotherapy: a Pilot Study[NCT05238467] | 42 participants (Actual) | Observational | 2021-05-21 | Completed | |||
| Epidemiology of COVID-19 Infection in Patients With Hematological Malignancies: A European Haematology Association Survey[NCT04733729] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2020-03-01 | Recruiting | |||
| The COVID-19 and Cancer Consortium (CCC19) Registry[NCT04354701] | 19,275 participants (Actual) | Observational [Patient Registry] | 2020-03-17 | Active, not recruiting | |||
| Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease[NCT04332991] | Phase 3 | 479 participants (Actual) | Interventional | 2020-04-02 | Completed | ||
| An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial[NCT04343768] | Phase 2 | 60 participants (Actual) | Interventional | 2020-04-09 | Completed | ||
| Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study[NCT04328961] | Phase 2/Phase 3 | 943 participants (Actual) | Interventional | 2020-03-31 | Completed | ||
| Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection[NCT04316377] | Phase 4 | 53 participants (Actual) | Interventional | 2020-03-25 | Active, not recruiting | ||
| Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome[NCT04341493] | Phase 4 | 44 participants (Actual) | Interventional | 2020-04-06 | Terminated (stopped due to Concerns about safety of Hydroxychloroquine) | ||
| Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19[NCT04322396] | Phase 2 | 117 participants (Actual) | Interventional | 2020-04-06 | Terminated (stopped due to Recommended by the DSMB) | ||
| the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19[NCT04521400] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-08-20 | Not yet recruiting | ||
| Diagnosis of Invasive Pulmonary Aspergillosis (IPA) - Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid in Patients With and Without COVID-19[NCT04848831] | 100 participants (Anticipated) | Observational | 2021-06-01 | Not yet recruiting | |||
| A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Intravenous Imatinib Mesylate (Impentri®) in Subjects With Acute Respiratory Distress Syndrome Induced by COVID-19[NCT04794088] | Phase 2 | 67 participants (Actual) | Interventional | 2021-03-14 | Terminated (stopped due to Due to the decline of COVID-19 patients on Dutch ICUs. A sample size reestimation based on blinded study data of 66 patients was furthermore favorable, indicating sufficient power to detect a difference in primary endpoint between groups.) | ||
| Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum[NCT04410562] | Phase 3 | 129 participants (Actual) | Interventional | 2020-05-13 | Completed | ||
| Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients[NCT04351516] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2020-04-21 | Withdrawn (stopped due to No Patients enrolled) | ||
| MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719] | 200 participants (Anticipated) | Interventional | 2020-11-08 | Recruiting | |||
| An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients[NCT04322123] | Phase 3 | 667 participants (Actual) | Interventional | 2020-04-01 | Completed | ||
| Study of COVID-19 Prognostic Factors in Hospitalized Patients[NCT05102708] | 3,725 participants (Actual) | Observational | 2021-11-25 | Completed | |||
| Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial[NCT04602507] | Phase 2 | 75 participants (Actual) | Interventional | 2020-12-10 | Terminated (stopped due to Lack of severe COVID-19 cases in the place of study) | ||
| Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial[NCT04331834] | Phase 3 | 275 participants (Actual) | Interventional | 2020-04-03 | Completed | ||
| Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19[NCT04667780] | Phase 3 | 102 participants (Actual) | Interventional | 2020-12-01 | Completed | ||
| PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)[NCT04363827] | Phase 2 | 2,300 participants (Anticipated) | Interventional | 2020-05-14 | Active, not recruiting | ||
| Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment[NCT04338698] | Phase 3 | 550 participants (Actual) | Interventional | 2020-04-22 | Completed | ||
| Real World Observational Database for COVID-19 Treatment and Outcomes[NCT04347993] | 4,496 participants (Actual) | Observational [Patient Registry] | 2020-03-27 | Active, not recruiting | |||
| A Case-Control Study on the Association Between Periodontal Health and Gingival Crevicular Level of Matrix Metalloproteinase-8 in Post COVID-19 Patients[NCT05950230] | 90 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
| Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project: Longitudinal Data and Case-control Study[NCT04907890] | 0 participants (Actual) | Observational | 2022-06-14 | Withdrawn (stopped due to Severe difficulties in enrolling individuals) | |||
| Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients[NCT04321278] | Phase 3 | 440 participants (Actual) | Interventional | 2020-03-28 | Completed | ||
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Thyroid Function Tests and the Status of Thyroid Autoantibodies in Hospitalized Covid-19 Patients and Their Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer[NCT04659200] | 20 participants (Actual) | Observational | 2020-09-01 | Completed | |||
| The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)[NCT04329923] | Phase 2 | 173 participants (Actual) | Interventional | 2020-04-09 | Terminated (stopped due to Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis) | ||
| Randomised Evaluation of COVID-19 Therapy[NCT04381936] | Phase 2/Phase 3 | 50,000 participants (Anticipated) | Interventional | 2020-03-19 | Recruiting | ||
| Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France)[NCT04356495] | Phase 2/Phase 3 | 412 participants (Actual) | Interventional | 2020-07-29 | Completed | ||
| A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19[NCT04392973] | 268 participants (Actual) | Interventional | 2020-05-21 | Completed | |||
| Calprotectin Involvement in Emergency Hematopoiesis Observed in Severe COVID-19[NCT04953312] | 55 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | |||
| A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Interferon Lambda 1A, Fluvoxamina + Budesonida, Fluoxetina + Budesonida in Mild COVID-19 and High Risk of Complications[NCT04727424] | Phase 3 | 6,246 participants (Anticipated) | Interventional | 2021-01-19 | Recruiting | ||
| A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With th[NCT04330690] | Phase 3 | 2,900 participants (Anticipated) | Interventional | 2020-03-18 | Active, not recruiting | ||
| The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes Mellitus[NCT04970719] | Phase 3 | 382 participants (Anticipated) | Interventional | 2021-07-10 | Recruiting | ||
| Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)[NCT04304053] | Phase 3 | 2,300 participants (Actual) | Interventional | 2020-03-18 | Completed | ||
| Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial[NCT05630339] | 150 participants (Actual) | Interventional | 2022-01-30 | Completed | |||
| Neuropsychological Sequelae as a Risk Factor for Long COVID-19 Fatigue[NCT05323318] | 200 participants (Anticipated) | Observational | 2022-04-01 | Recruiting | |||
| Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial[NCT04350723] | 400 participants (Actual) | Interventional | 2020-06-10 | Completed | |||
| Prospective Two-week Open-label Application Experimental Randomized Single-center Non-interventional Study of the Drug Ingaron in Patients With a New Coronavirus Infection COVID-19[NCT05386459] | 36 participants (Actual) | Observational | 2020-04-21 | Completed | |||
| Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study[NCT04325893] | Phase 3 | 259 participants (Actual) | Interventional | 2020-04-01 | Terminated (stopped due to decrease in number of eligible patients) | ||
| Nasal Irrigation to Reduce COVID-19 Morbidity[NCT04559035] | 239 participants (Actual) | Interventional | 2020-09-24 | Completed | |||
| "Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: The Hope Coalition"[NCT04403100] | Phase 3 | 1,968 participants (Anticipated) | Interventional | 2020-06-03 | Recruiting | ||
| Non-ventilated Prone Positioning in the COVID-19 Population[NCT05957588] | 216 participants (Actual) | Interventional | 2021-10-01 | Completed | |||
| Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19[NCT04420247] | Phase 3 | 142 participants (Actual) | Interventional | 2020-04-16 | Completed | ||
| Individual Patient Exposure and Response in Pediatric Lupus[NCT04358302] | 26 participants (Actual) | Interventional | 2020-09-28 | Completed | |||
| Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients[NCT05077332] | Phase 2 | 2,000 participants (Anticipated) | Interventional | 2021-12-29 | Active, not recruiting | ||
| Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)[NCT04366908] | Phase 2 | 517 participants (Actual) | Interventional | 2020-05-07 | Completed | ||
| Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial[NCT04449718] | 240 participants (Actual) | Interventional | 2020-06-01 | Completed | |||
| Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease: Double Blind, Controlled, Study[NCT04459247] | 40 participants (Actual) | Interventional | 2020-06-15 | Completed | |||
| The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients[NCT04321616] | Phase 2/Phase 3 | 700 participants (Anticipated) | Interventional | 2020-03-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial
| Intervention | participants (Number) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 1 |
Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Control | 2 |
Compare the rates of SARS-CoV 2 infections (number of events of symptomatic patients with a positive COVID-19 test) in the non-randomized comparator arm to the randomized hydroxychloroquine and placebo arms to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples. This analysis includes all randomized and non-randomized groups in the study. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Measurement of the seroprevalence of SARS-CoV 2 IgM and/or IgG positive samples in all arms of the study, randomized and non-randomized (Study Drug - Daily Dose, Study Drug - Weekly Dose, Placebo, and Non-Randomized Active Comparator). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
| Non-Randomized Active Comparator | 0 |
Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples in the randomized arms of the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
Compare the rates of SARS-CoV 2 symptomatic infections (number of events with both symptoms and positive test for COVID-19) between the randomized hydroxychloroquine treatment arms and the placebo control arm to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease. This analysis only includes only the randomized arms in the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
Examination of the correlation between HCQ drug levels and development of COVID-19 clinical symptoms and/or positive COVID-19 test results via weekly subject questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Correlation coefficient (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples. (NCT04341441)
Timeframe: 8 weeks
| Intervention | Inflammatory markers (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Examination of other clinical factors contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Clinical factors (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 0 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Number of adverse events. (Number) | |
|---|---|---|
| Adverse events (only Level 1 and 2) observed in the study. | Serious adverse events (Level 3 or 4). | |
| Non-Randomized Active Comparator | 2 | 0 |
| Placebo | 188 | 0 |
| Study Drug - Daily Dose | 206 | 0 |
| Study Drug - Weekly Dose | 193 | 0 |
After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status (NCT04491994)
Timeframe: 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care (SOC) | 5 |
| Intervention Group | 11 |
Statistical differences were evaluated using Student's t test for quantitative variables. In relation to the presence of the number of days with clinical symptoms of COVID-19 by double therapy vs. triple therapy. (NCT04673214)
Timeframe: 14 days
| Intervention | days (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cough | Fever | Headache | Rhinorrhea | Odynophagia | Diarrhea | Myalgia | Anosmia | Conjunctivitis | Chest pain | Dyspnea of movement | Dysnea at rest | Major symptoms | Minor symptoms | treatment start day | |
| DOUBLE THERAPY | 7 | 2 | 6 | 3 | 5 | 2 | 6 | 5 | 2 | 5 | 2 | 1 | 5 | 3 | 4 |
| TRIPLE THERAPY | 7 | 2 | 5 | 3 | 5 | 1 | 5 | 6 | 1 | 4 | 2 | 2 | 5 | 3 | 4 |
Statistical differences were evaluated using Student's t test for quantitative variables. The average duration of days with clinical symptoms of COVID-19 under early intervention treatment by outcome in the improvement of the modification of the clinical evolution of symptoms vs. therapeutic failure. (NCT04673214)
Timeframe: 14 days
| Intervention | Days (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cough | Fever | Headache | Rhinorrhea | Odynophagia | Diarrhea | Myalgia | Anosmia | Conjunctivitis | Chest Pain | Dyspnea of movement | Dyspnea at Rest | Major Symptoms | Minor Symptoms | |
| Modification of Evolution Clinic | 7 | 2 | 6 | 4 | 5 | 2 | 6 | 6 | 1 | 4 | 2 | 1 | 5 | 3 |
| Therapeutic Failure | 4 | 1 | 2 | 1 | 2 | 1 | 5 | 2 | 1 | 1 | 3 | 3 | 2 | 2 |
Statistical differences between clinical evolution vs therapeutic failure by type of treatment were evaluated using Pearson's Chi-square test as categorical variables. (NCT04673214)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Number of Participants with Improvement in Clinical Evaluation | Number of Participants with Therapeutic Failure | |
| Double Therapy | 44 | 2 |
| Triple Therapy | 59 | 6 |
Survival analysis. The time it takes for 50% of COVID-19 patients to improve symptoms during a 14-day follow-up with dual therapy vs. triple therapy (NCT04673214)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cought | Fever | Headache | Odynophagia | Rhinorrhea | Anosmia | Conjunctivitis | Diarrhea | Myalgia | Chest pain | Dyspnea of movement | Dyspnea at rest | |
| Double Therapy | 16 | 10 | 6 | 26 | 17 | 34 | 13 | 8 | 23 | 25 | 14 | 9 |
| Triple Therapy | 26 | 7 | 7 | 35 | 16 | 33 | 8 | 11 | 35 | 33 | 18 | 16 |
Number of days without fever from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 16 |
| Placebo Control Group | 17 |
Number of days outside the hospital from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days outside the ICU from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of Days without oxygen Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days from enrollment to hospitalization (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 6 |
| Placebo Control Group | 7 |
Number of days from enrollment to resolution of COVID-19 symptoms (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 11 |
| Placebo Control Group | 11 |
Number of vasopressor-free days through Study Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days without ventilator use from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
The age of the patients (years) in both groups were recorded at the time of inclusion. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Years (Mean) |
|---|---|
| Control Group | 66.23 |
| Study Group | 58.17 |
At the beginning of the study, the body temperatures (as degree celcius) of the patients were measured and the mean body temperature values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Degree celcius (Mean) |
|---|---|
| Control Group | 36.8 |
| Study Group | 36.9 |
At the beginning of the study, the heart rates (as per minute) of the patients were measured and the mean heart rate values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | beats per minute (Mean) |
|---|---|
| Control Group | 92 |
| Study Group | 88 |
The number of died patients were evaluated in study and control groups (NCT04646109)
Timeframe: Through study completion, an average of 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 9 |
| Study Group | 6 |
"The presence of at least two of the following criteria in patients at the end of 5th day were accepted as clinical response: Extubation in mechanically ventilated patients, respiratory rate <26/min, SpO2 level in room air >90%, PaO2/FiO2 >300 in patients receiving oxygen, presence of at least two of the 2-point reduction criteria in Sequential Organ Failure Assessment (SOFA) score." (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 11 |
| Study Group | 14 |
"The presence of at least two of the following criteria in patients on the 10th day were accepted as clinical response: Respiration rate between 22-24/min, SpO2 level in room air >95%, absence of oxygen requirement, observation of radiological improvement in control lung tomography and no need for intensive care." (NCT04646109)
Timeframe: 10 days (5 days ivermectin therapy plus 5 days follow-up)
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 16 |
| Study Group | 22 |
At the end of the follow-up period (10th day), patients in the study and control group were investigated by PCR test for SARS-CoV-2 and the negative results were recorded as percentage for both groups. (NCT04646109)
Timeframe: At the end of 10th day
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 3 |
| Study Group | 14 |
At the beginning of the study, the respiratory rates (as per minute) of the patients were measured and the mean respiratory rate values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | breaths per minute (Mean) |
|---|---|
| Control Group | 24.7 |
| Study Group | 24 |
"Adverse effects of ivermectin and drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the study group and and the number of participants were noted.~Adverse effects of drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the control group and and the number of participants were noted." (NCT04646109)
Timeframe: From the 6th day of study to the 10th day of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 0 |
| Study Group | 0 |
Baseline SpO2 values of the patients were recorded in both groups. Then, their treatments were started and SpO2 values at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in SpO2 values on the 1st, 3rd and 5th days after the basal value calculated graphically, the change in the SpO2 value at the end of the 5th day (primary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | percentage of peripheral capillary O2 (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 89.67 | 90.50 | 91.90 | 93.00 |
| Study Group | 89.93 | 92.85 | 93.07 | 93.52 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). SpO2 values at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in SpO2 values on the 6th, 8th and 10th days was calculated graphically, the change in the SpO2 value at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | percentage of peripheral capillary O2 (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 89.67 | 92.43 | 92.91 | 93.00 |
| Study Group | 89.93 | 94.54 | 94.24 | 95.35 |
Baseline serum D-dimer levels (mg/L) of the patients were recorded in both groups. Then, their treatments were started and serum D-dimer levels at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in serum D-dimer levels on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the serum D-dimer level at the end of the 5th day (primary endpoint) with the baseline level was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | mg/L (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 1.32 | 2.80 | 4.14 | 3.58 |
| Study Group | 1.25 | 1.40 | 3.24 | 5.85 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum D-dimer levels (mg/L) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in Serum D-dimer levels on the 6th, 8th and 10th days was calculated graphically, the change in the serum D-dimer level at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | mg/L (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 1.32 | 3.45 | 1.63 | 1.49 |
| Study Group | 1.25 | 1.37 | 0.89 | 0.71 |
Baseline serum ferritin levels (mg/dL) of the patients were recorded in both groups. Then, their treatments were started and serum ferritin levels at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in serum ferritin levels on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the serum ferritin level at the end of the 5th day (primary endpoint) with the baseline level was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 747.05 | 783.03 | 881.17 | 1028.24 |
| Study Group | 682.75 | 834.94 | 875.90 | 875.12 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum ferritin levels (mg/dL) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in serum ferritin levels on the 6th, 8th and 10th days was calculated graphically, the change in the serum ferritin level at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 747.05 | 1076.88 | 1097.57 | 1206.90 |
| Study Group | 682.75 | 628.45 | 433.48 | 494.71 |
Baseline Serum Lymphocyte counts (cell/mm^3) of the patients were recorded in both groups. Then, their treatments were started and Serum Lymphocyte counts at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in Serum Lymphocyte counts on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the Serum Lymphocyte count at the end of the 5th day (primary endpoint) with the baseline count was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | cell/mm^3 (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 1010 | 1034 | 977 | 968 |
| Study Group | 932 | 928 | 1021 | 1273 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum lymphocyte counts (cell/mm^3) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in serum lymphocyte counts on the 6th, 8th and 10th days was calculated graphically, the change in the serum lymphocyte count at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | cell/mm^3 (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 1010 | 916 | 1086 | 1256 |
| Study Group | 932 | 1403 | 1668 | 1698 |
Baseline PaO2/FiO2 ratios of the patients were recorded in both groups. Then, their treatments were started and PaO2/FiO2 ratios at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in PaO2/FiO2 ratios on the 1st, 3rd and 5th days after the basal ratio was calculated graphically, the change in the PaO2/FiO2 ratio at the end of the 5th day (primary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 197.44 | 181.83 | 174.77 | 180.13 |
| Study Group | 158.83 | 147.31 | 147.74 | 178.94 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). PaO2/FiO2 ratios at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in PaO2/FiO2 ratios on the 6th, 8th and 10th days was calculated graphically, the change in the PaO2/FiO2 ratio at the end of the 10th day (secondary endpoint) with the baseline ratio was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 197.44 | 204.28 | 211.75 | 220.78 |
| Study Group | 158.83 | 199.83 | 227.43 | 236.33 |
Baseline PNL/L ratio of the patients were recorded in both groups. Then, their treatments were started and PNL/L ratios at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in PNL/L ratios on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the PNL/L ratio at the end of the 5th day (primary endpoint) with the baseline ratio was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 7.48 | 7.74 | 9.26 | 9.88 |
| Study Group | 8.77 | 10.82 | 9.02 | 7.16 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). PNL/L ratios at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in PNL/L ratios on the 6th, 8th and 10th days was calculated graphically, the change in the PNL/L ratio at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 7.48 | 10.49 | 9.66 | 6.19 |
| Study Group | 8.77 | 6.90 | 5.81 | 7.34 |
The gender of patients (Male/female) in both groups were recorded at the time of inclusion. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Male | Female | |
| Control Group | 19 | 11 |
| Study Group | 21 | 9 |
A blood sample was taken from the patients included in the study group, after taking or during the first dose of ivermectin. From the blood samples, haplotypes and mutations that cause the function losing were investigated by performing sequence analysis of multidrug resistance 1 (MDR1)/ABCB1 and CYP3A4 genes with Sanger method. In case of detection of mutation, the patient were excluded from the study and if observed, side effects of ivermectin were noted. (NCT04646109)
Timeframe: At the first day of ivermectin therapy (1st day)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Mutation positive | Mutation negative | |
| Control Group | 0 | 0 |
| Study Group | 6 | 30 |
"At the beginning of the study, the patients were asked whether there were any of the following accompanying diseases and the percentage of patients with accompanying disease in both groups were recorded:~Diabetes mellitus~Hypertension~Coronary artery disease~Cardiac failure~Chronic obstructive pulmonary disease~Malignancy~Immunodeficiency" (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Diabetes Mellitus | Hypertension | Coronary artery disease | Cardiac failure | Chronic obstructive pulmonary disease | Malignancy | Immunodeficiency | |
| Control Group | 10 | 12 | 8 | 1 | 3 | 1 | 1 |
| Study Group | 9 | 15 | 5 | 0 | 6 | 0 | 0 |
"At the beginning of the study, the patients were asked whether there were any of the following clinical symptoms and the percentage of patients with any of the clinical symptoms in both groups were recorded:~Fever~Cough~Sore throat~Dispnea~Headache~Weakness~Myalgia~Diarrhea~Nausea or vomiting" (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fever | Cough | Sore throat | dyspnea | Headache | Weakness | Myalgia | Diarrhea | Nausea or vomiting | |
| Control Group | 13 | 14 | 1 | 19 | 2 | 11 | 7 | 0 | 0 |
| Study Group | 15 | 16 | 3 | 23 | 5 | 13 | 9 | 1 | 1 |
At the beginning of the study, the systolic and diastolic pressures (as mmHg) of the patients were measured and the mean systolic and diastolic pressure values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic pressure | Diastolic pressure | |
| Control Group | 124.61 | 73.43 |
| Study Group | 124.39 | 75.64 |
"Adverse effects of ivermectin and drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the study group and and the number of participants were noted.~Adverse effects of drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the control group and and the number of participants were noted." (NCT04646109)
Timeframe: At the first 5 days of study
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Nausea and vomiting | Increase in liver function tests | |
| Control Group | 2 | 1 |
| Study Group | 0 | 0 |
Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe) (NCT04308668)
Timeframe: baseline and 14 days
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment | -2.6 |
| Placebo | -2.33 |
Number of participants at 14 days post enrollment with active COVID19 disease among those who were asymptomatic at baseline. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 49 |
| Placebo | 58 |
Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the number of participants who report a score of 3. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 5 |
| Placebo | 8 |
Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID-19 infection. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 48 |
| Placebo | 55 |
Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 97 |
| Placebo | 63 |
Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 11 |
| Placebo | 9 |
Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease through study completion of 14 days. For those hospitalized within the 14-day study period, the protocol specified follow up would occur for up to 90 days to capture the final outcome of participants' hospitalization. Approximately 30-days was the maximal follow up for hospitalization outcome needed in the trial. (NCT04308668)
Timeframe: Approximately 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 1 |
Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 5 |
| Placebo | 9 |
Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe) (NCT04308668)
Timeframe: 5 and 14 days
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 5 | Day 14 | |
| Placebo | -2.05 | -3.08 |
| Treatment | -2.22 | -3.36 |
"Improvement of clinical condition of the patient defined by the COVID-19 WHO ordinal Outcomes score. This scale reflects a range from uninfected to dead, where 0 is no clinical or virological evidence of infection, 1 is no limitation of activities, 2 is limitation of activities, 3 is hospitalized, no oxygen therapy, 4 is oxygen by mask or nasal prongs, 5 is non-invasive ventilation or high-flow oxygen, 6 is intubation and mechanical ventilation, 7 is ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation), and 8 is death." (NCT04329832)
Timeframe: Assessed once on day 14 after enrollment (enrollment is day 0)
| Intervention | score on a scale (Median) |
|---|---|
| Day 14 WHO COVID Score: Hydroxychloroquine | 2.0 |
| Day 14 WHO COVID Score: Azithromycin | 2.0 |
Calculated as number of days patient not in hospital (NCT04329832)
Timeframe: Admission (day 1) to 28 days after admission (day 28)
| Intervention | Days (Median) |
|---|---|
| Hydroxychloroquine | 18.5 |
| Azithromycin | 21 |
Calculated as number of days patient not in an ICU (NCT04329832)
Timeframe: Admission (day 1) to 28 days after admission (day 28)
| Intervention | Days (Median) |
|---|---|
| Hydroxychloroquine | 18 |
| Azithromycin | 19 |
"Time to 1-point decrease in the WHO ordinal recovery score is defined as the number of days until the ordinal outcome score drops by 1 relative to baseline on the 8-point WHO COVID Ordinal Outcomes scale, which reflects a range from uninfected to dead, where 0 is no clinical or virological evidence of infection, 1 is no limitation of activities, 2 is limitation of activities, 3 is hospitalized, no oxygen therapy, 4 is oxygen by mask or nasal prongs, 5 is non-invasive ventilation or high-flow oxygen, 6 is intubation and mechanical ventilation, 7 is ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation), and 8 is death." (NCT04329832)
Timeframe: Admission (day 1) to 14 days after admission (day 14)
| Intervention | Days (Median) |
|---|---|
| Days to a 1-point Decrease in WHO COVID Scale in Hydroxychloroquine Arm | 7 |
| Days to a 1-point Decrease in WHO COVID Scale in Azithromycin Arm | 6 |
Calculated as number of days that patient is not on a ventilator up to day 28 days after admission (NCT04329832)
Timeframe: Admission (day 1) to 28 days after admission (day 28)
| Intervention | days (Median) |
|---|---|
| Ventilator-Free Days at Day 28 for Hydroxychloroquine Arm | 18 |
| Ventilator-Free Days at Day 28 for Azithromycin Arm | 18 |
"Vital status of the patient on day 15 will be determined using any of the following methods: medical record review, phone calls to patient or proxy.~There were two patients for whom we were unable to collect their vital status." (NCT04332991)
Timeframe: assessed on study day 15
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 18 |
| Placebo | 14 |
"Vital status of the patient at day 28 will be determined using any of the following methods: medical record review, phone calls to patient or proxy.~There were two patients for whom we were unable to collect their vital status." (NCT04332991)
Timeframe: assessed on study day 29
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 25 |
| Placebo | 25 |
"We will determine the COVID Ordinal Scale on study day 29~COVID Ordinal Scale defined as:~Death~Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04332991)
Timeframe: assessed on study day 29
| Intervention | score on a scale (Median) |
|---|---|
| Hydroxychloroquine | 6 |
| Placebo | 6 |
"We will determine the COVID Ordinal Scale for all patients on study day 3~COVID Ordinal Scale defined as:~Death~Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04332991)
Timeframe: assessed on study day 3
| Intervention | score on a scale (Median) |
|---|---|
| Hydroxychloroquine | 4 |
| Placebo | 4 |
"We will determine the COVID Ordinal Scale on study day 8~COVID Ordinal Scale defined as:~Death~Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04332991)
Timeframe: assessed on study day 8
| Intervention | score on a scale (Median) |
|---|---|
| Hydroxychloroquine | 5 |
| Placebo | 6 |
"We will determine the COVID Ordinal Scale for all patients on study day 15~COVID Ordinal Scale defined as:~Death~Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04332991)
Timeframe: Assessed on study day 15
| Intervention | score on a scale (Median) |
|---|---|
| Hydroxychloroquine | 6 |
| Placebo | 6 |
Defined as 28 days minus the number of days from randomization to discharge home.If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero. (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | days (Median) |
|---|---|
| Hydroxychloroquine | 21 |
| Placebo | 20 |
The number of days spent out of the ICU to day 28. Patients who die prior to day 28 are assigned zero ICU free days. (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | days (Median) |
|---|---|
| Hydroxychloroquine | 28 |
| Placebo | 28 |
We will determine the number of patients who are either dead or on ECMO ( extracorporeal membrane oxygenation) between enrollment and day 28 (NCT04332991)
Timeframe: Enrollment to Day 28
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 29 |
| Placebo | 28 |
We will determine the number of patients that experience acute kidney injury between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 37 |
| Placebo | 37 |
We will determine the number of patients that experience acute pancreatitis between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 5 |
| Placebo | 6 |
We will determine the number of patients that experience anemia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 139 |
| Placebo | 120 |
We will determine the number of patients that experience atrial arrhythmia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 15 |
| Placebo | 11 |
We will determine the number of patients that experience cardiac arrest between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 10 |
| Placebo | 4 |
We will determine the number of patients that experience elevation in aspartate aminotransferase or alanine aminotransferase to twice the local upper limit of normal between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 50 |
| Placebo | 65 |
We will determine the number of patients that experience lymphopenia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 92 |
| Placebo | 87 |
We will determine the number of patients that experience neutropenia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 4 |
| Placebo | 4 |
We will determine the number of patients that experience renal replacement therapy between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 10 |
| Placebo | 14 |
We will determine the number of patients that experience seizure between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 1 |
| Placebo | 0 |
We will determine the number of patients that experience severe dermatologic reaction between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 1 |
| Placebo | 1 |
We will determine the number of patients that experience symptomatic hypoglycemia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 10 |
| Placebo | 8 |
We will determine the number of patients that experience thrombocytopenia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 4 |
| Placebo | 5 |
We will determine the number of patients that experience ventricular arrhythmia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine | 5 |
| Placebo | 6 |
The number of calendar days between randomization and 28 days later that the patient is alive and without the use of oxygen therapy. Patients who die prior to day 28 are assigned zero oxygen free days. (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | days (Median) |
|---|---|
| Hydroxychloroquine | 21 |
| Placebo | 20 |
Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge. Patients who die prior to day 28 are assigned 28 days for time to recovery. (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | days (Median) |
|---|---|
| Hydroxychloroquine | 5 |
| Placebo | 6 |
The number of calendar days between randomization and 28 days later that the patient is alive and without the use of vasopressor therapy. Patients who die prior to day 28 are assigned zero vasopressor free days. (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | days (Median) |
|---|---|
| Hydroxychloroquine | 28 |
| Placebo | 28 |
Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days. (NCT04332991)
Timeframe: 28 days after randomization
| Intervention | days (Median) |
|---|---|
| Hydroxychloroquine | 28 |
| Placebo | 28 |
Participants who had a PCR-confirmed SARS-CoV-2 infection and met the Center for Disease Control (CDC) defined criteria for symptomatic COVID-19 disease. (NCT04328961)
Timeframe: 28 days from enrolment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ascorbic Acid | 26 |
| Hydroxychloroquine | 37 |
Polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-2) infection from self-collected samples collected daily for 14 days (NCT04328961)
Timeframe: Day 1 through Day 14 after enrolment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ascorbic Acid | 45 |
| Hydroxychloroquine | 53 |
Safety and tolerability of Hydroxychloroquine as SARS-CoV-2 PEP in adults (NCT04328961)
Timeframe: 28 days from start of Hydroxychloroquine therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ascorbic Acid | 46 |
| Hydroxychloroquine | 66 |
Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection from self-collected samples collected at study exit (NCT04328961)
Timeframe: Day 28 after enrolment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ascorbic Acid | 48 |
| Hydroxychloroquine | 58 |
"Time for no oxygen supplement (or regular oxygen supplement LTOT) if on oxygen during admission." (NCT04322396)
Timeframe: 14 days
| Intervention | hours (Median) |
|---|---|
| Control | 72 |
| Intervention | 72 |
PaCO2 measured in arterial puncture at baseline and 4 days. (NCT04322396)
Timeframe: 4 days
| Intervention | mmHg (Mean) |
|---|---|
| Control | 1.4 |
| Intervention | -3.0 |
PaO2 measured in arterial puncture at baseline and 4 days. (NCT04322396)
Timeframe: 4 days
| Intervention | mmHg (Mean) |
|---|---|
| Control | -0.2 |
| Intervention | -3.0 |
pH measured in arterial puncture at baseline and 4 days. (NCT04322396)
Timeframe: 4 days
| Intervention | pH (Mean) |
|---|---|
| Control | 0.0 |
| Intervention | 0.0 |
(NCT04322396)
Timeframe: 30 days
| Intervention | days (Median) |
|---|---|
| Control | 26 |
| Intervention | 26 |
(NCT04322396)
Timeframe: 14 days
| Intervention | days (Median) |
|---|---|
| Control | 4 |
| Intervention | 4 |
Length of stay in intensive care unit. (NCT04322396)
Timeframe: 14 days
| Intervention | days (Median) |
|---|---|
| Control | 11 |
| Intervention | 14 |
(NCT04322396)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Intervention | 1 |
(NCT04322396)
Timeframe: 14 days
| Intervention | days (Median) |
|---|---|
| Control | 9 |
| Intervention | 9 |
Number of days using non-invasive ventilation (NIV) if on NIV during hospitalization. (NCT04322396)
Timeframe: 14 days
| Intervention | days (Mean) |
|---|---|
| Control | 9.0 |
| Intervention | 6.7 |
(NCT04322396)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 1 |
| Intervention | 3 |
(NCT04322396)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 6 |
| Intervention | 9 |
Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 months (NCT04329923)
Timeframe: 2 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 3 HCQ | 4 |
| Cohort 3 Placebo | 4 |
Cohort 1 rate of hospitalization (NCT04329923)
Timeframe: until quarantine release
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 HCQ | 1 |
| Cohort 1 Placebo | 0 |
Cohort 1 rate of participant-reported secondary infection of housemates (NCT04329923)
Timeframe: until quarantine release, or approximately <20 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 HCQ | 2 |
| Cohort 1 Placebo | 2 |
Cohort 2 (hospitalized COVID-19 patients): median number of days until hospital discharge (NCT04329923)
Timeframe: until hospital discharge
| Intervention | days (Median) |
|---|---|
| Cohort 2 HCQ High Dose | 5.5 |
| Cohort 2 HCQ Low Dose | 4 |
Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 or 10 days (depending on CDC guidance at the time) have elapsed since the beginning of symptom onset. (NCT04329923)
Timeframe: until quarantine release or hospitalization
| Intervention | days (Median) |
|---|---|
| Cohort 1 HCQ | 8 |
| Cohort 1 Placebo | 11 |
303 reviews available for hydroxychloroquine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, | 2020 |
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans | 2021 |
Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Combined | 2021 |
Current treatment strategies for COVID‑19 (Review).
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Chloroquine; COVID-19; C | 2021 |
Possible mechanistic insights into iron homeostasis role of the action of 4-aminoquinolines (chloroquine/hydroxychloroquine) on COVID-19 (SARS-CoV-2) infection.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Homeostasis; Humans; Hydroxychlo | 2021 |
Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry.
Topics: beta-Cyclodextrins; Cholesterol; COVID-19; Humans; Hydroxychloroquine; Membrane Microdomains; Protei | 2021 |
Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Iverme | 2022 |
Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19.
Topics: Arrhythmias, Cardiac; Azithromycin; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; | 2022 |
COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Humans; H | 2022 |
Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Humans; Hydroxychloroquine; | 2022 |
Selenium in the Prevention of SARS-CoV-2 and Other Viruses.
Topics: COVID-19; Humans; Hydroxychloroquine; Ivermectin; SARS-CoV-2; Selenium | 2023 |
COVID-19 in patients with systemic lupus erythematosus: A systematic review.
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics | 2022 |
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19.
Topics: COVID-19; Humans; Hydroxychloroquine; Research Design | 2022 |
Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; Viral Load | 2022 |
Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19.
Topics: COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Hydroxychloroquine; Randomized Controll | 2022 |
Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review.
Topics: Aged; Antimalarials; Antiviral Agents; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherap | 2022 |
How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
Topics: Antirheumatic Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Friends; Humans; Hydroxychloro | 2023 |
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2023 |
Tuberculosis in individuals who recovered from COVID-19: A systematic review of case reports.
Topics: Adult; Azithromycin; COVID-19; Female; Humans; Hydroxychloroquine; Latent Tuberculosis; Male; Tuberc | 2022 |
Tuberculosis in individuals who recovered from COVID-19: A systematic review of case reports.
Topics: Adult; Azithromycin; COVID-19; Female; Humans; Hydroxychloroquine; Latent Tuberculosis; Male; Tuberc | 2022 |
Tuberculosis in individuals who recovered from COVID-19: A systematic review of case reports.
Topics: Adult; Azithromycin; COVID-19; Female; Humans; Hydroxychloroquine; Latent Tuberculosis; Male; Tuberc | 2022 |
Tuberculosis in individuals who recovered from COVID-19: A systematic review of case reports.
Topics: Adult; Azithromycin; COVID-19; Female; Humans; Hydroxychloroquine; Latent Tuberculosis; Male; Tuberc | 2022 |
Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
Topics: COVID-19; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic | 2022 |
Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
Topics: COVID-19; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic | 2022 |
Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
Topics: COVID-19; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic | 2022 |
Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
Topics: COVID-19; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic | 2022 |
Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Randomized Controlled Trials a | 2023 |
Generalized Pustular Figurate Erythema in Patients with COVID-19 Treated with Hydroxychloroquine: A Systematic Review.
Topics: Acute Generalized Exanthematous Pustulosis; COVID-19; COVID-19 Drug Treatment; Erythema; Humans; Hyd | 2022 |
Hydroxychloroquine for Non-Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Randomized Controlled Tr | 2023 |
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; Dexamethasone; Drug Repositioning; Humans; Hy | 2023 |
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.
Topics: Adult; Communicable Disease Control; COVID-19; Humans; Hydroxychloroquine; Multicenter Studies as To | 2023 |
Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.
Topics: COVID-19; COVID-19 Drug Treatment; Health Personnel; Humans; Hydroxychloroquine; Pre-Exposure Prophy | 2023 |
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API).
Topics: Antiviral Agents; Brazil; Communicable Diseases; COVID-19; Humans; Hydroxychloroquine; Ivermectin; P | 2023 |
Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Humans; | 2023 |
Much ado about nothing? Discrepancy between the available data on the antiviral effect of hydroxychloroquine in March 2020 and its inclusion in COVID-19 clinical trials and outpatient prescriptions.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Outpatients; SARS-C | 2023 |
Of chloroquine and COVID-19.
Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infecti | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
Emerging prophylaxis strategies against COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chemoprevention; Chloroquine; Clinical Trials as Topic; Coronavir | 2020 |
Epidemiological analysis of COVID-19 and practical experience from China.
Topics: Age Factors; Animals; Azithromycin; Betacoronavirus; China; Chiroptera; Clinical Laboratory Techniqu | 2020 |
Potential therapeutic agents against COVID-19: What we know so far.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; | 2020 |
Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Adrenal Cortex Hormones; Coronavirus Infections; COVID-1 | 2020 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antivi | 2020 |
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
Topics: Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe | 2020 |
Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroquine; Lupus Erythem | 2020 |
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infect | 2020 |
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
Topics: Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
Topics: Antimalarials; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVI | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; | 2020 |
COVID-19 and neuromuscular disorders.
Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Delivery of Heal | 2020 |
Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
Topics: Angiotensin-Converting Enzyme 2; Antibodies, Neutralizing; Antibody-Dependent Cell Cytotoxicity; Ant | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemi | 2020 |
Hydroxychloroquine and COVID-19.
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; H | 2020 |
Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; C | 2020 |
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1
Topics: Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiomyopathies; Cardiovascular Dis | 2020 |
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavir | 2020 |
American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the Un
Topics: Betacoronavirus; Cell- and Tissue-Based Therapy; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavir | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavir | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavir | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavir | 2020 |
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Chloroqu | 2020 |
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Continuous Positive Airway Pressure; | 2020 |
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Beta | 2020 |
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.
Topics: Biomedical Research; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Obse | 2020 |
Current status of potential therapeutic candidates for the COVID-19 crisis.
Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents, Non-Steroidal; A | 2020 |
Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin-Converting Enzyme Inh | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betac | 2020 |
COVID-19 in Children: Clinical Approach and Management.
Topics: Acute Lung Injury; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Clinical Laboratory T | 2020 |
Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Bone Marrow Transplantation; Clinical Laboratory | 2020 |
COVID-19 diagnosis and management: a comprehensive review.
Topics: Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; | 2020 |
Rethinking the role of hydroxychloroquine in the treatment of COVID-19.
Topics: Coronavirus Infections; COVID-19; Datasets as Topic; Heart; Humans; Hydroxychloroquine; Immunity, In | 2020 |
COVID-19: Immunology and treatment options.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infect | 2020 |
Cardiovascular manifestations and treatment considerations in COVID-19.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh | 2020 |
COVID-19: Therapeutics and Their Toxicities.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychl | 2020 |
A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.
Topics: Antimalarials; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID | 2020 |
CNS penetration of potential anti-COVID-19 drugs.
Topics: Animals; Azetidines; Betacoronavirus; Blood-Brain Barrier; Brain; Central Nervous System; Coronaviru | 2020 |
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; | 2020 |
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO | 2020 |
SARS-CoV-2 infection among patients with systemic autoimmune diseases.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Autoi | 2020 |
Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view.
Topics: Anti-Bacterial Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; | 2020 |
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
Topics: Adult; Betacoronavirus; Chemoprevention; Colchicine; Coronavirus Infections; COVID-19; Female; Human | 2020 |
COVID-19: Main therapeutic options.
Topics: Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus; Coronavirus Infectio | 2020 |
Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke.
Topics: Betacoronavirus; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Clinical Laborato | 2020 |
[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.
Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Diabetes Complications; | 2020 |
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Comorbid | 2020 |
Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19.
Topics: Antimalarials; Asymptomatic Diseases; Betacoronavirus; Blood Safety; Chloroquine; Contact Lenses; Co | 2020 |
Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?
Topics: Animals; Anti-Inflammatory Agents; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; | 2020 |
Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
Topics: Adult; Aged; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; | 2020 |
A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
Topics: Aminoquinolines; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavir | 2020 |
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavir | 2020 |
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Alanine; Anti-Infective Agents; Azithromycin; Betacoronavirus; Cardiovascul | 2020 |
Should coronavirus disease 2019 concern rheumatologists?
Topics: Antirheumatic Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Cardiovascular manifestation and treatment in COVID-19.
Topics: Anticoagulants; Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; | 2020 |
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
Topics: Antimalarials; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID- | 2020 |
QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Death, Su | 2020 |
Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Cardiovascular Di | 2020 |
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infecti | 2020 |
Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Topics: Androstenes; Angiotensin-Converting Enzyme 2; Anticholesteremic Agents; Antiviral Agents; Betacorona | 2020 |
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
Topics: Betacoronavirus; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Global Health; Heart | 2020 |
An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clinical Trials as Topic; Coronavirus Infections; COVI | 2020 |
Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
Topics: Adult; Antiviral Agents; Betacoronavirus; Child; Chloroquine; Clinical Trials as Topic; Coronavirus | 2020 |
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
Topics: Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Administration Sch | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D | 2020 |
Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO | 2020 |
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Topics: Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 229E, H | 2020 |
A current review of COVID-19 for the cardiovascular specialist.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Biomarkers; Card | 2020 |
Coronavirus Disease 2019: Clinical Review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; | 2020 |
Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; COVID-19; COVID-19 Drug Treatment; D | 2020 |
Approach to Acute Cardiovascular Complications in COVID-19 Infection.
Topics: Acute Coronary Syndrome; Anti-Bacterial Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin | 2020 |
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combinatio | 2020 |
Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqu | 2020 |
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Com | 2020 |
A review of potential treatments to date in COVID-19 patients according to the stage of the disease.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Treatment of COVID 19-Repurposing drugs commonly used in dermatology.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dermatology; Drug Repositioning; H | 2020 |
Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19.
Topics: Aminoquinolines; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Tr | 2020 |
[COVID-19 trials: surfing between expectations and illusions, looking forward to evidence].
Topics: Adenosine Monophosphate; Alanine; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroqui | 2020 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID- | 2020 |
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
Tackle the free radicals damage in COVID-19.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Azithromycin; Betacoronavirus; Clinical Trials | 2020 |
Left ventricular dysfunction in COVID-19: A diagnostic issue.
Topics: Azithromycin; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Cytokine Release Syndro | 2020 |
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2020 |
Hydroxychloroquine and coronavirus disease 2019.
Topics: Antimalarials; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychl | 2020 |
Emerging pharmacotherapy for COVID-19.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coron | 2020 |
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Mono | 2020 |
[Drug treatment of coronavirus disease COVID-19: evidence exists?]
Topics: Adenosine Monophosphate; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme In | 2020 |
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral | 2020 |
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antirheumatic Agents; Betacoronavirus; Coronaviru | 2020 |
Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
Topics: Alarmins; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, | 2020 |
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infe | 2020 |
Clinical trials for the prevention and treatment of COVID-19: current state of play.
Topics: Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID | 2020 |
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Betacoronavirus; CCR5 Receptor Antagonis | 2020 |
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Topics: Analgesics; Anti-Asthmatic Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anticoagulants; | 2020 |
Current pharmacological treatments for SARS-COV-2: A narrative review.
Topics: Adenosine Monophosphate; Adjuvants, Immunologic; Alanine; Antiviral Agents; Betacoronavirus; Clinica | 2020 |
Hydroxychloroquine for COVID-19: What is our Current State of Knowledge?
Topics: Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
Clinical management of COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Airway Management; Alanine; Antibodies, Monoclonal | 2020 |
BET 2: Hydroxychloroquine in the treatment of COVID-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Communication; Coronavirus Infections; COVID-19; COVID-19 Drug Tr | 2020 |
Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk.
Topics: Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Autopha | 2020 |
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.
Topics: Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Administration Schedule; Drug Rep | 2020 |
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Dru | 2020 |
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
Topics: Autoimmune Diseases; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxy | 2020 |
Is hydroxychloroquine beneficial for COVID-19 patients?
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chlor | 2020 |
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized | 2020 |
Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases.
Topics: Adaptive Immunity; Aged; Antirheumatic Agents; Comorbidity; Coronavirus Infections; COVID-19; COVID- | 2020 |
Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.
Topics: Adaptive Immunity; Adult; Anticoagulants; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; C | 2020 |
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antimala | 2020 |
Drug targets for COVID-19 therapeutics: Ongoing global efforts.
Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Coronav | 2020 |
SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice.
Topics: Aged; Antiviral Agents; Betacoronavirus; Chloroquine; Conjunctiva; Conjunctivitis, Viral; Coronaviru | 2020 |
Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antivi | 2021 |
Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.
Topics: Adenosine Monophosphate; Alanine; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical | 2020 |
Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
Topics: Azithromycin; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Role for antimalarials in the management of COVID-19.
Topics: Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVI | 2020 |
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; A | 2020 |
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; | 2020 |
Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
Topics: Arrhythmias, Cardiac; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hu | 2020 |
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Topics: Animals; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; | 2020 |
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Labo | 2020 |
Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Drug treatments for covid-19: living systematic review and network meta-analysis
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Centers for Disease Control and | 2020 |
A Perspective on Emerging Therapeutic Interventions for COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; COVID-19; Humans; Hydroxychloroqu | 2020 |
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydro | 2020 |
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Bias; C | 2021 |
Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Doxycycline; Humans; Hydroxychloro | 2020 |
Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2021 |
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal, Humanized; Antimalarials; Artesunate; Beta | 2020 |
Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Asymptomatic Diseases; Betacoronavirus; Biomarke | 2020 |
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Che | 2020 |
Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case report.
Topics: Adolescent; Blood Chemical Analysis; Ceftriaxone; China; Clinical Laboratory Techniques; Coronavirus | 2020 |
Where are we with understanding of COVID-19?
Topics: Antiviral Agents; Ataxia; Betacoronavirus; Communicable Disease Control; Coronavirus Infections; COV | 2020 |
Cancer therapy and treatments during COVID-19 era.
Topics: Angiotensin-Converting Enzyme 2; Antineoplastic Agents; Antiviral Agents; Betacoronavirus; Comorbidi | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized | 2020 |
Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
Topics: Antibodies, Antiphospholipid; Antirheumatic Agents; Antiviral Agents; Autoimmune Diseases; COVID-19; | 2020 |
Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype?
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Bartter Syndrome | 2020 |
Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine.
Topics: Artificial Intelligence; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Eye; Eye Disease | 2020 |
It Takes a Village…: Contending With Drug Shortages During Disasters.
Topics: Antiviral Agents; COVID-19; Critical Care; Disasters; Drug Combinations; Drug Industry; Drug Reposit | 2020 |
Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coron | 2020 |
Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19?
Topics: Animals; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pre-Exposure Pr | 2020 |
Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Combined | 2020 |
Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Electrocardiography; Global Health | 2020 |
A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; A | 2020 |
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Heart Diseases; Hospi | 2020 |
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus | 2020 |
Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
Topics: Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal; Antibodies, Monoc | 2021 |
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Azithromycin; Bayes Theorem; Bias; Chloroquine; COVID-19; COVID-19 Drug Treatment; | 2021 |
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavir | 2020 |
[Cardiovascular implications of SARS-CoV-2 infection: A literature review].
Topics: Acute Coronary Syndrome; Algorithms; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme | 2020 |
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
Topics: Antirheumatic Agents; Betacoronavirus; Colchicine; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronav | 2020 |
An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.
Topics: Adult; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Progression; Evidence-Based Medi | 2021 |
Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents.
Topics: COVID-19; Disinfection; Humans; Hydroxychloroquine; Infection Control; SARS-CoV-2 | 2020 |
Immunomodulatory Drugs in the Management of SARS-CoV-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Colchi | 2020 |
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
Topics: Antimalarials; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Outbreaks; Humans; Hydroxychl | 2021 |
Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients.
Topics: Azithromycin; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroquine; Pu | 2021 |
Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.
Topics: Angiotensin-Converting Enzyme 2; Apoptosis; Betacoronavirus; Coronavirus Infections; COVID-19; COVID | 2020 |
Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis.
Topics: Adenosine Monophosphate; Alanine; Antirheumatic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Tr | 2021 |
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus | 2020 |
Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychlor | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dose-Response Relati | 2021 |
Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tr | 2020 |
Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection.
Topics: Anti-Infective Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Comb | 2020 |
Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Primary Prevention | 2021 |
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hospitalization; Hum | 2021 |
Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
Topics: Antiviral Agents; Autophagy; Azithromycin; COVID-19; COVID-19 Drug Treatment; Endosomes; Humans; Hyd | 2020 |
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; | 2020 |
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Atrial Fibrillat | 2021 |
Familiar Dermatologic Drugs as Therapies for COVID-19.
Topics: Androgen Antagonists; Antimalarials; Antioxidants; Antiparasitic Agents; Chloroquine; Cinchona; COVI | 2021 |
Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Endpoint Deter | 2021 |
Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiotoxins; COVID-19; Female; Heart Diseases; Humans; | 2021 |
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combin | 2021 |
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.
Topics: Antimalarials; Cardiotoxicity; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 | 2021 |
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Emerging treatment strategies for COVID-19 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Tre | 2021 |
COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?
Topics: Antibodies, Monoclonal, Humanized; COVID-19; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immun | 2021 |
Chloroquine and its derivatives in the management of COVID-19: A scoping review
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Compassionate Use Trials; | 2020 |
Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead.
Topics: COVID-19; COVID-19 Drug Treatment; Federal Government; Government Agencies; Humans; Hydroxychloroqui | 2021 |
Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient.
Topics: Acute Kidney Injury; Administration, Inhalation; Amphotericin B; Anti-Bacterial Agents; Antibodies, | 2021 |
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.
Topics: COVID-19; COVID-19 Drug Treatment; Critical Illness; Hospitalization; Humans; Hydroxychloroquine; Lo | 2021 |
Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.
Topics: Arthritis, Rheumatoid; Betacoronavirus; Chikungunya Fever; Chikungunya virus; Coronavirus Infections | 2020 |
Decoding the silent walk of COVID-19: Halting its spread using old bullets.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydrox | 2021 |
Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine | 2021 |
Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations.
Topics: Antiviral Agents; COVID-19; COVID-19 Serotherapy; Cytokine Release Syndrome; Humans; Hydroxychloroqu | 2021 |
Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Odds Ratio; Randomized Controlled Tri | 2021 |
One year update on the COVID-19 pandemic: Where are we now?
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as | 2021 |
Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Artificial In | 2020 |
The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans | 2020 |
Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.
Topics: Animals; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme Inhibitors; Cytochr | 2020 |
A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2; Skin Diseases | 2021 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize | 2020 |
Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.
Topics: Antimalarials; Antiviral Agents; Cardiomyopathies; Chloroquine; COVID-19; COVID-19 Drug Treatment; H | 2021 |
Bringing evidence from press release to the clinic in the era of COVID-19.
Topics: Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Evidence-Based Medicine; | 2021 |
Liquid Chromatographic Methods for COVID-19 Drugs, Hydroxychloroquine and Chloroquine.
Topics: Animals; Antiviral Agents; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; H | 2021 |
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Dru | 2021 |
Possible treatment and strategies for COVID-19: review and assessment.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodie | 2020 |
Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2021 |
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; ERG1 Potassium Chan | 2021 |
Malaria and COVID-19: unmasking their ties.
Topics: Age Factors; Angiotensin-Converting Enzyme 2; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights.
Topics: Antigen Presentation; Antiviral Agents; Autophagic Cell Death; COVID-19; COVID-19 Drug Treatment; Hu | 2021 |
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics.
Topics: Acute Kidney Injury; Amantadine; Angiotensin-Converting Enzyme 2; Cathepsin L; Chloroquine; COVID-19 | 2020 |
Meningoencephalitis associated with COVID-19: a systematic review.
Topics: Adult; Aged; Antiviral Agents; Azithromycin; Confusion; Cough; COVID-19; COVID-19 Drug Treatment; Dy | 2021 |
COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Pandemics | 2021 |
The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.
Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; | 2020 |
Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asian Peopl | 2020 |
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Azithromycin; COVID-19; COVID-19 Drug Tr | 2020 |
COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.
Topics: Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Death, Sudden, Cardiac; Humans; Hydroxychlo | 2021 |
Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.
Topics: Anti-Infective Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drugs, Investigational; | 2021 |
The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.
Topics: Antibiotic Prophylaxis; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqu | 2021 |
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues.
Topics: COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Humans; Hydroxychloroquine; MAP Kinase Signali | 2020 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azeti | 2021 |
Variable Clinical Manifestations of COVID-19: Viral and Human Genomes Talk.
Topics: ADAM17 Protein; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensi | 2020 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Tre | 2021 |
Prophylaxis for COVID-19: a systematic review.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Antimalarials; Antivir | 2021 |
From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Topics: Animals; Antiparasitic Agents; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydrox | 2021 |
Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.
Topics: Adult; Anticonvulsants; Ataxia; Azithromycin; Clonazepam; Cough; COVID-19; COVID-19 Drug Treatment; | 2021 |
The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID | 2021 |
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; COVID-19; COVID-19 Drug Treatment; Humans; | 2021 |
COVID-19 and Its Implications for Thrombosis and Anticoagulation.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Antiphospholipid; Antibodies, Monoclo | 2021 |
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 | 2021 |
Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Fe | 2021 |
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.
Topics: COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Glucocorticoids; Humans; Hydroxychloroquine | 2021 |
The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Dru | 2021 |
Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic | 2021 |
Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.
Topics: Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Glucosephosphate Dehydrogenase Def | 2021 |
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Topics: Adult; Aged; Antimalarials; Antiviral Agents; Bias; Cause of Death; Chloroquine; COVID-19; COVID-19 | 2021 |
Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-C | 2021 |
Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Treatm | 2021 |
[The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized | 2021 |
What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.
Topics: Antiviral Agents; Cell Proliferation; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositio | 2021 |
Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.
Topics: Alphapapillomavirus; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; COVID-19; | 2021 |
Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review.
Topics: Antimalarials; Child; COVID-19; Critical Care; Hematologic Neoplasms; Humans; Hydroxychloroquine; Ne | 2021 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize | 2021 |
Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.
Topics: Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquin | 2021 |
Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Asia; Cesarean Section; COVID-19; COVID-19 Drug Trea | 2021 |
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Long QT Sy | 2021 |
The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis.
Topics: Azithromycin; Comorbidity; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Humans; | 2021 |
Hepatic transplant during SARS-CoV-2 (COVID-19) pandemic. A literature review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antivi | 2021 |
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chlor | 2021 |
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
Topics: Adult; Child; Chloroquine; Combined Modality Therapy; Comorbidity; COVID-19; COVID-19 Drug Treatment | 2021 |
The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Chloro | 2021 |
Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; | 2021 |
Prophylaxis against covid-19: living systematic review and network meta-analysis.
Topics: Anti-Infective Agents; Carrageenan; Chemoprevention; COVID-19; Global Health; Humans; Hydroxychloroq | 2021 |
Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
Topics: Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; E | 2021 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Antico | 2021 |
Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis.
Topics: Azithromycin; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; | 2021 |
Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
Topics: Antiviral Agents; COVID-19; Drug Therapy, Combination; Exanthema; Female; Humans; Hydroxychloroquine | 2021 |
Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A Review on Pathophysiology, Diagnosis, and Investigational Therapeuti.
Topics: Animals; Communicable Disease Control; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2021 |
Reimagining the peer-review system for translational health science journals.
Topics: Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Interdiscip | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Topics: 25-Hydroxyvitamin D 2; Adrenal Cortex Hormones; Adult; Azithromycin; Bias; Calcifediol; Cause of Dea | 2021 |
The understanding of the immunopathology in COVID-19 infection.
Topics: Adrenal Cortex Hormones; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokine Rele | 2021 |
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize | 2021 |
What would be the impact of COVID-19 on liver function of a patient with chronic hepatitis B? About a case and literature review.
Topics: Adult; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Hepatitis B, Chronic; Hosp | 2021 |
Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
Topics: COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Hydro | 2021 |
Epidemiology and Treatment Options for COVID-19: A Review.
Topics: Antiviral Agents; Chloroquine; Communicable Disease Control; COVID-19; Disease Outbreaks; Humans; Hy | 2020 |
Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents, Non-Ste | 2021 |
Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.
Topics: Antimalarials; Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2022 |
How trustworthy guidelines can impact outcomes.
Topics: COVID-19; Humans; Hydroxychloroquine; Lopinavir; Pandemics; SARS-CoV-2 | 2021 |
91 trials available for hydroxychloroquine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic.
Topics: COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2; Treatment Outcome | 2021 |
Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial.
Topics: Adult; Antiviral Agents; Communicable Diseases; COVID-19; COVID-19 Drug Treatment; Double-Blind Meth | 2021 |
Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial.
Topics: Benzamidines; COVID-19; Guanidines; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topi | 2021 |
Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.
Topics: COVID-19; COVID-19 Drug Treatment; Emergency Responders; Health Personnel; Humans; Hydroxychloroquin | 2022 |
Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission.
Topics: COVID-19; Humans; Hydroxychloroquine; Post-Exposure Prophylaxis; Risk Factors; SARS-CoV-2 | 2022 |
Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial.
Topics: Adult; Antimalarials; Antiviral Agents; COVID-19; Double-Blind Method; Female; Health Personnel; Hum | 2022 |
Hydroxychloroquine plus personal protective equipment versus personal protective equipment alone for the prevention of laboratory-confirmed COVID-19 infections among healthcare workers: a multicentre, parallel-group randomised controlled trial from India.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; Female; Health Personnel; Humans; Hydroxychloroquine; Indi | 2022 |
Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses.
Topics: COVID-19; Health Personnel; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2022 |
Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease.
Topics: Child; COVID-19; Double-Blind Method; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Prosp | 2022 |
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
Topics: Adenine; Anti-HIV Agents; COVID-19; COVID-19 Drug Treatment; Deoxycytidine; Double-Blind Method; Emt | 2023 |
Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.
Topics: Adult; Child; Clinical Trials Data Monitoring Committees; COVID-19; Dexamethasone; Female; Humans; H | 2022 |
Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID).
Topics: COVID-19; COVID-19 Vaccines; Delivery of Health Care; Humans; Hydroxychloroquine; Lactoferrin; SARS- | 2023 |
Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID).
Topics: COVID-19; COVID-19 Vaccines; Delivery of Health Care; Humans; Hydroxychloroquine; Lactoferrin; SARS- | 2023 |
Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID).
Topics: COVID-19; COVID-19 Vaccines; Delivery of Health Care; Humans; Hydroxychloroquine; Lactoferrin; SARS- | 2023 |
Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID).
Topics: COVID-19; COVID-19 Vaccines; Delivery of Health Care; Humans; Hydroxychloroquine; Lactoferrin; SARS- | 2023 |
The 'myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19' is far from reality.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Post-Exposure Prophylaxis; SARS-CoV-2 | 2023 |
Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).
Topics: COVID-19; COVID-19 Drug Treatment; Health Personnel; Humans; Hydroxychloroquine; Pre-Exposure Prophy | 2023 |
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.
Topics: COVID-19; COVID-19 Drug Treatment; Health Personnel; Humans; Hydroxychloroquine; Pandemics; SARS-CoV | 2023 |
The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
Promising clinical outcomes of nano-curcumin treatment as an adjunct therapy in hospitalized COVID-19 patients: A randomized, double-blinded, placebo-controlled trial.
Topics: COVID-19; Curcumin; Cytokines; Double-Blind Method; Humans; Hydroxychloroquine; SARS-CoV-2; Treatmen | 2023 |
Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Health Personnel; Humans; Hydroxychloroquine; N | 2023 |
Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.
Topics: Adult; Chloroquine; COVID-19; Humans; Hydroxychloroquine; Middle Aged; Nigeria; SARS-CoV-2; Treatmen | 2023 |
Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.
Topics: Acetylcysteine; Antiviral Agents; Atazanavir Sulfate; C-Reactive Protein; COVID-19; COVID-19 Drug Tr | 2023 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Topics: Adult; Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Drug | 2020 |
Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Humans; Hydroxychloroquine; | 2020 |
Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Humans; Hydroxychloroquine; | 2020 |
Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Humans; Hydroxychloroquine; | 2020 |
Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Humans; Hydroxychloroquine; | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Topics: Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pil | 2020 |
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
Topics: Adult; Antiviral Agents; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; H | 2020 |
Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial.
Topics: Adult; Anti-Infective Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID | 2020 |
The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progressi | 2020 |
An open-label cluster-randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC)-Protocol publication.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Adult; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Double-Blind Method; Female; Human | 2020 |
Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, | 2020 |
Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.
Topics: Antiviral Agents; Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; Double-Blind M | 2020 |
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug Therapy | 2020 |
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomise
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Ascorbic Acid; Betacoronavirus; Contac | 2020 |
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlle
Topics: Adolescent; Adult; Aged; Antiviral Agents; Betacoronavirus; Chemoprevention; Coronavirus Infections; | 2020 |
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomi
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; | 2020 |
Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combinatio | 2020 |
Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infection | 2020 |
Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; Human | 2020 |
Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug | 2020 |
Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.
Topics: Adult; Aged; Ambulatory Care; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Cor | 2020 |
Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
Topics: Antiviral Agents; Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Betacoronavirus; Chemoprevention; Clinical Laboratory Tec | 2020 |
Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Drug Therapy, | 2020 |
Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Topics: Age Factors; Aged; Aging; Ambulatory Care; Antiviral Agents; Betacoronavirus; Cause of Death; Clinic | 2020 |
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbi | 2020 |
Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada.
Topics: Adolescent; Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Health Personnel; Humans; Hydr | 2020 |
The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study prot
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combinatio | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Topics: Adult; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Female | 2020 |
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Coronavirus | 2020 |
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Coronavirus | 2020 |
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Coronavirus | 2020 |
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Coronavirus | 2020 |
Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Health Personnel; Humans; Hy | 2020 |
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Topics: Betacoronavirus; Cluster Analysis; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroqu | 2020 |
Torsades de Pointes in Coronavirus Disease 2019 Infection.
Topics: Aged; Antimalarials; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroqu | 2021 |
Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A struc
Topics: Azithromycin; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.
Topics: Acetaminophen; Adult; Antiviral Agents; Betacoronavirus; Cephalosporins; Coronavirus Infections; COV | 2020 |
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
Topics: Adult; Aged; Anti-Infective Agents; Azithromycin; Betacoronavirus; C-Reactive Protein; Coronavirus I | 2020 |
Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Double-Blind Method; Enzyme Inhibitors; Humans; H | 2020 |
Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; Enzyme Inhibitors; Health Person | 2020 |
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Coronavirus Infections; COVID-19; Dru | 2020 |
A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIv
Topics: Abortion, Habitual; COVID-19; Female; Fetus; Humans; Hydroxychloroquine; Immunosuppressive Agents; M | 2020 |
Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; Cross Infection; Double-Blind Method; Female; Hospitals, U | 2021 |
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID- | 2020 |
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to R
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Antimalarials; Antiviral Agents; Betacoron | 2020 |
Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antimalarials; Azithromycin; Betacoronavirus; C | 2020 |
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Clinical Protocols; C | 2020 |
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.
Topics: Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; | 2020 |
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COV | 2021 |
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
Topics: Adult; Anti-Infective Agents; COVID-19; Disease Transmission, Infectious; Double-Blind Method; Femal | 2021 |
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
Topics: Adult; Ambulatory Care; Antimalarials; Antiviral Agents; Carbamates; COVID-19; COVID-19 Drug Treatme | 2021 |
The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; COVID-19; COVID- | 2021 |
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; COVID | 2021 |
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Belgium; COVID-19; COVID | 2021 |
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.
Topics: Adult; Aged; Antimalarials; Antiparasitic Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Do | 2021 |
[Interferon gamma in the treatment of patients with moderate COVID-19].
Topics: Aged; Ampicillin; Anti-Infective Agents; Anticoagulants; Azithromycin; Blood Pressure; COVID-19; COV | 2021 |
Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
Topics: Adult; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Ferritins; Fibrin Fibrin | 2021 |
Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial.
Topics: Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Critical Care; Double-Blind Method; Huma | 2021 |
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial.
Topics: Adult; COVID-19; Humans; Hydroxychloroquine; Male; Middle Aged; Pharynx; Povidone-Iodine; Time Facto | 2021 |
Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
Topics: Antiviral Agents; Brazil; COVID-19; Drug Monitoring; Drug Therapy, Combination; Early Medical Interv | 2021 |
An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.
Topics: Adult; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; | 2021 |
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
Topics: Aged; Amides; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; Azithromycin; COVID-1 | 2021 |
Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial.
Topics: Child; Clinical Trials as Topic; COVID-19; Drug Monitoring; Humans; Hydroxychloroquine; Lupus Erythe | 2021 |
Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study.
Topics: COVID-19; Cross-Sectional Studies; Humans; Hydroxychloroquine; Pharmaceutical Preparations; Retrospe | 2021 |
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk.
Topics: Aged; COVID-19; Humans; Hydroxychloroquine; Prospective Studies; Randomized Controlled Trials as Top | 2021 |
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Viral; Antiviral Agents; Biomarkers; Cause of Death; C | 2021 |
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug The | 2021 |
Withania somnifera as a safer option to hydroxychloroquine in the chemoprophylaxis of COVID-19: Results of interim analysis.
Topics: Adult; COVID-19; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Prospective Studies; Treatme | 2021 |
Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance.
Topics: Adult; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Femal | 2021 |
985 other studies available for hydroxychloroquine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Azithromycin; C-Reactive Protein; Comorbidity; COVI | 2022 |
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
Topics: Adult; Amides; Azithromycin; Child; COVID-19; Hematologic Neoplasms; Humans; Hydroxychloroquine; Pyr | 2022 |
Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antiviral Agents; Azithrom | 2021 |
Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells.
Topics: Cell Line; COVID-19; COVID-19 Drug Treatment; Dendritic Cells; Endosomes; Humans; Hydroxychloroquine | 2022 |
COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Cobicistat; COVID-19; CO | 2021 |
Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Chi-Square Dist | 2021 |
COVID-19 myocarditis cardiac magnetic resonance findings in symptomatic patients.
Topics: Adult; C-Reactive Protein; Contrast Media; COVID-19; Female; Gadolinium; Humans; Hydroxychloroquine; | 2022 |
Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study.
Topics: Adrenal Cortex Hormones; Aged; COVID-19; COVID-19 Drug Treatment; Critical Care; Female; Heart Failu | 2021 |
'I hope you die': how the COVID pandemic unleashed attacks on scientists.
Topics: Azithromycin; Bullying; Communication; COVID-19; Female; Health Policy; Humans; Hydroxychloroquine; | 2021 |
Keeping Meta-Analyses Hygienic During the COVID-19 Pandemic.
Topics: Azithromycin; COVID-19; Humans; Hydroxychloroquine; Meta-Analysis as Topic; Pandemics | 2021 |
The relationship between Covid-19 and mucociliary clearance.
Topics: Adrenal Cortex Hormones; Adult; Amides; Antiviral Agents; Case-Control Studies; COVID-19; COVID-19 D | 2021 |
Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous Thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; | 2021 |
Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Cell Membrane; Chloroquine; Chromatography, High | 2022 |
Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases.
Topics: Adult; Aged; Antimalarials; Chromatography, High Pressure Liquid; Connective Tissue Diseases; COVID- | 2021 |
Hydroxichloroquine for COVID-19 infection: Do we have a final word after one year?
Topics: Clinical Trials as Topic; COVID-19; Humans; Hydroxychloroquine; Meta-Analysis as Topic; SARS-CoV-2; | 2021 |
Many trials of hydroxychloroquine for SARS-CoV-2 were redundant and potentially unethical: an analysis of the NIH clinical trials registry.
Topics: Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloro | 2022 |
Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Topics: BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Drug-Related Side Effects and Adverse Reactions; Humans | 2022 |
Pharmaceutical messianism and the COVID-19 pandemic.
Topics: COVID-19; Humans; Hydroxychloroquine; Pandemics; Pharmaceutical Preparations; SARS-CoV-2 | 2022 |
The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Behcet Syndrome; Comorbidity; COVID-19; COVID-19 Drug T | 2022 |
Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells.
Topics: Angiotensin-Converting Enzyme 2; Biomarkers; Comorbidity; Conjunctiva; COVID-19; COVID-19 Drug Treat | 2022 |
Factors Affecting the Incidence, Progression, and Severity of COVID-19 in Type 1 Diabetes Mellitus.
Topics: Adult; Biomarkers; Blood Cell Count; Blood Glucose; Blood Sedimentation; C-Reactive Protein; Comorbi | 2021 |
Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Female; Health Personnel; Humans; Hydrox | 2022 |
In silico investigation of the interactions of certain drugs proposed for the treatment of Covid-19 with the paraoxonase-1.
Topics: Aryldialkylphosphatase; COVID-19; Dexamethasone; Humans; Hydroxychloroquine; Molecular Docking Simul | 2023 |
Outpatient prescription patterns of COVID-19 drugs in the metropolitan area of Mexico City.
Topics: Adult; Azithromycin; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Prescriptions; Female; H | 2022 |
Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.
Topics: Animals; Blood; Blood Physiological Phenomena; Cardiomegaly; Cardiovascular Diseases; Cardiovascular | 2021 |
The polymorphism L412F in
Topics: Autophagy; Biomarkers; COVID-19; HEK293 Cells; Humans; Hydroxychloroquine; Male; Polymorphism, Singl | 2022 |
Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India.
Topics: COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Health Personnel; Humans; Hydroxychloroq | 2022 |
Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.
Topics: Administration, Inhalation; Aerosols; Algorithms; Cell Line; Chloroquine; COVID-19; Cytosol; Humans; | 2022 |
Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
Topics: Antiviral Agents; COVID-19; Furans; Humans; Hydroxychloroquine; Ligands; Molecular Docking Simulatio | 2022 |
Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients.
Topics: Aged; Antiviral Agents; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Correlatio | 2021 |
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug | 2022 |
Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever.
Topics: Antimalarials; Antiparasitic Agents; Communicable Disease Control; Contact Tracing; COVID-19; COVID- | 2022 |
Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases.
Topics: Animals; Antibodies, Monoclonal, Humanized; Arrhythmias, Cardiac; Azithromycin; COVID-19; COVID-19 D | 2022 |
Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists.
Topics: Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; France; Hosp | 2022 |
Technical procedures and REDCap tools for internet-based clinical trials.
Topics: Clinical Trials as Topic; COVID-19; Humans; Hydroxychloroquine; Internet; Research Design | 2022 |
From hydroxychloroquine to ivermectin: how unproven "cures" can go viral.
Topics: COVID-19; Humans; Hydroxychloroquine; Ivermectin; SARS-CoV-2 | 2022 |
COVID-19 disease characteristics in different pediatric age groups.
Topics: Adult; Child; Child, Preschool; COVID-19; Hospitalization; Humans; Hydroxychloroquine; Infant; Retro | 2022 |
Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; COVID-19; COVID-19 Drug Treatment; Humans; Hydro | 2022 |
COVID-19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy.
Topics: COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Infant, Newborn; Pregnancy; P | 2022 |
Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine-treated systemic lupus erythematosus patients.
Topics: Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroq | 2022 |
Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; Hydroxychloroqu | 2022 |
Decrease in Visual Acuity in a 77-Year-old Woman with Age-Related Macular Degeneration after a SARS-CoV-2 Infection Treated with Hydroxychloroquine.
Topics: Aged; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Macular Degeneration; S | 2022 |
Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.
Topics: Chemical and Drug Induced Liver Injury; COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects | 2023 |
Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia.
Topics: Azithromycin; Calcitriol; Colchicine; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Hu | 2022 |
Multi-Targeted Molecular Docking and Drug-Likeness Evaluation of some Nitrogen Heterocyclic Compounds Targeting Proteins Involved in the Development of COVID-19.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Heterocyclic Compounds; Humans; Hydroxychloroqu | 2023 |
The role of treatment with plasma exchange therapy in two pediatric toxic epidermal necrolysis cases related to COVID-19.
Topics: Child; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine; Plasma Exchange; RNA, Messenger; Ste | 2022 |
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2022 |
An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
Topics: Arrhythmias, Cardiac; Bradycardia; Cardiac Conduction System Disease; Cardiovascular System; COVID-1 | 2022 |
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.
Topics: Adult; Animals; Autoimmune Diseases; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Exanthema; Female; | 2022 |
COVID-19 drug research and the cohort multiple randomised controlled trial design.
Topics: Adult; COVID-19; Critical Illness; Humans; Hydroxychloroquine; Receptors, Interleukin-6; SARS-CoV-2 | 2022 |
Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design.
Topics: Adult; COVID-19; Critical Illness; Humans; Hydroxychloroquine; Receptors, Interleukin-6; SARS-CoV-2 | 2022 |
Impacts of the COVID-19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central Pennsylvania.
Topics: Acetaminophen; Ampicillin; Animals; Anti-Bacterial Agents; COVID-19; Dexamethasone; Doxycycline; Env | 2022 |
Rate of Recovery and Symptomatic Efficacy of a Polyherbal AYUSH Formulation in the Treatment of SARS-CoV-2 Disease: A Single-arm Trial.
Topics: COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2; Treatment Outcome | 2023 |
Systemic exposure to hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City.
Topics: Bayes Theorem; COVID-19; Humans; Hydroxychloroquine; New York City; Retrospective Studies | 2023 |
Authors' reply to: 'Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine'.
Topics: COVID-19; COVID-19 Drug Treatment; Erythema; Humans; Hydroxychloroquine | 2023 |
Using EHR data to identify coronavirus infections in hospitalized patients: Impact of case definitions on disease surveillance.
Topics: Antiviral Agents; COVID-19; Hospitalization; Humans; Hydroxychloroquine; SARS-CoV-2; United States | 2022 |
COVID-19 and Politically Motivated Reasoning.
Topics: Communicable Disease Control; COVID-19; Humans; Hydroxychloroquine; Pandemics; Politics; United Stat | 2022 |
Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: A retrospective, propensity-matched cohort study.
Topics: Arthritis, Rheumatoid; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine | 2023 |
Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemic.
Topics: Azithromycin; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Ethnicity; Humans; Hydroxychloroquin | 2022 |
Quality of hospital emergency department care for patients with COVID-19 during the first wave in 2020: the CALUR-COVID-19 study.
Topics: COVID-19; Emergency Service, Hospital; Hospitals; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; | 2022 |
Electrochemical Response of Redox Amino Acid Encoded Fluorescence Protein for Hydroxychloroquine Sensing.
Topics: Amino Acids; COVID-19; COVID-19 Drug Treatment; Dihydroxyphenylalanine; Humans; Hydroxychloroquine; | 2023 |
[COVID management at the Regional Hospital of Lambaréné (Gabon) from March 2020 to February 2021].
Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; Gabon; Hospitals; Humans; Hydroxychloroquine; Oxygen; | 2022 |
[Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020].
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Interf | 2021 |
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
Topics: Antibodies, Viral; Autoimmune Diseases; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine; Imm | 2022 |
Kinetics of Drug Molecule Interactions with a Newly Developed Nano-Gold-Modified Spike Protein Electrochemical Receptor Sensor.
Topics: Antiviral Agents; Bromhexine; COVID-19; Gold; Humans; Hydroxychloroquine; Kinetics; Ligands; Metal N | 2022 |
Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection.
Topics: Angiogenesis Inducing Agents; Biomarkers; COVID-19; Female; Fibrinolytic Agents; Humans; Hydroxychlo | 2022 |
Evaluation of Retinal Microvascular Impairment after COVID-19 and its Clinical Correlates Using Optical Coherence Tomography Angiography.
Topics: Adult; COVID-19; Female; Ferritins; Fluorescein Angiography; Fovea Centralis; Heparin, Low-Molecular | 2022 |
Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Interrupted Time Series Analysis; Ive | 2022 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Criti | 2023 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Criti | 2023 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Criti | 2023 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Criti | 2023 |
Hydroxychloroquine Mitigates Dilated Cardiomyopathy Phenotype in Transgenic D94A Mice.
Topics: Animals; Cardiomyopathy, Dilated; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Mic | 2022 |
Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset.
Topics: Azathioprine; Communicable Disease Control; COVID-19; Drug Prescriptions; Humans; Hydroxychloroquine | 2022 |
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic.
Topics: COVID-19; Epidemics; Humans; Hydroxychloroquine; Ivermectin | 2023 |
Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Cross-Sectional St | 2023 |
4-Aminoquinolines modulate RNA structure and function: Pharmacophore implications of a conformationally restricted polyamine.
Topics: Aminoquinolines; COVID-19; Humans; Hydroxychloroquine; Nucleic Acid Conformation; Pharmacophore; Pol | 2023 |
The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report.
Topics: COVID-19; Cross-Sectional Studies; Humans; Hydroxychloroquine; Immunosuppression Therapy; Lupus Eryt | 2023 |
Hydroxychloroquine: is there a role in long COVID?
Topics: Antimalarials; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Post-Acute COVID-19 Sy | 2023 |
COVID-19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats.
Topics: Adipose Tissue; Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Blood Pressure; C | 2023 |
Affinity binding of COVID-19 drug candidates (chloroquine/hydroxychloroquine) and serum albumin: Based on photochemistry and molecular docking.
Topics: Antiviral Agents; Chloroquine; Computer Simulation; COVID-19; COVID-19 Drug Treatment; Humans; Hydro | 2023 |
Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection
Topics: Antiviral Agents; Chloroquine; COVID-19; Heterocyclic Compounds; Humans; Hydroxychloroquine; Pandemi | 2023 |
[Multiform exudative erythema caused by hydroxychloroquine, diagnosed by epicutaneous tests: A case report].
Topics: COVID-19; COVID-19 Drug Treatment; Erythema; Female; Humans; Hydroxychloroquine; Hypersensitivity, D | 2023 |
Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study.
Topics: Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lopinavir; Ri | 2023 |
Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine.
Topics: Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; SARS- | 2023 |
The synergistic effect of Cu-MOF nanoparticles and immunomodulatory agent on SARS-CoV-2 inhibition.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Nanoparticles; SARS-CoV-2 | 2023 |
Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID-19.
Topics: Bias; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Observational Studies as Topic; | 2023 |
Cardiotoxicity of chloroquine and hydroxychloroquine through mitochondrial pathway.
Topics: Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochromes c; Humans; Hydroxychloro | 2023 |
Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients.
Topics: COVID-19; COVID-19 Drug Treatment; Drug Interactions; Humans; Hydroxychloroquine; Long QT Syndrome; | 2022 |
Curcumin attenuates hydroxychloroquine-mediated apoptosis and oxidative stress via the inhibition of TRPM2 channel signalling pathways in a retinal pigment epithelium cell line.
Topics: Adenosine Diphosphate Ribose; Apoptosis; Calcium; Cell Line; COVID-19; COVID-19 Drug Treatment; Curc | 2023 |
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2023 |
Hydroxychloroquine Attenuates hERG Channel by Promoting the Membrane Channel Degradation: Computational Simulation and Experimental Evidence for QT-Interval Prolongation with Hydroxychloroquine Treatment.
Topics: COVID-19; COVID-19 Drug Treatment; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; HEK293 | 2023 |
COVID-19 pharmaceuticals in aquatic matrices: The threatening effects over cyanobacteria and microalgae.
Topics: Azithromycin; Chlorella vulgaris; COVID-19; COVID-19 Drug Treatment; Ecosystem; Humans; Hydroxychlor | 2023 |
Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; H | 2023 |
Trends in COVID-19-Related Medication Use in US Nursing Homes, 2018-2022.
Topics: Azithromycin; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Hydroxychloroquine; Nursing | 2023 |
Validated spectrofluorimetric assay of two co-administered drug mixtures containing hydroxychloroquine with either moxifloxacin or ofloxacin as a drug regimen for hospital-acquired pneumonia in patients with COVID-19.
Topics: Anti-Bacterial Agents; COVID-19; COVID-19 Drug Treatment; Hospitals; Humans; Hydroxychloroquine; Mox | 2023 |
Comparison of COVID-19 Preprint and Peer-Reviewed Versions of Studies on Therapies for Critically Ill Patients.
Topics: COVID-19; Critical Illness; Humans; Hydroxychloroquine; Pandemics; Reproducibility of Results | 2023 |
Risk Factors associated with COVID-19 Patients in India: A Single Center Retrospective Cohort Study.
Topics: COVID-19; Humans; Hydroxychloroquine; Intensive Care Units; Retrospective Studies; Risk Factors; SAR | 2023 |
Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug-Related Side E | 2023 |
The Efficacy of Long-Term Hydroxychloroquine Use in the Prevention of COVID-19: A Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Propensity Score; Retrospectiv | 2023 |
Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress.
Topics: Animals; Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hydroxychloroquine; Mice; O | 2023 |
Toxicological effects of hydroxychloroquine sulfate and chloroquine diphosphate substances on the early-life stages of fish in the COVID-19 pandemic context.
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Larva; Pandemics; Zebrafish | 2023 |
EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
Topics: Aged; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Progressio | 2022 |
Hydroxychloroquine Toxicity in the Vital Organs of the Body:
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Liver; Male; Necrosis; Rats | 2023 |
Hydroxychloroquine reduces T cells activation recall antigen responses.
Topics: COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytokines; Humans; Hydroxychloroquine; Leukocy | 2023 |
Impact of prophylactic hydroxychloroquine on ultrastructural impairment and cellular SARS-CoV-2 infection in different cells of bronchoalveolar lavage fluids of COVID-19 patients.
Topics: Antiviral Agents; Bronchoalveolar Lavage Fluid; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxych | 2023 |
Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study.
Topics: Adult; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Testing; Humans; Hydroxychloroquine; Pand | 2023 |
The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.
Topics: Animals; Cardiotoxicity; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lung; Rats | 2023 |
Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Republic | 2023 |
Misinformation, Trust, and Use of Ivermectin and Hydroxychloroquine for COVID-19.
Topics: Adult; Communication; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Female; Humans; Hydroxyc | 2023 |
Simultaneous LC-MS/MS method for the quantitation of Azithromycin, Hydroxychloroquine and its metabolites in SARS-CoV-2(-/ +) populations using dried blood spots.
Topics: Azithromycin; Chromatography, Liquid; Communicable Disease Control; COVID-19; COVID-19 Drug Treatmen | 2023 |
Real-Life Data on Hydroxychloroquine or Chloroquine with or Without Azithromycin in COVID-19 Patients: A Retrospective Analysis in Brazil.
Topics: Aged; Arrhythmias, Cardiac; Azithromycin; Brazil; Chloroquine; Cohort Studies; COVID-19; COVID-19 Dr | 2023 |
Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2.
Topics: Angiotensin-Converting Enzyme 2; Antimalarials; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxych | 2024 |
Nasal spray of an IgM-like ACE2 fusion protein HH-120 prevents SARS-CoV-2 infection: Two investigator-initiated postexposure prophylaxis trials.
Topics: Angiotensin-Converting Enzyme 2; COVID-19; Humans; Hydroxychloroquine; Immunoglobulin M; Nasal Spray | 2023 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; | 2020 |
Insights from nanomedicine into chloroquine efficacy against COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?
Topics: Antiviral Agents; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin | 2020 |
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Trials as Topic; Confounding Factors, Epid | 2020 |
COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Angiotensin-Converting Enzyme 2; Antiviral Agents; Azit | 2020 |
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Reposi | 2020 |
COVID-19 in kidney transplant recipients.
Topics: Aged; Betacoronavirus; Cobicistat; Colchicine; Coronavirus Infections; COVID-19; Cytokines; Darunavi | 2020 |
Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic.
Topics: Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Health Knowledge, A | 2020 |
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatme | 2020 |
COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; H | 2020 |
What is the role of rheumatologists in the era of COVID-19?
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azetidines; Betacoronavir | 2020 |
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
Topics: Amino Acid Sequence; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxy | 2020 |
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies.
Topics: Antiviral Agents; Betacoronavirus; Communicable Disease Control; Coronavirus Infections; COVID-19; D | 2020 |
A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?
Topics: Aged; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; H | 2020 |
COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.
Topics: Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Chloroquine and hydroxychloroquine in covid-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO | 2020 |
Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fear; Human | 2020 |
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; France; Humans; Hydroxychloroquine; Pandemics; Pn | 2020 |
Can prophylactic drugs keep fragile health systems running?
Topics: Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; | 2020 |
Case Report: Death due to COVID-19 in Three Brothers.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Fatal Outcome; Genetic Predisposition to Di | 2020 |
Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple.
Topics: Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Breast Neoplasms; Cobicistat; Coronavirus | 2020 |
Regulators split on antimalarials for COVID-19.
Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Approval; Europe | 2020 |
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Ciliopathies; Cobicistat; Common Cold; | 2020 |
Delayed Initiation of Remdesivir in a COVID-19-Positive Patient.
Topics: Adenosine Monophosphate; Adult; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavir | 2020 |
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Betacoronavirus; Combi | 2020 |
Early impact of COVID-19 on transplant center practices and policies in the United States.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Betacoronavirus; Clinical Labor | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; | 2020 |
Does hydroxychloroquine combat COVID-19? A timeline of evidence.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Drug Approval; Humans; Hydroxychloroquine; Pandem | 2020 |
Drug Evaluation during the Covid-19 Pandemic.
Topics: Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 D | 2020 |
Practical implementation of COVID-19 patient flags into an antimicrobial stewardship program's prospective review.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Azithromycin; Betacoronavirus; Coronavirus Infecti | 2020 |
Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Asymptomatic Diseases; Azithromycin; Carrier State; C | 2020 |
Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Asymptomatic Diseases; Azithromycin; Carrier State; C | 2020 |
Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Asymptomatic Diseases; Azithromycin; Carrier State; C | 2020 |
Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Asymptomatic Diseases; Azithromycin; Carrier State; C | 2020 |
Chloroquine as a prophylactic agent against COVID-19?
Topics: Animals; Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Chlorocebus aethiops; Chlor | 2020 |
SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment.
Topics: Antirheumatic Agents; Arthritis; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxyc | 2020 |
Does hydroxychloroquine prevent the transmission of COVID-19?
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemi | 2020 |
Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19 Therapeutic Trials.
Topics: Antiviral Agents; Betacoronavirus; Breast Feeding; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infe | 2020 |
Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infecti | 2020 |
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Canada; Coronavirus Infection | 2020 |
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Canada; Coronavirus Infection | 2020 |
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Canada; Coronavirus Infection | 2020 |
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Canada; Coronavirus Infection | 2020 |
COVID-19 in solid organ transplant recipients: A single-center case series from Spain.
Topics: Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female | 2020 |
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, | 2020 |
COVID-19 Presenting as Acute Hepatitis.
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fever; Hepatitis, Viral, H | 2020 |
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Contraindications, Drug; Coronavirus Infection | 2020 |
The race against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Viral; Antiviral Agents; Betacoronavirus; Clinical Lab | 2020 |
Taking the Longer View of COVID-19.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemi | 2020 |
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Evid | 2020 |
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Cross Infection; Disease Outbreaks; Hospitals; Hu | 2020 |
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infec | 2020 |
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
Topics: Betacoronavirus; Chloroquine; Contact Tracing; Coronavirus Infections; COVID-19; COVID-19 Drug Treat | 2020 |
Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Angiotensin-Converting Enzyme Inhi | 2020 |
Off-Label Therapies for COVID-19-Are We All In This Together?
Topics: Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Industry; Drug Prescriptions; Drug U | 2020 |
Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Coronavirus Infections; COVID-19; Drug Combinati | 2020 |
Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak.
Topics: Adult; Anti-Retroviral Agents; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Dyspnea; Fa | 2020 |
Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Azithromycin; Betacoronavirus; Coronavirus | 2020 |
Case Report: The Importance of Novel Coronavirus Disease (COVID-19) and Coinfection with Other Respiratory Pathogens in the Current Pandemic.
Topics: Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Ceftriaxone; Chicago; Chronic Pain | 2020 |
COVID-19 infection in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Betacoronavirus; Blood Transfusion; Coronavirus I | 2020 |
COVID-19 infection in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Betacoronavirus; Blood Transfusion; Coronavirus I | 2020 |
COVID-19 infection in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Betacoronavirus; Blood Transfusion; Coronavirus I | 2020 |
COVID-19 infection in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Betacoronavirus; Blood Transfusion; Coronavirus I | 2020 |
COVID-19 in a high-risk dual heart and kidney transplant recipient.
Topics: Adenosine Monophosphate; Adult; Alanine; Betacoronavirus; Cardiomyopathy, Dilated; Coronavirus Infec | 2020 |
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
Topics: Antimalarials; Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Cardiotoxicity; Chloroquine; | 2020 |
Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS- | 2021 |
Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
Topics: COVID-19; Humans; Hydroxychloroquine; Rheumatic Diseases; Risk Factors; SARS-CoV-2 | 2021 |
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.
Topics: Adult; Agammaglobulinemia; Anti-Bacterial Agents; Betacoronavirus; Coronavirus Infections; COVID-19; | 2020 |
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).
Topics: Aged; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; COVID-19; Delivery of Health C | 2020 |
A case of SARS-CoV-2 pneumonia with successful antiviral therapy in a 77-year-old man with a heart transplant.
Topics: Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; | 2020 |
Topics: Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral | 2020 |
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.
Topics: Antimalarials; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2021 |
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
Topics: Antimalarials; Antirheumatic Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; C | 2020 |
Some drugs for COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiote | 2020 |
COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.
Topics: Aged; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Gluco | 2020 |
COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Comorbidity; Coronavirus Infec | 2020 |
Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Ele | 2020 |
G6PD deficiency in the COVID-19 pandemic: Ghost within Ghost.
Topics: Antimalarials; Antioxidants; COVID-19; COVID-19 Drug Treatment; Glucosephosphate Dehydrogenase Defic | 2021 |
Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Aquatic Organisms; Biological Products; Chloroqu | 2020 |
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Interactions; D | 2021 |
SLE patients are not immune to covid-19: importance of sending the right message across.
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV- | 2021 |
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' b
Topics: Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; | 2020 |
Against pandemic research exceptionalism.
Topics: Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloro | 2020 |
Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019.
Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqu | 2020 |
Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India?
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; India; Pandemics | 2020 |
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; | 2020 |
Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID | 2020 |
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
Topics: Azithromycin; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-1 | 2020 |
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Topics: Adult; Aged; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 2020 |
Patients with lupus are not protected from COVID-19.
Topics: COVID-19; Humans; Hydroxychloroquine; Immunosuppressive Agents; SARS-CoV-2 | 2021 |
COVID-19: an update on diagnostic and therapeutic approaches.
Topics: Betacoronavirus; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVI | 2020 |
Two distinct cases with COVID-19 in kidney transplant recipients.
Topics: Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Calcineurin Inhibitors; Coronavirus Infectio | 2020 |
Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
Topics: Antimalarials; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Co | 2020 |
Covid-19 treatment update: follow the scientific evidence.
Topics: Animals; Antiviral Agents; Betacoronavirus; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials | 2020 |
Hydroxychloroquine in Covid-19: Does the end justify the means?
Topics: Antibody Formation; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiovascular Diseases; Corona | 2020 |
Thoughts on COVID-19 and autoimmune diseases.
Topics: Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azetidines; Betacoronavirus; Chloroquine; Co | 2020 |
How to manage rheumatic patients during the coronavirus pandemic.
Topics: Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Di | 2020 |
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Azi | 2020 |
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Topics: Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavir | 2020 |
Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
Topics: Africa South of the Sahara; Anti-Inflammatory Agents; Antigen Presentation; Antimalarials; Antiviral | 2020 |
Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Malari | 2020 |
Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev
Topics: Antiviral Agents; Chloroquine; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Topics: Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroqui | 2020 |
The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Internet Searches for Unproven COVID-19 Therapies in the United States.
Topics: Betacoronavirus; Chloroquine; Consumer Health Information; Coronavirus Infections; COVID-19; COVID-1 | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19.
Topics: Adult; Azithromycin; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; CO | 2020 |
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, | 2020 |
Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Huma | 2020 |
Risks of hydroxychloroquine use for COVID-19 prophylaxis.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, | 2020 |
Response to: "Risks of hydroxychloroquine use for COVID-19 prophylaxis".
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, | 2020 |
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
Topics: Adult; Advisory Committees; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2020 |
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Topics: Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Hydr | 2020 |
"Reversed halo sign" on 3D CT in COVID-19.
Topics: Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Body Fluids; Coronavirus Infections; COVID- | 2020 |
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.
Topics: alpha-Glucosidases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infec | 2020 |
COVID-19 presenting with ophthalmoparesis from cranial nerve palsy.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Diplopia; Enzyme Inhibitors; Female; | 2020 |
COVID-19 and Fake News in the Dominican Republic.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Civil Disorders; | 2020 |
Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Coronavirus Infections; COVID-19; COVI | 2020 |
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Topics: Anti-Infective Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Death, Sudden, Cardiac; Dr | 2020 |
Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory.
Topics: Betacoronavirus; Blood Glucose; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Hyperg | 2020 |
Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatologic and rheumatologic patients already under treatment.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Betacoronavirus; Chronic Disease; Coronavirus Infect | 2020 |
Comment on: COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, | 2020 |
Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.
Topics: Aged; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
COVID-19 and Depression.
Topics: Anxiety; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Depression; Humans; Hydroxy | 2020 |
[Real-life data and Covid-19: The third avenue of reseach].
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug R | 2020 |
Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Blood Gas Analysi | 2020 |
[Potential harms associated with 4-aminoquinoline treatment].
Topics: Aminoquinolines; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infectio | 2020 |
Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Hydroxychloroquine; Pa | 2020 |
Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis.
Topics: Antimalarials; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2021 |
The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Topics: ADAM17 Protein; Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; | 2020 |
Discussing Evidence in the Fog of the Pandemic.
Topics: Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Treatment; Hydroxychloroquine; Pandemics; Randomiz | 2020 |
Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
Topics: Antineoplastic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychl | 2020 |
The Risks of Prescribing Hydroxychloroquine in COVID-19-Infected Patients With Schizophrenia.
Topics: Betacoronavirus; Contraindications, Drug; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqui | 2020 |
The COVID-19 Pandemic and Mayo Clinic Proceedings.
Topics: Adrenal Cortex Hormones; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2020 |
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Reposi | 2020 |
Respiratory Distress in Postanesthesia Care Unit: First Presentation of Coronavirus Disease 2019 in a 17-Year-Old Girl: A Case Report.
Topics: Adolescent; Airway Extubation; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus; Coronav | 2020 |
COVID-19: an unexpected indication for anti-rheumatic therapies?
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Ch | 2020 |
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Betacoronavirus; C-Reactive Protein; Coronav | 2020 |
COVID-19 and toxicity from potential treatments: Panacea or poison.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVI | 2020 |
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2020 |
Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Co | 2020 |
The Urgency of Care during the Covid-19 Pandemic - Learning as We Go.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Audio Interview: Studying Potential Covid-19 Therapies.
Topics: Adenosine Monophosphate; Alanine; Anti-Infective Agents; Azithromycin; Betacoronavirus; Controlled C | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.
Topics: Adult; Aged; Antirheumatic Agents; Betacoronavirus; Case-Control Studies; Coronavirus Infections; CO | 2020 |
The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.
Topics: Antimalarials; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatme | 2020 |
Case Report: Right Bundle Brunch Block and QTc Prolongation in a Patient with COVID-19 Treated with Hydroxychloroquine.
Topics: Betacoronavirus; Brunei; Bundle-Branch Block; Coronavirus Infections; COVID-19; Echocardiography; Fe | 2020 |
COVID-19 infection in children and adolescents with cancer in Madrid.
Topics: Adolescent; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Coronavirus Infections; COVI | 2020 |
Novel coronavirus 2019 (COVID-19): A case report and review of treatments.
Topics: Adenosine Monophosphate; Aged; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Clinical L | 2020 |
Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytochrom | 2020 |
Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; C-Reactive Pro | 2020 |
Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19).
Topics: Acute Generalized Exanthematous Pustulosis; Aged; COVID-19; COVID-19 Drug Treatment; Female; Humans; | 2020 |
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Emergencies | 2020 |
Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxych | 2020 |
Reactivation of COVID-19 pneumonia: A report of two cases.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Betacoronavirus; Coronavirus Infection | 2020 |
Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Drug Combinations; Female | 2020 |
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; | 2020 |
Biggest COVID-19 trial tests repurposed drugs first.
Topics: Adaptive Clinical Trials as Topic; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqu | 2020 |
Abdominal Visceral Infarction in 3 Patients with COVID-19.
Topics: Abdomen; Aged; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; | 2020 |
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Azathioprine; Betacoronavirus; Clinical Labora | 2020 |
[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bioethical Issues; Chloroquine; | 2020 |
In Vitro Data of Current Therapies for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID | 2020 |
[Brug af hydroxychloroquin til COVID-19].
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2020 |
Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Betacoronavirus; Chemoprevention; Coronavirus Infections | 2020 |
Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
Topics: Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 D | 2020 |
Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.
Topics: Aged; Biomarkers; C-Reactive Protein; Comorbidity; COVID-19; Female; Glucocorticoids; Heart Transpla | 2020 |
Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Betacoronavirus; Coronavirus Infections; | 2020 |
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Ceftriaxone; | 2020 |
No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit.
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV- | 2021 |
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Topics: Amino Acid Sequence; Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Betacoronaviru | 2020 |
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
Topics: Azithromycin; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Ther | 2020 |
COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm.
Topics: Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Enzyme Inhibitors; Huma | 2020 |
QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
Topics: Aged; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; C | 2020 |
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
Topics: Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dieta | 2020 |
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
Topics: Adolescent; Adult; Aged; Azithromycin; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatmen | 2021 |
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Coronavirus Infections; COVID-19; Fema | 2020 |
Dozens of coronavirus drugs are in development - what happens next?
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Coronavirus I | 2020 |
The emergence of methemoglobinemia amidst the COVID-19 pandemic.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Diabetes M | 2020 |
Acute meningoencephalitis in a patient with COVID-19.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronaviru | 2020 |
Emerging cardiological issues during the COVID-19 pandemic.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Coronary Artery Disease; Coronavirus Infect | 2020 |
COVID-19 infection also occurs in patients taking hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychl | 2020 |
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
Topics: China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Humans; Hydroxyc | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver | 2020 |
Steroid-Responsive Encephalitis in Coronavirus Disease 2019.
Topics: Akinetic Mutism; Antiviral Agents; beta 2-Microglobulin; Betacoronavirus; Coronavirus Infections; CO | 2020 |
Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?
Topics: Adult; Aged; Betacoronavirus; Bone Marrow; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Whatever Happened to Evidence-Based Practice During COVID-19?
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Practice; | 2020 |
Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Antiviral Agents; Azithromycin; Betacoronavirus; Coronav | 2020 |
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Decision- | 2020 |
Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre
Topics: Antimalarials; Arrhythmias, Cardiac; COVID-19; Humans; Hydroxychloroquine; Inflammation; Rheumatic D | 2021 |
Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
Topics: Antimalarials; Antirheumatic Agents; Arrhythmias, Cardiac; COVID-19; Humans; Hydroxychloroquine; Inf | 2021 |
[Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence].
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Eviden | 2020 |
Neuroleptic malignant syndrome in a COVID-19 patient.
Topics: Acute Kidney Injury; Antipsychotic Agents; Betacoronavirus; Bromocriptine; C-Reactive Protein; Coron | 2020 |
Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
Topics: Access to Information; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19 | 2020 |
Three Cases of COVID-19 Disease With Colonic Manifestations.
Topics: Adult; Aged; Anti-Bacterial Agents; Antimalarials; Astringents; Azithromycin; Betacoronavirus; Colit | 2020 |
The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Progressio | 2020 |
Lack of efficacy of hydroxychloroquine in covid-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Oxygen; Pandemics; Pn | 2020 |
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Betacoronavi | 2020 |
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
Topics: Anti-Bacterial Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy | 2020 |
COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coro | 2020 |
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev
Topics: COVID-19; Humans; Hydroxychloroquine; Intensive Care Units; Rheumatic Diseases; SARS-CoV-2 | 2021 |
SARS-CoV-2 infection in Spanish children with chronic kidney pathologies.
Topics: Adolescent; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Coronavirus Infections; COVI | 2020 |
Covid-19 and exacerbation of psoriasis.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19.
Topics: Acute Kidney Injury; Autophagy; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Crit | 2020 |
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection.
Topics: Aged; Aged, 80 and over; Antimalarials; Antiviral Agents; Coronavirus Infections; COVID-19; Female; | 2020 |
COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topi | 2020 |
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Death, Sudden, Ca | 2020 |
The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
Topics: Adrenal Cortex Hormones; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hyd | 2020 |
COVID-19 and QT interval prolongation: more than just drug toxicity?
Topics: Adrenergic beta-Agonists; Aged; Anti-Infective Agents; Azithromycin; Betacoronavirus; Clinical Labor | 2020 |
COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults.
Topics: Aged; Aged, 80 and over; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19 | 2020 |
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.
Topics: Azithromycin; Cardiotoxicity; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Electrocardiogr | 2020 |
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Betacoronavirus; Coronavirus | 2020 |
Trials and tribulations: so many potential treatments, so few answers.
Topics: Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19.
Topics: Acetic Acid; Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVI | 2020 |
Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid.
Topics: Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female; Hu | 2020 |
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; Drug Therapy, Combination; Female; Gr | 2020 |
Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
Topics: Antimalarials; Betacoronavirus; Bone Density Conservation Agents; Contraindications, Drug; Coronavir | 2020 |
Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed.
Topics: Age Factors; Antiviral Agents; Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; H | 2020 |
Are patients with systemic lupus erythematosus at increased risk for COVID-19?
Topics: Coronavirus; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV-2 | 2021 |
Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV-2 | 2021 |
Dr. Balevic,
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Evidence of Protective Effect of Hydroxychloroquine on COVID-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
Topics: Adult; Aged; Antitubercular Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Labora | 2020 |
Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.
Topics: Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination | 2020 |
Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Dr | 2020 |
Audio Interview: New Data on Remdesivir in Covid-19.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug C | 2020 |
Navigating COVID-19 in the developing world.
Topics: Antirheumatic Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Delivery of He | 2020 |
Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Topics: Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.
Topics: Antihypertensive Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Utiliz | 2020 |
Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical - Paraclinical follow up study of a case.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Atazanavir Sulfate; Betacoronavirus; Brain; Conscious | 2020 |
World War against COVID-19: How strong is our armamentarium?
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serothe | 2020 |
A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois.
Topics: Adult; Antiretroviral Therapy, Highly Active; Azithromycin; Betacoronavirus; CD4 Lymphocyte Count; C | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
The Rediscovery of Hydroxychloroquine in Allergic Diseases in the COVID-19 Era.
Topics: Adult; Anti-Allergic Agents; Antiviral Agents; Conjunctivitis, Allergic; COVID-19; COVID-19 Drug Tre | 2021 |
Risk of using hydroxychloroquine as a treatment of COVID-19.
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dose-Resp | 2020 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; France; Hu | 2020 |
Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices.
Topics: Adult; Aged; Betacoronavirus; Chromatography, Liquid; Coronavirus Infections; COVID-19; Drug Monitor | 2020 |
Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Patients with lupus with COVID-19: University of Michigan experience.
Topics: Arthritis, Rheumatoid; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; | 2020 |
Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin.
Topics: Azithromycin; COVID-19; Humans; Hydroxychloroquine; Incidence; Long QT Syndrome; Pandemics; Patients | 2020 |
Safety fears over drug hyped to treat the coronavirus spark global confusion.
Topics: Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Global Health; Humans; Hydr | 2020 |
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
Topics: Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Electrocardio | 2020 |
HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.
Topics: Adult; Antiviral Agents; Coronavirus Infections; COVID-19; Cross-Sectional Studies; Female; Health P | 2020 |
Characteristics of the initial patients hospitalized for COVID-19: a single-center report
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2020 |
Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Audio Interview: Diagnosis and Early Treatment of Covid-19.
Topics: Betacoronavirus; Chemoprevention; Clinical Studies as Topic; Coronavirus Infections; COVID-19; Healt | 2020 |
A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Betacoronavirus; Coronavirus Infections; COVID-19; D | 2020 |
Severe acute dried gangrene in COVID-19 infection: a case report.
Topics: Acute Disease; Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disseminat | 2020 |
Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?
Topics: COVID-19; COVID-19 Drug Treatment; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Hyd | 2021 |
SARS-CoV-2 Gastrointestinal Infection Causing Hemorrhagic Colitis: Implications for Detection and Transmission of COVID-19 Disease.
Topics: Aged; Antimalarials; Betacoronavirus; Colitis; Colonoscopy; Coronavirus Infections; COVID-19; Diagno | 2020 |
A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
Topics: Aged; Azithromycin; Betacoronavirus; Blood Transfusion; Continuous Renal Replacement Therapy; Corona | 2020 |
Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Resist | 2020 |
The pandemic's first major research scandal erupts.
Topics: Antimalarials; Arrhythmias, Cardiac; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Dat | 2020 |
Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase-deficient patient with COVID-19 infection.
Topics: COVID-19; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Huma | 2020 |
Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antivira | 2020 |
Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Drug | 2020 |
Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adolescent; Adult; Alanine; Antiviral Agents; Child; Child, Preschool; Coro | 2020 |
Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19.
Topics: Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; Hyd | 2020 |
SARS-CoV-2 infection in a highly experienced person living with HIV.
Topics: Aged; Anti-Bacterial Agents; Anti-HIV Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Co | 2020 |
Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Prescriptions; Elec | 2020 |
Response to: 'COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases' by Lopez-Medina
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics; Rheumatic Diseases; | 2021 |
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, | 2020 |
The coronavirus outbreak could make it quicker and easier to trial drugs.
Topics: Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Development; Drug | 2020 |
A case of subacute thyroiditis associated with Covid-19 infection.
Topics: Adult; Anti-Inflammatory Agents; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; C | 2020 |
Covid-19 and lung cancer: A greater fatality rate?
Topics: Aged; Aged, 80 and over; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Cross Infe | 2020 |
COVID-19 in lung transplant recipients: A case series from Milan, Italy.
Topics: Aged; Anti-Bacterial Agents; Anticoagulants; Blood Gas Analysis; COVID-19; COVID-19 Drug Treatment; | 2020 |
Clinically significant anticardiolipin antibodies associated with COVID-19.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiphospholi | 2020 |
Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak.
Topics: COVID-19; Disease Outbreaks; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Response to: 'Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak' by Holubar
Topics: COVID-19; Disease Outbreaks; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study.
Topics: Acute Kidney Injury; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic.
Topics: Adult; Coronavirus Infections; COVID-19; Diazepam; Drug Overdose; Drug-Related Side Effects and Adve | 2020 |
Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China.
Topics: Adolescent; Adult; Aged; Antibodies, Viral; Ascorbic Acid; Betacoronavirus; China; Coronavirus Infec | 2020 |
Coronavirus disease 2019 in pregnancy: early lessons.
Topics: Acute Kidney Injury; Adult; Anesthesia, General; Anti-Bacterial Agents; Antihypertensive Agents; Azi | 2020 |
Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
Topics: Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatmen | 2020 |
Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
Topics: Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatment; Endosomes; Humans; Hydrogen-Ion Concentra | 2020 |
[Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19].
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Erythe | 2020 |
Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; | 2020 |
Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Antirheumatic Agents; Betacoronavirus; Coronavirus | 2020 |
Acute maculopapular eruption in Covid-19 patient: A case report.
Topics: Adult; Antibodies, Monoclonal, Humanized; COVID-19; Histamine Antagonists; Hospitalization; Humans; | 2020 |
Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.
Topics: Antiviral Agents; COVID-19; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hydroxy | 2020 |
Big studies dim hopes for hydroxychloroquine.
Topics: Antimalarials; Big Data; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pn | 2020 |
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous.
Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Culture; Endp | 2020 |
Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.
Topics: Anti-Infective Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Biological Availability; Cor | 2020 |
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Topics: Adenosine Monophosphate; Alanine; Anticoagulants; Antiviral Agents; Biomarkers; Coronavirus Infectio | 2020 |
Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
Topics: Aged; Anti-Inflammatory Agents; Anticoagulants; Antihypertensive Agents; Azithromycin; Combined Moda | 2020 |
Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.
Topics: Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B; Azithromycin; Coronavirus Infe | 2020 |
Pharmacist's perspective on HCQ treatment of COVID-19.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Hospital Pharmacy Compounding against COVID-19 pandemic.
Topics: Administration, Oral; Antiviral Agents; Betacoronavirus; Blood Component Transfusion; Coronavirus In | 2020 |
Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient.
Topics: Aged; Anti-Bacterial Agents; Anticoagulants; Antimalarials; Azithromycin; Betacoronavirus; Ceftriaxo | 2020 |
Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Topics: Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Fem | 2021 |
Living evidence in response to controversies about the use of antimalarials in COVID-19.
Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; | 2020 |
A case of COVID-19 infection presenting with a seizure following severe brain edema.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Anticonvulsants; Azithromycin; Betacoronavirus; Brain | 2020 |
Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing.
Topics: Ambulatory Care; Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Presc | 2020 |
Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antiviral Agents; COVID-19; COVID-19 Drug Treatme | 2020 |
Comment on "Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine": Report of a COVID-19 patient with particular findings.
Topics: COVID-19; Erythema; Humans; Hydroxychloroquine; Pharmaceutical Preparations; SARS-CoV-2 | 2020 |
COVID-19 research: an opinion piece.
Topics: Anti-Retroviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug R | 2020 |
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
Topics: Adjuvants, Immunologic; Adult; Aged; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus I | 2020 |
Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
COVID-19 and hydroxychloroquine: Is the wonder drug failing?
Topics: Antimalarials; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
COVID-19, severe asthma, and biologics.
Topics: Acetates; Adrenergic beta-2 Receptor Antagonists; Amoxicillin-Potassium Clavulanate Combination; Ant | 2020 |
Cerebral Venous Thrombosis Associated with COVID-19.
Topics: Adult; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fem | 2020 |
The first case of COVID-19 pneumonia in a hemodialysis patient in Japan.
Topics: Aged; Anti-Infective Agents; Anticoagulants; Combined Modality Therapy; Comorbidity; Coronavirus Inf | 2020 |
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.
Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Brugada Syndrome; Ceftriaxone; Clinical Laborato | 2020 |
A case of an Infant with SARS-CoV-2 hepatitis early after liver transplantation.
Topics: Biliary Atresia; COVID-19; COVID-19 Testing; Female; Graft Rejection; Humans; Hydroxychloroquine; Im | 2020 |
Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy.
Topics: Adolescent; Adult; Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dr | 2020 |
Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
Topics: Administration, Oral; Aged; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; Blood Comp | 2020 |
Facts, not Fear: Safety of Hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Agranulocytosis; Anemia, Aplastic; Antirheumatic Agents; | 2020 |
COVID-19 in patients with lung cancer.
Topics: Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Betacoronavirus; Coronavirus Infections; COVID-19; CO | 2020 |
Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.
Topics: Antimalarials; Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli
Topics: Antimalarials; Arthritis, Rheumatoid; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combi | 2020 |
Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Delive | 2020 |
Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female | 2020 |
Fatal SARS-CoV-2 infection in a renal transplant recipient.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Deterioration; Coronavirus Infections; COV | 2020 |
Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.
Topics: Antiviral Agents; Comorbidity; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immuno | 2020 |
A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infec | 2020 |
Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie
Topics: Antimalarials; COVID-19; Humans; Hydroxychloroquine; Rheumatic Diseases; SARS-CoV-2 | 2021 |
COVID-19 pneumonia in kidney transplant recipients: Focus on immunosuppression management.
Topics: Acute Kidney Injury; Adult; Aged; Azithromycin; Calcineurin Inhibitors; COVID-19; COVID-19 Nucleic A | 2020 |
SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; Drug Thera | 2020 |
Heart transplant recipient patient with COVID-19 treated with tocilizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Cardiomyopathy, Dilated; C | 2020 |
Considerations of Managing Lichen Planopilaris With Hydroxychloroquine During the COVID-19 Pandemic.
Topics: Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Iran; Lichen Planus; Pandemics; Pneumo | 2020 |
Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
Topics: Antimalarials; COVID-19; Humans; Hydroxychloroquine; Interferon Type I; Nebulizers and Vaporizers; S | 2020 |
Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.
Topics: Aged; Anemia; Anticoagulants; Anticonvulsants; Antiviral Agents; Betacoronavirus; Calcium Channel Bl | 2020 |
Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience.
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Latin America; Pandemics; Rheumatic Dise | 2021 |
Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge.
Topics: Acute Kidney Injury; Ambulatory Care; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Azit | 2020 |
COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan.
Topics: Aged; Aged, 80 and over; Azithromycin; Coronavirus Infections; COVID-19; Diabetes Complications; Fem | 2020 |
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Azithromycin; Betaco | 2020 |
QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
[Therapeutic conflict in patients with COVID-19 and glaucoma].
Topics: Adrenergic beta-Antagonists; Antimalarials; Betacoronavirus; Bioaccumulation; Bradycardia; Coronavir | 2020 |
Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.
Topics: Blood Glucose; COVID-19; COVID-19 Drug Treatment; Diabetes Complications; Diabetes Mellitus; Glycemi | 2021 |
SARS-CoV-2 infection in kidney transplant recipients: Early report of five cases.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydr | 2021 |
Optimizing Medication Management During the COVID-19 Pandemic: It Takes a Village.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy; H | 2020 |
Imatinib for COVID-19: A case report.
Topics: Adult; Betacoronavirus; Biomarkers; C-Reactive Protein; Coronavirus Infections; COVID-19; Drug Combi | 2020 |
Chloroquine and COVID-19: A western medical and scientific drift?
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question.
Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; | 2020 |
Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis.
Topics: Chronic Disease; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Recurrence; Sarcoidosis | 2021 |
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Az | 2020 |
COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020.
Topics: Adult; Antimalarials; Coronavirus Infections; COVID-19; France; Humans; Hydroxychloroquine; Male; Pa | 2020 |
Effects of hydroxychloroquine treatment on QT interval.
Topics: Antirheumatic Agents; Atrial Fibrillation; Betacoronavirus; Coronavirus Infections; COVID-19; Drug M | 2020 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; A | 2020 |
Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.
Topics: Adult; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Hu | 2020 |
COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic.
Topics: COVID-19; Humans; Hydroxychloroquine; Pandemics; Rheumatic Diseases; Rheumatology; SARS-CoV-2 | 2021 |
Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19.
Topics: Adolescent; Adult; Antimalarials; Betacoronavirus; Case-Control Studies; Coronavirus Infections; COV | 2020 |
Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; | 2021 |
Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Child; Clinical Laborato | 2020 |
Idiopathic nonhistaminergic acquired angioedema in a patient with coronavirus disease 2019.
Topics: Adenosine Monophosphate; Adult; Alanine; Ampicillin; Angioedema; Betacoronavirus; Coronavirus Infect | 2020 |
Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
Topics: Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug | 2020 |
Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.
Topics: Aged; Antibodies, Neutralizing; Antiviral Agents; Betacoronavirus; Blood Grouping and Crossmatching; | 2020 |
US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; | 2020 |
Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cyt | 2020 |
Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease?
Topics: Acute Chest Syndrome; Adult; Analgesics; Anemia, Sickle Cell; Antiviral Agents; Azithromycin; Betaco | 2020 |
Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.
Topics: Betacoronavirus; Binding Sites; Catalytic Domain; Coronavirus 3C Proteases; Coronavirus Infections; | 2020 |
COVID-19 Clinical Trials: Unraveling a Methodological Gordian Knot.
Topics: Antimalarials; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Dexameth | 2020 |
Have the symptoms of patients with COVID-19 changed over time during hospitalization?
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Coronavirus Infections; Cough; COVID-19; Diar | 2020 |
Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Topics: Antimalarials; Betacoronavirus; Chloroquine; Contraindications, Drug; Coronavirus Infections; COVID- | 2020 |
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Topics: Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Concentration-dependent mortality of chloroquine in overdose.
Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus | 2020 |
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Topics: Acute Disease; Aged; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Azithromycin; | 2020 |
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
Topics: Adult; Aged; Antimalarials; Antiviral Agents; Arthritis, Rheumatoid; COVID-19; Drug Administration S | 2021 |
COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID- | 2020 |
U.K. megatrial outshines other drug studies.
Topics: Anti-Inflammatory Agents; Antimalarials; Coronavirus Infections; COVID-19; Dexamethasone; Humans; Hy | 2020 |
Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?
Topics: Antimalarials; Chloroquine; COVID-19; Fear; Humans; Hydroxychloroquine | 2022 |
Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Moreno
Topics: Antimalarials; Chloroquine; COVID-19; Fear; Humans; Hydroxychloroquine | 2022 |
Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.
Topics: Awareness; Betacoronavirus; Clinical Decision-Making; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
Covid-19: A systemic disease treated with a wide-ranging approach: A case report.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Azithromycin; China; Coronavirus Infecti | 2020 |
Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glucosephosphate Dehydro | 2020 |
Persistently positive severe acute respiratory syndrome coronavirus 2 (SARS-COV2) nasopharyngeal PCR in a kidney transplant recipient.
Topics: Adult; COVID-19; Female; Glomerulosclerosis, Focal Segmental; Humans; Hydroxychloroquine; Immunocomp | 2020 |
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
Topics: Aged; Coronavirus Infections; COVID-19; Critical Illness; Drug Combinations; Female; Humans; Hydroxy | 2020 |
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
Topics: Age Distribution; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Coronavirus Inf | 2020 |
Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
Topics: Aging; Antiviral Agents; BCG Vaccine; Chemoprevention; Chloroquine; Coronavirus Infections; COVID-19 | 2020 |
Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
[Cardiovascular safety of hydroxychloroquine in the COVID-19 pandemic].
Topics: Betacoronavirus; Cardiology; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; | 2020 |
[Cardiac adverse effects of hydroxychloroquine and the need for tests].
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
The use of IV vitamin C for patients with COVID-19: a case series.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anti | 2020 |
Management of crash and burn patients with SARS-CoV-2 associated ARDS.
Topics: Adult Stem Cells; Angiotensin-Converting Enzyme 2; Azithromycin; Blood Component Transfusion; COVID- | 2020 |
Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics | 2021 |
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India.
Topics: COVID-19; Humans; Hydroxychloroquine; India; Lupus Erythematosus, Systemic; Pandemics; SARS-CoV-2 | 2021 |
FDG PET/CT evaluation of a patient recovering from COVID-19.
Topics: Albumins; Betacoronavirus; Budesonide; Clinical Laboratory Techniques; Convalescence; Coronavirus In | 2020 |
Topics: COVID-19; Humans; Hydroxychloroquine; Patients; SARS-CoV-2 | 2020 |
The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; H | 2020 |
Cancer Progression Is Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
Clinical improvement of severe COVID-19 pneumonia in a pregnant patient after caesarean delivery.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Ceft | 2020 |
COVID-19, hydroxychloroquine and the eighth alternative.
Topics: Antimalarials; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, V | 2020 |
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Darunavir; Electrocard | 2021 |
Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antimalarials; Betacoronavirus; Coronavirus Infections; | 2020 |
Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug R | 2020 |
SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view.
Topics: Aged; Axitinib; Azithromycin; Betacoronavirus; Carcinoid Tumor; Comorbidity; Coronavirus Infections; | 2020 |
Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data
Topics: Age Factors; Aged; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cross-Sectiona | 2021 |
Risch Responds to "How to Consider Low Reported Death Rates in COVID-19".
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin?
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Thera | 2020 |
RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS".
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019.
Topics: Adolescent; Anti-Infective Agents; Azithromycin; Child; Coronavirus Infections; COVID-19; Electrocar | 2020 |
Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimalarials; Azithromycin; COVID-19; COVID- | 2021 |
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betaco | 2020 |
Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.
Topics: Aged; Antimalarials; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Mi | 2021 |
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; SARS | 2021 |
Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.
Topics: Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fe | 2020 |
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Topics: Animals; Azithromycin; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; COVI | 2020 |
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Betacoronavirus; Clinical Decision-Making; Coro | 2020 |
Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
Topics: Adult; Aged; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; | 2020 |
Hydroxychloroquine-Associated Thrombotic Thrombocytopenic Purpura
Topics: ADAMTS13 Protein; Aged; Angiography; COVID-19; Humans; Hydroxychloroquine; Male; Plasmapheresis; Pul | 2020 |
High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; | 2020 |
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine.
Topics: Acetylcysteine; Adult; Antioxidants; Antirheumatic Agents; Betacoronavirus; Biomarkers; C-Reactive P | 2020 |
A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece.
Topics: Anti-Bacterial Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Coronavirus Infections; COVID-19; | 2020 |
COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Betacoronavirus; Cor | 2020 |
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Bin | 2020 |
Medication utilization in patients in New York hospitals during the COVID-19 pandemic.
Topics: Antiviral Agents; Coronavirus Infections; COVID-19; Drug Industry; Drug Utilization; Health Facility | 2020 |
Chloroquine in fighting COVID-19: good, bad, or both?
Topics: Autophagy; Cardiovascular Diseases; China; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 | 2020 |
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiv | 2020 |
A Case of 45-Year Man Who Succumbed to Coronavirus Disease 2019 (COVID-19).
Topics: Anti-Bacterial Agents; Anticoagulants; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus; | 2020 |
Diarrhoea: An Atypical Presentation of COVID-19.
Topics: Azithromycin; Betacoronavirus; Coronavirus; Coronavirus Infections; Cough; COVID-19; Diarrhea; Femal | 2020 |
COVID-19 Pulmonary Infection with Pneumothorax in a Young Patient.
Topics: Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus; | 2020 |
CT Scan Findings of Five Mildly Symptomatic COVID Patients from India.
Topics: Azithromycin; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydrox | 2020 |
Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
End-stage heart failure secondary to low-dose hydroxychloroquine treatment.
Topics: COVID-19; Heart Failure; Humans; Hydroxychloroquine | 2021 |
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Description of 3 patients with myasthenia gravis and COVID-19.
Topics: Adult; Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Case-Control S | 2020 |
Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs.
Topics: Azithromycin; Bayes Theorem; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatm | 2020 |
The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug R | 2020 |
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Topics: Amino Acid Motifs; Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Betacoronavirus; | 2020 |
Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; Drug A | 2020 |
Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19".
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dust; Huma | 2020 |
Hydroxychloroquin for COVID-19 Why was so much hype?
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Clinical Laboratory Tech | 2020 |
COVID-19 reveals Brugada pattern in an adolescent patient.
Topics: Antiviral Agents; Brugada Syndrome; C-Reactive Protein; Chest Pain; Consanguinity; Cough; COVID-19; | 2020 |
Searching for COVID-19 treatments: First, do no harm.
Topics: Antiviral Agents; Azithromycin; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repo | 2020 |
Auditory Cinchonism in COVID Era.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Communicating Science in the Time of a Pandemic.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Communication; Coronavirus Infe | 2020 |
[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
Topics: Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID- | 2020 |
Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronaviru | 2020 |
Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Age | 2020 |
Inpatient Care during the COVID-19 Pandemic: A Survey of Italian Physicians.
Topics: Adult; Aged; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Betacoronavirus; | 2020 |
Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idio | 2021 |
SARS CoV-2 infection among patients using immunomodulatory therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized | 2021 |
Hydroxychloroquine is no miracle cure for covid-19 infection -imaging and clinical course in an elderly female.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hy | 2020 |
Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocol | 2020 |
Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.
Topics: Adult; Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Comorbidity; Coronavirus Infections; C | 2020 |
Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
Topics: Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV- | 2021 |
Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).
Topics: Anemia; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hu | 2020 |
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, | 2021 |
Possible synergistic effects of hydroxychloroquine and steroids in COVID-19, time for a nuanced approach. Comment on Arshad et al.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Hydroxychloroquine in COVID-19: Taking care of statistics to take care of patients.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coinfe | 2020 |
Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.
Topics: Angiotensin-Converting Enzyme 2; Biflavonoids; Binding Sites; Catechin; Computational Biology; COVID | 2021 |
Hilar lymphadenopathy, a novel finding in the setting of coronavirus disease (COVID-19): a case report.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Enzyme Inhibitors; Female; Humans; Hydroxyc | 2020 |
Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality].
Topics: Adrenal Cortex Hormones; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2020 |
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.
Topics: Anti-Inflammatory Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Health | 2020 |
Glucocorticoid-Induced Bacterial Endocarditis in COVID-19 Pneumonia - Something to Be Concerned About?
Topics: Aged; Anti-Bacterial Agents; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; COVID-1 | 2020 |
Hydroxychloroquine for COVID-19: Myths vs facts.
Topics: COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroquine; SARS-CoV-2 | 2020 |
Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
Topics: Aged; Antibodies, Monoclonal, Humanized; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; | 2020 |
Evaluation of retinotoxicity of COVID-19 treatment: Hydroxychloroquine and lopinavir/ritonavir.
Topics: Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Drug Co | 2021 |
Saudi Society of Maternal-Fetal Medicine guidance on pregnancy and coronavirus disease 2019.
Topics: Anticoagulants; Antiviral Agents; Betacoronavirus; Congenital Abnormalities; Coronavirus Infections; | 2020 |
Scarcity of Hydroxychloroquine and Personal Protective Equipment (PPE) during Challenging Times of COVID-19 Pandemic.
Topics: COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Humans; Hydroxychloroquine; Infection Control; | 2020 |
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azithr | 2020 |
Trust in the Time of COVID-19.
Topics: Antimalarials; COVID-19; Humans; Hydroxychloroquine; Practice Patterns, Physicians'; SARS-CoV-2; Tru | 2020 |
Implications of SARS-CoV-2 infection for patients with rheumatic disease.
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Rheumatic Diseases; SARS-CoV-2 | 2022 |
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agen | 2020 |
A Patient With Bilateral Conjunctivitis Positive for SARS-CoV-2 RNA in a Conjunctival Sample.
Topics: Administration, Ophthalmic; Administration, Oral; Adult; Antirheumatic Agents; Antiviral Agents; Con | 2021 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
Factors associated with hospital admission for COVID-19 in HIV patients.
Topics: Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coronavirus Infections; COVID-19; Female; H | 2020 |
Airway Hygiene in COVID-19 Pneumonia: Treatment Responses of 3 Critically Ill Cruise Ship Employees.
Topics: Aged; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Tr | 2020 |
On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Death; Chlorocebus aethiops; Coronavirus Infections | 2020 |
Case Report: COVID-19 Recovery from Triple Infection with
Topics: Adult; Antitubercular Agents; Antiviral Agents; Betacoronavirus; Coinfection; Convalescence; Coronav | 2020 |
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimal | 2020 |
Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glucosephos | 2020 |
New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Envelope Proteins; Coronavirus Infection | 2020 |
A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island.
Topics: Adrenal Cortex Hormones; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combin | 2020 |
Melkersson-Rosenthal Syndrome Induced by COVID-19.
Topics: Adrenal Cortex Hormones; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug The | 2021 |
Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain.
Topics: Adult; Biological Therapy; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Dyspnea; Fema | 2021 |
COVID-19 in a young liver transplant recipient: caution for drug-drug interactions.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coron | 2020 |
Questions asked through two examples of dilemmas of publication ethics in the process of COVID-19.
Topics: Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqui | 2020 |
Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.
Topics: Antimalarials; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; COVID-1 | 2020 |
Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pregnancy; SARS-CoV-2 | 2021 |
Targeting NLRP3 inflammasome in an animal model for Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; COVID-19; Humans; Hydroxychloroquine; Inflammasomes; Middle East Respiratory Syndrome Coron | 2021 |
First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug C | 2020 |
Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.
Topics: Aged; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Comorbidity; Coronavirus | 2020 |
Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumat | 2020 |
Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients.
Topics: Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus.
Topics: Antibody Formation; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Huma | 2020 |
Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2020 |
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Betacoronavirus; C-Reactive Protein; Coro | 2020 |
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Topics: Aged; Anti-Infective Agents; Azithromycin; Betacoronavirus; Biomarkers; Coronavirus Infections; COVI | 2020 |
Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States.
Topics: Adult; Aged; Comorbidity; COVID-19; Hospitalization; Humans; Hydroxychloroquine; Male; Respiration, | 2021 |
Neutropenic fever in COVID-19 in kidney transplant patient.
Topics: Adult; Azithromycin; Cefepime; COVID-19; COVID-19 Drug Treatment; Febrile Neutropenia; Female; Human | 2021 |
Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Cohort Studies; COVID-19; Female; Humans; Hydroxychlo | 2020 |
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Therapy, | 2020 |
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.
Topics: Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Female; Hospital Mortality; Humans; Hydr | 2020 |
Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; France; Hospitalization; Humans; Hydroxychloroquine; | 2023 |
Flexibilization of Science, Cognitive Biases, and the COVID-19 Pandemic.
Topics: Azithromycin; Betacoronavirus; Bias; Cognitive Science; Coronavirus Infections; COVID-19; COVID-19 D | 2020 |
The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dust; Humans; Hydroxychl | 2020 |
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Topics: Amino Acid Sequence; Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Betacoronaviru | 2020 |
Reply to: "QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights".
Topics: Arrhythmias, Cardiac; Azithromycin; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pharmacogenetic | 2020 |
Characteristics and Management of Children with COVID-19 in Turkey
Topics: Adolescent; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Coron | 2020 |
SARS-CoV-2 infection: diagnostic testing results occasionally require special attention.
Topics: Antibodies, Viral; Betacoronavirus; Coronavirus Infections; COVID-19; Enzyme-Linked Immunosorbent As | 2020 |
Will Evidence-based Medicine Survive the COVID-19 Pandemic?
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Me | 2020 |
Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
Topics: Betacoronavirus; Compassionate Use Trials; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights.
Topics: Azithromycin; COVID-19; Humans; Hydroxychloroquine; Incidence; Long QT Syndrome; Pandemics; Pharmaco | 2020 |
Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib.
Topics: Aged; Anaplastic Lymphoma Kinase; Anti-HIV Agents; Betacoronavirus; Carbazoles; Carcinoma, Non-Small | 2020 |
Viral exanthema as manifestation of SARS-CoV-2 infection: A case report.
Topics: Administration, Topical; Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory | 2020 |
[Skin manifestations associated with the new coronavirus SARS-CoV-2 disease].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Betacoronavirus; Betamethasone; Causalit | 2020 |
An infection-oriented approach for thoracic endovascular aortic repair in a SARS-CoV-2 positive patient. A case report.
Topics: Anesthesia, Local; Antibiotic Prophylaxis; Anticoagulants; Antiviral Agents; Aortic Aneurysm, Thorac | 2020 |
Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.
Topics: Antimalarials; Brazil; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Human | 2020 |
Urticarial vasculitis in a COVID-19 recovered patient.
Topics: Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Histamine Antago | 2020 |
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
Response to 'Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic' by Chuah
Topics: COVID-19; Hospitalization; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics; Ter | 2022 |
Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect?
Topics: Aged; Anti-Infective Agents; Anticoagulants; Azithromycin; Cardiac Surgical Procedures; Combined Mod | 2020 |
COVID-19 Outcomes Among Solid Organ Transplant Recipients: A Case-control Study.
Topics: Aged; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Orga | 2021 |
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Benzamidines; Betacoronavirus; Coro | 2020 |
Chest Computed Tomography Findings in Asymptomatic Patients with COVID-19.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Bronchiectasis; Bronchioles; Bro | 2020 |
Therapeutic delivery: industry update covering June 2020.
Topics: Antibodies, Monoclonal; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Delivery Systems; Dru | 2020 |
Response to: 'Implications of SARS-CoV-2 infection for patients with rheumatic disease' by Lin
Topics: COVID-19; Humans; Hydroxychloroquine; Rheumatic Diseases; SARS-CoV-2 | 2022 |
Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.
Topics: Anti-Retroviral Agents; Betacoronavirus; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Posit | 2020 |
Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda.
Topics: Adult; Age Factors; Betacoronavirus; Body Mass Index; Cohort Studies; Coronavirus Infections; COVID- | 2020 |
Alopecia areata in a patient with SARS-Cov-2 infection.
Topics: Alopecia Areata; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Host-Pathogen Interact | 2020 |
Unexplained Methemoglobinemia in Coronavirus Disease 2019: A Case Report.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Antioxidants; Ascorbic Acid; Betacoron | 2020 |
First-time Diabetic Ketoacidosis in Type 2 Diabetics With Covid-19 Infection: A Novel Case Series.
Topics: Anti-Bacterial Agents; COVID-19; Crystalloid Solutions; Diabetes Mellitus, Type 2; Diabetic Ketoacid | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; | 2020 |
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus Infec | 2020 |
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Autophagy; Betacoronaviru | 2020 |
Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials.
Topics: Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; | 2020 |
Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19.
Topics: Aged, 80 and over; Betacoronavirus; Bradycardia; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azithromycin; Cell Line, Tumor; Cisplatin; | 2020 |
Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
Topics: Anti-Infective Agents; Betacoronavirus; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19; | 2020 |
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19.
Topics: Aged; Aged, 80 and over; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; | 2020 |
COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients.
Topics: Adult; Antirheumatic Agents; Betacoronavirus; Clinical Laboratory Techniques; Communicable Disease C | 2020 |
Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; COVID-19; Female; Humans; Hydroxychloroquine; Ma | 2021 |
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients.
Topics: Azithromycin; Betacoronavirus; Cell Membrane Permeability; Coronavirus Infections; COVID-19; COVID-1 | 2020 |
Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection.
Topics: Action Potentials; Aged; Antiviral Agents; Arrhythmias, Cardiac; Cardiotoxicity; Coronavirus Infecti | 2020 |
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
Topics: Aged; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Cohort Studies; Coronavir | 2020 |
Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.
Topics: Azithromycin; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
Topics: Aged; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; C | 2020 |
Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Cli | 2020 |
Hydroxychloroquine for prophylaxis of COVID-19 physicians survey: Despite lack of evidence, many would take or give to dear ones, and despite the perceived necessity of an RCT, few would participate.
Topics: Antiviral Agents; Attitude of Health Personnel; Clinical Competence; COVID-19; COVID-19 Drug Treatme | 2020 |
Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimalarials; Azithromycin; COVID-19; Drug Therapy, | 2021 |
Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus; F | 2020 |
Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report.
Topics: Adult; Antiviral Agents; Betacoronavirus; Blood Chemical Analysis; Coronavirus Infections; COVID-19; | 2020 |
Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
Topics: Betacoronavirus; Catalytic Domain; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; CO | 2020 |
Hydroxychloroquine early in pregnancy and risk of birth defects.
Topics: Abnormalities, Drug-Induced; Adult; COVID-19; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnan | 2021 |
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Topics: Adult; Aged; Antimalarials; Cardiovascular Diseases; Chloroquine; COVID-19; COVID-19 Drug Treatment; | 2021 |
Unfolding of sickle cell trait by coronavirus disease 2019 (COVID-19) infection.
Topics: Adrenal Cortex Hormones; Anticoagulants; Azithromycin; Combined Modality Therapy; COVID-19; COVID-19 | 2020 |
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Antirheu | 2020 |
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Biological Availability; Coronavirus Infections; COVI | 2020 |
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical | 2021 |
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
Topics: Arrhythmias, Cardiac; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; Hydrox | 2020 |
Thrombotic microangiopathy: COVID-19 or hydroxychloroquine?
Topics: COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2; Thrombotic Microangiopathies | 2020 |
SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus.
Topics: Adult; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Dyspnea; | 2020 |
Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.
Topics: Azithromycin; COVID-19; Drug Therapy, Combination; Hospitalization; Humans; Hydroxychloroquine; SARS | 2021 |
Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course.
Topics: Antimalarials; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Foreca | 2021 |
Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.
Topics: Azithromycin; COVID-19; Drug Therapy, Combination; Hospitalization; Humans; Hydroxychloroquine; SARS | 2021 |
The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study.
Topics: Adult; Aged; Ambulatory Care; Antirheumatic Agents; Arab World; Betacoronavirus; Coronavirus Infecti | 2020 |
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients.
Topics: Adult; Coronavirus Infections; COVID-19; Enzyme Inhibitors; Female; Hospital Mortality; Humans; Hydr | 2020 |
Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therap | 2020 |
Revisiting the cardiovascular risk of hydroxychloroquine in RA.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Arthritis, Rheumatoid; Azithromycin; Ca | 2020 |
Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
Topics: Action Potentials; Adolescent; Adult; Aged; Antiviral Agents; Azithromycin; Cardiotoxicity; COVID-19 | 2020 |
Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model.
Topics: Animals; Black or African American; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disea | 2020 |
Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Fe | 2020 |
Azithromycin in patients with COVID-19: Friend or foe?
Topics: Azithromycin; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Hypothesis: The electrical properties of coronavirus.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Heart Conduction System; Host Microb | 2020 |
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Asthma; Betacoronavirus; Clinical Trials, Phase | 2020 |
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antivira | 2021 |
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Topics: Aged; Antiviral Agents; Azetidines; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Drug Combinat | 2021 |
COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients.
Topics: Aged; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Carcinoma, Squamous Cell; Coronaviru | 2021 |
[Resilience in COVID-19 times: general considerations on the recovery of a 93-year-old patient on haemodialysis treatment].
Topics: Aged, 80 and over; Antibodies, Viral; Betacoronavirus; Calcitriol; Clinical Laboratory Techniques; C | 2020 |
A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects.
Topics: Administration, Oral; Computer Simulation; COVID-19; COVID-19 Drug Treatment; Healthy Volunteers; Hu | 2020 |
Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases.
Topics: Aged; Aged, 80 and over; Azithromycin; COVID-19; COVID-19 Drug Treatment; Death, Sudden, Cardiac; Dr | 2021 |
Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure.
Topics: Adult; Aged; Aged, 80 and over; Air Filters; Algorithms; Antibodies, Monoclonal, Humanized; Antirheu | 2021 |
Characteristics and Management of Children With COVID-19 in a Tertiary Care Hospital in Turkey.
Topics: Adolescent; Amides; Antiviral Agents; Child; Child, Preschool; COVID-19; COVID-19 Drug Treatment; Fe | 2021 |
Rapidly rising methemoglobinemia in a patient with severe COVID-19 treated successfully with red cell exchange transfusion.
Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; Erythrocyte Transfusion; Humans; Hydroxychloroquine; | 2021 |
Acute aortic dissection in a patient with Williams syndrome infected by COVID-19.
Topics: Adolescent; Anti-Bacterial Agents; Antiviral Agents; Aortic Aneurysm; Aortic Dissection; Aortic Sten | 2021 |
Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.
Topics: Aged; Clinical Trials as Topic; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Databases, Factua | 2020 |
A possible application of hinokitiol as a natural zinc ionophore and anti-infective agent for the prevention and treatment of COVID-19 and viral infections.
Topics: Anti-Infective Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Homeostasis; Humans; Hyd | 2020 |
The First Case of an HIV Patient Diagnosed with COVID-19 in Korea.
Topics: Adult; Betacoronavirus; CD4 Lymphocyte Count; Coronavirus Infections; COVID-19; HIV Infections; Huma | 2020 |
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; CO | 2020 |
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.
Topics: Aged; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; | 2021 |
Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy.
Topics: Abnormalities, Drug-Induced; Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Congenital Abno | 2020 |
The first wave of COVID-19 in Malta; a national cross-sectional study.
Topics: Adult; Aged; Antiviral Agents; Azithromycin; Coronavirus Infections; COVID-19; Drug Utilization; Fem | 2020 |
Not throwing away our shot.
Topics: Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Emergencies; Humans; Hydr | 2020 |
Experience in the management of severe COVID-19 patients in an intensive care unit.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal, Humanized; Antiviral Age | 2020 |
How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Child; COVID-19; Cross-S | 2020 |
Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive.
Topics: Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Information | 2021 |
Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine.
Topics: Aged; Aged, 80 and over; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Hospital Mortality; | 2021 |
Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; China; Comorbidity; COVID-19; COVID-19 Drug | 2020 |
Perinatal mortality and morbidity of SARS-COV-2 infection during pregnancy in European countries: Findings from an international study.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Asia; Asymptomatic Infections; Austr | 2021 |
Main challenges of electrolyte imbalance in older patients with COVID-19 and risk of QT prolongation. Response.
Topics: Aged; COVID-19; Electrolytes; Humans; Hydroxychloroquine; Long QT Syndrome; SARS-CoV-2 | 2021 |
A case of COVID-19 Convalescent Plasma Donation in Greece: Directed donation for compassionate use in the donor's critically ill father.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antifungal Agents; Antiviral Agents; Cardioton | 2020 |
Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Dif | 2020 |
Community use of antibiotics during the COVID-19 lockdown.
Topics: Adenoviridae; Anti-Bacterial Agents; Antimicrobial Stewardship; Azithromycin; Cephalosporins; COVID- | 2021 |
Management of Irrational Self-Purchase of Hydroxychloroquine During the COVID-19 Pandemic: Experiences From the Largest Healthcare System in Taiwan.
Topics: Azithromycin; COVID-19; Delivery of Health Care; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2; | 2021 |
In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19; trial stopped for futility.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxych | 2020 |
Hydroxychloroquine prescribing habits and impact of the COVID-19 pandemic.
Topics: COVID-19; Dermatology; Humans; Hydroxychloroquine; Practice Patterns, Physicians' | 2021 |
Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.
Topics: Aged; Anti-Bacterial Agents; Antimalarials; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
QT Interval in Patients With COVID-19-Reply.
Topics: Azithromycin; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
Topics: Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; | 2020 |
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.
Topics: Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV- | 2021 |
Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cyto | 2020 |
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimalarials; Antiviral Agents; Chlorocebus aeth | 2020 |
Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials.
Topics: COVID-19; COVID-19 Drug Treatment; Epidemiologic Research Design; Female; Geographic Mapping; Humans | 2021 |
Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Antibodies, Neutralizing; Azithromycin; Binding Sites; COVID-19; CO | 2021 |
Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Betacoronavirus; Biopsy; Coronavirus Infections; C | 2020 |
System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.
Topics: Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; HSP90 Heat-Shock Proteins; Human | 2020 |
US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty?
Topics: COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, P | 2021 |
The first cancer patient with COVID-19 in Slovakia.
Topics: Adenocarcinoma; Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
Does hydroxychloroquine reduce mortality for COVID-19?
Topics: Azithromycin; COVID-19; Humans; Hydroxychloroquine; Italy; SARS-CoV-2 | 2020 |
Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
Topics: Adult; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Human | 2021 |
COVID-19 and antimalarials. Have we been doing it wrong all along?
Topics: Anti-Bacterial Agents; Antimalarials; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Interact | 2021 |
Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2021 |
Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Italy; SARS-CoV-2 | 2020 |
Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Antimalarials; Biopsy; Coronavirus Infections; COV | 2020 |
Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Dr | 2020 |
Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study.
Topics: Adenosine Monophosphate; Alanine; Azithromycin; Chloroquine; Communication; Coronavirus Infections; | 2020 |
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
Topics: Chloroquine; Cohort Studies; Coronavirus Infections; COVID-19; Female; Heart; Humans; Hydroxychloroq | 2020 |
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude to Health; Biological Products; Chloroq | 2021 |
Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Thera | 2020 |
Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 Pandemic.
Topics: Antirheumatic Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; COVID-19; COVID- | 2021 |
Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.
Topics: Adult; COVID-19; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Post-Exposure Prophylaxis; S | 2020 |
Scientists criticize use of unproven COVID drugs in India.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase | 2020 |
Drug-induced QT prolongation in COVID-19 pneumonia: influence on in-hospital survival.
Topics: Antimalarials; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; Hospital Mortality; H | 2021 |
The clinical manifestations and interval changes of reverse-transcriptase quantitative polymerase chain reactions among different specimens of coronavirus disease 2019 patients.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Ma | 2021 |
Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Topics: Ampicillin; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Child; COVID-19; | 2021 |
Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report.
Topics: Anemia, Hemolytic; COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Erythrocyte Transfusion; Gl | 2020 |
Safe and effective medication utilization in pediatric patients requiring rehabilitation services during the Coronavirus pandemic of 2019.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Child; COVID-19; COVID-19 Drug Tr | 2020 |
Causal inference methods for small non-randomized studies: Methods and an application in COVID-19.
Topics: Antiviral Agents; Causality; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Humans; Hy | 2020 |
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020.
Topics: Aged; Aged, 80 and over; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; F | 2020 |
[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Very severe COVID-19 in the critically ill in Tunisia.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COV | 2020 |
Impact of Coronavirus Disease 2019 (COVID-19) on Patients With Congenital Heart Disease Across the Lifespan: The Experience of an Academic Congenital Heart Disease Center in New York City.
Topics: Academic Medical Centers; Adult; Aged; Azithromycin; Cohort Studies; COVID-19; Female; Genetic Disea | 2020 |
COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report.
Topics: Adult; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Diagnosis, Differ | 2020 |
Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Aged; Alanine; Antibodies, Monoclonal, Humanized; | 2020 |
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Cardiovascular Diseases; Comorbidity; COV | 2020 |
Predictors and outcomes of healthcare-associated infections in COVID-19 patients.
Topics: Aged; Antibodies, Monoclonal, Humanized; Coinfection; COVID-19; COVID-19 Drug Treatment; Cross Infec | 2021 |
Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science.
Topics: Acquired Immunodeficiency Syndrome; Anthropology, Medical; Antimalarials; Antiviral Agents; Chloroqu | 2020 |
Hydration-Induced Disorder Lowers the Energy Barriers for Methyl Rotation in Drug Molecules.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; Crystallography, X-Ray; Dexamethasone; | 2020 |
Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers.
Topics: Antimalarials; Case-Control Studies; COVID-19; Cross-Sectional Studies; Health Personnel; Humans; Hy | 2021 |
Clinical Characteristics and Outcomes of 905 COVID-19 Patients Admitted to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran.
Topics: Adult; Aged; Comorbidity; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Female; | 2020 |
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Topics: Antiviral Agents; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Therapy, Combin | 2021 |
Pharmacokinetics under the COVID-19 storm.
Topics: Aged; Computer Simulation; COVID-19; Drug Interactions; Humans; Hydroxychloroquine; Liver Diseases; | 2023 |
An immune-based biomarker signature is associated with mortality in COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anti | 2021 |
COVID-19: Panama stockpiles unproven drugs.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ivermectin; Panama; Self Care; Social | 2020 |
The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19.
Topics: Antimalarials; Antiviral Agents; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Humans; | 2021 |
Hydroxychloroquine for COVID-19: Balancing contrasting claims.
Topics: COVID-19; Humans; Hydroxychloroquine; Italy; SARS-CoV-2 | 2020 |
COVID-19 mortality risk factors in older people in a long-term care center.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Female; | 2021 |
Fatal Cerebral Edema in a Child With COVID-19.
Topics: Anti-Bacterial Agents; Anticonvulsants; Brain Edema; Child; COVID-19; COVID-19 Drug Treatment; Diagn | 2021 |
Physician Health in the Times of COVID-19.
Topics: Adult; Betacoronavirus; Child; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COV | 2020 |
Audio Interview: New Studies of Covid-19 Transmission.
Topics: COVID-19; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Pandemics | 2020 |
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antiviral Agents; Comorbidity; CO | 2021 |
Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.
Topics: Age Factors; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Bias; Clinical Tr | 2021 |
Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Ch | 2021 |
COVID-19 and Cardiac Concerns for Psychiatric Patients.
Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular | 2020 |
Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Congenital Abnormalities; COVID-1 | 2020 |
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.
Topics: Adolescent; Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Female; Hematologic Neopla | 2020 |
Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
Topics: Adult; Aged; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; Comorbidity; COVID-19; COVID | 2021 |
Electrocardiogrammes d´un patient COVID-19 traité par l´association hydroxychloroquine et azithromycine.
Topics: Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Electrocardiography; Human | 2020 |
Summary for Patients: Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Post-Exposure Proph | 2021 |
Reply to 'Taking a stand against the politicization of medical research: how "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of science'.
Topics: Biomedical Research; COVID-19; Humans; Hydroxychloroquine | 2021 |
Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimalarials; Azithromycin; COVI | 2020 |
COVID-19 Pneumonia during Hydroxychloroquine Treatment of Rheumatoid Arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; COVID-19; Female; Humans; Hydroxych | 2020 |
Molecular Descriptors of Some Chemicals that Prevent COVID-19.
Topics: Adenosine Monophosphate; Alanine; Biflavonoids; Catechin; COVID-19; Humans; Hydroxychloroquine; Quan | 2021 |
A case of severe course of COVID-19 treated with experimental therapy.
Topics: Aged; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Im | 2020 |
Bail-out extracorporeal membrane oxygenation for hydroxychloroquine intoxication: a warning for COVID-19 health-care givers.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Caregivers; Comorbidity; COVID-19; Extracorporeal Membr | 2021 |
[Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine].
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; COVID- | 2021 |
Persistent hiccup: A rare presentation of COVID-19.
Topics: Baclofen; Biomarkers; COVID-19; COVID-19 Testing; Fever; Hiccup; Humans; Hydroxychloroquine; Male; M | 2021 |
Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.
Topics: Angiotensin-Converting Enzyme 2; Antimalarials; Binding, Competitive; Cell Membrane; Chloroquine; Ch | 2021 |
SARS-CoV‑2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms.
Topics: Adult; Aged; COVID-19; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pandemics; SARS-CoV-2 | 2021 |
Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; COVID | 2021 |
Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Adult; Aged; Alanine; Anti-Bacterial Agents; Antib | 2020 |
"Say Ninetynine": It's Never too Late to Recover from COVID-19.
Topics: Aged, 80 and over; Antibodies, Monoclonal; COVID-19; Hospitalization; Humans; Hydroxychloroquine; Im | 2021 |
[The medicinal treatment of COVID-19: a brief update].
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Dru | 2020 |
[Chloroquine for COVID-19: a hype or not?]
Topics: Advertising; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Mass Media; Netherlands; | 2020 |
A retrospective comparison of drugs against COVID-19.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Viral; COVID-19; COVID-19 Drug | 2021 |
Update to living WHO guideline on drugs for covid-19.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; | 2020 |
Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study.
Topics: Adult; Aged; Blood Coagulation; Chloroquine; Coinfection; Comorbidity; Cough; COVID-19; COVID-19 Dru | 2020 |
Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Ill | 2021 |
Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report.
Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Asymptomatic Infections; Az | 2020 |
Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; COVID-19; Disease Susceptibility; Female; Humans; Hyd | 2021 |
Challenges in diagnosing hydroxychloroquine myopathy during the COVID-19 pandemic.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; COVID-19; Diagnosis, Differential; Humans; Hyd | 2020 |
QT Interval Monitoring and Drugs Management During COVID-19 Pandemic.
Topics: COVID-19; Humans; Hydroxychloroquine; Pandemics; Pharmaceutical Preparations; SARS-CoV-2 | 2021 |
No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; COVID-19; COVID-19 Drug Treatment; Female; | 2021 |
Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.
Topics: Adjuvants, Immunologic; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; COVID-19; COVID-19 | 2021 |
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
Topics: Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cysti | 2020 |
Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons.
Topics: COVID-19; COVID-19 Drug Treatment; Epigenesis, Genetic; Humans; Hydroxychloroquine; Immunity, Innate | 2020 |
Long-term application of hydroxychloroquine could not prevent the infection of COVID-19.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Interferon | 2020 |
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; | 2020 |
Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Hu | 2021 |
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antirheumatic Agents; Child; COVID-19; | 2020 |
Knowledge, anxiety and the use of hydroxychloroquine prophylaxis among health care students and professionals regarding COVID-19 pandemic.
Topics: Adult; Anxiety; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Female; Health Knowledge | 2020 |
Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
Topics: Azithromycin; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2; Viral Load | 2021 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Doxycycline as an Alternative to Azithromycin in Elderly Patients.
Topics: Administration, Oral; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; COVID-19 | 2021 |
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Can we use hydroxychloroquine to treat COVID-19 now?
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Topics: COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Hydroxychloroquine (HCQ): real treatment or false hope?
Topics: Antiviral Agents; Azithromycin; Controlled Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatme | 2021 |
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Topics: Antiviral Agents; Azithromycin; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatm | 2021 |
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Advanced statistical methods and designs for clinical trials for COVID-19.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI | 2021 |
[Clinical progression of the first wave of novel coronavirus infection in Ostrava].
Topics: Adenosine Monophosphate; Aged; Alanine; Amides; COVID-19; Czech Republic; Female; Humans; Hydroxychl | 2020 |
Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
Topics: Antiviral Agents; Ascorbic Acid; COVID-19; COVID-19 Drug Treatment; Drug Development; Drug Repositio | 2021 |
"Can Nature Heal and be a Possible Remedy for the Management of Covid-19?"
Topics: COVID-19; Flavonoids; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2021 |
Research shows racial disparity, mortality data for patients with cancer and COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Black or African American; COVID-19; COVID-19 Dr | 2021 |
Regarding: "Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019".
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?
Topics: Black or African American; Contraindications, Drug; COVID-19; COVID-19 Nucleic Acid Testing; Critica | 2021 |
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.
Topics: Adult; Aged; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Hydroxychloroquine; | 2021 |
Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.
Topics: COVID-19; Dexamethasone; Humans; Hydroxychloroquine; Multicenter Studies as Topic; Pandemics; Patien | 2020 |
Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.
Topics: COVID-19; Dexamethasone; Humans; Hydroxychloroquine; Multicenter Studies as Topic; Pandemics; Patien | 2020 |
Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.
Topics: COVID-19; Dexamethasone; Humans; Hydroxychloroquine; Multicenter Studies as Topic; Pandemics; Patien | 2020 |
Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.
Topics: COVID-19; Dexamethasone; Humans; Hydroxychloroquine; Multicenter Studies as Topic; Pandemics; Patien | 2020 |
COVID-19 infection in symptomatic pregnant women at the midpoint of the pandemic in Spain: a retrospective analysis.
Topics: Adult; Anosmia; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; C-Reactive Protein; Cesarea | 2020 |
Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
Topics: COVID-19; COVID-19 Drug Treatment; Disease Progression; Humans; Hydroxychloroquine; Lupus Erythemato | 2023 |
A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
Topics: Adenosine Monophosphate; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Al | 2021 |
Estimation of the uncertainty of values assigned to calibration materials prepared in-house: An example for hydroxychloroquine calibrators in blood-hemolysate-based matrix.
Topics: Antimalarials; Calibration; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; | 2021 |
Urticaria as a first clinical manifestation of COVID-19.
Topics: Acetaminophen; Adult; Antiviral Agents; Cetirizine; COVID-19; COVID-19 Drug Treatment; Dermatologic | 2020 |
Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; | 2021 |
Streptococcus pneumoniae coinfection in hospitalised patients with COVID-19.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Alanine; Anti-Bacterial Agents; Anti-Inflam | 2021 |
Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.
Topics: Animals; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-C | 2021 |
Efficacy of canakinumab in mild or severe COVID-19 pneumonia.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antiviral Agents; Combined Modality Therapy; COVID-19; COVI | 2021 |
Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients.
Topics: Antimalarials; Antiviral Agents; Comorbidity; COVID-19; Female; Heart Transplantation; Humans; Hydro | 2021 |
Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Body Mass Index; Comorbid | 2021 |
Response to a massive SARS-CoV-2 infection in a nursing home transformed into a caring center.
Topics: COVID-19; Humans; Hydroxychloroquine; Nursing Homes; RNA, Viral; SARS-CoV-2 | 2021 |
[2020: Evidence-Based Medicine odyssey. The fall and rise of evidence-based medicine in the year of coronavirus.]
Topics: Access to Information; Antiviral Agents; Brazil; Clinical Trials as Topic; COVID-19; COVID-19 Drug T | 2021 |
High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Nasopharynx; RNA, Viral; Russia; SARS | 2021 |
A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Binding Sites; Boron Compounds; COV | 2021 |
[Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients].
Topics: Aged, 80 and over; Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; F | 2021 |
In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Th | 2021 |
Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report.
Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Female; H | 2020 |
Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.
Topics: Angiotensin-Converting Enzyme 2; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychlo | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prediction of Single Point Mutations in Human Coronavirus and Their Effects on Binding to 9-O-Acetylated Sialic Acid and Hidroxychloroquine.
Topics: Binding Sites; Coronavirus Infections; Coronavirus OC43, Human; COVID-19; Humans; Hydroxychloroquine | 2020 |
SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.
Topics: Biomarkers; Cell Plasticity; COVID-19; COVID-19 Drug Treatment; Cytokines; Dendritic Cells; Host-Pat | 2021 |
Steroid harms if given early in COVID-19 viraemia.
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Treatment; Dexamethas | 2021 |
SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy-Is there a link?
Topics: COVID-19; COVID-19 Drug Treatment; Dysbiosis; Gastrointestinal Microbiome; Humans; Hydroxychloroquin | 2021 |
Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; COVID-19; COVID-19 Drug Treatment; Critical Illness; Hospital | 2021 |
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum
Topics: Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Chloroquine; Ch | 2021 |
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithro | 2021 |
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Anticoagulants; COVID-19; COVID-19 Seroth | 2021 |
The hydroxychloroquine debate: a therapeutic dilemma for general practitioners.
Topics: COVID-19; COVID-19 Drug Treatment; Female; France; General Practitioners; Guideline Adherence; Human | 2021 |
Myositis due to COVID-19.
Topics: Adult; Amides; Antiviral Agents; C-Reactive Protein; COVID-19; COVID-19 Nucleic Acid Testing; Creati | 2021 |
COVID-19 and the generation of novel scientific knowledge: Research questions and study designs.
Topics: Bias; COVID-19; Humans; Hydroxychloroquine; Pandemics; Research Design | 2021 |
Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Disea | 2021 |
A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Azithromycin; Child; COVID-19; COVID-19 Drug Treatment; F | 2021 |
Features of patients that died for COVID-19 in a hospital in the south of Mexico: A observational cohort study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 1; Female; Hos | 2021 |
Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'".
Topics: COVID-19; Humans; Hydroxychloroquine; Patient Care Planning | 2021 |
The epidemiological and clinical profile of COVID-19 in children: Moroccan experience of the Cheikh Khalifa University Center.
Topics: Adolescent; Azithromycin; Child; Child, Preschool; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucle | 2020 |
Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; An | 2021 |
Clinical features and outcomes of hospitalized COVID-19 patients in a low burden region.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Adult; Aged; Alanine; Anti-Bacterial Agents; Antim | 2021 |
A COVID-19 pregnant patient with thrombotic thrombocytopenic purpura: a case report.
Topics: Acute Kidney Injury; Amphetamine-Related Disorders; Antiviral Agents; COVID-19; Drug Combinations; E | 2021 |
A living WHO guideline on drugs to prevent covid-19.
Topics: Chemoprevention; Clinical Decision-Making; COVID-19; Humans; Hydroxychloroquine; Immunologic Factors | 2021 |
Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Canada; Child; | 2021 |
Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?
Topics: Angiotensin-Converting Enzyme 2; COVID-19; COVID-19 Drug Treatment; Folic Acid; Humans; Hydroxychlor | 2021 |
Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine | 2021 |
Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Topics: Antiviral Agents; Chlorpromazine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug | 2021 |
Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea.
Topics: Adult; Antiviral Agents; Cohort Studies; COVID-19; COVID-19 Nucleic Acid Testing; Drug Repositioning | 2021 |
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromyc | 2021 |
Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown.
Topics: Australia; COVID-19; COVID-19 Drug Treatment; Enzyme Replacement Therapy; Gaucher Disease; Humans; H | 2021 |
Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; | 2021 |
Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019.
Topics: Abatacept; Antirheumatic Agents; Arthritis, Rheumatoid; COVID-19; COVID-19 Drug Treatment; COVID-19 | 2022 |
Hydroxychloroquine + azithromycin treatment in elderly patients.
Topics: Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Frail Elderly; Hum | 2021 |
Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
Topics: Adenosine Monophosphate; Aged; Alanine; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; C | 2021 |
Impact of COVID-19 infections on hemodialysis patients in the province of Blida, Algeria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algeria; Antiviral Agents; COVID-19; Female; Hospitaliza | 2020 |
Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data.
Topics: Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Dr | 2021 |
Risk factors and frequency of COVID-19 among healthcare workers at a tertiary care centre in India: a case-control study.
Topics: Adult; Case-Control Studies; COVID-19; Female; Health Personnel; Humans; Hydroxychloroquine; India; | 2021 |
Guidelines should not pool evidence from uncomplicated and severe COVID-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatme | 2021 |
Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice.
Topics: Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Electrocardiography; Hum | 2021 |
COVID-19 progression in kidney transplant recipients: a single-center case series.
Topics: Acute Kidney Injury; Adult; Antimalarials; Antiviral Agents; COVID-19; Disease Progression; Female; | 2021 |
System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India.
Topics: Adult; Antimalarials; Contraindications, Drug; COVID-19; Electrocardiography; Female; Humans; Hydrox | 2021 |
Prolonged QT predicts prognosis in COVID-19.
Topics: Azithromycin; COVID-19; Electrocardiography; Female; Humans; Hydroxychloroquine; Long QT Syndrome; M | 2021 |
Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy.
Topics: Aged; COVID-19; Cross-Sectional Studies; Female; Humans; Hydroxychloroquine; Incidence; Male; Middle | 2021 |
Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.
Topics: COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxyc | 2023 |
Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers.
Topics: Animals; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychl | 2021 |
Management of Chloroquine and Hydroxychloroquine Poisoning: Do Not Miss the Time of Tracheal Intubation and Mechanical Ventilation.
Topics: Chloroquine; COVID-19; Humans; Hydroxychloroquine; Intubation, Intratracheal; Respiration, Artificia | 2021 |
Response to: "Management of Chloroquine and Hydroxychloroquine Poisoning: Do Not Miss the Time of Tracheal Intubation and Mechanical Ventilation".
Topics: Chloroquine; COVID-19; Humans; Hydroxychloroquine; Intubation, Intratracheal; Respiration, Artificia | 2021 |
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Case-Control Studies; COVID-19; CO | 2021 |
Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature.
Topics: Aged; Anti-Infective Agents; Bacteremia; Catheter-Related Infections; Coinfection; Combined Modality | 2021 |
"I had to be with bodyguards with guns"-attacks on scientists during the pandemic.
Topics: Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Firearms; Humans; Hydroxychloroquine; L | 2021 |
Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Comorbidity; COVID-19 | 2021 |
Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety.
Topics: Antirheumatic Agents; Anxiety; Civil Defense; Community Pharmacy Services; COVID-19; COVID-19 Drug T | 2021 |
Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
Topics: COVID-19; COVID-19 Drug Treatment; Disease Progression; Humans; Hydroxychloroquine; Lupus Erythemato | 2023 |
Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients.
Topics: Adenosine Monophosphate; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-1 | 2021 |
Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic.
Topics: Aged, 80 and over; Anti-Infective Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; COVID-19 | 2021 |
Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities.
Topics: Acute Kidney Injury; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Boston; Comorbidity | 2021 |
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treat | 2021 |
Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-Inflammatory Agen | 2021 |
Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2.
Topics: A549 Cells; Animals; Caco-2 Cells; Cell Line; Cell Survival; Chlorocebus aethiops; Chloroquine; Colo | 2021 |
Determinants of IgG antibodies kinetics after severe and critical COVID-19.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Viral; Body Mass Index; Convalescence; COVID-19; COVID-19 | 2021 |
Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients.
Topics: Action Potentials; Acute Disease; Aged; Anti-Bacterial Agents; Biomarkers; Convalescence; COVID-19; | 2021 |
Clinical course and outcome of patients with COVID-19 in Mumbai City: an observational study.
Topics: Adult; Aged; Comorbidity; COVID-19; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychlo | 2021 |
Antiviral treatment selection for SARS-CoV-2 pneumonia.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Lopinavir; SARS-CoV-2; Treatment Outcome | 2021 |
Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; C-Reactive Protein; COVID-19; COVID-19 Drug Treatm | 2021 |
Trends Over Time in the Risk of Adverse Outcomes Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Topics: COVID-19; Humans; Hydroxychloroquine; Intensive Care Units; Respiration, Artificial; SARS-CoV-2; Uni | 2022 |
Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
Topics: Acute Kidney Injury; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Creatinine; Drug The | 2021 |
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
Topics: Administrative Claims, Healthcare; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and ov | 2021 |
Biological markers and follow-up after discharge home of patients with COVID-19 pneumonia.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Comorbidity; COVID-19; COVID-19 Drug Treatment; Creatine | 2021 |
How COVID broke the evidence pipeline.
Topics: Child, Preschool; Clinical Decision-Making; Clinical Trials as Topic; COVID-19; Dexamethasone; Evide | 2021 |
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Famot | 2021 |
Methemoglobinemia in COVID-19.
Topics: Adult; Aged; Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ma | 2021 |
Hydroxychloroquine and Potential Drug Interactions in Older Adults.
Topics: Aged; Antiviral Agents; COVID-19; Drug Interactions; Humans; Hydroxychloroquine | 2020 |
Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic.
Topics: Adenosine Monophosphate; Adult; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2021 |
Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients.
Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Azithromycin; Brazil; | 2021 |
How to face COVID-19: proposed treatments based on remdesivir and hydroxychloroquine in the presence of zinc sulfate. Docking/DFT/POM structural analysis.
Topics: Antiviral Agents; Azithromycin; COVID-19; Humans; Hydroxychloroquine; Molecular Docking Simulation; | 2022 |
Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study.
Topics: Aged; Amides; Antiviral Agents; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Drug Admini | 2021 |
Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Viral; Antiviral Agents; Asymptomatic Infections; Commun | 2021 |
QT interval prolongation in geriatric patients treated for SARS-COV-2 infection: OCTA-COVID study.
Topics: Aged; Azithromycin; COVID-19; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; SAR | 2021 |
Management of COVID-19 pneumonia in a child with NEMO deficiency.
Topics: Amides; Antiviral Agents; Azithromycin; Child; COVID-19; COVID-19 Serotherapy; Ectodermal Dysplasia; | 2021 |
Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany-An Ethical Analysis.
Topics: Adenosine Monophosphate; Alanine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Ethical A | 2021 |
COVID-19: Patient care after discharge from the Intensive Care Unit.
Topics: COVID-19; Critical Care; Humans; Hydroxychloroquine; Intensive Care Units; Middle Aged; Patient Disc | 2021 |
Multi-system inflammatory syndrome in children during the coronavirus disease 2019 in Saudi Arabia: Clinical perspective from a case series.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Child; Child, Preschool; COVID-19; COVID-19 Drug | 2021 |
Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
Topics: Adenosine Monophosphate; Adolescent; Alanine; Antimalarials; Antineoplastic Agents; Antiviral Agents | 2021 |
National early warning score on admission as risk factor for invasive mechanical ventilation in COVID-19 patients: A STROBE-compliant study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Ea | 2021 |
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Topics: Aged; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Azithromycin; Comorbidity; COVID-19; | 2021 |
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.
Topics: Anti-Bacterial Agents; Antimalarials; Azithromycin; COVID-19; COVID-19 Drug Treatment; Female; Follo | 2021 |
COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alanine; Antibodie | 2021 |
Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
Topics: Aged; Analgesics; Cardiovascular Diseases; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Diuret | 2021 |
Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents.
Topics: Aged; COVID-19; Humans; Hydroxychloroquine; Nursing Homes; Outpatients; SARS-CoV-2 | 2021 |
An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.
Topics: Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Survival; Cells, Cultured; Chlorocebus aethio | 2021 |
COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; COVID-19; Female; H | 2021 |
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Dru | 2021 |
Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID | 2021 |
Drug-induced QTc interval prolongation in PCR-positive non-ICU COVID-19 patients with diverse findings on chest computed tomography.
Topics: Adult; Azithromycin; COVID-19; Electrocardiography; Female; Humans; Hydroxychloroquine; Male; Middle | 2021 |
Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis.
Topics: Anti-Bacterial Agents; Commerce; COVID-19; COVID-19 Drug Treatment; Drug Compounding; Drug Utilizati | 2021 |
Toward a Coronavirus Knowledge Graph.
Topics: Chloroquine; Computer Graphics; COVID-19; Databases, Factual; Hemorrhagic Fever, Ebola; Humans; Hydr | 2021 |
The molecular dynamics of possible inhibitors for SARS-CoV-2.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Binding Sites; COVID-19; Humans; Hydroxychloroqui | 2022 |
Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort.
Topics: COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Hydroxychloroquine; Incidence; Prospect | 2022 |
Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Cell Line; Chlorocebu | 2021 |
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; D | 2021 |
Open-source institutional guideline recommendations during the COVID-19 pandemic.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Administ | 2020 |
Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry.
Topics: Aged; Antirheumatic Agents; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Cross-Sectio | 2021 |
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19.
Topics: Africa South of the Sahara; Chloroquine; COVID-19; COVID-19 Drug Treatment; Databases, Genetic; Gene | 2021 |
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering.
Topics: Aged; Aged, 80 and over; Antimalarials; Cluster Analysis; COVID-19; COVID-19 Drug Treatment; Female; | 2021 |
Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19.
Topics: Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Publishing; | 2021 |
QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine.
Topics: Adult; Aged; Aged, 80 and over; Azithromycin; COVID-19; COVID-19 Drug Treatment; Electrocardiography | 2022 |
[Chronic inflammatory bowel diseases: what happens when SARS-CoV-2 occurs? Preliminary results from a study conducted at the Hassan II University Teaching Hospital in Fes, Morocco (a case report)].
Topics: Adult; Azithromycin; COVID-19; COVID-19 Drug Treatment; Female; Hospitals, University; Humans; Hydro | 2021 |
Assessment of clinical outcomes in renal transplant recipients with COVID-19.
Topics: Acute Kidney Injury; Adult; Aged; Comorbidity; COVID-19; Female; Humans; Hydroxychloroquine; Immunoc | 2021 |
Computational study for identifying promising therapeutic agents of hydroxychloroquine analogues against SARS-CoV-2.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Molecular Docking Simulation; Molecul | 2022 |
Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Anti-Inflammatory Agents; Antiviral Agent | 2021 |
Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Amides; Antiviral Agen | 2021 |
Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19.
Topics: Antimalarials; Arrhythmias, Cardiac; Chemoprevention; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2022 |